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ABSTRACT
This thesis investigates the use of manual measures of brain structure delineation on 
MR scans in order to assess atrophy in dementia. It further investigates the automation 
of atrophy measures. A new protocol for outlining the cingulate is described and was 
applied to groups of Alzheimer’s disease (AD) and control subjects. The application of 
existing hippocampal and amygdala protocols to a group of pathologically-confirmed 
AD, frontotemporal lobar degeneration (FTLD) and controls is detailed. This analysis 
shows cross-sectional measurements were useful subject-group discriminators and that 
patterns of atrophy within and between structures may distinguish diseases.
Manual delineation of regions (cingulate and hippocampus) was extended to 
longitudinal studies to establish atrophy rates in groups of AD, FTLD and controls. The 
cingulate was shown to be at least as affected as the hippocampus by disease. 
Hippocampal atrophy rates from inter-scan intervals of six months were compared with 
measurements in the same subjects of one-year intervals. Results from studies 
combining cross-sectional and longitudinal hippocampal data are described. These 
assess the asymmetry of the structure and investigate the pre-symptomatic decrease in 
volume in familial AD subjects.
Semi-automated techniques were performed which utilise registration of serial 
hippocampi to assess change longitudinally. Results show the semi-automated 
techniques to be reliable and consistent with manual measures. These techniques were 
then applied to scans from a multi-centre clinical trial and again consistency with 
manual measures was assessed.
The generation of fully-automated template-based hippocampal segmentations is 
described. The approximate regions generated from the template were used to quantify 
the boundary shift integral and the resultant atrophy rates were compared with manual 
rates revealing automated measures to be consistent with manual measures.
These results are put within the context of other similar studies by performing a meta­
analysis of hippocampal atrophy rates. Implications for diagnosis and monitoring 
disease progression are discussed.
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AIMS OF THIS THESIS
The Problem
Alzheimer’s disease (AD) is a growing socio-economic and healthcare problem affecting 
approximately 20% of the world’s population over 80 years of age (Dawbam and Allen, 2001). 
Structural MR imaging is a non-invasive means of assessing one result of the AD pathology, 
namely atrophy. Structures of the brain such as the hippocampus are affected early in the 
disease (Braak and Braak, 1991), and as a result there is great interest in measuring this 
structure at one time-point or using multiple time-points, to assess change. There is also 
evidence that another brain structure, the cingulate gyrus, is also affected in AD (Braak et al., 
1993). Measurement of such substructures may aid: a) differentiation of dementia from 
normally ageing subjects, b) the differential diagnosis of dementia, c) the ability to track disease 
over time, and d) our understanding of the natural history of the disease. Manual measures of 
such structures are the “gold standard” for assessing volume at one time-point or change in 
volume over time. This type of analysis is both time-consuming and requires highly-trained 
operators and as a result this assessment is restricted to specialist centres. The increased 
automation of such measures may improve the utility of this type of volumetric analysis in a 
clinical situation and may prove useful in clinical trials of potentially disease-modifying 
therapies.
Aims
1. To assess the existing manual delineation protocols of the hippocampus cross-sectionally and 
longitudinally in dementia in terms of differential diagnosis and distinguishing AD subjects 
from controls.
2. To develop and assess manual segmentation protocols of the cingulate gyrus in order to 
analyse volumes at one time-point and change over time.
3. To assess semi-automated measures of hippocampal atrophy rates in their ability to separate 
AD subjects from controls. These measures are to be compared with the “gold standard” 
manually-derived rates.
4. To develop and assess automated means of measuring hippocampal change over time which 
may have utility for clinical situations or clinical trials. Again these automated measures are to 
be compared with the “gold standard” manually-derived rates.
5. To assess location and distribution of atrophy within and between brain structures in order to 
aid differentiation of diseases and understand their natural history.
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1. IMAGING CEREBRAL ATROPHY IN DEMENTIA
1.1. Introduction
Alzheimer’s disease (AD) is the most common cause of dementia affecting over 5% of 
the population above the age of 60 (Dawbam and Allen, 2001). The prevalence of AD 
doubles every five to ten years above the age of 60 (Small et al., 1997). In 2000, 15% 
of the population in Europe was aged over 65 years and nearly 3% over 80 years. By 
2030 it is projected that these numbers will increase to 24% and 6% respectively 
(Kinsella and Phillips, 2005). With this ageing population, AD poses a serious and 
growing public health problem and increasing economic burden. For each affected 
individual and their carers and families AD represents a devastating personal loss.
With symptomatic treatments for AD available and development of disease modifying 
therapies underway, accurate diagnosis of patients with AD as well as methods for 
monitoring disease progression are essential to allow maximum benefit to be derived 
from treatment.
At the earliest stages of AD, cognitive symptoms as well as brain appearances on 
neuroimaging often overlap with those seen in the normally-ageing population. An 
additional challenge relates to differentiation of changes seen in AD from those of other 
dementias. For a minority of AD patients a gene has been identified which allows early 
and even pre-symptomatic diagnosis. However in the majority, those with sporadic AD, 
a definite diagnosis is only possible with visualization of the characteristic 
histopathological appearances of the disease in cerebral tissue usually at post-mortem.
The assessment of cerebral atrophy is increasingly seen as valuable in identifying a 
pattern of atrophy that helps distinguish AD from other causes of dementia and normal 
ageing. Rates of atrophy provide a marker of, and in some cases predict, disease 
progression. This chapter focuses on how these advances in imaging techniques and 
applications have been made and assesses their current and potential applications.
-  19 -
1.2. Dementia
Dementia can be defined as an acquired deficit in multiple domains of cognitive 
function, including memory in the presence of normal consciousness (Rossor, 1993). 
This broad clinical syndrome may be generated by a large number of causes including 
neurodegenerative diseases such as AD.
1.2.1. Alzheimer’s Disease
1.2.1.1.Pathology of AD
AD is characterised by progressive accumulation of extra-cellular aggregated 6 amyloid 
(A8) plaques and intra-cellular neurofibrillary tangles (NFT) made of abnormally 
hyperphosphorylated tau protein. This pathology typically begins in the entorhinal 
cortex and progresses to involve the hippocampus before affecting the cortex widely 
(Braak and Braak, 1991). As a result of these pathological processes, biological 
changes occur in the brain on a microscopic level including neurotransmitter loss, 
dendritic pruning of neurons and neuronal cell death. One consequence of these 
changes at a macroscopic level is cerebral atrophy.
1.2.1.2. Clinical Presentation o f AD
Alzheimer’s disease most commonly presents with impairment of episodic memory 
which progresses to involve other cognitive domains. A “definite” diagnosis of AD can 
only be given when brain tissue is examined pathologically; until such time, clinical 
diagnosis can only be termed either “possible” or “probable” according to NINCDS- 
ADRDA criteria (McKhann et al., 1984).
Alzheimer’s disease can be divided into sporadic (SAD) and familial (FAD) forms. The 
vast majority of cases is sporadic and has a late onset (over 65 years of age). A smaller 
proportion of the disease is young onset (before 65 years of age) and sporadic. An even 
smaller proportion is young onset and classed as familial. In this sense, familial refers 
to a disease with autosomal dominant inheritance usually with a predictable age of 
disease onset. Mutations in three genes have been found to be causative for autosomal 
dominant AD: these are amyloid precursor protein (APP) and presenilin 1 and 2 (PS1 
and PS2). These young onset familial cases account for much less than 5% of all cases.
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1.2.2. Mild Cognitive Impairment
Mild cognitive impairment (MCI) represents a transitional stage between normal ageing 
and dementia. A diagnosis of MCI is made where a person has cognitive complaints 
and evidence of cognitive deficits, which are insufficient to fulfil criteria for dementia. 
MCI can be classified as amnestic, multiple cognitive domains, single non-memory 
cognitive domain or vascular. The term amnestic mild cognitive impairment (aMCI) 
has been proposed to describe the major sub-group of MCI where memory deficits 
predominate in the absence of global cognitive and functional impairment. Subjects 
with aMCI have been reported to have an annual conversion rate to a formal diagnosis 
of AD of 6 to 25% (typically around 10%) compared with 0.2 to 4% in the age- 
equivalent general population (Petersen et al., 2001a). This disease group is important 
as the people within it are potentially at an early stage of the neurodegenerative disease 
process. As such they may derive most benefit from a disease modifying therapy for 
AD, should it become available.
1.2.3. Frontotemporal lobar degeneration (FTLD)
A large number of non-AD pathological processes can cause dementia including 
dementia with Lewy bodies (DLB) vascular disease (VaD), Creutzfeld Jakob disease, 
human immunodeficiency virus, corticobasal degeneration, and progressive 
supranuclear palsy amongst others. Frontotemporal lobar degeneration (FTLD) 
describes a group of neurodegerative conditions which cause atrophy predominantly in 
the frontal and anterior temporal cortex. Distinction between AD and FTLD is 
important, as the treatments and prognoses can be very different. There are a number of 
different clinical syndromes associated with FTLD and numerous histological and 
immunohistochemical classifications of underlying pathology. The clinical presentation 
does not necessarily reflect the pathology; however there is a relationship between the 
distribution of atrophy and the clinical syndrome. For a comprehensive review of 
FTLD, see Neary et al. (Neary et al., 2005).
1.2.3.1.FTLD Pathology 
FTLD can be subdivided into a number of disease types (see Figure 1.1). These can be 
described by the following histological and immunohistochemical features on 
inspection:
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A) Dementia lacking distinctive histological features (DLDH), with 
microvacuolation of the upper cortical layers present on histological inspection but no 
other pathological features.
B) Frontotemporal lobar degeneration of the ubiquitinated type (FTLD-U) with 
presence of microvacuolation in the upper cortical layers and with rounded ubiquitin- 
reactive only neurounal inclusions and dystrophic neurites within the frontal or temporal 
neocortex or the hippocampal dentate cells.
C) Pick type disease (PiD) with tau-reactive rounded intraneuronal inclusions 
(Pick bodies) and swollen achromatic neurons (Pick’s cells).
D) Mutations in the tau gene on chromosome 17 (FTDP-17) causing 
microvacuolation and tau reactive NFTs and / or Pick-like bodies, and, on occasion, 
tangles in the glial cells in the cortical white matter.
1.2.3.2. Clinical Presentations of FTLD 
Frontotemporal dementia or frontal variant frontotemporal dementia (fvFTD) is 
associated with a progressive behavioural syndrome which is associated primarily with 
atrophy of the frontal and anterior temporal lobes. Some of these frontal patients also 
develop motor-neuron disease (MND) and these cases are often named FTD-MND. 
Clinical criteria for discriminating these cases from AD were developed by the Lund 
and Manchester groups (The Lund and Manchester Groups, 1994). These criteria do 
not include other subtypes of FTLD. Progressive non-fluent aphasia (PNFA) is a term 
used to describe those patients with progressive speech production problems with 
preserved word comprehension. This is associated with atrophy focussed particularly 
on the left perisylvian region (Mesulam, 2001). Semantic dementia (SD) is associated 
with progressive problems with comprehension of words and naming of objects and 
other sensory stimuli. This is associated with severe and often asymmetric (left > right) 
atrophy of the temporal lobes. Neary (Neary et al., 1998) recognised these syndromes 
of FTLD and these were included in guidelines published by McKhann et al. (Mckhann 
et al., 2001). There is one further syndrome which may be classed a specific clinical 
subtype of FTLD which is not specifically delineated in existing criteria; focal right 
temporal lobe atrophy associated with behavioural changes, and topographical 
disorientation combined with prosopagnosia (Evans et al., 1995; Rosen et al., 2006; 
Thompson et al., 2004c).
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FTLD
Pathological Subtypes
DLDH FTLD-U PiD* FTDP-17*
Dementia lacking Frontotemporal lobar Pick type Mutations in the tau gene
histological features degeneration o f the disease on chromosome 17
ubiquitinated type
Figure 1.1 Pathological and clinical subtypes o f FTLD.
*These pathological subtypes are often referred to as tauopathies.
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Clinical Subtypes
fvFTD PNFA SD RTLA
Frontal variant 
frontotemporal 
dementia
Progressive 
non-fluent 
aphasia
Semantic Right temporal 
dementia lobe atrophy
1.3. Imaging techniques
With the development of different imaging techniques biological features can be 
assessed (see Figure 1.2). Brain atrophy can be visualised using structural 
neuroimaging, and what this reveals about AD will be the focus of this chapter. 
However, for completeness a brief description of other imaging techniques which reveal 
additional biological changes or deficits in the AD brain will be included.
1.3.1. Functional Imaging Techniques 
A number of different techniques come under the umbrella of functional imaging. 
These techniques include single photon emission computerised tomography (SPECT), 
positron emission tomography (PET), proton magnetic resonance spectroscopy (MRS), 
diffusion tensor imaging, and functional magnetic resonance imaging (fMRI). Each 
technique is applied to reveal different information about the functioning of the brain 
(see Figure 1.2). One method utilises PET which measures metabolism through 
quantifying uptake of labeled glucose (18FDG-PET) over the whole brain (Alexander et 
al., 2002). Patterns of 18FDG-PET uptake can aid the differentiation of dementias: 
decreased temporoparietal uptake of 18FDG is found in AD, whereas in the 
frontotemporal lobar dementias there is decreased 18FDG uptake in the frontal, anterior 
temporal and medial temporal cortices. SPECT has shown similar results to 18FDG- 
PET in AD and a comparison of the two methods is reviewed in (Silverman, 2004). 
One of the most fast-moving research areas is molecular imaging where radiotracers 
such as the ‘Pittsburgh-B compound’, nC-PIB has been used in PET studies to visualise 
amyloid in vivo differentiating patients with mild AD from controls (Klunk et al., 
2004). A growing area of research investigates how to combine information gained by 
different modes of imaging to give a full picture of the functioning and structure of the 
brain and its sub-regions (for a review see (Galanaud et al., 2003)). As this thesis is 
concerned with structural MR imaging, no more detail about these functional or multi­
modal techniques are given, however for overall reviews of imaging techniques used in 
dementia, see (Masdeu et al., 2005; Petrella et al., 2003).
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Imaging in AD
Structural
MRI
M AGNETIC
RESONANCE
IM AGING
Different acquisitions 
are possible with 
MRI. In addition to 
excluding other 
causes o f dementia 
M RI may identify 
patterns o f atrophy 
characteristic o f a 
dem enting disease 
(e.g. T1 weighted 
M RI, or signal 
change suggesting 
vascular disease of 
CJD on T2 or 
FLAIR).
CT
COM PUTERISED
TOM OGRAPHY
A quick, cheap and 
widely available 
technique.
Particularly useful at 
imaging vascular 
lesions and tissue 
calcification.
Functional
SPECT PET DTI
SINGLE PHOTON 
EM ISSION 
COM PUTERISED 
TOM OGRAPHY
This measures blood 
perfusion within the 
brain and shows 
relatively less 
perfusion in the 
temporoparietal areas 
o f  the brain in AD 
com pared with 
normal controls.
POSITRON
EM ISSION
TOM OGRAPHY
This measures a 
number o f  functions 
in the brain including 
blood flow and 
oxygen or glucose 
metabolism. Uptake 
o f labelled glucose 
(FDG) is reduced in 
AD. Binding o f other 
radioligands can also 
be assessed using 
PET such as PIB 
which binds to 
amyloid.
MRS fMRI
DIFFUSION 
TENSOR IMAGING
This measures 
diffusivity o f water 
within the brain to 
give a measure o f 
structural integrity of 
tissues. This is often 
used to measure 
relative dam age of 
white matter in 
patients with 
ischemic white 
matter disease, 
however it can also 
be applied to grey 
matter structures.
M AGNETIC
RESONANCE
SPECTRA
Proton NMR spectra 
measures relative 
quantification o f both 
brain metabolites and 
at higher resolutions, 
neuro transmitters. 
Changes in relative 
levels o f these 
chemicals in different 
parts o f the brain can 
be seen in AD and 
MCI.
FUNCTIONAL MRI
This measures 
changes in the 
oxygenation of the 
blood following brain 
excitation after tasks. 
This reveals a map o f 
excitation caused by 
performing tasks and 
can illustrate 
functional deficits in 
AD patients.
Figure 1.2 Overview o f the different imaging methods used to assess dementias.
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1.3.2. Structural lma2ins Techniques 
Structural imaging allows the visualisation of brain anatomy. Either magnetic 
resonance imaging (MRI) or computed tomography (CT) can be used for this type of 
investigation. Choice of imaging modality is often dependent on many factors. CT is 
cheap and widely available. The short acquisition times required by CT may be 
advantageous when scanning patients who have difficulty keeping still. However, the 
radiation dose required to acquire an image is relatively high and currently the image 
resolution and tissue contrast is inferior to MR. CT scanning technology has become 
increasingly sophisticated in recent years however MR is still considered to be the 
modality of choice for imaging atrophy. MR has been established as a safe, non- 
invasive and high resolution means of brain imaging and is increasingly available in 
clinical practice. MR avoids radiation but scanners are not so widely available and the 
images are sensitive to patient movement. In addition, the powerful magnetic fields 
used make this an unsuitable investigation for those with pacemakers or metal implants. 
European and US guidelines for the investigation of possible dementia recommend that 
all patients undergo either MRI or CT if possible (Knopman et al., 2001; Waldemar et 
al., 2000). Neuroimaging is important as it excludes rare but potentially treatable causes 
of cognitive problems, such as brain neoplasms, subdural haematomas, and aids in the 
diagnosis of vascular and degenerative causes of dementia (Scheltens et al., 2002).
1.3.2.1.CT and MRI
CT and MR imaging are acquired in very different ways and can give differing 
information about the structure imaged. CT uses X rays to create an image that reflects 
absolute tissue density. With MR, tissue types can be differentiated by their relatively 
different T1 and T2 values. Cerebrospinal fluid (CSF) appears dark on T1 images but 
bright in proton density and T2 images. See Figure 1.3 which shows a T1-weighted MR 
image and a T2-weighted MR image.
As in functional imaging, high resolution structural MRI scans have been used to image 
amyloid plaques. Plaques have been observed in both mice (Jack, Jr. et al., 2004) and 
human post-mortem brain samples (Benveniste et al., 1999). However, this high 
resolution imaging requires long scanning times together with high field strengths 
which can not be used in vivo. Consequently, current MRI cannot be used to image the 
histopathological features of AD in humans in vivo because even large amyloid plaques
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(approx. 100 microns in diameter) are ten times smaller than the typical resolution 
(approx 1mm) of clinical imaging. Nevertheless, MR imaging allows visualization of 
cerebral atrophy, the macroscopic effect of the pathological process in AD. The degree 
of cerebral atrophy measured on MRI over time has been found to correlate with the 
pathology found at post mortem (Silbert et al., 2003).
Figure 1.3 a) A “slice” of a T1-weighted MR image and b) T2-weighted MR image of 
the brain.
- 2 7 -
1.3.3. Cross-sectional imaging techniques
1.3.3.1. Visual inspection 
The most common form of analysis in clinical practice for both MRI and CT images is 
simple visual inspection. Different diseases can present with different patterns of 
atrophy which can be visualised on CT and MR. AD is characterised by bilateral small 
hippocampi in the earlier stages followed by generalised cerebral atrophy, whereas 
FTLD presents with a more asymmetric pattern with more frontal and temporal atrophy 
and less posterior atrophy, see Figure 1.4. The gradient of atrophy in these diseases 
may help differentiate them from each other (more posterior loss in AD compared with 
more anterior loss in FTLD). However, patterns of atrophy do not always differentiate 
one disease from another, for example AD and DLB overlap in their appearances as 
both show generalised posterior atrophy; although DLB shows relatively less 
hippocampal atrophy.
The characteristic hallmarks of some diseases may be easier to identify with different 
modalities, for example the vascular lesions present in vascular dementia are better 
demonstrated on T2-weighted MR images including FLAIR (fluid attenuated inversion 
recovery) rather than using Tl-weighted acquisition. Although visual inspection is the 
most common form of scan analysis, and can successfully identify certain types of 
pathology, the sensitivity and specificity for certain diagnoses can be low. This is often 
due to co-existence of pathologies (e.g. AD and vascular dementia) or the overlapping 
appearances of differing diseases (e.g. AD and DLB and with normal ageing). The 
great inter-individual variability seen in brain morphology means that the subtle patterns 
of atrophy seen in the earliest stages of a disease may be hard to detect. It may be only 
when the disease is more advanced that a characteristic pattern of atrophy can be 
visualised, which is suggestive of a particular diagnosis.
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Gradient of atrophy Gradient of atrophy 
Control AD FTLD
Figure 1.4 Cross-sectional MR images showing a normal control, an AD subject and an FTLD subject.
AD is characterised by relatively small but symmetrical hippocampi. FTLD can present with either frontal or asymmetric temporal atrophy, the 
example shown is o f an fvFTD subject. Differences between disease patterns are confounded by the large degree o f inter-individual variability, for 
example this normal control has relatively large asymmetric ventricles.
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To quantify the characteristic differences seen with neuroimaging, specific visual rating 
scales for different markers of disease have been developed. In AD the reduction in the 
size of the medial temporal lobe can be semi-quantitatively estimated using the 
Scheltens scale (Scheltens et al., 1992) (see Figure 1.5). This technique grades the 
scans relative to a template scale according to size of the choroidal fissure, height of the 
hippocampus, size of the temporal hom and collateral sulcus. This method is 
reproducible both between and within raters (Scheltens et al., 1992). For VaD a number 
of scales have been developed to quantify the ischemic vascular load seen on MR scans 
(Scheltens et al., 1998). These methods are useful in the clinical setting as they are easy 
to apply by a rater, require minimal training before use, and have been validated 
extensively.
1.3.3.2.Linear measures 
Simple quantification of the cerebral atrophy seen on MRI and CT imaging can be 
achieved using linear measures of brain regions. Techniques applicable to CT include 
measurement of the minimum thickness of the medial temporal lobe (Jobst et al., 1992) 
or the radial width of the temporal hom (Frisoni et al., 2002b). In terms of MR imaging, 
techniques including the width of the temporal hom of the lateral ventricles have been 
described (Frisoni et al., 1996c). Some of these techniques have been validated 
extensively and much like visual ratings are quick and easy to apply in a clinical setting 
with relatively little training. However, there are potential limitations with this type of 
technique including inconsistencies and dependence on the “slice” chosen which may 
lead to relatively poor sensitivity and specificity (e.g. 79% and 69% respectively for AD 
vs. normal ageing and other dementias for height of the hippocampus (Pucci et al.,
1998), 75% and 93% respectively for AD vs. normal controls for width of the medial 
temporal hom (Frisoni et al., 2002b)).
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Figure 1.5 Scheltens scale o f medial temporal lobe atrophy.
This scale assesses characteristics o f temporal lobe atrophy within the area circled. Rating involves evaluation of the height o f the hippocampus, and 
the widening of the choroidal fissure, temporal hom and collateral sulcus (scale 0-4, with 0 being normal and 4 being atrophied).
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1.3.3.3. Volume measures 
The remainder of this chapter will focus on MR imaging. Cross-sectional comparisons 
of brain volume give approximate insight into the amount of brain atrophy that may 
have occurred during the disease process. Analysis may be performed on a computer 
workstation using software which enables the user to outline structures in an automated 
or semi-automated fashion (see Figure 1.6) (Freeborough et al., 1997; Smith et al., 
2001). Although measurements may be reproducible between research groups there is 
often a large degree of overlap in brain volume between AD patients and controls. This 
overlap may be reduced with correction for estimated pre-morbid brain size, using 
measures such as total intracranial volume (TIV) (Whitwell et al., 2001). This type of 
correction does not remove overlap altogether due to the large degree of inter-individual 
variability in volume of brain structures. Whole brain volume analysis gives a measure 
of general brain atrophy but no indication of how one region of the brain has changed 
compared to another. As different dementias are characterised by differing patterns of 
atrophy, this measure is not specific enough to be diagnostically useful.
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TIV Brain
Figure 1.6 Segmentation of whole brain and total intracranial volume (TIV).
Whole brain measurement is often performed on every “slice ” o f an MR scan. This gives an accurate estimate o f brain volume which can be highly 
reproducible between raters (less than 1% mean absolute difference). TIV is a more regular shape and therefore may be estimated using a proportion 
of the slices or thicker slices. As a result, TIV is often measured at regular intervals o f the scan, for example, every 10 slices. This gives an estimate of 
premorbid brain size/head size which can be used to correct other volumetric measures, removing inter-individual variability such as sex differences. 
TIV is also highly reproducible between raters (less than 1% mean absolute difference).
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1.3.3.4.Regional measures o f atrophy
A wealth of regional volumetric studies dating back to the early 1990s involved 
manually outlined smaller brain structures or regions of interest (ROI) which quantified 
the patterns of regional atrophy seen on the MR images. Figure 1.7 demonstrates 
segmentation of the hippocampus and amygdala. These structures have been of interest 
for both early diagnosis and progression of disease. Similar to whole brain measures, 
TIV correction of these volumes reduces variability between individuals and increases 
separation between normal controls and AD groups.
1.3.3.5. Computational anatomy: comparing anatomy at the 
group level
In recent years the field of computational anatomy has developed, resulting in 
automated and semi-automated techniques that can assess brain volumes and shapes 
both within and between subject groups. This can be achieved on the scale of the whole 
brain, or on smaller structures within the brain.
1.3.3.6. Voxel Based Morphometry (VBM)
Voxel based morphometry (VBM) is a statistically-driven image analysis package 
which is widely used to analyse large numbers of scans on a group level. VBM 
provides an environment in which scans of differing subject groups can be compared on 
a voxel by voxel basis throughout the image. In this way no a priori assumptions are 
made about which areas of the scan may be affected by a disease. Such analysis 
requires many pre-processing steps including spatial normalisation, segmentation, 
modulation and smoothing which results in production of tissue density maps for each 
group. For a detailed description of these methods see Ashbumer et al. (Ashbumer and 
Friston, 2000). Using these methods tissue density maps can be compared using t tests 
at every voxel with pre-selected significance cut-offs and multiple comparison 
correction. These methods have allowed comparison of patterns of atrophy and tissue 
loss between AD and normal ageing (Baron et al., 2001; Karas et al., 2003; Rombouts 
et al., 2000). Differences in group sizes, disease severity, image quality, arbitrary 
significance cut-offs, and multiple comparison correction techniques have led to some 
discrepancies in findings between research groups.
- 3 4 -
Figure 1.7 Segmentation of hippocampus (H) and amygdala (A).
These segmentations are usually performed on every “slice” the structure is present in an automated or semi-automated fashion (using 
pre-set intensity thresholds determined by mean whole-brain intensity). These areas are known to be affected early in the disease over and 
above whole brain atrophy, however the error in their measurement is relatively high (approximately 5% of the structure volume.)
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1.3.3.7.Surface-based techniques 
Cortical mapping is another technique which assesses the whole brain and involves 
several pre-processing steps including: segmentation of the brain into grey matter, white 
matter, and CSF, creation of a surface map of the grey matter-CSF border, and non­
linear transformation of the surface to that of a template brain. Once all brains are 
within the same spatial framework with all sulci and gyri well matched, a number of 
different variables can be assessed. These variables include grey matter density, cortical 
thickness or gyral pattern variability. Statistical models can then be applied to these 
variables at all the points of the surface and a resulting map can display that variable or 
differences in the variable between groups on a template brain. For a review see 
Thompson et al. (Thompson et al., 2004b). Surface techniques can also be used to 
assess differences in smaller structures of the brain, for example the hippocampus. A 
number of studies have used these techniques to assess the differences in shape and 
volume of hippocampi between AD and control groups (Csemansky et al., 2000).
1.3.4. Longitudinal Measures
1.3.4.1 .Introduction
When comparing scans across different subjects there is inherently a large degree of 
inter-individual variability. Comparison of two scans taken at different time-points 
from the same individual reduces the problem of the between-subject variability in 
morphology. In this case each patient acts as their own control and information can be 
obtained regarding disease progression. Quantification of change allows calculation of 
rates of cerebral atrophy, and improves differentiation between normal ageing and 
pathological processes (Fox et al., 1996a; Jack et al., 1998).
1.3.4.2. Registration and measuring change in the whole brain 
To improve the visual assessment of serial images, scans can be co-registered (spatially 
matched) using a variety of techniques with differing levels of complexity. The 
registration process utilises software to enable one scan to be matched to the other. As 
well as allowing better visual assessment of obvious changes, more subtle changes may 
become apparent. Registration allows better localisation of atrophy than visual 
assessment alone and thus allows more precise measures of subtle changes. This 
matching also allows whole brain changes to be calculated semi-automatically, by co­
registering the images and then estimating the change between the two brain regions
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using a subtraction image (baseline scan -  registered-repeat scan). These registration- 
based techniques have been used extensively to measure change in the whole brain. 
The technical details regarding registration and longitudinal brain change quantification 
are described in Chapter 2.
1.3.4.3.Measuring change in focal areas -  manual 
measurement
In addition to measuring whole-brain volume change over time, it is possible to measure 
smaller areas within the brain. Changes in the CSF spaces such as the lateral ventricles 
provide markers of brain change over time and have been used in clinical trials owing to 
the ease of segmentation and reproducible nature of protocols employed. Although 
these features on MR are sensitive markers of disease progression, they are not specific 
to any particular disease, as change in ventricle size does not localise the loss of brain 
tissue to specific regions.
Focal changes within the brain can be detected longitudinally using manual 
segmentation (Du et al., 2004; Jack et al., 1998; Kaye et a l, 1997). Levels of change in 
these areas may also be higher than whole brain change. However, many of these 
measurements have an inherently higher level of measurement error compared with 
whole brain. This is due to difficulty in reproducible anatomical localisation and 
delineation of these structures, and standardization of segmentation protocols.
1.3.4.4. Group analyses: Longitudinal VBM and cortical 
mapping
Packages such as VBM, mentioned earlier in the text, are also able to perform group 
analyses of change over time. This can be achieved either by comparing the same group 
at baseline and assessing significant changes at repeat imaging (essentially looking 
cross-sectionally at both time-points); or by importing the deformations from non-linear 
registrations into VBM and assessing statistical differences between groups (Scahill et 
al., 2002). An example of the latter analysis is demonstrated below in Figure 1.10. 
Cortical mapping of grey matter density (described earlier) has also been applied 
longitudinally in a group of AD revealing similar results to longitudinal VBM in AD 
(Thompson et a l, 2003).
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1.4. Clinical applications of techniques -  imaging a continuum
This section discusses how research using many of the techniques described above has 
shed light on the progression of AD from pre-symptomatic stages of the disease, to 
amnestic MCI, and finally conversion to AD. Figure 1.8 illustrates this spectrum of 
clinical progression and papers which have demonstrated features of the disease at each 
point.
1.4.1. Normal ageing 
Cerebral structures change over time as a result of apparently healthy ageing. It is 
unclear how much of this is due to an inevitable intrinsic ageing process as opposed to 
low levels of damage due to multiple pathologies. In order to discriminate “normal” 
age-related changes from those associated with neurodegenerative disease, it must be 
known in what way this normal change occurs. However there is often difficulty in 
defining a cohort that reflects the ‘normal population’. Study cohorts vary regarding 
cognitive ability, vascular risk factors, and ‘normal’ scan appearances. Initial studies of 
normal ageing involved qualitative comparison of MRI scans through visual 
assessment. These studies aimed to distinguish between subjects of differing age based 
on the prominence of certain characteristics including sulcal depth, signal 
hyperintensities and ventricular size. With the development of quantitative imaging 
techniques cross-sectional imaging studies revealed differences in the brain in elderly 
populations compared with that of younger populations. These changes included 
smaller whole brain, temporal lobe and hippocampal volumes, together with greater 
ventricular volumes (Gur et al., 1991; Mueller et al., 1998; Scahill et al., 2003) as well 
as progressive accumulation of white matter changes (Wolfson et al., 2005).
Using VBM Good et al. were able to image a large cohort of healthy volunteers and 
compare patterns of atrophy across individuals (Good et al., 2001). They observed a 
linear increase in the CSF compartments with age. Regionally atrophic changes were 
more prominent in the frontal and parietal cortices than the temporal and occipital 
cortices. There was also an apparently linear loss of grey matter volume asymmetrically 
in both parietal lobes, pre- and post-central gyri, insula, anterior cingulate cortex and 
left middle frontal gyrus. They described relative preservation of amygdalae, 
hippocampi and entorhinal cortices although it was noted that subtle changes may not 
have been identified due to poor alignment of the medial temporal lobe substructures.
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The axiom of “a lack of statistically significant difference does not mean there is not a 
difference...,” is very relevant for voxel-based measures assessing “t” or “p” values.
With cross-sectional imaging, age-related changes could only be inferred as different 
individuals were being studied at multiple time points. Accordingly, there was potential 
for confounding age and cohort effects. However longitudinal studies allow the use of a 
subject as their own control, and therefore circumvent these confounding factors. As in 
the cross-sectional studies, global grey matter loss has been demonstrated in elderly 
individuals with medial temporal lobe, prefrontal cortex, and parietal changes detected 
with advancing age (Tisserand et al., 2004).
As well as locating regions of atrophy, these longitudinal studies provided information 
on how fast these changes occur. Ventricular size has been reported to increase by 
around 1.5cm3 per year in individuals with a mean age of 70 and a range of 59-85 yrs 
(Resnick et al., 2000).
Longitudinal work has shown that with increasing age there is an acceleration in 
atrophy rates, with the increase in rates of tissue loss being most noticeable after 70 
years of age (Scahill et al., 2003). Rates of global atrophy of 0.2% a year at age 30-50 
and of 0.4% at age 70-80 have been reported in very healthy subjects (Fox et al., 2000; 
Jack et al., 2000; Jack et al., 2004; Wang et al., 2002). Likewise hippocampal atrophy 
rates increase from around 0.1-0.2% a year in those aged 30-50, to 0.8% in those in 
their mid-70s, rising further to 1.5-2% a year at 80-90 (Fox and Schott, 2004; Jack et 
al., 2000). These more elderly cohorts may include a number of individuals with early 
AD (Mueller et al., 1998). Both this pattern and non-linearity of atrophy has been 
supported by work using cortical mapping techniques (Sowell et al., 2004).
In summary there are both grey matter and white matter volume losses with ageing, 
with regional gray matter loss more prominent in the frontal and parietal rather than 
other cortical regions. The relationship between ageing and cerebral atrophy is non­
linear, with certain regions of the brain changing at different times to others.
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Normal Ageing MCI AD
de Leon et a l (1989) -  Atrophy in hippocampal 
region a good marker of AD from controls
Jack et al (1992) -  Reduced hippocampal volume 
in AD compared to controls
Fox et al £1996) -  Atrophy rates in preclinical
familial AD higher than controls 
Good et al (2001) -  Decrease in grey ■
matter with age using voxel based
morphometry Freeborough and Fox (1997) -  Linear registration
and BSI allows visualisation and quantification of 
Scahill et al (2003) -  Rates of brain atrophy atrophy________________________________________
increase with age Freeborough and Fox (1998) -  Fluid registration
reveals localisation of atrophy in AD
Kaye et al (1997) -  Hippocampal rates of atrophy in preclinical dementia predicts decliners 
Jack et al (1999) -  Hippocampal volume predictive of those who convert to AD
Rombouts et al (2000) -  Reduced grey matter in 
sporadic AD compared to controls using voxel 
based m orphom etry
Jack et al (2000) -  Rates of hippocampal atrophy of MCI decliners than MCI stable. Decliners had similar atrophy rates to AD
Csemansky et al (.2001) -  Smaller hippocampal volume predicts decline to AD 
Scahill et al (2002) -  Change in patterns of loss with disease progression using voxel based morphometry 
Chan et al (2003) -  Rates of brain atrophy accelerate with severity of familial AD 
Rusinek et a l (2003) -  Medial temporal lobe atrophy predicts future neuropsychological decline
Silbert et al (2003) -  Correlation between NFT load and brain volume at post mortem in cognitively impaired people. No such 
relationship in normal controls
Cross sectional imaging and psychology -  group differences
Cross sectional imaging and longitudinal psychology -  
predicting decline
Longitudinal imaging and psychology -  correlations in decline
Longitudinal imaging and psychology -  prediction o f AD 
prior to change in clinical status
Figure 1.8 Diagram showing spectrum of disease and papers demonstrating imaging 
features of the disease.
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1.4.2. Sporadic AD
Imaging of cerebral atrophy initially sought to identify patterns of atrophy that were 
typical for AD, thus differentiating this disease process from normal ageing and other 
neurodegenerative diseases. Visual assessment of MR images characteristically 
revealed small hippocampi with attendant generalised cerebral atrophy, compared with 
normal controls. This accorded with the pathological staging of AD progression (see 
below). Semi-quantitative measurement of hippocampal atrophy has been shown to be 
useful at discriminating AD from normal controls with some studies reporting high 
sensitivities and specificities (see (Scheltens et al., 2002) for a review). These measures 
have also been correlated with memory scores (Scheltens et al., 1992). Observations 
such as these have been quantified by cross-sectional volumetric studies which revealed 
smaller volumes in many structures when compared with normally ageing controls. 
These include medial temporal lobe sub-structures such as hippocampi (Jack, Jr. et al., 
1992), entorhinal cortex (Juottonen et al., 1998), amygdala (Cuenod et al., 1993), and 
cingulate gyrus (Killiany et a l, 2000). These changes have been mirrored by 
significant grey matter losses shown using VBM (Baron et al., 2001; Rombouts et al., 
2000). (See Figure 1.9 below for a typical distribution of grey matter loss). High­
dimensional mapping techniques have shown cross-sectional differences between AD 
and normally-ageing subjects. These include greater asymmetry in sulcal patterns in 
AD together with greater variability of the boundary of structures such as the corpus 
callosum (Thompson et al., 1998). Grey matter loss has also been mapped in AD, and 
this suggested that losses were especially marked in the temporo-parietal areas 
(Thompson et al., 2001).
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Figure 1.9 Cross-sectional VBM showing typical pattern of grey matter loss in AD compared with controls showing temporal lobe (including 
hippocampus) and cortical involvement in the disease process.
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Medial temporal lobe substructures have been noted to be different from healthy 
controls at a very early stage of clinical decline. Accordingly many studies have sought 
to elucidate whether measures of atrophy in these regions could be used to identify AD 
in its earliest stages.
MRI studies in subjects with mild AD have consistently demonstrated reduced 
hippocampal volumes (Killiany et al., 1993; Laakso et al., 1995). Measurement of this 
area has also been shown to improve differentiation of AD from other diseases 
(Wahlund et al., 2000). Analysis of the hippocampus using high-dimensional mapping 
techniques has also revealed differences between AD and control groups at one time- 
point and over two time-points. Cross-sectionally, the combination of surface deformity 
and volume has been able to distinguish between patients with AD and controls 
(Csemansky et al., 2000). In mild to moderate AD, the hippocampal volume is 
typically decreased by 20-30% (see Table 1.1) with similar values being found both for 
amygdala and entorhinal cortex losses.
However, many have postulated that the entorhinal cortex, located in the anterior 
parahippocampal gyrus is the earliest structure to be affected in AD (Arnold et al., 
1991; Braak et al., 1993). Entorhinal cortex volume losses have been found to be 
greater than hippocampal volume losses in mild to moderate AD compared to normal 
controls (Du et al., 2001), although in terms of discriminating between AD and controls, 
entorhinal cortex and hippocampal measurements appear equally good (Juottonen et al.,
1999). It has been noted that patient classification significantly improves if entorhinal 
cortex and hippocampal measurements are combined, implying that AD is characterised 
by atrophy of both hippocampus and entorhinal cortex; the diagnostic advantage of 
greater losses in the entorhinal cortex being undermined by the variability in its 
measurement. Early involvement of the amygdala has been suggested by several groups 
(Laakso et al., 1995; Lehericy et al., 1994) and in some cases there was shown to be a 
greater difference in amydala size than parahippocampal gyrus in mild AD (Krasuski et 
al., 1998).
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Table 1.1 Cross-sectional hippocampal, entorhinal cortex and amygdala volumes in different studies.
Study
Author, Year
Details
(n), mean MMSE, mean age of both groups
Structure
Ratio of region (xlOOO) of interest volume to 
TIV unless indicated otherwise (SD)
% volume loss 
relative to controls
(Jack, Jr. et al., 1992)
C (22), N/A 
DAT (20), N/A ~ 75 y
Hippocampus
(total)
C 2.8 (0.141:) 
DAT 2.0 (0.22$) 29$
(Lehericy et al., 1994)
C (8), 29 
AD (18), 22$ = 70y
Hippocampus
(total)
C 2.38 (0.22$) 
AD 1.66(0.33$) 30
(Laakso et al., 1995)
C (16), 29 
AD (32), 23 ~ 70 y
Hippocampus
C L 3.36 (0.51) C R 3.71 (0.45) Cl 
AD L 2.08 (0.55) Cl AD R 2.3 (0.59) Cl 33
(Krasuski et al., 1998)
C (21), 30 
AD (13), 24 n ©
Hippocampus
(average)
C 2.07 (0.29) 
AD 1.68 (0.24) 19
(Von Gunten et al., 
2000)
C (14)
memory problems and depression (14),27+
~ 5 8  y
Hippocampus
C L  1.87 (0.31) C R  1.92 (0.26)
Patients L 1.89 (0.19) Patients R 1.97 (0.17)
L 6$ 
R 4$
(Xu et al., 2000)
C (30), 29 
MCI (30), 26 
AD (30), 21 = 78 y
Hippocampus
(total)
C 3.71 (0.49$) 
MCI 3.25 (0.60$) 
AD 2.87 (0.60$)
MCI 12$ 
AD 23$
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Study
Author, Year
Details
(n), mean MMSE, mean age of both groups
Structure
Ratio of region (xlOOO) of interest volume to 
TIV unless indicated otherwise (SD)
% volume loss 
relative to controls
(Laakso et al., 2000a)
C (30), 29
AD (30), 24 70 y
Hippocampus
C L 137.6 (23.6) * C R 149.6 (24.5) * 
A D L 99.5 (25.1)* A D R  101.8 (27.9)*
L 284 
R 32$
(Chan et al., 2001b)
C (10), N/A
AD (10), N/A ~ 60 y
Hippocampus
CL1.9 (0.2) C R  2.4 (0.3)
A D L 1.5 (0.2) AD R  2.0 (0.4)
L 21$ 
R 17*
(Du et al., 2001)
C (40), 29 
MCI (36), 26
AD (29), 18 ~ 1 5 y
Hippocampus
(total)
C 6.33 (0.80) TIV corrected mis 
MCI 5.66 (0.86) TIV corrected mis 
AD 4.60 (1.01) TIV corrected mis
MCI 11 
AD 27
(Mega et al., 2002)
C (10), 29
A AMI (10), 29 = 7 0 y
Hippocampus
C L 2.09 (0.36) O C R  2.24 (0.53) O 
AAMI L 1.89 (0.30) O AAMI R 1.81 (0.26) O
L 10* 
R 19*
(Marquis et al., 2002)
C (60), 28 
QD (48), 28
PCI (38), 28 ~ 80 -86 y
Hippocampus
C 1370.3 (178.9) mm3 
QD 1242.5 (189.4) mm3 
PCI 1240.0 (190.8) mm3
QD 9* 
PCI 10*
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Study
Author, Year
Details
(n), mean MMSE, mean age of both groups
Structure
Ratio of region (xlOOO) of interest volume to 
TIV unless indicated otherwise (SD)
% volume loss 
relative to controls
(Killiany et al., 2002)
C (28), 29
questionables (73), 29
AD (16), 24 = 70 y
Hippocampus
(total)
C 3.54 (0.05V) 
questionables 3.81 (0.06V) 
AD 3.19 (0.04V)
questionables -8$ 
AD 10$
(Lehericy etal., 1994)
C (8), 29
AD (18), 221: = 7 0 y
Amygdala
C 1.77 (0.25$) 
AD 1.12(0.17$) 37
(Laakso et al., 1995)
C (16), 29
AD (32), 23 = 70 y
Amygdala
C LI.85 (0.23) D C R 1.69 (0.24) Q 
AD LI.51 (0.46) Q AD R 1.46 (0.50) Q 14-18
(Krasuski et al., 1998)
C (21), 30
AD (13), 24 = 7 0 y
Amygdala
C 1.35 (0.24) 
AD 0.91 (0.24) 33
(Von Gunten et al., 
2000)
C (14), N/A
memory problems and depression (14), 27+
= 58 y
Amygdala
C L  1.31 (0.10) C R  1.37 (0.13)
Patients L 1.18 (0.19) Patients R 1.27 (0.16)
L 15$ 
R 13$
(Chan et al., 2001b)
C (10), N/A
AD (10), N/A ~ 60 y
Amygdala
C L  1.21 (0.13) C R  1.32 (0.17)
AD L 0.96 (0.10) AD R 1.05 (0.17)
L 21$ 
R 20$
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Study
Author, Year
Details
(n), mean MMSE, mean age of both groups
Structure
Ratio of region (xlOOO) of interest volume to 
TIV unless indicated otherwise (SD)
% volume loss 
relative to controls
(Laakso e ta l,  2000a)
C (30), 29
AD (30), 24 = 70 y
Entorhinal cortex
C L 81.3 (20.0)* C R 86.2 (21.9)*
AD L 58.6 (17.5)* AD R 62.9 (21.2)*
L 28$ 
R 23$
(Xu et al., 2000)
C (30), 29 
MCI (30), 26
AD (30), 21 = 7 8 y
Entorhinal cortex 
(total)
C 0.56 (0.16$) 
MCI 0.44 (0.1 It) 
AD 0.35 (0.1 If)
MCI 21* 
AD 38*
(Du et al., 2001)
C (40), 29 
MCI (36), 26
AD (29), 18 =75 y
Entorhinal cortex 
(total)
C 2.73 (0.61) TIV corrected mis 
MCI 2.39 (0.63) TIV corrected mis 
AD 1.662 (0.50) TIV corrected mis
MCI 13 
AD 39
(Chan et al., 2001b)
C (10), N/A
AD (10), N/A = 60 y
Entorhinal cortex
C L 0.24 (0.05) C R 0.25 (0.07)
AD L 0.17 (0.04) AD R 0.15 (0.04)
L 29$ 
R 4 0 |
(Killiany et al., 2002)
C (28), 29
questionables (73), 29
AD (16), 23 = 70 y
Entorhinal cortex 
(total)
C 0.030 (0.01V) 
questionables 0.021 (0.01¥) 
AD 0.012 (0.004V)
questionables 30t 
AD 60*
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Key
L left 
R right
total = left plus right 
AD Alzheimer’s disease 
MCI mild cognitive impairment 
C control
AAMI age associated memory impairment
DAT dementia of Alzheimer’s type
Questionables questionable AD
QD questionable dementia
PCI persistent cognitive impairment
MMSE Mini Mental State Examination
£2 head size correction made by dividing volume by brain area
*head size correction made by dividing volume by intracranial area
d> no head size correction
$ calculated from information given in the paper
¥ reported as SD but more compatible with standard error of the mean
y years old
N/A not available
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Although measures of entorhinal cortex atrophy provide an early and specific marker of 
AD, measurement reproducibility can be affected by methodological difficulties such as 
reliably distinguishing the entorhinal cortex region, often made more problematic by 
poor grey or white matter differentiation on scans. Measurements of hippocampal 
change are sensitive as an imaging marker of AD and with the development of semi­
automated measurement techniques, often simpler to identify and measure (Haller et al., 
1996). Although a relatively sensitive marker of AD, hippocampal atrophy is not 
specific to Alzheimer’s disease as significant atrophy of the hippocampus occurs in 
DLB, vascular dementia and FTLD (especially anteriorly in FTLD) (Barber et al., 2000; 
Chan et al., 2001b; Du et al., 2002).
Volumetric longitudinal MR studies in control and AD group comparisons have allowed 
changes and rates of change in cerebral structures to be related to clinical stage and 
monitored in parallel. These studies have demonstrated an increase in whole brain 
atrophy rates (Fox and Freeborough, 1997) of 2-3% per year which is several times 
greater that that seen in age-matched controls (see Table 1.2). Rates of brain atrophy 
are not linear throughout the disease. In AD rates of brain atrophy have been shown to 
increase gradually over several years before the onset of symptoms and to accelerate as 
the disease progresses (Chan et al., 2003). In this study the mean yearly loss of brain 
volume rose by an average of approximately 0.3% per year (95%CI 0.15-0.50) before 
subjects became symptomatic, reaching a rate of loss of over 2% per year (95%CI 2.3- 
3.3) by the time the mini mental state examination (MMSE) had fallen to 23/30. VBM 
has been used to establish patterns of tissue loss with differing disease severity, 
demonstrating a shift in the anatomical distribution of atrophy with disease progression 
in a mixed group of FAD and SAD subjects (Scahill et al., 2002) (see Figure 1.10). 
Early AD subjects have increased rates of hippocampal (Jack et al., 1998) and 
entorhinal cortex atrophy (Du et al., 2004). Increased inward deformation of the 
hippocampal surface and decreased volume over time has also been shown 
longitudinally using high deformation techniques with rates of change similar to that 
found by manual volumetry (Wang et al., 2003). In one study of early AD the 
entorhinal cortex atrophy rate was measured at 7.1+/-3.2% per year, slightly higher than 
that of the hippocampus (5.9+/- 2.4% per year) (Du et a l, 2004). Cognitive impairment 
correlated significantly with atrophy rates of both entrohinal cortex and hippocampus. 
As with the cross-sectional work, atrophy rates of the hippocampus and entorhinal 
cortex were comparable in differentiating between AD and controls (see Table 1.3).
- 4 9 -
Rates of loss seem to vary between studies probably reflecting both differences in 
measurement techniques and subject groups.
With disease progression, the inferolateral regions of the temporal lobes become more 
involved. Increased rates of parietal lobe atrophy are seen at all stages, whilst frontal 
lobe changes, and then finally occipital losses appear to occur later in the disease 
process. This grey matter loss has also been identified longitudinally using high­
dimensional mapping, with loss starting in the temporal and limbic cortices and 
progressing to the frontal and occipital brain regions with relative sparing of the primary 
sensory-motor areas. This loss also correlates with decline in neuropsychology scores 
(Thompson et al., 2003). Infra-tentorial changes have been studied but appear to be 
minor relative to cortical losses.
By comparing post-mortem findings to previously obtained MR images 
histopathological changes can be directly related to cerebral atrophy (Silbert et al., 
2003). In cognitively impaired individuals, but not in normal controls, there is a 
relationship between NFT accumulation and total brain volume as well as rate of brain 
volume change. There is also a strong correlation between amyloid plaque deposition 
and rate of increase in ventricular size. Rates of global brain atrophy were reported 
again as around 2% per year in AD with this excess atrophy mirroring the accumulation 
of AD pathology found at post-mortem.
There has been much interest in the predictive value of both cross-sectional and 
longitudinal imaging of the brain at a stage before a diagnosis of AD can be made 
clinically. Medial temporal lobe substructures have shown positive predictive value in 
identifying those who will go on to decline to AD from MCI or control status (Jack et 
al., 1999; Jack et al., 2000; Killiany et al., 2000). Identification of predictive factors 
has been the subject of much research in both AD and MCI and is more fully addressed 
in the following sections.
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Figure 1.10 Longitudinal VBM in subjects at differing stages o f AD compared with controls showing a shift in atrophy from hippocampus 
to neocortex as the disease progresses from a) presymtomatic b) mild and c) moderate AD.
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Table 1.2 Table o f whole brain rates o f change in / lD, MCI and normal ageing
Author, year
Subject group (n) ~ mean 
age
Mean (SD) % rate of 
atrophy
Approximate
Interval
(years)
(Fox and 
Freeborough, 1997)
C (19)
AD (9) ~ 54 y
C 0.24 (0.32) 
AD 2.78 (0.92)
1
(Fox et a l, 2000)
C (18)
AD (18) ~ 65 y
C 0.41 (0.47) 
AD 2.37 (1.11)
1
(O'Brien et al., 
2001)
C (20)
AD (9) ~ 75 y
C 0.5 (0.7) 
AD 2.0 (0.9)
1
(Bradley et al., 
2002)
C (34) 2 with possible AD 
AD (5) ~ 65-70 y
C 0.2 (0.23) 
AD 2.14 (0.52)
0.2-0.6
(Wang etal., 2002)
C (14)
AD (14) ~ 70 y
C 0.4 (0.5) 
AD 2.4 (1.2)
1
(Jack et al., 2004)
C stable (40)
C converter (15)
MCI stable (15)
MCI converter (26)
AD slow progressor (31) 
AD fast progressor (33)
~ 76-80 y
C stable 0.4 (0.3)
C converter 0.8 (0.5) 
MCI stable 0.4 (0.4) 
MCI converter 0.8 (0.5) 
AD slow prog. 0.6 (0.7) 
AD fast prog. 1.4 (1.1)
1-4
(Jack, Jr. et al., 
2005)
C (91)
MCI (72) ~ 80 y
C 0.5 (1.0) 
MCI 0.7 (0.7)
1
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Author, year
Subject group (n) ~ mean 
age
Mean (SD) % rate of 
atrophy
Approximate
Interval
(years)
(Schott et al., 
2005)
C (19)
AD (38) ~ 70 y
C 8.1 (5.0) mls/year 
AD 20.8 (11.2) mls/year 
AD 2.2 (1.2)
1
(Kaye et al., 2005)
C (88)
Very mild AD (23)
Mild AD (27)
Moderate AD (17)
~ 75-80 y
C 0.49 (1.4)
Very mild AD 1.2 (1.7) 
Mild AD 2.0 (2.2) 
Moderate AD 2.5 (2.0)
1.5-2.5
Key
AD Alzheimer’s disease 
C control
MCI mild cognitive impairment 
y years old
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Table 1.3 Table of hippocampi rates o f change in AD, MCI and normal ageing
Study
Author, Year
Details
Subject group (n), -mean age y
Annualised loss as % 
Mean (SD)
Interval
(years)
(Kaye et al., 
1997)
C (18)
Pre-clin. dementia (12)
-  85-90 y
C 2.09
Pre-clin dementia 2.33 3-4
(Jack et al., 
1998)
C (24)
AD (24) -  80 y
C 1.55 (1.38) 
AD 3.98 (1.92)
2
(Laakso et al., 
2000b)
C (8)
AD (27) -  70 y
C 3.6 (15.1)A 
AD 7.2 (20.1)A
3
(Jack et al., 
2000)
C (58) -  80 y 
MCI (43) -  77 y 
AD (28) -  74 y
C 1.9 (1.1) 
MCI 3.0 (1.6) 
AD 3.5 (1.8)
3
(Cardenas et al., 
2003)
C (16) -  76 y 
Cl (6) -  70 y 
AD (7) -  76 y
C 1.8 (0.8) 
Cl 1.9 (2.3) 
AD 5.4 (2.8)
2-3
(Jack et al., 
2004)
C stable (40)
C converter (15)
MCI stable (15)
MCI converter (26)
AD slow progressor (31)
AD fast progressor (33)
-  76-80 y
C stable 1.4 (1.2)VF 
C converter 3.3 (2.4)^ 
MCI stable 1.8 (1.7)¥ 
MCI converter 3.3 (2.9)^ 
AD slow prog. 3.0 (4.5)XP 
AD fast prog. 3.6 (3.2)4/
1-4
(Du et a l, 2004)
C (25)
AD (20) -  75 y
C 0.8 (1.7) 
AD 5.9 (2.4)
2
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Study
Author, Year
Details
Subject group (n), -mean age y
Annualised loss as % 
Mean (SD)
Interval
(years)
(Hashimoto et 
al., 2005)
AD (93) -  70 y AD 5.04 (2.54) 1
(Jack, Jr. et al., 
2005)
C (91)
MCI (72) -  80 y
C 1.7 (1.4) 
MCI 3.3 (2.7)
1
(Thompson et 
a l, 2004a)
C (14)
AD (17) -  70 y
C 2.1 (2.8)
AD 6.8 (10.2)*
1-3
(Jack et al., 
2003)
AD (192) = 73 y AD 4.9 (-0.5-15.2)# 1
(Wang et al., 
2003)
C (26)
DAT (18) -  74 y
C L 4.0 R 5.5A 
DAT L 8.3 R 10.2A
2
(Fox et al., 2005) AD placebo (57) -  70 y AD placebo 2.86 (3.19)A > 1
(Kaye et al., 
2005)
C (88)
Very mild AD (23)
Mild AD (27)
Moderate AD (17) -  80 y
C 2.2 (6.0)
Very mild AD 4.3 (7.4) 
Mild AD 2.9 (7.8) 
Moderate AD 3.2 (6.8)
2
(Mori et al., 
2002)
AD APOE s4+ (38)
AD APOE s4 -(17) -  70 y
AD e4+ 9.76(4.27) 
AD 8 4 -  6.99 (4.24)
1
Key
y approximate mean age of subjects in study in years. Given for different subject groups
if these appear different.
AD Alzheimer’s disease 
C control
MCI mild cognitive impairment 
DAT dementia of Alzheimer Type 
Cl cognitive impairment 
Pre. clin: pre-clinical
t  results presented here are 1/3 of those quoted in paper as change was presented as loss 
over a three year period.
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* given by personal communication
# median and range
A percentage loss over interval (i.e. not annualised) 
APOE Apolipoprotein gene
Table 1.4 Table of ventricular rates o f change in AD, MCI and normal ageing
Study
Author, Year
Details
Subject group (n), ~ mean age y
Annualised loss 
Mean (SD)
Interval
(years)
(Jack et al., 1998)
C (24)
AD (24) ~ 80 y
C 6.15% (7.69) A 
AD 14.16% (8.47) A
2
(Wang etal., 2002)
C (14)
AD (14) ~ 70 y
C 0.79 ml 
AD 8.20 ml
1
(Wang etal., 2002)
C (14)
AD (14) ~ 70 y
C 1.9% (4.2) 
AD 13.8% (4.8)
1
(Bradley et al., 2002)
C (32) 2 with possible AD 
AD (5) ~ 65-70 y
C 4.1% (0.9) 
AD 13.0% (2.4)
0.2-0.6
(Silbert et a l, 2003)
C (8)
AD (20) over 80 y
C 3.3 ml (3.5) 
AD 5.5 ml (3.2)
4
(Jack, Jr. et al., 2005)
C (91)
MCI (72) ~ 80 y
C 2.4% (2.0) 
MCI 3.3% (2.3)
1
(Kaye et al., 2005)
C (88)
Very mild AD (23)
Mild AD (27)
Moderate AD (17) ~ 8 0 y
C 3.5% (3.8)
V. mild AD 7.4% (4.4) 
Mild AD 9.9% (5.8) 
Mod. AD 12.1% (4.8)
2
Key
y approximate mean age of subjects in study in years. Given for different subject groups
if these appear different.
AD Alzheimer’s disease 
C control
MCI mild cognitive impairment 
A temporal horns only
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Table 1.5 Table o f  entorhinal cortex rates o f change in AD, MCI and normal ageing
Study
Author, Year
Details
Subject group (n) -mean age y
Annualised loss 
Mean (SD)
Interval
(years)
(Cardenas et 
al., 2003)
C (16) -  76 y 
Cl (6) -  70 y 
AD (7) -  76 y
C 2.6% (2.5) 
Cl 6.5% (4.8) 
AD 9.3% (4.4)
2-3
(Jack et al., 
2004)
C stable (40)
C converter (15)
MCI stable (15)
MCI converter (26)
AD slow progressor (32)
AD fast progressor (33)
-  76-80 y
C stable 2.9 (2.6)¥
C converter 5.1 (5.1)^ 
MCI stable 3.7 (3.7)¥ 
MCI converter 6.8 (4.4)¥ 
AD slow prog. 8.0 (5.8)^ 
AD fast prog. 8.4 (9.2)x¥
1-4
(Du et al., 
2004)
C (25)
AD (20) -  75 y
C 1.4 (2.0) 
AD 7.1 (3.2)
2
(Jack, Jr. et 
al., 2005)
C (91)
MCI (72) -  80 y
C 5.0 (3.6) 
MCI 7.0 (4.3)
1
Key
y approximate mean age of subjects in study in years. Given for different subject groups 
if these appear different.
AD Alzheimer’s disease 
C control
MCI mild cognitive impairment 
Cl cognitive impairment 
medians (inter-quartile ranges)
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1.4.3. Familial AD
MRI studies carried out in populations at risk of developing Alzheimer’s disease owing 
to inheritance of presenilin PS1 or PS2 or APP mutations have led to characterisation of 
familial AD and to the defining of a ‘preclinical’ phase of dementia. Serial MR 
scanning of individuals within 5-8 years of the historical onset of the disease showed 
that significant hippocampal atrophy was detectable on MRI at an early stage in the 
disease when subjects were still apparently asymptomatic (Fox et al., 1996b). 
Registration of serial MRI in these FAD subjects demonstrated that rates of atrophy 
increased at an early stage prior to the onset of measurable cognitive deficit, with a 
median rate of global atrophy of 1.0% per year (95% Cl 0.78-1.88) (Fox et al., 2001). 
Schott et al. measured medial temporal lobe atrophy in their series at 5.7 % per year 
(95% Cl 3.62 -7.83). Extrapolation of these rates of atrophy back in time suggested that 
medial temporal lobe atrophy might have commenced at least 3.5 years prior to onset of 
symptoms (Fox et al., 2001; Schott et al., 2003). These findings clearly outline the 
disease continuum that is present in Alzheimer’s disease from a presymptomatic phase 
to cognitive decline sufficient to fulfil criteria for AD. Individuals with familial 
Alzheimer’s disease have an earlier age of onset and often different clinical features to 
those with sporadic AD and therefore care must be taken in relating these results to 
sporadic AD directly (Rossor et al., 1996). However a similar picture has been 
described using serial MR imaging in the early stages of sporadic AD as described 
below.
1.4.4. Amnestic MCI and presymptomatic sporadic AD 
Comparison of studies performed in this group of patients is complicated by the wide 
number of diagnostic criteria used for MCI subjects in imaging studies. These have 
ranged from isolated memory impairment to one domain (non-memory) cognitive 
impairment or multi-domain mild cognitive impairment. The proportion of AD subjects 
may therefore vary widely between studies with ‘MCI’ groups comprising of variable 
amounts of ‘worried well’ subjects and non-AD pathology.
Research groups have increasingly recognised the MCI subjects as important in terms of 
diagnosis and treatment and therefore have sought to identify the earliest imaging 
markers in MCI much like the approach in AD. In 1989 de Leon et al. published an 
important study showing that qualitative estimates of hippocampal atrophy in memory- 
impaired subjects predicted decline to AD (de Leon et al., 1989). Later studies also
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have shown that in subjects with MCI, small baseline hippocampal size is predictive of 
subsequent conversion to AD (Jack et a l, 1999).
Du et al. found that entorhinal cortex and hippocampal volume measurements were 
significantly reduced in MCI compared to controls (Du et a l, 2001). The magnitude of 
entorhinal cortex atrophy was similar to that of hippocampal atrophy in MCI. Volume 
losses were not as great as were seen in AD. Killiany et a l, in a three year follow-up 
study of patients with varying degrees of cognitive impairment, found that overall 
classification into MCI and control groups with the entorhinal cortex was better than 
85% (Killiany et a l, 2002). However, Du et a l found that the hippocampus was better 
than the entorhinal cortex in distinguishing MCI from controls and even adding the 
entorhinal cortex to the hippocampus did not improve classification (Du et a l, 2001). 
Xu et a l found that the entorhinal cortex and hippocampus had equivalent 
discrimination power between MCI and controls and between AD and MCI (Xu et a l,
2000). This suggested that, as in AD, the entorhinal cortex offers little practical 
advantage over the hippocampus in differentiating MCI from controls. The relative 
merits of hippocampal and entorhinal cortex measures remains controversial with 
advocates for both structures.
A B C D
Figure 1.11 Demonstration of hippocampal shrinkage over time in an individual who at presentation and nine month interval had subjective memory 
complaints.
Time-points A: baseline, B: nine months after baseline imaging, C: two years after baseline imaging, and D: three years after baseline imaging.
By the final scan D the individual had progressed to fulfill criteria for AD. The individual had subsequent post-mortem confirmation of AD.
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Longitudinal studies have shown that MRI measures of medial temporal lobe atrophy 
combined with neuropsychometric tests have a high predictive value for progression to AD 
(Amaiz and Almkvist, 2003; Petersen et al, 2001b). One study (Jack et al., 2000) 
demonstrated that over a period of three years significantly greater hippocampal atrophy 
had occurred in a group of MCI individuals who progressed to a diagnosis of AD than 
those who remained cognitively stable. Interestingly a proportion of their control group 
also deteriorated cognitively over the follow-up period to become rediagnosed as MCI. 
They had a significantly higher rate of hippocampal atrophy than the rest of the control 
group. This suggests that a prodromal phase also exists prior to MCI in sporadic 
Alzheimer’s disease where cerebral atrophy and specifically hippocampal atrophy is taking 
place but definite cognitive impairment may not be clinically detectable (see Figure 1.11 
for an example). Rates of control-converter subjects (who started the study as controls but 
at follow-up had AD) and MCI-converter subjects were similar to those of AD, whereas 
stable MCI rates were similar to those of stable normal subjects, indicating that MRI 
measures of change correlated more closely with disease progression than with clinical 
assessment at baseline. This also implies that the rate of hippocampal atrophy increases 
prior to the MCI stage but then seems to stay relatively constant (at around 3-4% per year) 
as MCI progresses to established AD. Similarly, another longitudinal study (Rusinek et al., 
2003), demonstrated that medial temporal lobe (MTL) atrophy was able to predict which 
individuals with normal baseline cognitive functioning would convert to a diagnosis of 
MCI. The overall accuracy of the MTL prediction was 89% with a specificity of 94% and 
sensitivity of 77%.
There has been some debate as to whether medial temporal lobe structures or measures of 
whole brain atrophy or ventricular size most closely correlate with disease progression. 
One group compared hippocampi, entorhinal cortex, ventricles and whole brain atrophy 
rates to address this question. They found whole brain atrophy and ventricle size correlated 
most strongly with disease progression. They also found their MR measurements aligned 
better with disease progression (subjects changing clinical diagnoses, e.g. MCI to AD) than 
their measures of neuropsychometric change (Jack et al., 2004).
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Volumetric measures are free from subjective effects such as motivation, general health, 
anxiety, depression or fatigue that may contribute to cognitive test and rating scale 
variability. Where it is uncertain if an individual reaches criteria for mild cognitive 
impairment or other diagnosis, MRI provides an objective measure of disease, adding 
clinical certainty and perhaps giving information regarding prognosis.
1.5. Conclusion
With the potential development of disease modifying therapies, parallel development and 
assessment of surrogate markers of disease progression for use in clinical trials is 
increasingly important. Studies have suggested that change in MRI atrophy rates may 
correlate better with disease progression than change on cognitive tests or clinical rating 
scales (Jack et al., 2004). Measures of atrophy rates for different areas of the brain using 
different techniques are also being evaluated so that the most suitable ones may be used in 
such trials. One such study which aims to assess this is the Alzheimer’s disease 
neurobiology initiative (ADNI): website http://www.loni.ucla.edu/ADNI. A major aim of 
such studies is to assess whether the addition of different MRI measures of change to 
therapeutic trials will allow smaller sample numbers or shorter, more efficient trials.
Major progress has been made in quantitative imaging of the brain over the last ten years. 
Advances in imaging and research tools have proved useful clinically and have allowed 
better characterisation of the disease process. Currently, structural imaging is 
recommended as part of the diagnostic process to differentiate other pathology from 
neurodegenerative causes of cognitive impairment. It also provides a useful adjunct to both 
neuropsychometric and clinical assessments in the differential diagnosis and in monitoring 
disease progression. In the future, structural imaging may provide useful prognostic 
information as well as acting as a potential surrogate marker for disease progression or 
regression in clinical trials for AD. There is a requirement for greater automation of 
structural imaging techniques in order to evaluate the number of scans taken clinically in 
addition to those from clinical trials.
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2. REGISTRATION, SEGMENTATION AND USE OF TEMPLATES
2.1. Chapter introduction
Scan registration and segmentation are essential for many imaging analyses. They have 
enabled research in neuroimaging to progress from visual assessments to automated 
measurement techniques where images from hundreds of patients can be assessed 
simultaneously. Registration refers to the aligning of one or a number of images so that 
they are in the same spatial framework. Segmentation is the delineation of structures or 
tissue types within an image. Registration and segmentation are intrinsically linked; many 
forms of registration require some form of segmentation to enable the registration 
procedure to be successful and to ensure the images are aligned over regions of interest. 
Segmentation of some structures is best performed following registration to ensure that 
similar arbitrary decisions are made for all subjects. Registration and segmentation can 
combine to make powerful tools to assess MR images. They are able to localise and 
quantify differences between subjects or within a subject over time. Application of these 
techniques has moved imaging in dementia from the exclusion of other possible causes to 
become a predictive tool with diagnostic utility (Scheltens et al., 2002).
Segmentation of structures within the brain is important both for diagnosis and as a marker 
of disease progression. Whole brain atrophy may be common to many diseases but 
different diseases have distinctive patterns of atrophy in specific brain regions. As a result, 
segmentation of different areas of the brain has been employed in order to i) understand the 
natural history of the disease and ii) develop reliable non-invasive markers of the disease. 
Many of the “gold standard” methods of segmentation are time consuming and therefore 
techniques which are able to increase the automation of such measurements improve the 
likelihood of such a technique being widely applicable. In this chapter, the basis of 
developing reliable markers and increased automation of these markers using registration 
and segmentation will be discussed.
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2.2. Intra-subject registration of images
To improve the visual assessment of serial images, scans can be co-registered using a 
variety of techniques with differing levels of matching. The registration process removes 
the effect of differing head positions of the subject in the scanner and brain positions within 
the skull by transforming and resampling one scan to match the other (see Figure 2.1). In 
addition to allowing both obvious and subtle changes to be visualised, registration allows 
such changes to be localised and measured. Such procedures (for example, those described 
in detail in (Friston et al., 1995a; Jenkinson and Smith, 2001; Ostuni et al., 1997; Thevenaz 
et al., 1998; Woods et al., 1998; Zhilkin and Alexander, 2000)) can be run through a 
number of different packages some of which are freely available.
2.3. Unear and non-linear registration and the resulting 
correspondence
Linear registration describes techniques where the parameters required to map the source 
scan to the target scan are applied equally to every voxel within the image. The result of 
this process is a resampling of the source image to the target image producing a pair of 
aligned images. Non-linear registration describes when registration parameters are allowed 
to vary throughout the image which allow for the source and target image to be more 
accurately matched (see Figure 2.1). The choice of which registration technique should be 
employed depends on the question being addressed and the validity and accuracy of the 
answer will depend on the registration procedure employed.
The result of any registration is that the two co-registered images are in correspondence, i.e. 
one point on one image corresponds to a particular point on the other image. These two 
points will, in theory, represent the same type of tissue in each scan. However, no 
measurement, or in this case scan, is completely accurate and in some applications of 
registration, for example image-guided neurosurgery, it is important to know what the 
margin of error is in order to know how to interpret the co-registered scans.
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Baseline Follow-up Unregistered
Registration
Registered 6dof Registered 12dof Non-linear Registered
Figure 2.1 Figure to show the effect of registration methods.
Difference images (baseline image -  repeat image) of the unregistered', and six degrees of freedom, affine, and non-linear registered images 
are shown. Registration of at least six degrees of freedom will remove positional changes. With increasing degrees of freedom (zero for 
unregistered to infinite for non-linear) increasing levels of matching between the baseline and registered images are achieved.
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The use of registration in serial imaging of dementia, where tissue is lost between the two 
imaging time-points, complicates the issues of correspondence. No longer will every point 
between the images correspond following rigid-body registration as the atrophy that has 
occurred means that tissue is lost and replaced by fluid. The assumption that many atrophy 
measures make is that images should not change over time, and therefore the lack of 
correspondence between scans (often seen at the borders of the brain) is a measure of the 
amount of atrophy the brain has undergone.
2.4. Components of the registration procedure
Registration is achieved when transformation parameters are determined which, when 
applied, will match one image to another. To achieve this, registration algorithms have 
been developed to estimate these transformation parameters. Often the first operation 
which is required for registration to be performed is the determination of a region over 
which the images are to be matched. This may be the segmentation of a brain region or 
may be a method to generate a region which approximates to the inside of the skull. Next, 
the transformation parameters necessary to match the source to the target scan are 
calculated by an optimisation process. Finally, these transformation parameters are applied 
to the source image by interpolation.
Registration algorithms are usually composed of a number of differing components. These 
include: i) a similarity measure which calculates how well the two images match, ii) a 
transformation model which determines how the images can be transformed, and iii) an 
optimisation process which determines whether the similarity measure can be improved. 
Most registration algorithms are solved iteratively until exit criteria are met.
2.4.1. Similarity measures used for resistration 
The similarity of an image pair is usually based on a point, contour or voxel intensity 
correspondence between the images. The voxel intensity similarity can be cross­
correlation, sums of squared differences, ratio image uniformity, mutual information or 
normalised mutual information. For a review of these differing techniques see Crum et al. 
(Crum et al., 2004a) or Hill et al. (Hill and Batchelor, 2001).
- 6 6 -
2.4.2. Interpolation schemes used for registration 
Interpolation is necessary to estimate transformation parameters and for image 
transformation as the estimates of voxel intensity values are needed for voxels between 
those in the original image. Once the optimum transformation parameters are obtained the 
source image can be resampled to match the space of the target image. A number of 
interpolation schemes are available for doing this. Techniques include those where values 
of the nearest voxel are taken, to those which take a weighted average from a number of 
voxels. Tri-linear interpolation generates new values based upon the mean of adjacent 
voxels which are weighted according to their distance from the point. This form of 
interpolation is prone to errors and as a result can reduce the sensitivity to detect subtle 
changes between scans (Hawkes, 2001). Windowed-sinc interpolation is most commonly 
used and has been shown to be relatively fast and accurate (Thacker et al., 1999).
2.5. Application o f linear registration
For a review of technical details of these registration techniques see Ashbumer et al. 
(Ashbumer et al., 2003). Several automated techniques have been designed to accurately 
spatially match scans (Collins et al., 1994; Freeborough et al., 1996b; Jenkinson and Smith, 
2001; Woods et al., 1998). These are based upon matching voxels according to specific 
similarity measures such that all structures approximate to corresponding regions on each 
scan of a registered pair. Such registrations can be performed on the whole image or can be 
based upon matching the two brain areas of the scans following semi-automated brain 
segmentation (Freeborough et al., 1997) or automated brain extraction (Smith et al., 2001). 
Brain-brain registration means that only the two brains alone are spatially matched rather 
than the skulls or non-brain material. This prevents the potential changes in relative brain 
to skull position or chemical shift within the skull and scalp affecting the brain matching. 
The simplest form of registration is rigid registration which involves rotations and 
translations (see Figure 2.2) in the x, y and z axes of the image. This type of registration 
aligns scans but does not remove fluctuations in voxel size (voxel drift) due to changes in 
the scanner over time as it does not scale the source image to match the target. A nine 
degrees of freedom (dof) registration or rigid plus scaling registration is commonly used. 
The added scalings, in the x, y and z axes are able to remove changes in voxel size over 
time and this type of registration has been validated extensively (Freeborough et al., 
1996b). The spatial matching of the images may be improved further by adding shears in
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the x, y and z planes to make a 12 dof (affine) registration. However, by increasing the 
level of matching, some atrophy may be removed by the registration process, leading to 
underestimation of atrophy.
2.6. Quantifying change in the brain following linear registration
The amount of loss that has occurred in the brain over time can be calculated by applying 
semi-automated procedures such as the brain boundary shift integral (BBSI) to a pair of 
scans. This has been validated (Freeborough and Fox, 1997) as a robust and accurate 
measure of brain loss. The technique is summarised below in Figure 2.3. Briefly, the BBSI 
calculates change at the border of the brain and quantifies this change in intensity between 
the two scans at this border as brain loss. This loss can be visualised by colour overlays 
and can give a value for loss of brain tissue. Other techniques have also been developed 
that measure whole brain loss in a similar way (SIENA) (Smith et al., 2001). Although 
these techniques are able to quantify loss they are unable to determine precisely where this 
loss occurred. Loss visualised at the border of the brain may mean loss of grey matter 
directly below the grey matter-CSF border or may be a secondary effect of white matter 
loss at some distance from the border; usually changes at the brain surface reflect multiple 
contributions and readjustments to losses at a cellular level.
These methods have been used successfully to quantify rates of whole brain atrophy in 
normal ageing and AD, originally in (Fox and Freeborough, 1997) and more recently in 
comparisons carried out to evaluate differences between atrophy rate measures and clinical 
disease progression in AD using a modified version of SIENA (Jack et al., 2004). There is 
much interest in these rates of atrophy as possible surrogate markers for therapeutic effect 
in drug trials. However there are limitations to the use of whole brain atrophy as a 
surrogate marker, and it may be that rates of localised atrophy provide a better indicator of 
disease progression. This will be discussed in more detail in the final section.
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Translations 
3 dof in x, y and z
Rotations 
3 dof in x, y and z
Scalings
3 dof in x, y and z 
Shears
3 dof in x, y and z
Key
Planes of the image
Baseline image
Repeat image
Figure 2.2 Schematic representation of registration with increasing degrees of freedom.
Numbers of degrees of freedom increase incrementally by three as each level of matching is applied in the three dimensions of the image (x, 
y and z).
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Figure 2.3 Representation of the boundary shift integral (BSl) measure in one dimension.
The boundary shift measure is represented by the hatched section of the graph. This change is measured over an area of the brain which is 
represented by the grey area of the brain to the right. This area is the union minus the intersection of these two registered brain regions, 
resulting in an area which encompasses the border of the brain.
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2.7. Non-linear registration
Linear registration is unable to localise atrophy to specific tissues and as a result non-linear 
techniques have been developed not only to assess how much change occurs between scans, 
but from which tissues the loss occurred. Such non-linear techniques can be applied 
following some degree of linear spatial matching described above to remove positional 
differences within the brain. These techniques aim to remove all differences between the 
images by iterative solving of equations which model how the brain tissue intensities may 
have changed. The brain can be modeled, for example, as a viscous compressible fluid 
(Christensen et al., 1996; Freeborough and Fox, 1998), or as elastic material (He and 
Christensen, 2003). Other forms of non-linear registration exist, for example, free form 
deformation based on B splines (Rueckert et al., 1999; Studholme et al., 2001). The result 
of a non-linear registration is a registered repeat image (which should match the baseline 
image exactly), and a deformation field which describes how each voxel should be 
transformed to match the source to the target. This deformation field can be used to 
calculate a stretch (Jacobian) file which attributes values to voxels corresponding to the 
amount of contraction or expansion each voxel has had to undergo for the images to match. 
The stretch file can be visualised as a colour overlay on the baseline image which can give 
information regarding where atrophy has occurred (see Figure 2.4). The values in the 
stretch file can also be integrated over brain areas (for example, whole brain region) which 
can give a value corresponding to amount of loss within that region over time.
2.8. Bias field inhomogeneity
Both linear and non linear registration techniques and their corresponding methods of 
atrophy quantification can greatly aid assessment of a disease progression. However, it is 
beneficial for scan pairs (target and source images) to be of similar quality for the 
quantifications and localisations of change to be accurate. Similar scan pair quality means 
similar grey matter / white matter contrast, and intensity inhomogeneity (bias) between 
scans. Bias is caused by a number of factors: inhomogeneity of the magnetic field of the 
MR system, inhomogeneity of the radiofrequency pulse or nonuniformity in the sensitivity 
of the receiver coils used to detect the MR signal. A number of different techniques have 
been used to remove this bias field on individual images, for example the intensity 
histogram sharpening technique: N3 (Sled et al., 1998). Other techniques have been 
developed to differentially adjust the bias field of a scan pair such that the bias field of the
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difference image is corrected to make the bias of the scan pair similar (see Figure 2.5) 
(Lewis and Fox, 2004). This form of bias correction will only correct for differential bias 
but will not correct for bias common to both images. Differential bias correction can be 
applied with or without individual scan bias correction.
2.9. Segmentation
Many areas of the brain are of interest to researchers investigating potential surrogate 
markers of disease. Analysis of regions is either cross-sectional (comparing volumes 
between groups) or longitudinal (comparing rates of change in structures over time). Serial 
volumetric analyses are best completed on either nine dof or affine registered images as 
these types of registration include scalings which corrects for the inevitable changes in MRI 
magnetic field due to scanner gradient change (Whitwell et al., 2004b) or positional 
changes of a subject relative to fixed scanner geometry (Gunter et al., 2003). Such scanner- 
related changes can result in fluctuation of voxel sizes which can complicate comparisons 
of such measures (Whitwell et al., 2001). The “gold standard” of image segmentation is 
manual measures, however these are operator-intensive and are subject to manual errors. 
As a result, more automated techniques are being developed to improve the applicability of 
regional segmentation in a clinical scenario.
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Baseline Repeat Difference Fluid
contracting 4b b i  expanding
Baseline Repeat Difference Fluid
Figure 2.4 Baseline, nine dof registered repeat, difference image and stretch file created from fluid registration of the two nine dof 
registered scans in both control and AD over the same interval.
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Dasenne Registered repeat Difference image BSI overlay
DBC corrected DBC corrected DBC corrected
Figure 2.5 Differential bias correction (DBC) on registered images.
Top showing registration without DBC and below showing with DBC. The boundary shift integral overlay on DBC corrected images shows 
less artefactual cererbellar gain (green) whilst maintaining real loss (red).
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2.10. Common terms used to describe aspects of segmentation
When new methods or segmentation protocols are discussed or new segmentation-based 
markers are developed, certain terms are used to describe characteristics of the method of 
segmentation.
Accuracy of segmentation is difficult to measure. This is because what is segmented on a 
scan is not real tissue which can be histologically characterised but is only a representation 
of the macroscopic brain structure. As a result there exists no true “gold standard” as there 
are no studies which quantify the real volume of structure and compare this with MR 
volume in vivo. One of the main problems with potentially comparing a structure on a scan 
with that structure at post-mortem is the fact that the brain will change in size due to 
changes following death. One study has imaged the brain following death and compared 
the volumes of the real hippocampi with volumes on the post-mortem imaged brains 
(Gosche et al., 2001). Owing to few of these types of studies being performed and the 
impracticality of measuring real volume in vivo, the “gold standard” of segmentation is 
regarded to be manual segmentation and this is against what most new segmentation-based 
techniques are measured. Manual segmentation is also prone to errors which originate from 
differing interpretation of a protocol by different raters, any artefacts which may be present 
on the scans and the scan acquisition protocol.
Volumes of structures measured by new protocols can be compared with manually 
segmented volumes using a form of voxel overlap. A simple measure of intra-observer 
repeatability can be obtained by comparing the volumes of a structure segmented on pairs 
of scans acquired over a short space of time, using the following formula:
2.10.1. Measurement of segmentation accuracy
2 * \ V 1 - V 2
Fractional volume difference =
Equation 2.1
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However, random segmentation errors can result in a similar reported segmented volume 
obtained by labelling a different set of voxels. A more stringent measure of repeatability is 
the volumes of voxels which are labelled consistently in the two segmentations.
This can be determined using the following formula:
VoD s  _  VoS 
VoD + VoS VoD + VoS
Equation 2.2
In words, the voxel difference D is the fraction of inconsistently labelled voxels and the 
voxel similarity S is the fraction of consistently labelled voxels. VoS (the Volume of 
Similarity) is the volume of the intersection of the two regions; VoD (the Volume of 
Difference) is the volume of the union minus the intersection. For two segmentations in 
complete agreement D = 0 and S = 1. For two segmentations in complete disagreement (i.e. 
non-overlapping but which could nonetheless have the same volume) D = 1 and S = 0. For 
all other region pairs 0 <  D < 1. These measures are similar to those discussed by 
Andreasen et al. (Andreasen et al., 1996) and have been used in one form or another by a 
variety of studies (see Table 2.1).
2.10.2. Measurement of reliability of segmentation 
Reliability is defined as the degree to which multiple assessments of a subject agree 
(sometimes this is referred to as reproducibility). This can be calculated either within or 
between raters. Reliability can be measured a number of ways but the figure that is often 
quoted in the text of volumetric papers is the quantification described in Equation 2.1. 
However, a more standard statistical approach is the reliability co-efficient or intraclass 
correlation coefficient (ICC) (see below) (Bartko, 1966; Ebel, 1951; Fleis, 1986). This 
describes the proportion of variation that is not due to measurement error where the value 
has extremes of 0 and 1 where unity shows a method to be completely reliable.
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reliability coefficient = ( a h +  o  )
Equation 2.3
where Ob denotes between subject variance and aw denotes within subject variance
2.11. Subdivision of segmentations
As discussed earlier in section 2.3.2 there may be areas of a structure that are more variable 
in volume and shape compared with others or more affected by a disease process than 
others. To understand the natural history of a particular disease and / or improve precision 
of a marker, segmented structures may be subsequently subdivided. For example, the head 
of the hippocampus may be more reduced in volume relative to the tail in AD, therefore 
measuring the tail in addition to the head of hippocampus may only add noise and 
variability to the measure. Specific analysis of the hippocampal head volumes may reveal 
improved group discrimination of the AD subjects from normal controls. One issue which 
requires consideration is the problem of scale with regards to subdividing structures; a large 
structure will be viewed and segmented at a different level of magnification, and including 
or excluding some voxels in one part of the segmentation may not affect the fractional 
volume difference of that measure. However, if this large region is subdivided, the 
inclusion / exclusion of these voxels may be a relatively higher proportion of the volume of 
the structure which will have a greater effect on the fractional volume. Therefore a 
different level of attention to detail may be necessary in the volume estimation of the 
subregion. When subdividing a structure, it is important to assess whether it is appropriate 
in terms of accuracy and reliability or whether it is better to develop a strict protocol for 
that region alone.
2.12. Reducing amount of work in segmentation
2.12.1. Segmenting fewer slices 
One way of reducing the amount of operator time when segmenting a region is to only 
measure a part of it, and estimate the volume of the missing slices by interpolation (see 
Figure 2.6). This method is particularly applicable when a structure is relatively smooth 
and areas between drawn slices do not deviate in size or shape such that interpolation
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between slices when estimating volume is relatively accurate. If a structure is relatively 
similar throughout two planes e.g. a rectangle then there may be no benefit in measuring 
anything other than the first or last slice. In reality, there are few brain regions that meet 
these criteria and therefore this type of measure is not widely used when investigating a 
structure of interest. One example of a measure where this has been validated is TIV as the 
inside of the skull is usually a smooth structure (See Appendix Four for details and Figure 
1.6) (Whitwell et al., 2001).
2.72.2. Increased automation 
A number of techniques have been described that may increase the degree of automation of 
delineation of structures in the brain. The need for accuracy of these segmentations 
depends upon the use of the mask, i.e. it may just be used for sampling voxel values within 
that region which may not require a high level of accuracy, or it may be the volume of that 
mask is required and therefore the need for accuracy is greater. Table 2.1 shows different 
studies which have used automated segmentation of the hippocampal region in order to 
assess cross sectional volumes in AD vs. controls or rates of change in those volumes in 
similar subject groups. Increased automation will be discussed in more detail later.
2.13. Inter-subject registration and correspondence
This chapter has only considered intra-subject registration until this point. However, 
increasing the automation of segmentation techniques often requires the registration of one 
subject’s scan to another (often referred to as a template or atlas) on which segmentations 
of structures or tissue types have already been defined. Correspondence is most difficult to 
define when aligning scans of different subjects whether this is one subject to another or 
when combining many images to make a template image. Most inter-subject 
correspondences can then be defined either in anatomical terms, such as one temporal lobe 
aligning with all other temporal lobes, or in geometric terms, such as the matching of 
curvature of a gyrus between scans.
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a) Regular
3D Shape
Cross
sectional
“slices”
Figure 2.6 Reducing the number of slices in a segmentation.
Measuring fewer slices and interpolating the spaces between the segmented slices is accurate when a structure does not vary in terms of 
shape throughout the image (a). Inaccuracies in the estimation of volume by interpolating between the few measured slices will occur when 
regions vary in shape throughout the image particularly in areas between slices (b).
b) Irregular
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2.14. Templates: images and regions of interest
Templates are usually created to allow one of two things to happen; either to place many 
images into the same stereotaxic space for analysis (such as statistical parametric mapping 
(SPM) (Friston et al., 1995b)) or VBM (Ashbumer and Friston, 2000)) or to propagate 
labels in order to delineate specific structures (Fischl et al., 2002) (see Figure 2.7). 
Templates are usually one of two types, either population (made from a number of subjects) 
or single-person based. Often these templates will have regions of interest delineated 
directly on them (making them an atlas) or will have labels which are averages of many 
different segmentations made on the original images. Choice of type of template depends 
upon the problem being addressed; this may be putting people into a similar spatial 
framework so that segmentations may be performed more precisely, so that differences in 
structure can be assessed, or it may be that labels from a template are to be transformed 
back onto the scans of individuals. The scale of the analysis also needs consideration as a 
template which may be appropriate for the analysis of the whole brain may be too sparse in 
detail to use with respect to small areas such as the hippocampus. Many of the advances 
made in templates are attributable to researchers involved in fMRI, where the signal 
detected by the fMRI may be meaningless without localisation to specific areas of the 
brain. Many of these templates for localising fMRI signal to specific brain structures are 
applicable to structural MRI and therefore these will also be discussed.
2.14.1. Single person and cohort templates 
The most recognised and widely reported single person template or atlas was that made by 
Talairach (Talairach and Toumoux, 1988). This is, by definition, a space rather than an 
image as the images that make up this template are not contiguous in three dimensions. 
The template space was a framework developed from a 60 year old normally-aged female 
from France who came to post-mortem. Certain planes were defined in the template brain 
which form the basis of a co-ordinate system which can define tissue type according to 
position such that any given brain can be aligned and scaled to this space to define relevant 
areas. The main limitations of Talairach template space are that it is made up of one 
person, only one side of the brain was atlased and reflected and it may be subject to post­
mortem artefact.
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A cohort-based template is one where an additional subject is scanned within a study using 
the same imaging protocol and is then excluded from the group analysis but is instead used 
as a template image. The advantages to this type of template are that the scanner and 
protocol will be the same as those others in the study, reducing the amount of problems 
caused by such differences. Segmentations of any labels or regions on such images will be 
performed using the same protocol or interpretation of a protocol as those within a research 
group which reduces potential bias attributable to segmentation differences (Carmichael et 
a l, 2005). Limitations of this approach include the fact that these types of template do not 
allow for any of the normal variation seen between subjects; they may introduce bias as the 
template image is from one subject group and many subject groups are being assessed; they 
may cause difficulty in comparing results across studies; and results are subject to the 
quality of template image. However, for small structures, this may be the best form of 
template image to use as population-based templates may be too indistinct at smaller scales. 
A number of studies have utilised this form of template (Csemansky et al, 2000; Wang et 
al, 2003). Another template developed by Harvard is of a single patient who has many 
sections of the brain manually outlined, producing a well-defined atlas, (Kikinis et al., 
1996) and was originally designed for surgical planning, segmentation and teaching. The 
brain image and regions can be freely downloaded and as a result it has been used to 
segment the hippocampus in several studies (Carmichael et al, 2005).
Some attempts have been made to circumvent the problems associated with single-person 
templates. One template developed by the Montreal Neurological Institute (MNI) was that 
of imaging the same subject 27 times. The average image of the registered images gave a 
very clear image with reduced noise. This template has been segmented to aid the 
localisation of signal on functional MR images in SPM (Tzourio-Mazoyer et al., 2002). To 
limit the amount of bias introduced by having a single person template, another study has 
described a method of transforming the single-person template into the average space of all 
subjects in the study (Kochunov et al., 2002). This technique not only reduces such bias 
but also retains the resolution and image quality associated with using a single person 
template.
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MNI 305
Figure 2.7 Schematic diagram showing basic uses of template images. 
Arrows represent direction of registration.
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2.14.2. Population-based templates 
As a result of the problems associated with single-person templates, population-based 
templates have been developed. One example is the MNI305 template (Mazziotta et al., 
1991; Mazziotta et al., 1995) (see Figure 2.7). The template was created from 305 normal 
control brains which were processed for radiofrequency inhomogeneity, aligned and 
averaged to create the image seen in Figure 2.7. This template image is in approximate 
Talairach space and functions exist to transform co-ordinates from the MNI 305 space to 
Talairach co-ordinates which are more widely used (see: http://www.mrc-
cbu.cam.ac.uk/Imaging/Common/mnispace.shtml). One further template is named the 
ICBM152 template and is related to the MNI 305 as it was created by transforming 152 
normal control subject scans into the space of the MNI 305 template and averaging the 
resultant images. This template is the standard template used in packages such as SPM 
(Ashbumer and Friston, 1999). Another group have built up an atlas of young individual 
scans registered to the ICBM152 template and transformed the regions defined on the 
original scans to this space. The resulting average template image and template regions are 
designed to automatically segment regions on new scans (Hammers et al., 2003).
In addition to normal-subject-group templates there is a need to develop templates that are 
disease specific. Thompson et al. have produced a template which is comprised of 
geometrically aligned scans of AD patients which creates an average map of the rendered 
surfaces. In addition to an average of the surface of the brain other variables such as grey 
matter density and variance in gyral structure can be mapped. The AD template developed 
was shown to be significantly different to that made using matched control scans 
(Thompson et al., 2001). This study highlights the potential bias that may be introduced by 
using a template made of normal scans in a study where disease and controls are being 
assessed.
Although population-based templates may be useful in localising differences at a group 
level they have been shown to be less able to aid in the segmentation of small areas such as 
hippocampus compared with cohort templates (Carmichael et al., 2005).
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2.15. A utomation o f hippocampal measurements
Owing to early involvement of the hippocampus in AD and involvement of the structure in 
other diseases such as temporal lobe epilepsy and schizophrenia, efforts have been made to 
automate the segmentation of the structure to enable the volume to be estimated. In 
addition, the measurement of progression of atrophy in this area has also been targeted to 
improve upon entirely operator-dependent measures. A number of different techniques 
have been described to achieve these aims and these are described in Table 2.1. Many 
template images with labeled regions exist which were developed for alternative uses (for 
example fMRI activation map localisation (Hammers et al., 2002; Hammers et al., 2003; 
Tzourio-Mazoyer et al., 2002), and although these could be used potentially for 
hippocampal segmentation or atrophy detection, these have not been included as they have 
not been formally assessed.
2.15.1. Cross-sectional hippocampal segmentation
The vast majority of segmentation techniques have been evaluated for cross-sectional 
hippocampal volume estimation. Comparisons between accuracy of different techniques 
are difficult to make owing to the different methods of assessing accuracy of 
segmentations. One paper compared a number of different registration techniques and 
templates but only freely available templates and registration techniques were considered 
(Carmichael et al., 2005). Their main findings were that single-person cohort template 
images, site-specific hippocampal segmentations, and fully deformable registration 
methods improved hippocampal delineation. One automated technique has been applied in 
many further research studies (Csemansky et al., 1998; Csemansky et al., 2005; Wang et 
al., 2001; Wang et al., 2003). Not all techniques have been developed to segment 
hippocampi accurately; one technique samples the intensity within an approximate 
hippocampal region, made from the union of a number of manually-delineated control 
subjects (Webb et al., 1999). Although this technique was applied to temporal lobe epilepsy 
patients it has not been applied to or assessed within AD.
2.15.2. Longitudinal hippocampal segmentation
Two techniques that claim to automatically segment hippocampal regions on serial images 
such that change in volume can be detected over time are those of (Du et al., 2004; Wang et 
al., 2003). These methods are based upon the application of the cross-sectional technique
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described by Haller et al. (Haller et al., 1997) applied to serial images. However, there is 
still some level of operator input required for this technique to achieve accurate results 
(manual placement of landmarks to constrict the warping of the template onto individual 
scans). One technique listed in Table 2.1 is semi-automated as it is necessary to manually 
delineate the baseline hippocampus in order for the region to be propagated by non-linear 
transformation derived from a local intra-subject fluid registration (Crum et al., 2001). 
Although this method achieves highly accurate segmentations of repeat hippocampi, the 
limiting factor when considering the use of this technique is the need for the labour- 
intensive segmentation of the baseline region in order to generate a rate of atrophy.
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Table 2.1 Semi-automated and automated hippocampal segmentation techniques
Study Objective of paper Subject groups Hippocampal 
volume/rate 
of change
Segmentation methods employed Operator Input Methods used to assess 
accuracy of segmentation 
compared with manual
(Gosche et al., 2001) Assessing hippocampal 
volumes and 
relationship to Braak 
staging
51 PM confirmed 
cases. Mixed 
pathological 
statuses: different 
AD stages
Volume Prior probability and intensity 
No template 
PM images only
Operator selects 
first section
Correlation (r) between 2 manual 
raters compared with correlation 
between each rater and the 
automated method
(Ghanei et al., 1998) Description of new 
method of segmentation
Only 2 hippocampi 
segmented. No 
relevant clinical 
information
Volume Surface based deformable contours 
with edge tracking
Some manual 
intervention
Variation of similarity of voxel 
overlap on each slice of on 
hippocampus
Comparison with manual 
segmentation
(Pitiot et al., 2004) Description of 
hippocampal 
segmentation method
Unclear Volume Mesh based registration and 
complex algorithm including shape 
and distance constraints
Unclear Mean absolute surface difference 
of automated segmentation 
compared with manual
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Study Objective of paper Subject groups Hippocampal 
volume/rate 
of change
Segmentation methods employed Operator Input Methods used to assess 
accuracy of segmentation 
compared with manual
(Carmichael et al., 
2005)
Evaluation of publicly 
available registration 
algorithms and 
templates
20 AD, 19 MCI, 
15 controls
Volume Registration of atlas image to 
individual subjects and propagation 
of region
None Similarity index
(Wang et al., 2003) Assessing volume and 
shape changes 
longitudinally
18 Mild DAT and 
26 controls
Volume, rate 
and shape 
change
Haller et al. 19%-1997 technique 
used
Landmarks 
manually placed
Cohort template 
delineated
None
(Webb et al., 1999) Automatic detection of 
hippocampal atrophy 
for use in epilepsy 
patients prior to surgery
15 TLEs 14 
controls
Intensity
within
approximate
hippocampal
region
Union region made of 30 normal 
hippocampi, global and then local 
affine registration
Analysis of intensity in ROI
None once union 
region made
None
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Study Objective of paper Subject groups Hippocampal 
volume/rate 
of change
Segmentation methods employed Operator Input Methods used to assess 
accuracy of segmentation 
compared with manual
(Shen et al., 2002) To asses the size and 
shape using a 
deformable shape 
model
10 subjects Volume Surface-based geometric model 
combined with prior probability map
Manual landmarks Similarity index variation 
(overlap error as a percentage)
(Ashton e t a i ,  1997) Assessing novel feature 
extraction technique in 
ability to assess 
asymmetry of volumes
9 TLE subjects Volume A priori shape and region growing Manual planting of 
seeds
Percentage difference in volume.
Slice by slice differences in 
volume.
(Crum et al., 2001) Assessment of fluid- 
based measures in 
detecting change over 
time
15 controls 12 AD Rates Intra subject fluid 
Manual (outline baseline)
Segmentation of
baseline
hippocampus
Voxel difference using same day 
scan-pairs
(Haller et al., 1997) Assessing template 
based segmentation 
methods
9 controls 9
schizophrenic
patients
Volumes Non-linear (fluid) registration of 
template hippocampus onto new 
scans.
Segmentation of 
the template 
hippocampus
Manual landmarks
Percentage difference in volume 
of the automated technique 
performed twice. Percentage 
difference in volume of the 
manual performed twice
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Study Objective of paper Subject groups Hippocampal 
volume/rate 
of change
Segmentation methods employed Operator Input Methods used to assess 
accuracy of segmentation 
compared with manual
(Duchesne et al., 
2002)
Evaluating new method 
of segmentation against 
manual and existing 
automated method
80 normal subjects Volumes Intensity based methods with shape 
description
Manual
segmentation of 
training set
Similarity index compared with 
manual segmentation
(Fischl et al., 2002) Description of new 
method of propagating 
many labels from a 
template
134 subjects:
25 controls, 92 AD 
with various 
longitudinal 
outcomes
Volumes Registration of a template to 
subjects with incorporation of 
spatial and probabilistic information
None Version of similarity index.
(Hsu et al., 2002) Assessing template 
based segmentation 
methods
20 controls, 20 
cognitively 
impaired and 20 
AD subjects
Volumes Technique based on Haller et al. 
1997, i.e. segmentation of template 
hippocampus followed by fluid- 
based registration and segmentation 
of hippocampi constrained by 
manually-placed landmarks
Segmentation of 
the template 
hippocampus and 
placement of 
manual landmarks
ICC of automated volumes 
compared with ICC of manual 
volumes. These measures based 
on 10 elderly subjects.
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Study Objective of paper Subject groups Hippocampal 
volume/rate 
of change
Segmentation methods employed Operator Input Methods used to assess 
accuracy of segmentation 
compared with manual
(Du et a l 2004) Establishing whether 
hippocampus or 
entorhinal cortex 
atrophy rate is higher
25 Normal controls 
20 AD subjects
Rate of 
change
Same as Hsu et al. 2002 performed 
at two time-points per subject 
allowing rate of change to be 
calculated
Segmentation of 
the template 
hippocampus and 
placement of 
manual landmarks
None
Key
TLE temporal lobe epilepsy 
DAT dementia of Alzheimer type 
PM Post-mortem 
AD Alzheimer’s disease 
MCI Mild cognitive impairment
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2.16. Chapter conclusions
Both segmentation and registration have been discussed in this chapter as these two 
parts of image analysis are often intertwined; accurate automated segmentation is 
difficult to perform without registration and accurate automated registration often 
requires some form of prior segmentation to limit the areas over which the registrations 
are performed. Segmentation and registration form the backbone of many image 
analysis techniques. However, there is still much work to be done in many areas; either 
to either improve accuracy of automatic segmentations or measure rates of atrophy or to 
allow analysis of many subjects within a true stereotaxic spatial framework where 
accurate correspondences have been achieved.
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3. METHODS OVERVIEW
3.1. Subjects
Subjects for the studies described in this thesis were recruited from the following 
sources:
3.1.1. The Specialist Cognitive Disorders Clinic
This clinic is based at the National Hospital for Neurology and Neurosurgery, Queen 
Square, London. This is a tertiary referral centre, and consequently these subjects tend 
to represent younger patients and those where there is more diagnostic uncertainty than 
a typical elderly population. The subjects recruited from the clinic included individuals 
with sporadic or familial AD, FTLD and other more unusual dementias. All subjects 
underwent full clinical and neuropsychological assessment. Diagnosis was made 
according to the criteria detailed in Appendix One.
3.1.2. Familial AD project
This is an ongoing longitudinal research project following individuals with a strong 
family history of histologically-proven AD. These families have, in many cases, 
subsequently been found to have mutations in the PS1 or APP genes. Affected 
individuals and asymptomatic family members at risk of developing the disease undergo 
annual assessments. These include a full history and neurological examination, MMSE, 
detailed neuropsychology and an MRI scan. This provides valuable information about 
presymptomatic individuals who subsequently go on to develop the disease, aiding in 
the understanding of the earliest signs of the disease. This cohort currently includes 30 
affected and 48 at-risk individuals under follow-up with clinical and imaging 
assessments.
3.1.3. M1R1AD
The Minimum Interval Resonance Imaging in AD (MIRIAD) project aimed to 
determine the shortest interval required to detect volumetric change based on MRI, to 
distinguish AD subjects from normal controls. Approximately 50 individuals with 
sporadic AD and 26 control subjects were recruited and followed over a period of at 
least one year. These subjects mainly consisted of individuals over the age of 55 
attending the Specialist Cognitive Disorders Clinic and their spouses. Individuals with 
AD had MMSE scores in the range of 12-26 at baseline assessment.
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Subjects were assessed at baseline and at 2, 6, 14, 26, 38 and 52 weeks. At baseline all 
subjects underwent a full history, neurological examination, MMSE and detailed 
neuropsychology. Speed tests were performed at each visit and MMSE was repeated at 
26 and 52 weeks. At 52 weeks the initial clinical diagnosis was reassessed and 
neuropsychology was repeated. Apolipoprotein (APOE) genotyping and 
electroencephalograms (EEG) were performed on patients alone. A volumetric MR 
scan was performed at each visit. At baseline, 6 weeks and 38 weeks two scans were 
acquired on the same day. In addition, MRS was performed at weeks 2, 26 and 52. A 
subset of these subjects (n=39) were assessed and scanned at 18 months, and at two 
years (n=22).
3.1.4. Normal controls
Neurologically healthy individuals with no family history of dementia are recruited to 
act as normal controls. These are largely recruited from spouses of affected or at-risk 
study members and a number of normal volunteers. All subjects have a detailed history 
taken and undergo a neurological examination, MMSE and a brief memory test, as well 
as MRI assessment. The spouses of study subjects are usually scanned on the same day 
as their partners and therefore have as closely comparable MR acquisitions as possible.
3.1.5. Pathologically-proven cases
As a result of being a patient at the Specialised Cognitive Disorders Clinic, a number of 
patients undergo brain biopsy to determine the cause of disease (see section 3.2). In 
addition to this, a number of patients followed through clinic have agreed to a post­
mortem to accurately diagnose the cause of dementia. Such cases are valuable as 
pathological evidence of disease is the “gold standard” of diagnosis. As a result, the 
scans obtained for clinical reasons, prior to death are a valuable resource for assessing 
group separation using different methodologies as there is diagnostic certainty. Some of 
these subjects were enrolled in other studies, such as MIRIAD. Seventy-nine subjects 
have had post-mortem confirmation of disease and at least one scan. Approximately 
half of these subjects have had a number of scans although these scans are of variable 
quality and some longitudinal imaging was performed on different scanners.
All subjects gave written informed consent for involvement in imaging studies and the 
Local Ethics Research Committee had given approval for all studies.
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3.2. Clinical assessment
All subjects attending the Specialist Cognitive Disorders Clinic undergo comprehensive 
diagnostic evaluation. A full history, including family history, is taken together with a 
close informant. A full medical examination is performed as well as a neurological 
assessment. In addition, almost without exception, the following investigations are 
usually performed:
1. Detailed neuropsychology, in order to establish the nature and severity of any 
cognitive deficits.
2. Standard screening blood tests to exclude other treatable causes of cognitive 
problems such as impaired renal or liver function, B12 and thyroid function.
3. EEG to exclude seizures, or identify patterns indicative of a particular type of 
dementia.
4. Neuroimaging will typically involve at least one MRI assessment. This can 
exclude treatable causes such as tumours and subdural haematomas, or may indicate 
progressive neurodegeneration suggestive of some type of dementia pathology.
In the appropriate setting individuals may also undergo:
1. Genetic testing. In the case of individuals with a known genetic mutation in the 
family, genetic testing may be offered to determine whether a subject is carrying the 
mutation. This is supported by a full genetic counselling service.
2. Lumbar puncture and CSF analysis. This investigation can be used to detect 
inflammation due to e.g. meningitis or encephalitis, or to detect local CNS immune 
responses due to e.g. MS.
In a small number of subjects a brain biopsy may be performed. This is an invasive 
procedure which involves taking a small amount of brain tissue usually from the right 
(or non-dominant) frontal lobe. Definitive diagnosis can be obtained in this way by 
identifying a particular pathology. This technique is not used routinely, but may be 
suggested in the case of young individuals with dementia where it may be more likely 
that there are other treatable causes, especially if cerebral vasculitis is considered.
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3.3. Imaging
3.3.1. Acquisition
All images were acquired on a 1.5T Signa MRI scanner (General Electric, Milwaukee, 
Wisconsin, USA) using a spoiled gradient echo technique. Scans generally included a 
sagittal T1-weighted scout sequence, an axial dual-echo sequence (T2-weighted and 
proton-density weighted) and a Tl-weighted volumetric image (124 contiguous 1.5mm 
slices). Imaging parameters varied according to the study, and details are given in 
Appendix Three.
3.3.2. Software and processing
Digitised images were transferred to a Sun workstation (Sun Microsystems Inc., 
Mountain View, CA) for analysis. Images which were judged on visual inspection to 
show a significant intensity gradient were corrected using the N3 correction algorithm 
(Sled et al., 1998) outlined in Chapter 2 (page 71).
3.3.2.1.MIDAS
The MIDAS (Medical Information Display and Analysis System) software 
(Freeborough et al., 1996a; Freeborough et al., 1997) runs on both Unix and Linux 
platforms and is implemented in the C programming language. This software allows 
simultaneous multiplanar display of 3D data. Brain structures can be outlined using both 
semi-automated and manual techniques. The whole brain segmentation tool within 
MIDAS is semi-automated and uses interactive thresholding, together with a series of 
erosions and dilations, to isolate brain tissue from other structures such as scalp and 
dura (see Figure 1.6 and Appendix Four).
Manual segmentation of brain sub-structures, such as the hippocampus, can be 
performed using a mouse-driven cursor. The simultaneous display of orthogonal views 
allows the operator to outline the structure in the coronal view whilst the segmentation 
is updated in real time in the sagittal or axial view. This aids in decisions about where 
boundaries should be defined (see Appendix Four). Both rigid-body, rigid-body plus 
scalings and shears, and fluid registration, as described in Chapter 2, can be 
implemented within the MIDAS software.
- 9 5 -
3.3.2.2.STATA
STATA (Stata Coporation, College Station, TX, USA) is a standard statistical package 
used for producing graphs and performing basic statistical analysis. This was used for 
the majority of statistical analysis and graph production within this thesis.
3.3.2.3.SAS
SAS (SAS Institute, Inc, Cary, NC, USA) was used for some statistical analysis as it 
allows complex models to be created where variances and covariances do not have to be 
similar.
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4. CROSS SECTIONAL RESULTS USING MANUAL SEGMENTATION
4.1. Chapter introduction
The “gold standard ” of region delineation
Manual segmentation of regions within the brain is currently the “gold standard” of 
volumetric analysis. Although some semi-automated techniques exist which enable 
delineation of substructures (see Table 2.1 for examples of hippocampal segmentation), 
none of these have become completely automated and been clinically validated against 
manual measures. Assuming scanning protocols and qualities remain constant across a 
study, cross-sectional measures give a quantification of the volume of a structure which 
represents i) the amount of atrophy which has occurred up to the point at which the scan 
was taken, ii) the normal inter-individual variability in structural volume iii) errors in 
delineation caused by incorrect interpretation of protocols and iv) noise in the 
measurements made by the scanner. The first of these measures of variability can be 
caused by disease and result in some disease groups having smaller regions in specific 
areas of the brain compared with other neurological diseases or control groups. As a 
result, researchers are interested in i), taking into account ii) whilst reducing or 
eliminating iii) and iv). Some aspects of the inter-individual variability mentioned in ii) 
can be reduced by head-size correction such as TIV adjustment, however if there is an 
association between TIV and disease, this can reduce sensitivity of the measures. The 
third source of variability (manual delineation errors) can be controlled to some extent 
by repeated measurement and by time consuming careful editing. This chapter 
concentrates on the resulting “gold standard” cross-sectional volumetric measures.
Structures delineated in AD and FTLD
The subregions usually targeted for delineation are often those for which there is 
existing evidence of the region being affected in some way by the disease process. This 
evidence is most often demonstrated by either visual inspection of MR images, which 
often report reduction of specific areas of the brain (Likeman et al., 2005), or 
differences noticed between disease groups and controls within another imaging 
modality such as MRS (Kizu et al., 2004), SPECT (Matsuda et al., 2002) or PET (Valla 
et al., 2001). Other sources of evidence include pathological studies, some of which 
describe stages of disease and therefore give potential targets for early diagnosis (Braak 
et al., 1993). Within Alzheimer’s disease there are many regions which have been 
assessed; these are usually within the temporal lobe or are part of the limbic system as
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these areas are known to be affected by the disease, with specific structures affected 
early in the disease course (entorhinal cortex, hippocampus, amygdala and to a lesser 
extent the cingulate gyrus). In FTLD, studies on temporal lobe structures have also 
been performed, but owing to the heterogeneity of the clinical syndromes and the 
location of atrophy, more anterior regions such as frontal lobes have also been assessed. 
Results from some cross-sectional volumetric studies in AD are summarised in Table 
1. 1.
Limitations
There are limitations to the application or the interpretations of the results of manually- 
performed volumetric cross-sectional techniques. One is that developing reliable 
protocols can take a considerable length of time; even when such protocols have been 
developed they can take much time to apply to new scans and as a result these 
techniques are not applicable in routine clinical situations. With such studies, the 
division of two types of variation (inter-individual and prior atrophy) cannot be 
differentiated; for this serial analysis of scans is required. Although differences in sizes 
of structures have been found between many different disease groups, the diagnostic 
utility of such measures is limited by the natural variation in sizes of structures even 
following whole head size correction.
Chapter outline
In this chapter the application of new protocols to delineate structures of interest are 
described and assessed. In addition, existing protocols for the hippocampus and 
amygdala are applied to groups of pathologically-confirmed subjects.
4.2. Developing protocol for ROI delineation for cross sectional
studies
4.2.1. Introduction
MRI-based volumetric measurements have proven to be useful for quantifying regional 
cerebral atrophy occurring in AD (Fox et a l, 2001). Post-mortem studies have 
demonstrated that the atrophy in AD is associated with its defining histopathological 
changes, i.e. the accumulation of neurofibrillary tangles and amyloid plaques, 
accompanied by widespread neuronal and synaptic loss (Braak and Braak, 1991; 
Delacourte et al., 1999; Gomez-Isla et al., 1996; Rohn et al., 2001; Uylings and de 
Brabander, 2002). The implication therefore, is that the macroscopic changes of
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progressive regional and global atrophy are a closely linked consequence of the 
underlying pathological processes in AD.
As discussed earlier in Chapter 1 (see page 41), the hippocampus and entorhinal cortex 
are thought to be the earliest sites of pathological involvement in AD at least by 
neurofibrillary tangles (Braak and Braak, 1991) and many volumetric MRI studies have 
focused on these regions in sporadic and familial AD, confirming their early 
involvement in vivo (Fox et al., 1996a; Jack et al., 1999; Schott et al., 2003). More 
recently, volumetric, functional and neuropathological studies have also highlighted 
another area of the brain that appears to be involved from the very earliest stages of the 
disease: the cingulate cortex (Baron et al., 2001; Braak and Braak, 1993; Callen et al., 
2001; Fox et al., 2001; Frisoni et al., 2002a; Killiany et al., 2000; Minoshima et al., 
1997; Scahill etal., 2002).
The cingulate cortex is a structurally and functionally heterogeneous region, located on 
the medial surface of the brain. It can be subdivided into an anterior cingulate (AC) and 
a posterior cingulate (PC) cortex (Baleydier and Mauguiere, 1980; Vogt et al., 1979). 
The PC is subdivided further into the ventro-medially located retrosplenial cortex (RS) 
and the more dorsally located PC ‘proper’, (Vogt et al., 2001). The RS has particularly 
dense connections with the medial temporal lobe and demonstrates neurofibrillary 
changes at an earlier histopathological stage of AD, compared with the rest of the PCC 
(Braak and Braak, 1993; Insausti et al., 1987; Kobayashi and Amaral, 2003; Lavenex et 
al., 2002; Suzuki and Amaral, 1994). In view of these connectional and 
neuropathological differences, cingulate subregions may differ with respect to their 
amount and rate of atrophy in AD. Methods to assess regional cingulate atrophy on MRI 
accurately, may therefore provide insights into how the disease progresses and might 
ultimately be used to improve the diagnostic accuracy in very early stages of the disease 
(Baron et al., 2001; Chetelat and Baron, 2003; Kelly et al., 1997).
Previous imaging studies have demonstrated atrophy in the posterior cingulate gyrus in 
AD. However, these studies either used different criteria to delineate and subdivide the 
cingulate cortex and did not subdivide the PC (Callen et al., 2001; Killiany et al., 2000), 
or used semiautomatic techniques (Baron et al., 2001; Fox et a l, 2001; Frisoni et al., 
2002a; Scahill et al., 2002), which may lack anatomic specificity for relatively small 
structures such as the RS (Ashbumer and Friston, 2000; Crum et al., 2003; Tisserand et
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a l, 2002). Several studies have demonstrated atrophy in the AC in later stages of the 
disease but this was variably located in its rostral (Frisoni et al., 2002a; Scahill et al.,
2002) or its more caudal parts (Callen et al., 2001; Killiany et al., 2000).
The aim of this study was to develop and validate a delineation protocol, suitable for 
measuring atrophy of the different regions of the cingulate gyrus and subsequently to 
examine the regional pattern of cingulate atrophy in AD. For this purpose the volumes 
of the different cingulate regions of interest in early-onset familial AD patients were 
compared with those of age and sex-matched control subjects. Early-onset FAD patients 
were studied as the diagnosis of AD can be made with relative certainty owing to their 
known genetic risk. Moreover, in these patients co-morbidity, such as vascular disease, 
is less of a confound. It was also important to assess whether this protocol could 
reproducibly detect cortical volume reduction in smaller regions of the cingulate gyrus 
such as the retrosplenial cortex.
4.2.2. Subjects and methods 
Ten subjects with familial Alzheimer’s disease, fulfilling criteria for probable AD 
(McKhann et al., 1984) (see Appendix One) and ten healthy age- and sex-matched 
controls recruited from the spouses of patients and healthy volunteers were selected for 
this study. Eight patients had genetic testing that confirmed mutations known to be 
pathogenic for AD (six in APP; two in PS-1) and two patients came from autosomal 
dominant pedigrees with pathology in a first degree relative. Subject demographics are 
described in Table 4.1. Subjects underwent annual MRI, MMSE (Folstein et al., 1975) 
(see Appendix Two) and detailed clinical and neuropsychological assessment as part of 
an ongoing longitudinal research project. Subjects had no medical history of 
cerebrovascular or other chronic neurological disease, systemic disorders or major 
psychiatric illnesses. The study was approved by the Local Research Ethics Committee 
and all subjects had given written informed consent.
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Table 4.1 Subject demographics
Controls AD subjects
Number 10 10
M/F 5/5 4/6
Mean age, years (SD) 51.0 (8.0) 51.8 (7.4)
MMSE score /30
mean (SD) 29.9 (0.4) 10.6 (6.2)
range 29-30 5-21
4.2.2.1 Magnetic resonance imaging acquisition 
T1-weighted volumetric MR brain scans were acquired as described by the standard 
protocol in Appendix Three. The scans were acquired as 124 contiguous 1.5mm 
coronal slices and were transferred to a Sun workstation (Sun Microsystems Inc., 
Mountain View, CA) for analysis.
4.2.2.2.Image analysis 
Prior to segmentation, all scans were globally registered to the MNI 305 template using 
a six degrees of freedom registration algorithm (Mazziotta et al., 1995). This ensured all 
scans were measured in a similar orientation to improve consistency of segmentation. 
The software package MIDAS was used for all manual segmentation (see Chapter 3, 
page 95). In order to prevent potential laterality bias, each image was presented twice in 
random order; once normally and once flipped across the midsagittal line, producing 
two scans, each a mirror image of the other. This enabled the ROIs to be consistently 
measured on the right-hand side of the presented image, whether the ROI was left or 
right. This methodology is hereafter referred to as “mirror-image volumetry”. 
Measurements were performed by raters who were blind to the clinical diagnosis.
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Cingulate borders were established using a combination of intensity thresholding and 
manual tracing using a mouse-driven cursor. A threshold setting between 70-110% of 
the mean brain intensity of the whole brain was used to give consistent delineation of 
cortical grey matter from CSF and white matter. Whole brain segmentation was 
performed using a previously described technique (Freeborough et al., 1997; Schott et 
al., 2003). All regional cingulate boundaries were manually outlined and edited.
4.2.2.3. Reproducibility 
In order to assess intra- and inter-rater reproducibility, regional cingulate volumes of 10 
patients (20 hemispheres) were each measured twice by two different raters. 
Subdivisions of the posterior cingulate gyrus (PC, RS) were measured twice by one 
rater, in order to assess the feasibility of separating these two regions in the further 
analysis. Reproducibility for the whole cingulate gyrus and component parts was 
assessed by calculating within-subject standard deviations and reliability coefficients 
(Bartko, 1966; Ebel, 1951;Fleis, 1986).
4.2.2.4.Statistical analysis 
Statistical analyses were conducted using the statistical package STATA versions 6 and 
8 and Microsoft Excel 2000. In order to normalize scans for individual differences in 
head size, TIV was calculated from T1-weighted scans, using a previously described 
semi-automated technique (Whitwell et al., 2001) (see Appendix Four). The logs of the 
mean cingulate ROI volumes of the control group were regressed against the logs of the 
mean TIV measures to establish the slope of the relationship between TIV and cingulate 
volume (Free et al., 1995). The resulting coefficient (a) was used to correct the 
cingulate volumes as follows:
h i*  = hi ( t0 / t i ) a
Equation 4.1
where hj* is the adjusted cingulate volume, h\ the crude cingulate volume, tj the TIV for 
the ith individual and to the mean TIV.
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Differences in volumes between a) AD-cases and controls, b) cingulate subdivisions 
and c) left and right sides were assessed using a random effects generalised least squares 
regression model. All volumes were log-transformed (to allow estimation of percentage 
differences) and two-way interaction terms were included to investigate the extent to 
which a) the difference between AD-cases and controls differed between regions, b) the 
left-right difference differed between regions and c) the left-right difference differed 
between AD-cases and controls. Pair-wise contrasts were used to investigate 
interactions where a global interaction test was statistically significant.
4.2.3. The protocol
4.2.3.1. Cingulate borders 
The cingulate gyrus largely comprises Brodmann’s areas 24, 23, 29, 30 and part of 31 
and effort was taken to confine the analysis to these regions as much as possible. The 
rules that were applied for delineation of cingulate boundaries and subdivisions were 
based upon cytoarchitectonic, connectional and macroscopic studies (Groenewegen and 
Uylings, 2000; Ono et al., 1990; Sanz Arigita et al., 2003; Tisserand et al., 2002; 
Uylings et al., 2000; Vogt et al., 1995; Vogt et al., 2001; Vogt and Vogt, 2003). 
Indicated below is a step-by-step procedure which describes how the macroscopic MRI 
delineations of the ROI can be roughly compared with microscopically defined 
Brodmann areas. It is essential to emphasise explicitly, that macroscopic features like 
sulci often do not coincide precisely with cytoarchitectonic borders (Uylings et al., 
2005; Zilles, 2004).
4.2.3.2.Sulcal patterns and variability: Demarcation of 
cingulate boundaries
Figure 4.1 illustrates the gyri and sulci used to demarcate cingulate gyrus borders. The 
cingulate gyrus (CG) arches around the corpus callosum on the medial surface of the 
brain and is separated from this structure by the callosal sulcus (cas) (Figure 4.1.A). The 
cingulate sulcus (cs) forms the border between the cingulate gyrus and the antero- 
dorsally located paracingulate gyrus (PCG) (Paus et al., 1996; Tisserand et al., 2002) 
and the (pre)motor cortex (MC) (Figure 4.1.A). The paracingulate gyrus may be heavily 
segmented (Figure 4.1.A) or more continuous (Figure 4.1.B) and may share a common 
origin with the cingulate gyrus (Figure 4.1.C). Rostral parts of the cingulate gyrus often 
contain a shallow secondary sulcus, running parallel to the cingulate sulcus (Ono et al., 
1990) (Figure 4.1.A-B, white arrowheads). Even in these cases the cingulate gyrus was
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always easy to distinguish from the antero-dorsally located paracingulate gyrus. The 
cingulate sulcus continues up until the appearance of the marginal ramus (mr), from 
whence it continues as the splenial sulcus (sps) (Vogt et al., 1995) (this has also been 
termed subparietal sulcus (Ono et al., 1990)) (Figure 4.1.A). The splenial sulcus is 
highly variable in its pattern and often contains extensions directed towards the corpus 
callosum, which were included in the analysis (Figure 4.1.B-C, black arrowheads). The 
cingulate sulcus and splenial sulcus were sometimes interrupted and in such cases the 
shortest possible line between the interrupted segments of the sulcus was drawn (see for 
example Figure 4.1.C, curved arrow).
As the cingulate gyrus curves around the anterior part of the corpus callosum a 
transition takes place from Brodmann’s area 24 to 25. In accordance with Tisserand 
(Tisserand et al., 2002), the most caudal coronal slice on which the inner curvature of 
the genu of corpus callosum was visible was taken as the ventral-posterior border 
between areas 24 and 25 (Figure 4.1.B). In this manner area 25 was approximately 
excluded from the analysis. Area 25 is a more simple cortical structure than 24 (Vogt et 
al., 1995; Vogt et al., 2004). Posteriorly, the cingulate gyrus curves around the 
splenium of the corpus callosum where it ventrally borders the parahippocampal cortex. 
The most ventral axial slice on which the curvature of the splenium of the corpus 
callosum was visible has been taken as the macroscopic ventral border of the cingulate 
gyrus with the parahippocampal cortex, since no cingulate cortex is present below this 
edge (Vogt et al., 2001) (Figure 4.1.B).
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Figure 4.1 Demarcation of the cingulate gyrus.
(A-C) Sagittal sections o f MRI scans o f 3 representative brains indicating the sulci, 
gyri, and reference points used to demarcate cingulate gyrus borders. (D) Coronal, 
(E,F) axial, and (G, H) sagittal sections, demonstrating cingulate gyrus borders within 
the relevant sulci. The asterisk indicates the site where the cingulate sulcus, splenial 
sulcus, and marginal ramus meet. Ac-line and pc-line in C: cutoff sections through the 
posterior edge of the anterior commissure (ac) and the posterior edge of the posterior 
commissure (pc) respectively, used for subdividing the cingulate gyrus, a/r =  
anterior/rostral; cas =  callosal sulcus; CG =  cingulate gyrus; cs = cingulate sulcus; d 
=  dorsal; MC =  (pre)motor cortex; mr =  marginal ramus; p/c = posterior/caudal; PCG 
=  paracingulate sulcus; sps =  splenial sulcus; v =  ventral: 31 =  Brodmann area 31.
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Cingulate areas located dorsal to the corpus callosum were delineated on coronal slices 
(Figure 4.1.D), whereas cingulate areas located anterior and posterior to the corpus 
callosum were delineated on axial slices (Figure 4.1.E, F) respectively. On the right side 
of Figure 4.1.D-F the cortical grey matter has been automatically delineated from CSF 
and white matter using a threshold setting between 70-110% of the mean brain intensity 
of the whole brain. On the left side of the figures the cingulate gyrus has been 
delineated. Cingulate gyrus borders were always set between the ventral and dorsal 
banks of the callosal sulcus and the cingulate sulcus (Sanz Arigita et al., 2003). The 
grey matter of the splenial sulcus was not included in the analysis (Figure 4.1.F). The 
splenial sulcus is surrounded by Brodmann’s area 31 (Vogt et al., 2001). Effort was 
taken to exclude the major part of area 31, since it is also located on the parasplenial 
lobules postero-dorsal to the cingulate gyrus (Vogt et al., 2001), which was not a region 
of interest (illustrated on sagittal sections in Figure 4.1.G-H). However, a small part of 
area 31 is located on the medial surface of the cingulate gyrus and cannot be delineated 
macroscopically (Figure 4.1.G, approximate border indicated by dotted line). Figure
4.1.G is a more medial section of the brain in Figure 4.I.C. In order to improve 
consistency the entire medial surface of the cingulate gyrus was included in the analysis 
and thus also included a small part of area 31. The grey matter located within the 
splenial sulcus was removed in sagittal slices (Figure 4.1.H). Note that in Figure 4.1.H 
extensions of the splenial sulcus directed towards the corpus callosum were included in 
the analysis (black arrowheads).
4.2.3.3.Cingulate ROI subdivisions 
The most caudal coronal slice on which the anterior commisure (ac) was visible (Figure
4.1.C, ac-line) and the most caudal coronal slice on which the posterior commisure was 
visible (Figure 4.1.C, pc-line) were used to subdivide the cingulate gyrus. The 
orientation of the coronal slices in the scans corresponds with the ac- and pc-line in 
Figure 4.I.C. The resulting subdivision of the cingulate gyrus and its borders within the 
sulci, together with the approximate location of the relevant Brodmann’s areas, is 
indicated in Figure 4.2. Anterior parts of the cingulate gyrus were subdivided into a 
rostral ROI (termed rostral AC (RAC), located anterior to the ac-line) and a caudal ROI 
(termed caudal AC (CAC), located between the ac- and pc-line) (Figures. 4.2.A-C). 
Although both anterior cingulate regions approximately correspond to Brodmann’s area 
24, more recent studies have demonstrated a number of cytological and functional 
differences between them justifying a subdivision (Vogt et al., 2003; Vogt and Vogt,
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2003). Although the cingulate and paracingulate gyrus share a common origin in this 
specific brain a slight indentation is visible in the medial part of the grey matter, which 
was taken as the border between these regions (Figure 4.2.B, arrow). The posterior 
region of the cingulate gyrus (located caudal to the pc-line) was divided into a posterior 
cingulate ROI (termed PC) and the retrosplenial cortex (RS) (Figure 4.2.A, D, E). The 
border between the PC and the RS is the only border that can be delineated objectively 
and macroscopically (Vogt et al., 2001). The retrosplenial cortex corresponds with 
Brodmann’s areas 29 and 30 and is located in the depth of the callosal sulcus and does 
not appear on the medial surface of the cingulate gyrus, which comprises area 23 
(Figure 4.2.D-E). Thus, when manually indicating the border of the RS (black line in 
Figure 4.2.D-E) care was taken not to include any medially located voxels.
^ c a u d il AC
29/30
Figure 4.2 Subdivisions o f the cingulate gyrus.
(A) Sagittal, (B-D) coronal, and (E) axial views of the same MRI scan illustrating the 
location of the cingulate subdivisions together with approximate corresponding 
Brodmann areas. (A) The orientation and location of the sections in 2B-E  have been 
indicated. (B, C) Coronal sections through the rostral and caudal AC respectively. (D) 
Coronal and (E) axial section through the PC and RS. Abbreviations are the same as in 
Figure 4.1.
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4.2.4. Results
4.2.4.1 .Reproducibility 
Reproducibility, expressed in terms of reliability coefficient and SDs as percentages are 
given in Table 4.2. Intra-and inter-rater reliability coefficients were comparable and 
ranged from 91.4%-99.4%. Considering the high reproducibility for the PC and the RS 
(>91.9%, (Donner and Eliasziw, 1987)), these two regions were fitted separately into 
the statistical model and not pooled together.
Table 4.
Cingulate
Rostral AC
Caudal AC
PC + RS
PC
RS
RC = reliability co-efficient, AC -  anterior cingulate, PC = posterior cingulate, RS is 
retrosplenial cortex
2 Reproducibility o f cingulate segmentation.
Intra-rater reproducibility Inter-rater reproducibility
Left Right Left Right
RC(%) SD(%) RC(%) SD(%) RC(%) SD(%) RC(%) SD(%)
99.4 2.4 98.5 2.8 97.9 4.1 99.1 2.2
97.8 5.6 99.1 2.7 93.5 9.3 99.2 2.5
97.9 3.9 97.8 3.8 98.8 2.8 98.4 3.2
96.2 7.9 98.5 4.4 94.9 9.2 98.9 3.8
94.4 10.4 98.3 5.1 * * * *
91.9 9.1 92.4 8.3 * * * *
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4.2.4.2. Cingulate subdivision volumes 
The TIV corrected cingulate ROI volumes for both groups are shown in Figure 4.3.
Left
AD
Right
AD
Left
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Right
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Cingulate
gyrus
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PC 3500
CO 3000
E
E, 2500
8
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3
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8 500
i— 0
Mean 7687 5613 9361 6845 2202 1260 2463 1344
SD 1738 1591 908 1281 396 621 525 513
Rostral
AC
RS
Mean 3292 2459 4459 3589 348 264 366 297
SD 1170 928 458 1210 70 90 97 75
Caudal
AC
Mean 1741
SD 481
1479
280
2006
248
1468
337
Figure 4.3 Volumes of the cingulate gyrus and its subdivisions in controls (C) and AD 
subjects.
Mean values (SD) and the scatterplots are displayed. PC- posterior cingulate, AC  =  
anterior cingulate, RS =  retrosplenial cortex.
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There was statistically significant evidence of a group by region interaction (i.e. that the 
magnitude of the difference between AD-cases and controls differed between regions 
combining over hemispheres) (p=0.0025), a hemisphere by region interaction 
(p=0.034), but no evidence of a group by hemisphere interaction (i.e. no evidence that 
the case-control difference differed between the left and right side combining over 
regions) (p=0.8). Accordingly, the two-way interaction between group and hemisphere 
was dropped from the model effectively pooling the differences between AD-cases and 
controls over left and right sides. All of the cingulate ROIs were significantly smaller in 
cases compared to controls with the difference in the PC being significantly larger than 
that in each of the other cingulate regions (p<0.01) (see complete group separation on 
Figure 4.3): rostral AC: 22.5% (95% Cl 6.2-35.9%) smaller, p=0.009; caudal AC: 
20.7% (95% Cl 4.1-34.4%) smaller, p=0.017; PC: 44.1% (95% Cl 32.4-54.8%) smaller, 
p<0.001; RS: 21.5% (95% Cl 5.1-35.1%) smaller, p=0.012 (Figure 4.3).
On average, cingulate volumes were larger on the right side in all regions in both AD- 
cases and controls, with some evidence (p=0.034) that the magnitude of the left-right 
difference varies between regions. This left right difference was greatest for the rostral 
AC and this was the only region where the difference was statistically significant
(p<0.001).
Despite the fact that mean volumes for all four cingulate ROIs differed significantly 
between cases and controls, Figure 4.3 shows that there was considerable group overlap 
which was least in the posterior cingulate ROI. Sensitivity and specificity values for the 
PC were calculated to determine how well these data might classify individuals into 
their diagnostic groups. With a cut-off value of 1880mm3 for the mean of the left and 
right PC, sensitivity was 90%, specificity 100%, positive predictive value 100% and the 
negative predictive value was 91%.
The wide range of MMSEs in the patient group raises the possibility that the results are 
driven by the very severe cases. To investigate this, Pearson correlation coefficients 
between MMSE scores and cingulate volumes were calculated. None of the volumes of 
the cingulate ROIs showed a correlation with MMSE scores that was statistically 
significant or large enough to support such a hypothesis: rostral AC r = -0.36 (p = 0.38); 
caudal AC r = -0.35 (p = 0.39); PC r = -0.23 (p = 0.59); RS r = 0.04 (p = 0.93).
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4.2.5. Discussion
Using an MR-based manual delineation protocol for the cingulate gyrus all four 
cingulate ROIs (RAC, CAC, PC, RS) showed significant atrophy in familial AD 
patients compared with controls. Within the cingulate gyrus the volume reduction was 
the greatest in the PC ROI. The analysis detected previously described left-right 
hemisphere asymmetries in cingulate volumes (right>left), which accords with other 
studies (Paus et al., 1996; Watkins et al., 2001). The severity of the volume loss did not 
differ between left and right cingulate regions in the AD subjects.
A potential source of variability in region-based manual outlining results from difficulty 
in accurately correlating cytoarchitectonic borders in histological sections with gross 
anatomical landmarks on MR-scans in vivo. Often the macroscopic sulci do not coincide 
with borders of microscopically cytoarchitectonical defined cortical areas (Uylings et 
al., 2005; Zilles, 2004). A high degree of inter-individual variability in sulcal patterns, 
as is the case with the cingulate gyrus, further adds to this problem (Paus et al., 1996; 
Vogt et al., 1995). Although manual demarcation of brain regions is time consuming it 
is still the “gold standard” of region of interest measurement on MRI (Crum et al., 
2003; Tisserand et al., 2002). This manual demarcation protocol was standardised as 
much as possible and yielded high inter- and intra-rater reliability coefficients, ranging 
from 91.9-99.4%. The landmarks selected to define the borders of the cingulate gyrus 
and its subdivisions in the present study were based on extensive examination of 
morphological and cytoarchitectonic studies and the analysed cingulate subregions 
approximate to Brodmann’s areas 24 (rostral + caudal AC), 29+ 30 (RS) and 23 (PC).
Separate evaluation of these regions in AD may be relevant taking into account the fact 
that neurofibrillary tangles in the RS are present in relatively early neuropathological 
stages of AD and precede pathological changes in area 23 and 24 (Braak and Braak, 
1993). These tangles are not present in healthy controls and therefore may represent pre- 
clinical stages of AD (Ma et a l, 1994). Furthermore, in non-human primates, rostral 
area 24 and the RS have dense reciprocal connections with the entorhinal and 
(para)hippocampal cortex, whereas caudal area 24 and area 23 do not (Insausti et al., 
1987; Kobayashi and Amaral, 2003; Lavenex et al., 2002; Suzuki and Amaral, 1994). 
Considering the differences in medial temporal lobe connections and temporal patterns 
of neuropathological involvement, it is interesting that not the RS but the PC ROI (~
- I l l  -
area 23) showed the greatest volumetric loss in the present study. The apparent selective 
vulnerability of area 23 in AD cannot be explained as secondary to deafferentiation as a 
result of medial temporal lobe damage. Rather, this selective volume loss seems to be 
related to neurodegeneration, since a number of neuropathological studies have 
demonstrated severe neuron losses in area 23 in those cases with clinically established 
symptoms of AD (Vogt et al., 1990; Vogt et al., 1998).
The PC ROI was capable of separating AD subjects from controls with a high 
sensitivity (90%) and specificity (100%). Measurements of the medial temporal lobe 
have found similar levels of sensitivity and specificity (Juottonen et al., 1999; Killiany 
et al., 2002; Scheltens et al., 1992). Although the number of subjects in the present 
study is small, this region seems promising as a diagnostic indicator of AD. Previous 
macroscopic MRI studies have demonstrated posterior cingulate cortex atrophy in AD 
patients using semi-automated techniques (Baron et al., 2001; Frisoni et al., 2002a; 
Scahill et al., 2002). According to these authors, the atrophy appeared to predominate 
around the splenial sulcus, including the dorsal part of the posterior cingulate gyrus, 
which partially corresponds with the findings. Atrophy of the rostral (but not the 
caudal) AC was not evident until later stages of the disease (Frisoni et al., 2002a; 
Scahill et al., 2002). Automated methods require spatial normalization and smoothing 
techniques and are probably less suitable for analysing highly variable cortical regions 
(AC) or small areas (e.g. RS) (Ashbumer and Friston, 2000; Crum et al., 2003; Mosconi 
et al., 2005). A manual region of interest study has shown significant atrophy of the 
caudal AC and the PC in AD but did not find any significant atrophy in the rostral AC. 
However, this study included the paracingulate gyrus in the AC and did not subdivide 
the posterior cingulate gyrus and thus did not assess the retrosplenial cortex separately 
(Callen et al., 2001). Many of the studies detailed in the literature feature disease 
groups which have been clinically defined. In this study, there was confirmation of 
disease in most cases and although the groups are not large, there is a high level of 
confidence in the diagnosis.
In the present study a manual delineation protocol to measure atrophy of four different 
cingulate regions on MRI has been described and validated. The present study is the 
first to find significant atrophy of all four cingulate regions in Alzheimer’s disease. The 
delineation protocol has also been shown to be capable of detecting atrophy in smaller 
regions of the cingulate gyrus, such as the retrosplenial cortex. To my knowledge, this
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study is the first to assess separately the volumes of the posterior cingulate and the 
retrosplenial cortex. Considering the connectional and functional heterogeneity of these 
areas, regional cingulate atrophy measures may aid in understanding the way in which 
the disease begins and progresses and may also help in the search for diagnostic 
markers of early AD.
4.3. Differences between AD and FTLD in the hippocampus and
amygdala
4.3.1. Introduction
In the elderly population AD is the most common cause of dementia (Dawbam and 
Allen, 2001). However in patients presenting with dementia under the age of 65, the 
prevalence of FTLD approximates that of AD (Ratnavalli et al., 2002). Differentiating 
AD from FTLD is important as prognosis and management is different. A diagnosis of 
AD is suggested if memory decline is an early clinical feature, while prominent 
behavioural and language dysfunction suggests a diagnosis of FTLD. However, recent 
clinicopathological studies have identified cases of FTLD with prominent episodic 
memory loss (Graham et al., 2005), and a frontal presentation of AD has been described 
(Galton et al., 2000; Johnson et al., 1999). The overlap in clinical features and 
diagnostic uncertainty, especially in the early stages has led to interest in imaging to 
help differentiate FTLD from AD (Koeppe et al., 2005).
Prominent hippocampal atrophy has been demonstrated to be the signature pattern of 
atrophy on MRI in AD (Callen et al., 2001; Convit et al., 1993; Jack et al., 1997; 
Krasuski et al., 1998; Lehericy et al., 1994) (see Table 1.1 for a review of cross- 
sectional measures from the literature), while more anterior temporal losses including 
severe amygdala atrophy has been suggestive of FTLD (Boccardi et al., 2002; Boccardi 
et al., 2005; Chan et al., 2001b; Galton et al., 2001). These findings support the clinical 
presentations since hippocampal damage is linked to loss of episodic memory (Vargha- 
Khadem et al., 1997) and amygdala damage has been associated with emotional and 
behavioural dyscontrol (Boccardi et al., 2005; Rosen et al., 2002c).
Pathology remains the “gold standard” in the diagnosis of AD and FTLD. While 
several MRI studies have examined the ability of volumetric measures to differentiate 
clinically diagnosed FTLD from AD (Boccardi et al., 2002; Boccardi et al., 2003; Chan 
et al., 2001b; Frisoni et al., 1999; Galton et al., 2001; Laakso et al., 2000a; van de Pol
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et al., 2006) in the absence of histopathological confirmation there is uncertainty in 
clinical diagnostic accuracy, with a potential for circularity in study design. Therefore, 
this study assessed the value of hippocampal and amygdala measurements in separating 
AD and FTLD from controls and from one another, in a completely pathologically 
defined cohort of AD and FTLD cases.
4.3.2. Subjects and methods: Use of PM/biopsy cases 
4.3.2.1.Subjects
Ten pathologically confirmed AD patients, and 17 pathologically confirmed FTLD 
patients (five Pick’s disease (PiD), eight with ubiquitin-only immunoreactive neuronal 
inclusions (FTLD-U), three tau positive with tau exon 10+16 mutations (tau exon 
10+16), and one dementia lacking distinctive histology (DLDH)) were included in this 
study. Pathological diagnosis was based upon the most recent consensus criteria 
(McKhann et al., 2001). Pathological confirmation by biopsy rather than post-mortem 
was available in four of the AD and two of the FTLD subjects.
Medical records were reviewed and the clinical presentation, disease duration and 
MMSE score (Folstein et al., 1975) at the time of the MRI study were recorded. A 
family history of dementia was present in all tau exon 10+16 cases, two FTLD-U cases 
and one AD case. The FTLD patients were classified using established clinical criteria 
into fvFTD (n=12), SD; (n=4) and PNFA (n=l) (Neary et al., 1998). None of the FTLD 
patients had any clinical evidence of motor neuron disease. Ten healthy age-matched 
controls without evidence or symptoms of cognitive decline were also included in the 
study. Subject demographics are reported in Table 4.3.
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Table 4.3 Subject Demographics.
Controls AD FTLD
Number 10 10 17
M/F 6/4 7/3 11/6
Age (years):
mean 55.9 57.0 56.4
(standard deviation) (11.1) (8.8) (10.2)
MMSE (/30):
mean 28.5 14.7 21.6
(standard deviation) (1.4) (5.7) (6.5)
Sporadic /Familial NA 9/1 12/5
Mean disease duration NA 3.1* 3.5
(years) at time of scan (0.7) (2.0)
Mean time from scan to
death (years) in those 
coming to post-mortem
(6 AD and 15 FTLD)
NA 3.7$
(2.3)
4.5$
(2.1)
Key
* Disease duration not available in one AD patient
$ data only available for those subjects that came to autopsy (6 AD and 15 FTLD cases)
4.3.3. Image Analysis
4.3.3.1.Image Acquisition 
Images were acquired in the standard way as described in Appendix Three. If an 
individual had more than one diagnostic scan, the earliest scan was chosen for inclusion 
in the study.
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4.3.3.2.Manual Segmentation 
The software package MIDAS was used for all image analysis (see page 95). Prior to 
tracing all scans were registered to a standard template (MNI 305) (Mazziotta et al., 
1995). In addition, mirror-image volumetry was used such that traces were performed 
on the right-hand side of the presented image (see page 101). The operators were 
blinded to the subject’s identity, diagnosis, and left-right orientation of the scan. 
Amygdala (Whitwell et al., 2005b) and hippocampal (Scahill et al., 2003) 
measurements were performed (see Appendix 4).
4.3.3.3.Statistical Analysis 
Data were analysed using STATA version 8, and SAS (see page 96). Volumes were 
adjusted for head-size differences using the TIV derived according to a previously 
described protocol (Whitwell et al., 2001) (see Appendix Four). Standardisation was 
carried out separately for the amygdala and hippocampus. For both structures this 
assumed a linear relationship between log transformed values and log TIV with the 
slopes of the associations estimated from left and right measurements in an expanded 
control group to improve precision (see Equation 4.1) (Free et al., 1995).
In order to minimise the number of hypothesis tests carried out, a structured analysis 
was carried out using linear mixed models with interaction terms, and disease group- 
specific unstructured covariance matrices. Such an approach extends Analysis of 
Variance by removing the requirement for homogeneity of variances. Such models were 
used to make comparisons between geometric mean volumes by i) disease group (FTLD 
vs. AD vs. controls in the primary analysis), ii) amygdala vs. hippocampus and iii) 
structural laterality. Contrasts of mean levels were used to estimate effect sizes and 
Wald tests used to test the statistical significance of interaction terms and main effects. 
Models of this type were also used to make comparisons between geometric mean 
volumes by FTLD subtype. Because unstructured covariance models do not facilitate 
comparison of variances between disease groups and regions, direct product covariance 
matrices (amygdala/hippocampus ® left/right side) were used to compare variances 
between i) disease groups, ii) amydgala and hippocampus and iii) structural laterality. A 
likelihood ratio test was used to compare the fit of a model where disease group specific 
amygdala and hippocampal variances were assumed constant with one where they were 
allowed to be different. A similar approach was used to compare left and right sided 
variances. In a similar comparison of variances by disease groups left and right side
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variances were assumed to be the same. In addition sensitivities for certain specificity 
cut-offs were calculated to test the relative utility of both structures in discriminating 
subject groups.
4.3.4. Results
There was no significant difference in age or gender distributions between the FTLD, 
AD and control groups (Table 4.3). MMSE scores were significantly higher in the 
control group than both the AD and FTLD groups (p<0.003), and significantly higher in 
the FTLD group than the AD group (p=0.03). There was no significant difference in 
disease duration and time to death between the FTLD and AD groups.
Hippocampal and amygdala volumes from the three subject groups are shown in Table 
4.4 and displayed as scatter-plots in Figure 4.4 and Figure 4.5. Relationships between 
the hippocampus and amygdala in each of the three subject groups on left and right 
sides are shown in Figure 4.6 and Figure 4.7 respectively. Analysis using linear mixed 
models on log transformed values showed no evidence (p > 0.2 all comparisons) that 
proportionate differences in volumes between disease groups differed between 
amygdala and hippocampus and/or between hemispheres, or that proportionate 
differences in volumes between hemispheres differed between amygdala and 
hippocampus. Averaging over left and right regions the geometric mean amygdala and 
hippocampal volumes were respectively 15.0% (95% Cl 4.2%, 24.5%) and 16.4% (95% 
Cl 5.9%, 25.6%) lower in AD than controls. In FTLD the equivalent differences were 
43.0% (95% Cl 31.9%, 52.6%) in the amygdala and 36.1% (95% Cl 27.5%, 43.7%) in 
the hippocampus. The difference in volumes between the FTLD and AD groups was 
statistically significant (p<0.01 in both regions).
There was no evidence (p>0.2) that the direct product unstructured covariance matrices 
did not provide a good fit to the data. Such models demonstrated that variability in 
hippocampus and amygdala volumes relative to mean levels was greater in the FTLD 
group than the AD group, and greater in patients than controls (p<0.001 for all cases vs. 
controls; p=0.02 for AD vs. FTLD pooling over structures) as suggested by the 
coefficients of variation reported in Table 4.4. There was no evidence of differences in 
variability between amygdala and hippocampal volumes (pooling over left and right and 
disease groups) or between structures on the left and right (pooling over disease groups 
and structures).
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As anticipated from the comparison of means, all four volumes (left and right 
hippocampus, and left and right amygdala) could significantly discriminate AD (vs. 
controls), and FTLD (vs. controls and vs. AD) using regression models (p< 0.05). When 
the specificity was set at 80%, the sensitivity for detection of AD subjects from controls 
ranged from 65% in the right amygdala to 80% in the left amygdala with both 
hippocampal measures falling within this range. In comparison, the sensitivity for 
detection of FTLD from controls was over 90% in all structures and reached 100% in 
the right hippocampus. In addition, for a specificity of 80% the right amygdala could 
discriminate FTLD and AD subjects with a sensitivity of 88% whilst the sensitivity for 
the other three structures ranged from 50 to 71%.
- 118-
Table 4.4 Mean, (95% Cl), SD, and CV (100*(SD/mean)) o f volumes of TIV adjusted hippocampus and amygdala in controls, AD and FTLD subjects.
Volume mm3 Controls 
Left Right
AD
Left Right
FTLD
Left Right
Amvsdala 
Mean (95% Cl) 
SD 
CV
1555 (1491, 1619) 
89 
5.7
1618(1514, 1721) 
144 
8.9
1314(1128, 1500) 
260 
19.8
1415 (1258, 1573) 
221 
15.6
940(747, 1133) 
375 
39.9
976 (830,1122) 
283 
29.0
Hippocampus 
Mean (95% Cl) 
SD 
CV
2898 (2723,3073) 
245 
8.5
2967 (2727, 3207) 
336 
11.3
2410 (2088, 2732) 
449 
18.6
2534 (2276, 2792) 
361 
14.2
1883 (1643,2123) 
466 
24.7
1962 (1722, 2203) 
468 
23.9
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Controls AD
Figure 4.4 Left amygdala and hippocampal volume in controls AD and FTLD.
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Figure 4.5 Right amygdala and hippocampal volume in controls AD and FTLD.
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Figure 4.6 Left hippocampal and amygdala volume in controls, AD and FTLD.
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Figure 4.7 Right hippocampal and amygdala volume in controls, AD and FTLD.
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4.3.4.1. Subgroups of FTLD 
The FTLD group was subdivided pathologically into FTLD-U, tau exon 10+16, PiD and 
DLDH. Owing to the presence of only one subject in the DLDH group, this group was 
removed from the pathological subgroup analysis. There was no evidence for differences 
in mean hippocampal or amygdala volumes between the three remaining groups (p>0.5).
The FTLD group was also subdivided clinically into fvFTD, SD and PNFA. The amygdala 
and hippocampal volumes in these subgroups are shown in Figure 4.8 and Figure 4.9. 
Owing to there being only one individual in the PNFA group, this group was removed from 
further analysis. There was evidence that the ratio of geometric mean volumes in the two 
subtypes differed between the amygdala and hippocampus (p=0.018) and by hemisphere 
(p=0.0004). On average the left hippocampus was 14% smaller in SD than in fvFTD, 
whilst the right hippocampus was 37% larger. On average the left amygdala was 39% 
smaller in SD than in fvFTD, whilst the right amygdala was only 1% smaller. These 
differences can be seen graphically in Figure 4.10 and Figure 4.11 which represent area per 
slice along the length of the union of the hippocampal and amygdala regions. These profiles 
also show the relatively greater involvement of anterior regions compared with posterior 
regions in both fvFTD and SD, compared to AD and controls.
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Figure 4.8 Volumes of left hippocampus and amygdala in clinical subtypes of FTLD.
FTD is the frontal variant of FTLD, SD is semantic dementia and PNFA is progressive non-fluent aphasia.
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Figure 4.9 Volumes of right hippocampus and amygdala in clinical subtypes of FTLD.
FTD is the frontal variant of FTLD, SD is semantic dementia and PNFA is progressive non-fluent aphasia.
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Figure 4.10 Left amygdalo-hippocampal complex area profiles along the posterior to anterior axis (sagittal view) in controls, AD and two 
clinical phenotypes of FTLD.
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Figure 4.11 Right amygdalo-hippocampal complex area profiles along the posterior to anterior axis (sagittal view) in controls, AD and two 
clinical phenotypes of FTLD.
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4.3.5. Discussion
This study examined the patterns of amygdala and hippocampal atrophy in pathologically 
confirmed cases of FTLD and AD. Volumes of both structures were reduced in both the 
FTLD and AD groups compared with controls, consistent with previous studies (Boccardi 
et al., 2002; Boccardi et al., 2003; Callen et al., 2001; Chan et al., 2001b; Frisoni et al., 
1999; Jack et al., 1997; Krasuski et al., 1998; Lehericy et al., 1994). In addition, the 
volumes of both structures were smaller in FTLD than in AD; the amygdala was reduced 
by 43% and hippocampus by 36% in FTLD compared with controls, compared with only 
15% and 16% respectively in AD. Atrophy of the hippocampus is clearly not specific to 
AD. However, the pattern of atrophy (see Figure 4.10 and Figure 4.11) varies between 
groups. Indeed, severe patterns of amygdala and hippocampal atrophy especially if 
associated with severe amygdala atrophy or asymmetry are suggestive of FTLD.
Previous MRI studies have found greater or similar degrees of hippocampal atrophy in AD 
compared to FTLD (Frisoni et al., 1999) although atrophy was predominantly located in the 
more anterior portions of the hippocampus in FTLD (Laakso et al., 2000a). However, 
severe patterns of focal lobar atrophy are observed in FTLD at post-mortem; gyri are often 
so thin that they have a “knife-blade” appearance (Gustafson et al., 1992). So it is perhaps 
unsurprising that medial temporal lobe structures such as the amygdala and hippocampus 
may be severely affected. Furthermore, hippocampal sclerosis is common in FTLD 
(Josephs et al., 2004). The finding of smaller amygdala volumes in FTLD than AD is 
consistent with data from clinically defined groups (Chan et al., 2001b; Galton et al., 2001; 
Whitwell et al., 2005b). Another study reported the amygdala to be larger in FTLD than 
AD although the AD group in that study was nearly a decade older than the FTLD group 
(Boccardi et al., 2002).
Measurements of both the hippocampus and amygdala provided good discrimination of 
FTLD and AD subjects from controls. The specificity of 80% and sensitivity of 75% for 
discrimination of AD from controls using the hippocampal (left) volume is similar to 
previous hippocampal studies (Xu et al., 2000). The discrimination of FTLD subjects from 
controls was achieved with a specificity of 80% and sensitivities greater than 90% for all 
structures, reaching 100% for the right hippocampus, which is superior to that found in
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some studies (Frisoni et al., 1999). Comparisons between studies are difficult however 
because of differences between subject groups (especially since pathology is often lacking) 
and differences in severity of disease at the time of the scan. Previous studies have found 
poor discrimination between AD and FTLD using single volumetric measures (Frisoni et 
al., 1999; Whitwell et al., 2005b). This study however suggested that for a specificity of 
80% both the right hippocampus and amygdala could differentiate FTLD from AD with 
sensitivities over 70%. This improved discrimination may be a result of this study utilising 
a pathologically confirmed cohort, as recent studies suggest that only between 63 and 79% 
of pathologically-confirmed FTLD cases are correctly classified clinically on their first 
assessment (Knopman et al., 2005; Rosen et al., 2002b).
In the FTLD subgroup analysis, a clear differential pattern of amygdala and hippocampal 
atrophy by pathological subtype was not found. This is consistent with a previous study 
that showed medial temporal lobe atrophy in all three pathological subtypes (Whitwell et 
al., 2005a). However, when dividing the FTLD group by clinical subtype, marked 
differences in the patterns of atrophy were found. First, the SD patients showed a more 
asymmetrical pattern of atrophy than the fvFTD group with much greater atrophy on the 
left, and second, the SD group had disproportionately smaller amygdala volumes compared 
with the hippocampus than the fvFTD group. This is consistent with previous volumetric 
studies on clinically diagnosed patients that have shown asymmetric temporal lobe atrophy, 
with particularly severe amygdala atrophy, in SD patients (Chan et al., 2001b; Gal ton et al., 
2001; van de Pol et al., 2006; Whitwell et al., 2005b), yet relatively symmetrical atrophy in 
patients with fvFTD (Boccardi et al., 2002; Rosen et al., 2002a; van de Pol et al., 2006). 
These findings support the idea that the clinical phenotype in FTLD reflects the pattern of 
tissue loss more closely that the molecular pathology of the diseases. Both SD and fvFTD 
also showed relatively greater involvement of anterior than posterior regions of the 
amygdalo-hippocampal structure. This anterior-posterior gradient has been previously 
reported in SD patients (Chan et al., 2001b).
The main strength of this study is the pathological confirmation of disease in all cases. 
However, a limitation of using a pathologically-defined patient group is that the study may 
be biased towards cases which were difficult to diagnose during life. Another limitation
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with all studies of this type is that of accurately matching AD and FTLD patients for 
disease severity. Although the MMSE has been useful as a measure of disease severity in 
AD, it is a less comparable measure in FTLD. Owing to this potential problem the disease 
duration of all patients was also assessed. Both the AD and FTLD groups had similar mean 
disease duration of approximately three years. Finally, the patient groups were also 
relatively small in this study. Therefore more subtle differences that may exist in 
hippocampal and amygdala atrophy between AD and FTLD, and between the pathological 
and clinical subgroups of FTLD, may not have been detected.
In conclusion, this study has shown that both the hippocampus and amygdala are reduced in 
volume in pathologically confirmed cases of AD and FTLD compared with controls, with 
the greatest loss shown in the FTLD subjects. This demonstrates firstly that hippocampal 
atrophy is not specific to AD, and secondly that severe or asymmetrical patterns of 
amygdala and hippocampal atrophy suggest pathological FTLD. Both hippocampus and 
amygdala provide good discrimination of disease groups from controls, and between 
disease groups.
4.4. Chapter conclusions
This chapter describes the development of new segmentation protocols and their 
application to a small group of Alzheimer’s disease and control subjects at one imaging 
time-point. The chapter further describes the application of existing protocols in a group of 
post-mortem confirmed AD, FTLD and age-matched controls. Although there are 
limitations with this type of single time-point analysis, principally as it is confounded by 
inter-individual variability, this chapter demonstrates that the use of cross-sectional 
measures is reliable and can find differences in volumes of structures in different diseases. 
For diagnosis, the ideal situation is that subjects only have scanning at one time-point as 
diagnosis can potentially be reached quickly, and therefore it is important to understand the 
utility and limitations of such imaging techniques.
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5. LONGITUDINAL REGIONAL CHANGE USING MANUAL SEGMENTATION
5.1. Chapter introduction
Adding another dimension to cross-sectional change
As assessed in Chapter 4, cross-sectional volumetric measures of regions of interest can 
reveal patterns of atrophy which may i) distinguish between different diseases (Chan et al, 
2001b) ii) give quantitative information regarding the areas of the brain that have 
degenerated prior to the acquisition of the MR scan and iii) predict which subjects may 
clinically progress in the future (Jack et al., 2000; Killiany et al., 2000). However there are 
a number of problems associated with cross-sectional analysis. First, there is a large degree 
of inter-individual variation which confounds the interpretation of individual results even 
following the application of procedures which allow adjustments for head size (Jack et al., 
1998). Secondly, information from one time-point gives no real or accurate information 
regarding the progression of disease and the rate of this change. Four dimensional analyses 
(the additional dimension being time) of regions of interest can give this information and 
therefore aid in the understanding of the underlying disease processes and provide potential 
markers of disease progression.
The “gold-standard” technique for measuring longitudinal change
Much like cross-sectional analysis, the “gold standard” of longitudinal analysis of 
substructures of the brain is manual delineation; whereas whole brain change is often 
calculated using semi-automated techniques (Fox and Freeborough, 1997; Jack et al., 2004; 
O'Brien et al., 2001). The majority of published results of longitudinal brain substructure 
change have applied cross-sectional delineation protocols to both baseline and follow-up 
scans (Du et al., 2004; Jack et al., 1998; Jack et al, 2004; Scahill et al., 2003) (see Table 
1.3-Table 1.5 for a list of studies). The change in volume is then calculated as an 
annualised proportional loss compared with the original baseline volume. Manual 
delineation is considered to be the best technique of detecting change in substructures as 
many of these, such as the hippocampus, are small in volume, complex in shape and 
difficult to delineate automatically; the hippocampus has borders which are a mixture of 
different tissue types (see Figure 8.10). Manually-generated longitudinal results also give a 
comparison with which new semi-automated or automated techniques can be compared.
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Regions of interest
As outlined in Chapter 1 (page 37, and Table 1.3-Table 1.5), many of the areas which have 
been studied longitudinally are those which have initially been studied cross-sectionally. 
These regions were originally targeted by researchers as they were found to be affected by 
the disease determined by: visualization of structural imaging, reduced metabolism or 
function measured by functional imaging (Valla et al., 2001) or altered metabolite levels 
detected by MRS (Kizu et al., 2004), or have been found to be affected pathologically 
(Braak et al., 1993). Changes in the volume of brain regions studied on serial volumetric 
MR can either be measures of global change such as whole brain change (Table 1.2) or 
ventricular change (Table 1.4), or measure change in specific substructures such as the 
hippocampus and entorhinal cortex (see Table 1.3 and Table 1.5 respectively).
Limitations of these techniques
These measures have potential use and as such have been used in trials as surrogate 
markers of progression (Fox et al., 2005; Jack et al., 2003; Krishnan et al., 2003) in 
addition to many large studies (see Table 1.3). However, manual outlining is labour- 
intensive (often months of prior training is required), subject to human error and requires 
highly skilled operators; often the level of change calculated within the region 
approximates to the level of error genenerated from uncorrelated errors in the delineation of 
matched baseline and repeat regions. As a result the use of these techniques in a clinical 
situation is limited to specialist referral centres and exceptional cases.
Chapter outline
This chapter describes the application of manual delineation protocols to specific disease 
groups in order to answer questions regarding i) differential four dimensional patterns of 
atrophy in sub-regions of the brain known to be affected by specific diseases, and ii) the 
intervals over which change can be measured in the hippocampus in AD.
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5.2. Application o f cingulate ROI protocol to longitudinal studies
5.2.1. Introduction
As discussed in Chapter 4 (see page 97) cross-sectional volumetric MRI studies of the 
cingulate gyrus have revealed significantly lower cingulate volumes in AD compared with 
controls (Callen et al., 2001; Killiany et al, 2000). This concurs with voxel-based 
morphometric (VBM) data which also reveals reduced grey matter density in the cingulate 
gyrus in AD, more specifically in the posterior region (Baron et al., 2001; Frisoni et al., 
2002a; Scahill et al., 2002). Magnetic resonance spectroscopy (MRS) in AD patients shows 
metabolite changes in the posterior section of the cingulate gyrus compared with controls 
(Kizu et al., 2004). PET and SPECT studies have also revealed hypometabolism in the 
cingulate gyrus in AD compared with controls, especially in the posterior section (Matsuda 
et al, 2002; Minoshima et al., 1997; Valla et al., 2001). In FTLD, there have been fewer 
studies; VBM has shown predominant decrease in grey matter volume of the posterior 
cingulate (Whitwell et al, 2004a) and less cingulate atrophy in the posterior section of the 
cingulate with relatively more anterior temporal change compared with AD (Boxer et al., 
2003), and MRS has shown metabolite changes in the posterior cingulate region compared 
with controls (Kizu et al., 2004).
The hippocampus has been more extensively studied as discussed in the previous chapters 
(see page 113 and Table 1.1 and Table 1.3). Structural imaging based studies (mainly 
MRI) have shown increased atrophy of the hippocampus in established AD (Chan et al., 
2001b; de Leon et al., 1994; Jack et al., 1998), and in individuals with presymptomatic 
familial AD (Fox et al, 1996b; Schott et al., 2003) or subjects with mild cognitive 
impairment (MCI) at higher risk of progressing to AD (Jack et al., 2004). Autopsy studies 
in AD suggest that hippocampal atrophy, independent of neurofibrillary tangles, predicts 
memory deficits (Mortimer et a l, 2004). As discussed and shown in the previous chapter 
(see page 113), the hippocampus may also be severely affected by the progression of FTLD 
with increased atrophy of this structure particularly seen in FTLD variants with temporal 
lobe predominance (e.g. semantic dementia) (Frisoni et al., 1999; Laakso et al., 2000a). 
Hippocampal atrophy in semantic dementia may be at least as severe as in AD although 
usually with a more anterior focus (Chan et al., 2002).
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As discussed in the previous chapter (see page 113) at early stages of AD and FTLD it can 
be difficult to differentiate between the two diseases clinically and although this may be 
easier as the diseases progress, both diseases may be misdiagnosed. Assessment of MRI 
scans might aid this differential diagnosis and provide information about the progression of 
these diseases. In order to establish whether volumetric measures are truly useful in 
distinguishing disease groups from each other, studies should be ideally performed using 
scans of subjects with pathologically-confirmed disease as clinical diagnosis is not 100% 
accurate.
This study aimed to establish the rates of atrophy of the cingulate and hippocampus in 
confirmed AD and FTLD compared with controls. The secondary aim was to establish the 
distribution of atrophy rates along the length of the cingulate gyrus. The hypothesis was 
that these may be different between groups with more anterior loss in FTLD.
5.2.2. Subjects and methods 
5.2.2.1.Subjects
Nineteen AD patients (ten pathologically, eight genetically confirmed by chromosomal 
analysis and one autosomal dominant inheritance of AD with post-mortem in a first degree 
relative), eight FTLD patients (six pathologically confirmed and two from autosomal 
dominant pedigrees with pathology in a first degree relative), and 11 healthy controls of a 
similar age (one of which had normal brain reported at post-mortem) were included in this 
study. Subject demographics are reported in Table 5.1. Where both genetic and 
pathological confirmation of disease was obtained, patients were included in the 
pathological group. None of the patients or controls were on medication that would be 
likely to influence these results. One control subject was normotensive on treatment for 
hypertension. None of the controls had any diseases that may have influenced these results. 
An exclusion criteria for the controls was the presence of neurological or psychiatric 
morbidity. Hypertension was not an exclusion factor.
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Within the FTLD group a mixture of pathologies were reported at post-mortem. Three 
patients had FTLD-U: ubiquitin positive, tau and alpha-synuclein negative, abnormal 
neuritis and neuronal, intra-cytoplasmic inclusions in the frontal cortices or the 
hippocampal dentate fascia. Three patients had a positive family history of FTLD with tau 
exon 10+16 C-T (cytosine to thymine) splice site mutations. Of those remaining with post­
mortem in a family member one had tau exon 10+16 and one had FTLD-U. With respect to 
clinical presentation, five of the group were of the frontal variant, two had semantic 
dementia and one had progressive non-fluent aphasia.
5.2.2.2.Image Acquisition 
All subjects had two volumetric T1-weighted studies acquired one-two years apart in a 
standard manner (see Appendix Three).
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Table 5.1 Subject Demographics.
Controls AD FTLD
Number 11 19 8
M/F 5/6 10/9 3/5
Age (years):
Mean 56.0 56.3 55.9
(SD) (14.3) (10.6) (7.6)
MMSE (/30) at first scan: 
Mean 29 20 24
(SD) (1) (7) (6)
Sporadic /Familial NA 8/11 2/6
Pathological /Genetic
confirmation of status 1/0 11/8 6/2
Scan interval (days):
Mean 430 567 453
(SD) (238) (292) (181)
Interval between mid-point of 
scans and death (years):
Mean NA 3.9* 4.9¥
(SD) (1.9) (0.7)
(* Data available in 8 cases;i f  data available in 6 cases)
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5.2.2.3.Manual Segmentation 
Scans were transferred to a Sun workstation. The software package MIDAS was used for 
all manual segmentation (Freeborough et al., 1997). The boundaries of the structures were 
traced with two orthogonal views visible.
The cingulate was defined as the grey matter of the cingulate gyrus including the 
retrosplenial cortex (approximating to Brodmann areas 23,24,24’,29 and 30) (Vogt et al., 
2001). Measurements were taken from sagittal slices from the medial to lateral boundaries 
and this region was edited in the coronal view. The posterior limit of the cingulate gyrus 
was taken as the splenial sulcus, the superior and anterior limit as the bottom of the 
cingulate sulcus and the inferior limit as the corpus collosum. Using the brain mask in 
MIDAS, a consistent threshold of 70% and 110% of mean brain intensity was applied to 
the ROI to exclude lower intensity voxels which were predominantly CSF, and higher 
intensity voxels that were predominantly white matter. See Figure 5.1, and for a full 
anatomical description, see Chapter 4, page 103.
The hippocampus was defined as including the hippocampus proper, the subiculum and the 
alveus. Measurements were taken from coronal slices from the posterior to anterior 
boundaries using a standard neuroanatomical atlas (Duvemoy, 1998). The posterior limit of 
the HF was defined as the coronal slice where the longest length of the crus of the fornix 
was seen (Watson et al., 1992). The hippocampus was bounded superiorly, medially and 
laterally by CSF and inferiorly by the white matter of the subiculum. The head of the 
hippocampus was delineated from the amygdala by inclusion of the alveus, which was best 
seen as a band of high signal intensity on the sagittal sections. A consistent threshold of 
70% of mean brain intensity was applied to exclude voxels with a lower intensity which 
were predominantly CSF. Again this mean brain intensity was calculated automatically 
using the MIDAS generated brain mask, see Figure 5.2 and Appendix Four.
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Figure 5.1 A schematic representation of the cingulate gyrus and its subdivisions.
The cingulate is outlined in the sagittal view, from medial to lateral parts using strict 
relative-to-brain thresholds of 70% and 110% to aid delineation of grey matter from CSF 
and white matter respectively. This region is then edited coronally. Small numbers of 
partial volume voxels (which may contain both CSF and grey matter) may be included in 
the segmentation by use of these thresholds. Subdivisions are manually determined using 
the anterior and posterior comissures as cut-offs. Cingulate gyrus anterior to the anterior 
commissure is considered to be rostral anterior cingulate (RAC), cingulate posterior to the 
posterior commissure is posterior cingulate (PC) and cingulate between these regions is 
caudal anterior cingulate (CAC).
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Figure 5.2 Segmentation of the hippocampus.
This structure is outlined coronally and then edited in the sagittal view. The hippocampus 
includes the hippocampus proper, the subiculum and the alveus.
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Prior to ROI measurement, all scans were rigidly registered (six degrees of freedom) to a 
standard 305 template (Mazziotta et al., 1995) to ensure all scans were in a similar 
orientation. The repeat images were then accurately registered onto the baseline using a 
nine degrees of freedom registration (Woods et al., 1998). Scans were measured using 
mirror-image volumetry (see page 101) with the baseline and registered-repeat scans were 
presented simultaneously in a random order. ROIs were then manually edited in both 
coronal and sagittal views. Analysis was performed blinded to the subject’s name, 
diagnosis, left-right orientation of the scan and whether measurements were being 
performed on the baseline or registered-repeat image. Mean intra-rater variability 
(calculated as a reliability co-efficient) was 0.98 in the hippocampus and in the cingulate 
gyrus. Mean intra-rater variability (calculated from the ratio of the absolute difference in 
measurements to the mean in each person) was 3% in the hippocampus and 4% in the 
cingulate gyrus. These values were based upon 20 hippocampi segmented twice and six 
cingulate gyri segmented twice. No time limits were imposed, and the average 
segmentation time was 45 minutes per hippocampus and 50 minutes per cingulate.
5.2.2.4.Subdivision segmentation 
After cingulate segmentation, the region was subdivided into posterior cingulate (PC) 
which included the retrosplenial cortex, caudal anterior cingulate (CAC) and rostral anterior 
cingulate (RAC) which approximate to Brodmann areas 23+29+30, 24’, and 24 
respectively. This was achieved by dividing the cingulate using the anterior and posterior 
commisures as predetermined cut-offs. Cingulate gyrus anterior to the anterior commisure 
was labelled rostral anterior cingulate, cingulate posterior to the posterior commisure was 
labelled posterior cingulate, and the section between was labelled caudal anterior cingulate, 
see Figure 4.2.
5.2.2.5.Statistical Analysis 
Data were analysed using STATA version 8, and SAS (see page 96). Left and right ROI 
volumes were summed. Volumes for cross-sectional analysis were corrected for TIV with 
TIV derived according to a previously described protocol (Whitwell et al., 2001). 
Standardisation was performed separately for the cingulate and hippocampus. For both
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structures this was carried out assuming a linear relationship between log-transformed 
values and log TIV with the slopes of the associations estimated in the control group (Free 
et al, 1995) (see Equation 4.1). Atrophy rates were analysed on a logarithmic scale [(log 
(follow-up volume/baseline volume))/interval] in order that doublings and halvings in 
volume be treated as effects of equal magnitude. Mean atrophy rates were calculated by 
back transformation with SDs calculated from variance transformation formulae.
Three separate linear mixed models (fitted using proc mixed in SAS) were used to i) 
compare cingulate rates of atrophy (on a logarithmic scale) in the three patient groups, ii) to 
compare hippocampal rates with cingulate rates in the three groups and iii) to compare 
regional cingulate rates of atrophy. Each of these models allowed the variance of, and the 
covariances between, regional atrophy rates to differ between patient groups. Contrasts of 
mean levels were used to compare the combined disease groups with controls and to 
compare the FTLD group with the AD group. In the second model a further contrast was 
used to investigate whether the magnitude of the difference between cingulate and 
hippocampal rates differed between FTLD and AD patients. In the third model a further 
contrast was used to investigate whether the magnitude of the difference between posterior 
and rostral anterior cingulate rates differed between FTLD and AD patients. Likelihood 
ratio tests were used to compare variances between groups.
Standard methods were used to calculate sample sizes that gave 90% statistical power to 
detect a significant difference in atrophy rates between the RAC and PC in AD and FTLD 
at the 5% significance level.
ROC curves were used to investigate the ability of cingulate and hippocampal rates to 
differentiate between groups. Their discriminatory ability was compared using logistic 
regression models relating them individually and together to odds of disease (AD vs. 
controls and FTLD vs. Controls).
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5.2.3. Results
Table 5.2 and Figure 5.3 show volumes and rates of atrophy in cingulate and hippocampus 
in the three subject groups. The mean and standard deviations of baseline and repeat 
volumes of cingulate and hippocampus show a large degree of overlap between the subject 
groups.
Table 5.2 Volumes and rates o f atrophy of the cingulate gyrus and hippocampus in control, 
Alzheimer's disease, and frontotemporal lobar degeneration subject groups.
All volumes are adjusted for TIV. Rates are expressed as a percentage of baseline volume 
annualised.
Controls AD FTLD
Cingulate Volumes (mm3) 
Mean (SD) - baseline 
Mean (SD) - follow-up
17100(2879) 
17137 (2842)
14886 (2325) 
13653 (2692)
14851 (3277) 
13415 (3357)
Cingulate Atrophy rates (% year_1)
Mean
95% CIs
SD
-0.3 
-1.1, 0.5 
1.2
5.9 
4.2, 7.5 
3.5
8.6 
5.1, 11.9 
4.1
Hippocampus Volumes (mm3) 
Mean (SD) - baseline 
Mean (SD) - follow-up
5959 (649) 
5984 (623)
4672 (567) 
4435 (608)
3567 (748) 
3323 (709)
Hippocampal Atrophy rates (% year ~’)
Mean
95% CIs
SDs
-0.1 
-0.7, 0.5 
0.8
3.4 
2.3, 4.4 
2.2
5.2 
0.6, 9.6 
5.4
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Figure 5.3 Total (left + right) cingulate and total (left + right) hippocampal annualised rates of atrophy in controls, AD and FTLD groups.
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Taking the mean of the results in the two disease groups, cingulate atrophy rates were, on 
average 7.5% per year higher (p<0.0001) and more variable (p=0.001) than in controls. The 
mean rate in FTLD patients was slightly higher than that in AD patients, but this difference 
was not statistically significant (p=0.7). Age was not found to be a statistically significant 
predictor of atrophy rate in the cingulate (p = 0.6) and adjusting for age had little effect on 
the estimated differences between groups.
Again taking the mean of the results in the two disease groups, hippocampal atrophy rates 
were, on average 4.2% per year higher (p<0.01) than in controls. The magnitude of this 
difference was significantly less (p=0.01) than that seen for cingulate atrophy rates. 
Although hippocampal atrophy rates were somewhat higher in the FTLD patients than in 
the AD patients this difference was not statistically significant (p=0.4). Furthermore there 
was no evidence (p=0.7) that the magnitude of the difference between cingulate and 
hippocampal atrophy rates differed between the two disease groups. There was no 
evidence of a significant correlation between cingulate and hippocampal atrophy rates in 
AD (p = 0.18, R = 0.32) or FTLD (p = 0.23, R = 0.48).
The ROC curves presented in Figure 5.4 and Figure 5.5 show the ability of both cingulate 
and hippocampal rates of atrophy to differentiate between AD and controls and FTLD and 
controls respectively. Cingulate atrophy rates were significant discriminators of AD from 
controls (p=0.01) although hippocampi were significantly better (p=0.037). Cingulate 
atrophy rates discriminated perfectly between FTLD and controls whereas hippocampal 
rates were significant predictors (p=0.044), although not perfect. Neither cingulate nor 
hippocampal atrophy rates were significant differentiators between the AD and FTLD 
groups (p>0.1).
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5.2.3.1. Subdivisions
Table 5.3 shows mean (SD) rates of atrophy for each subdivision in each subject group. 
Pooling results across subdivisions and disease groups there was strong evidence 
(p<0.0001) of a difference in mean rates of atrophy between cases and controls. Amongst 
the AD group rates were highest in the posterior region and lowest in the rostral anterior 
region whilst among the FTLD this trend was reversed. Neither of these trends achieved 
statistical significance, and although there was considerable overlap between the two 
groups there was evidence that the positive and negative trends in the two disease groups 
were statistically significantly different from each other (p=0.03). Retrospective power 
calculations showed that in order to have 90% power to detect a significant difference in 
atrophy rates between the PC and the RAC in AD subjects, 79 subjects would be required. 
Analogous statistics in the FTLD group showed that 131 subjects would be required to 
detect a difference between the PC and RAC regions.
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Table 5.3 Rates of atrophy of subdivisions of the cingulate gyrus in the control, Alzheimer’s 
disease and frontotemporal lobar degeneration subject groups.
Atrophy Rates 
% year -1
Controls AD FTLD
Rostral Anterior Cingulate
Mean 0.1 4.9 9.7
95% CIs -3.1, 3.3 2.5, 7.3 4.5, 14.6
SD 4.7 5.0 5.8
Caudal Anterior Cingulate
Mean 0.4 6.4 7.4
95% CIs -1.4, 2.2 4.5, 8.1 3.8, 10.9
SD 2.7 3.7 4.2
Posterior Cingulate
Mean -1.6 7.7 7.6
95% CIs -3.9, 0.5 4.9, 10.5 -3.8, 11.4
SD 3.3 5.8 4.6
5.2.4. Discussion
This study aimed to establish rates of atrophy of cingulate gyrus and hippocampus in 
groups of confirmed AD, FTLD and a group of controls. Cross-sectional volumes of 
hippocampi and cingulate showed a large degree of overlap of the subject groups. 
Significantly higher rates of cingulate atrophy in both disease groups compared with 
controls was found. To date there are no other published rates of atrophy of the cingulate in 
AD or FTLD. However, the main finding of this study is consistent with cross-sectional 
volumetric data which show decreased volume of the cingulate gyrus in AD (Callen et al., 
2001; Killiany et al., 2000).
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Significantly higher rates of atrophy for the hippocampus compared with controls was 
found in both AD (3.4% per year) and FTLD (5.2% per year). Several studies by Jack and 
colleagues of older sporadic AD cases (mean ages 74-79 years in the different studies) have 
reported annualised rates of hippocampal atrophy of 3-4% with age-matched controls 
(mean ages 77-80 years) having rates of atrophy of 1.4-1.7% per year (Jack et al., 1998; 
Jack et al., 2000; Jack et al., 2004). Other groups have reported rates of atrophy in AD to 
be 5-6 % per year (mean age -76 years) and 0.8% per year in control subjects (mean age 
-76 years) (Cardenas et al., 2003; Du et al., 2004).
Hippocampal atrophy rates in FTLD were also significantly greater than controls which is 
consistent with published cross-sectional literature which have shown reduced hippocampal 
volumes in FTLD (Frisoni et al., 1999; Laakso et al., 2000a). Differences in this study 
compared with published data may be due to differences in subjects; for example the mean 
age of the subjects was low and more than half of the AD group had familial AD (Mosconi 
et al., 2003; O'Riordan et al., 2002). In addition, some differences may be ascribed to 
variation in segmentation protocols and differences in image quality and acquisition 
(Pruessner et al., 2000).
These results also show the heterogeneity present in rates of change within the control and 
disease groups. This heterogeneity may only be partly explained by manual errors, or scan 
artefact; a significant component of the heterogeneity may be due to true differences in 
progression of disease, severity of disease or disease duration. With respect to the findings, 
it is surprising not to find greater heterogeneity within the FTLD group where there was a 
mixture of pathologies and clinical presentations. Manual outlining errors are inevitable in 
structures that vary so highly in morphology between subjects and have a number of 
arbitrary cut offs and subjective judgements in outlining. In particular, it can be difficult to 
delineate the left and right cingulate gyri in controls with little atrophy as the falx cerebri 
within the interhemispheric fissure may make the left and right gyri appear continuous.
This study found that hippocampal rates of atrophy were superior to cingulate rates in 
separating AD from controls although both were significant predictors. Many other 
imaging methods have been assessed for their ability to separate AD from controls. Within
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structural imaging, cross-sectional semi-quantitative measurement of hippocampal atrophy 
has been shown to discriminate AD from controls with a high sensitivity (87%) and high 
specificity (93%) (Scheltens et al., 1992). A combination of linear measures of the medial 
temporal lobe have also proved useful with a sensitivity of 86% for a specificity of 95% 
(Frisoni et al., 1996b). Cross-sectional quantitative measurement of specific ROIs have also 
shown similar levels of sensitivity and specificity to this study, especially in the 
hippocampus and entorhinal cortex (Juottonen et al., 1999; Killiany et al., 2002; Pennanen 
et al., 2004). Visual analysis and grading of PET images in pathologically confirmed cases 
gave similar levels of discrimination of AD from controls compared with the volumetric 
methods reported in this study (Hoffman et al, 2000). Co-varying patterns of cerebral 
blood flow measured on PET images showed sensitivities of between 76-94% and 
specificities of 64-81% when separating AD from controls (Scarmeas et al., 2004).
This study found cingulate atrophy to be superior to hippocampal atrophy in separating 
FTLD from controls. Discrimination was superior to those quoted for one cross-sectional 
volumetric study (49% sensitivity for the hippocampus and 52% for the entorhinal cortex 
when specificity was set at 90%) (Frisoni et al., 1999). In another study, change in brain 
size has shown better separation between FTLD and controls with specificities of around 
80% for a sensitivity of 90% (Chan et al., 2001a). However, comparison between FTLD 
studies is confounded by differences in pathological disease types, ages and disease 
severities. With respect to separating AD from FTLD, neither cingulate nor hippocampal 
rates were found to be significant predictors of disease group. This is in keeping with other 
MR studies which have found cross-sectional volumetric measures of the hippocampus to 
be poor discriminators of FTLD from AD (Frisoni et al., 1996a; Frisoni et al., 1999). Other 
imaging techniques have shown good sensitivity and specificity such as SPECT. 
Comparison of the anterior-posterior gradients of SPET images gave a sensitivity of 86% 
and a specificity of 93% when separating FTLD from both AD patients and controls 
(Nagao et al., 2004).
Manual segmentation of ROIs is currently considered to be the “gold standard” in 
measurement of atrophy in this region. This requires the outlining of the ROI on each MRI 
“slice”. However, errors in manual delineation become very important when differences
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are being measured; for example the hippocampus typically loses 3-6 % of its volume over 
a year in AD (Cardenas et al., 2003; Jack et al., 1998) which is the same order of 
magnitude as delineation errors in hippocampal measurement (Chan et al., 2001a). As a 
result, various other methods have been proposed to assess hippocampal size and/or 
atrophy rates either more easily and/or more precisely (see Chapters 8 and 9: pages 203 and 
243) (Crum et al., 2001; Csemansky et al., 2000; Haller et al., 1996). Further research is 
required to establish whether similar gains can be made in the cingulate region.
A strength of this study is the relative certainty of diagnosis in all patients in the disease 
groups. However, there was not this level of certainty with respect to the control group 
apart from one individual who subsequently had a post-mortem revealing a normal brain. 
One limitation of the study was that scan pairs (baseline and repeat) were sometimes of 
differing quality. The fact that the mean ages for all groups was young and that the disease 
groups were predominantly familial cases means this study in not necessarily generalisable 
to an older, almost exclusively sporadic disease population. The sporadic disease group 
were relatively young (average age 64 years old compared with 50 in the familial group). 
This is because the sporadic group were chosen to reduce the confound of age when 
comparing with the FTLD group and, as a tertiary referral centre, early cases of sporadic 
AD are often referred. Further research is required in older AD and FTLD groups and in 
patients with milder disease.
5.2.4.1.Subdivisions
The secondary aim of the study was to establish whether subdivision of the cingulate 
revealed any differences in atrophy patterns between the disease groups. This study has 
shown a statistically significant difference in patterns of atrophy along the cingulate 
between AD and FTLD, with higher rates for AD in the posterior and higher rates for 
FTLD in the anterior. The higher rate of atrophy in the posterior cingulate in AD is 
consistent with published data which shows smaller volumes in the posterior cingulate 
region in AD (Callen et al., 2001; Killiany et al., 2000) or decreased grey matter density in 
the posterior cingulate (Baron et al., 2001; Scahill et al., 2002). In addition there were 
higher rates of atrophy in the most anterior portion of the cingulate in FTLD compared with 
other subdivision rates. Data from current literature is scarce regarding discrete cingulate
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subdivision involvement in FTLD although studies have shown predominant involvement 
of the posterior cingulate (Whitwell et al., 2004a) but potentially reduced posterior 
cingulate involvement compared with AD (Boxer et al., 2003). The trends shown within 
groups in cingulate subdivisions, e.g. the posterior section being more affected than anterior 
in AD and the anterior being more affected than the posterior in FTLD potentially 
reflecting greater cortical involvement in posterior regions in AD and frontal regions in 
FTLD, were not significant partly owing to the high variability in these regions. As a result 
of this great variability, relatively large sample sizes (79 for AD and 131 for FTLD) may be 
required to detect a significant difference. Further research is required to establish whether 
better methods of subdivision can be achieved combined with improved atrophy detection 
or segmentation methodologies.
In conclusion, the cingulate gyrus is severely affected in both AD and FTLD. Rates of 
cingulate atrophy are as significant as the much more extensively studied hippocampus. 
Atrophy rates of both structures are significant differentiators of disease groups from 
controls with similar levels of discriminatory ability implying perhaps that these different 
components of the limbic system have a similar and possibly concomitant involvement in 
the AD process. There is a trend for more anterior cingulate atrophy in FTLD and more 
posterior cingulate atrophy in AD, which may be useful in the differential diagnosis of 
these conditions.
5.3. Minimum interval needed for hippocampal segmentation
5.3.1. Introduction
Surrogate markers of the atrophy caused by AD are being developed and validated to 
enable assessment of potentially disease-modifying therapies; the assumption being that 
alteration in the atrophy rate of the brain would reflect the disease modification. Measures 
of brain change over time have been shown to be valuable markers of disease progression 
in untreated patients (Fox, 1999) and as a result have been used as outcome measures in 
clinical trials (Jack et al., 2003; Krishnan et al, 2003).
Whole brain change may not be as sensitive as localised changes in specific areas of the 
brain such as the hippocampus. This may be particularly true in the early stages of disease
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and it is at this stage of the disease where most benefit may be derived from the patient 
following their treatment. Therefore areas of the brain that are known to be specifically 
targeted by the disease process have also been used as outcome measures in clinical trials 
(Jack et al., 2003; Krishnan et al., 2003).
The interval over which most atrophy rates are calculated is at least one year. This is to 
ensure that the change over time is greater than the error incurred in estimation of the 
change. The shorter the inter-scan interval and the more automated the marker, the less 
resource-consuming a study or trial may be and the faster results can be analysed. In 
addition, in a clinical setting there may be potential for rapid clinical feed-back to both 
patient and physician. In this section intervals of less than 12 months were assessed as to 
whether they can give reasonable rates of atrophy in a group of AD and controls.
5.3.2. Subjects and methods 
Subject demographics are described in Table 5.4. Thirty-six subjects from the MIRIAD 
cohort (see page 92) with probable AD according to NINCDS-ADRDA criteria (McKhann 
et al., 1984) (see Appendix One), were included. All AD patients had a MR scan 
compatible with this diagnosis. Twenty age-matched control subjects were also recruited. 
Ethical approval was received from the Local Research Ethics Committee. All subjects 
gave written informed consent, and underwent a comprehensive clinical assessment 
including the MMSE (see Appendix Two). Treatment with an acetyl-cholinesterase 
inhibitor was not an exclusion criterion for the AD group, however treatment usage was 
carefully monitored. No control subject had subjective complaints or objective evidence of 
cognitive impairment. No subject was taking diuretic or steroid therapy during the study.
5.3.2.1.MRI Scan Acquisition 
Scans were acquired on a 1.5T Signa Unit (GE Medical Systems, Milwaukee) according to 
the MIRIAD protocol described in Appendix Three. Each patient was scanned at baseline, 
six, and 12 months. Scans were performed on the same scanner, using the same acquisition 
parameters, and each subject was scanned at a consistent time of day.
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Table 5.4 Subject demographics.
Controls AD
Number 20 36
M/F 10/10 14/22
Mean (SD) age in years 69.1 (7.0) 69.6 (7.3)
Mean (SD) baseline MMSE 29.5 (0.7) 19.4 (4.1)
6m mean interval to baseline 
(SD) in days 181 (6) 179 (8)
12m mean interval to 
baseline (SD) in days 364(18) 365 (18)
AD is Alzheimer’s disease, 6m is six month and 12m is twelve month
5.3.2.2.Scan Processing 
All scans were transferred to a Sun workstation (Sun Microsystems, Mountain View, CA) 
for analysis. Regions defining whole brain were obtained (segmented) from all 124 
contiguous slices using a semi-automated iterative morphologic technique using MIDAS 
(see Appendix Four). Each scan triplet (baseline, six, and 12 month) was registered to the 
MNI 305 brain average (Mazziotta et al., 1995) using a six degrees of freedom (dof) 
registration. Subsequently, each triplet was co-registered by registering the repeat scans to 
the baseline image using nine dof. Hippocampi were segmented using the protocol 
described elsewhere (see Appendix Four) using mirror-image volumetry (see page 95) in
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triplets with scans being presented to the operator in a random order with the operator being 
blinded to order of scans, scan laterality, and subject information.
5.3.2.3.Statistical Analysis 
Hippocampal rates of atrophy were calculated for total (left plus right) hippocampus. Data 
were analysed using STATA version 8 and SAS (see page 96). Annualised rates of atrophy 
were calculated using log transformed volumes thereby assuming a constant proportionate 
rate of hippocampal loss. Within each group, differences between annualised atrophy rates 
calculated using six-month and one-year interval scans were analysed using paired t-tests 
for means and Pitman’s tests for variances. At each time-point, between-group 
comparisons of atrophy rates were made using t-tests allowing for unequal variances.
Sample sizes for randomised controlled clinical trials required to achieve a particular 
statistical power to detect a particular proportional reduction in an outcome variable in 
cases (AD) are proportional to the square of the coefficient of variation (CV) of the 
outcome variable in cases. The relative numbers of patients required for two different 
outcome variables is therefore given by the square of the ratio of the respective CVs. 95% 
bootstrap confidence intervals (bias corrected) for such relative sample sizes (using a 
logarithmic transform for reasons of symmetry on a relative scale) were calculated using 
1000 replicates to compare the two atrophy rates.
5.3.3. Results
Table 5.5 shows the mean (SD) annualised rates of total (left plus right) hippocampal 
atrophy rates for manual methods using the six and 12 month interval scans in the control 
and AD groups. Although the mean atrophy rate in AD subjects was slightly higher using a 
twelve-month interval rather than six, neither this difference (p=0.18) nor the analogous 
comparison in controls (p=0.69) was significant. However, at an individual level there 
were considerable differences in rates measured over the different intervals (Figure 5.6 A: 
95% reference range on the difference: -4.24 to 4.96). Results from six-month interval 
scans were more variable than that at 12-months in controls (p=0.007) (Figure 5.6 B). In 
AD subjects the difference was not significant (p=0.98), perhaps reflecting the lower power
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to detect differences through greater between-subject variability in atrophy rates. Using 
AD subjects, the relative sample size for the atrophy rates at 12 months compared with six 
did not show a significant reduction in sample size at 12 months 0.71 (95% CIs 0.29 1.50).
Table 5.5 Annualised atrophy rates calculated as a percentage of baseline volume from the 
six and 12 month interval scan data using manual measures._________________________
Controls AD p value
Annualised mean 
(SD) 6 month rate
0.41 (1.69) 3.95 (3.01) <0.0001
Annualised mean 
(SD) 12 month rate
0.28 (0.93) 4.57 (2.98) <0.0001
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Figure 5.6 A) Bland-Altman plot of six and 12 month interval atrophy rates, B) annualised 
atrophy rates expressed as a percentage of baseline volume using manual methods.
- 158-
5.3.4. Discussion
In this study it was found that annualised atrophy rates from six-month interval scans were 
similar to twelve-month interval scans. The variances were higher using the six-month 
interval scans, which is not surprising since any errors would have been doubled by 
annualising the rates. However, the increase in variance was not sufficient to make the 
differences in sample sizes calculated between the six- and twelve-month interval rates 
significantly different. The mean rates of atrophy in the AD and controls groups were also 
slightly but non-significantly lower using the six-month interval than the twelve-month 
interval rates in both controls and AD patients. This may be simply chance or because the 
amount of atrophy seen between the six month and baseline scans was not large enough to 
visualise and therefore these differences are not incorporated into the segmentation of the 
hippocampus. The effect of this being a potential bias was theoretically reduced by being 
blinded to the date and loading the scans in a random rather than chronological order. 
However, in some cases the order of the scans may be obvious to the operator, especially 
when a large amount of atrophy has occurred.
Mean atrophy rates were around 3-4.5% per year in AD compared with less than 0.5% per 
year in controls. This is within the range of previously published hippocampal rates of 
atrophy for AD patients of this age group; 3-4% per year (Jack et al., 1998; Jack et al., 
2000; Jack et al., 2004) 5.4% per year (Cardenas et al, 2003) 5.9% per year (Du et al., 
2004). However, the rate of atrophy in the control group is lower than that quoted in these 
studies; 0.8% per year (Du et al., 2004) 1.4-1-9% per year (Jack et al., 1998; Jack et al., 
2000; Jack et al., 2004) 1.8% per year (Cardenas et al., 2003) 2% per year (Kaye et al, 
1997). Differences in the ages of these control groups may account for some of the 
variation in reported rates of atrophy (Scahill et al., 2003). Additionally, the control 
subjects in this study may have been healthier. Other explanations of differences, for 
example the use of different segmentation methodologies or scanning protocols by different 
research groups, may also account for some of the differences reported (Pruessner et al., 
2000).
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Despite finding large and significant differences in AD subjects’ rates of atrophy from 
controls a large degree of overlap between subject groups was still observed. This may 
reflect true group heterogeneity, scan artefacts or measurement error in both subject groups. 
In the AD group this may reflect different progression or stage of disease. In this study 
there was histological (autopsy) confirmation of disease in only two of the AD group and 
one of the controls, therefore there may be some uncertainty as to the pathological status of 
all of the subjects. One strength of this study is that one operator (myself) carefully 
segmented all hippocampi. This means that inter-rater variability was not a confounding 
factor in the calculated manual atrophy rates.
Only one other study of hippocampal atrophy over short inter-scan interval imaging has 
been reported in the literature. However in this study, with an inter-scan interval of 24 
weeks, the amount of hippocampal loss was not reported as an annualised rate of atrophy it 
was instead calculated as a total percentage reduction (Krishnan et al., 2003). The 
percentage reduction over this period of time was calculated to be 8.2% in the placebo arm, 
leading to an approximate and surprisingly high annualised rate of 18% loss per annum. 
This rate exceeds all others quoted in the literature (see above and Table 1.3). Other short 
interval studies have been performed measuring whole brain change and change of 
ventricle volume. One study looked at whole brain change and whole ventricular change in 
short interval imaging using multiple scanning time-points (Bradley et a l, 2002). This 
small study (seven AD subjects) found that increase in ventricular volume and decrease in 
brain volume over short inter-scan intervals was a reliable marker of possible or probable 
AD. This study also established that increasing the inter-scan interval to one year decreased 
the number of people needed for a trial required to detect a reduction in atrophy rate 
although this was not significant. The greater 12 month interval also reduced the amount of 
people required to detect a standard amount of atrophy owing to increased precision.
Other published work using data from this study found that ventricular change, measured 
using ventricular BSI, was a good marker of disease status using a six month interval 
(Schott et al., 2005). This study also showed that increasing the interval to one year 
decreased the number of patients required as a result of increased precision. However, it 
may be that localised changes warrant assessment, and with increasingly automated
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techniques available for measuring hippocampal change, this may be possible as an 
additional measure with little extra operator input. Reductions in scan acquisition artefact 
may also improve the utility of hippocampal measures.
5.3.5. Conclusions
Change in the hippocampus can be measured at intervals less than one year; however there 
is as expected an increased variance in annualised atrophy rates with the shorter scanning 
intervals. Nonetheless, rates over six months were consistent with the 12 months results at 
a group level. This finding has implications in both clinical and trial settings where a six 
month interval may allude to the eventual results and allow more frequent monitoring of 
patients.
5.4. Chapter conclusions
Substructures of the brain can be measured precisely enough that change can be calculated 
over time. The amount of change and its location has been shown to be different in 
different diseases (AD vs. FTLD in both the cingulate and hippocampus). Application of 
manual delineation to serial imaging reveals patterns of atrophy which can be used to 
differentiate different diseases. Subdivision of structures is possible and can reveal 
underlying patterns of atrophy that may differ between different groups in a large structure 
which is affected in both AD and FTLD. Manual measures can be precise enough to 
measure changes at intervals less than one year. These results have been shown in well- 
defined groups of patients, many of which contain subjects which have pathological- or 
genetic-confirmation of their diagnosis. This work gives a benchmark with which more 
automated techniques can be compared.
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6. COMBINED CROSS-SECTIONAL AND LONGITUDINAL STUDIES
6.1. Chapter Introduction
Background
As shown in Chapters 4 and 5, both cross-sectional and longitudinal studies can further the 
understanding of degenerating diseases and aid their diagnoses. Cross-sectional studies 
give a measure of the amount of loss before the scan was taken and the existing normal 
variation. Longitudinal studies, which calculate the rate of loss in a structure give a 
measure of the progression of the disease and have less confounding problems with inter­
individual variability as each person acts as their own control. Owing to the different 
information provided by each approach, studies which combine information from both are 
often useful when investigating disease-related questions.
Chapter outline
In this chapter, results are presented from two studies which combine both cross-sectional 
and longitudinal data to answer specific questions: i) whether hippocampal asymmetry is a 
potential marker of AD and ii) whether hippocampal atrophy can be detected in 
presymtomatic cases of familial AD.
6.2. Is hippocampal asymmetry affected by AD?
6.2.1. Introduction
There is considerable interest in using MRI measures as an aid to early diagnosis. 
Numerous imaging studies have shown that cross-sectional hippocampal atrophy is a 
consistent finding in AD (Chan et al., 2001b; Jack et al., 1997; Lehtovirta et al., 1995); 
indeed the presence of hippocampal atrophy has been shown to be predictive of a diagnosis 
of AD and of symptom onset (de Leon et al., 1989; Fox et al., 1996b; Kaye et al., 1997; 
Rusinek et al., 2003). There have been some longitudinal MRI studies of hippocampal 
volumes, and these have shown that rates of hippocampal atrophy in patients with AD are 
significantly increased compared with controls (Du et al., 2004; Jack et al., 1998; Jack et 
al., 2000; Jack et al., 2004; Laakso et al., 2000b).
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In contrast to focal neurodegenerative conditions such as FTLD, AD is usually considered 
to involve generalised symmetrical cortical atrophy (Chan et al., 2001b). However, the 
normal human brain has some asymmetry. Right-greater-than-left asymmetry has been 
reported in normal subjects when whole hemisphere (Gur et al., 1991), temporal (DeCarli 
et al., 1994; Jack et al., 1989) or frontal lobes (Howard et al., 1995; Weinberger et al., 
1981) are compared. Several MRI studies have shown the right hippocampus to be larger 
than the left in normal subjects (Csemansky et al., 1998; Csemansky et al., 2000; Geroldi 
et al., 2000; Jack et al., 1989; Laakso et al., 2000b; Mervaala et al., 2000; Pruessner et al., 
2000; Soininen et al., 1994; Wang et al., 2001), with estimates of the magnitude of this 
asymmetry of up to 10% (Soininen et al., 1994). However, not all studies report significant 
hippocampal asymmetry (Bhatia et al., 1993; Fox et al., 1996b; Golebiowski et al., 1999; 
Kaye et al., 1997) and two studies have reported the left hippocampus to be marginally 
larger than the right (Ashtari et al., 1999; Cook et al., 1992).
The effect of the progression of AD on hippocampal asymmetry is unclear. Whilst one 
study suggested that the natural right-greater-than left asymmetry in brain structures is 
reduced or even reversed in AD (Geroldi et al., 2000), another reported considerable 
heterogeneity in the degree and direction of hippocampal asymmetry in a very small 
number of patients with early AD (Fox et al., 1996b). Two studies have reported a dose- 
dependent reduction in the degree of hippocampal asymmetry associated with the APOEe4 
allele (a known genetic risk factor for AD), with homozygotes exhibiting reversal of the 
normal asymmetry (Geroldi et al., 2000; Soininen et al., 1995), although another study 
failed to reproduce this finding in a group of cognitively normal subjects homozygous for 
APOEe4 (Reiman et al., 1998). Soininen et al. (Soininen et al., 1994) demonstrated a 
reduction in the degree of hippocampal asymmetry in subjects with age-associated memory 
impairment. If hippocampal asymmetry does alter in early AD the implication is that 
asymmetric atrophy must be occurring at an early stage of the disease, suggesting that one 
hemisphere or hippocampus is more vulnerable to the disease.
In addition to being of possible diagnostic value, it is important to understand the natural 
history of hippocampal changes in AD since measures of hippocampal volume have been 
proposed as outcome measures in trials of potentially disease-modifying therapies in AD.
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It is important to understand whether there is a left-right difference as it might be possible 
to confine measurement of this structure (which is operator-intensive) to one hippocampus. 
The aim of this study was to establish whether there is true asymmetry in hippocampal 
volumes or atrophy rates in both patients and controls, using a technique (mirror-image 
volumetry) in which the investigator is blinded to the right-left orientation of the scans, 
thereby preventing laterality bias.
6.2.2. Materials and Methods 
6.2.2.1.Subjects
Subjects were seen at the Dementia Research Centre at The National Hospital for 
Neurology and Neurosurgery, and were all taking part in ongoing neuroimaging studies. 
Ethical approval for the study had been given by the Local Research Ethics Committee, and 
all subjects gave written informed consent. All subjects underwent clinical assessment 
including the MMSE (Folstein et al., 1975) (see Appendix Two), and all patients in the AD 
group fulfilled standard NINCDS-ADRDA criteria (McKhann et al., 1984) for the 
diagnosis of probable AD (see Appendix One).
Fifty controls and 32 patients with AD each had two serial volumetric MRI assessments. 
All patients in this study had their MRI scans reported by an experienced neuroradiologist 
as compatible with the diagnosis of AD. The AD group comprised 13 FAD and 19 SAD 
cases. Genetic confirmation of disease was available in 11 FAD cases and one post-mortem 
confirmation of disease was available on a further FAD case. APOE genotyping was 
available on a subset of AD patients (13 FAD and 11 SAD). Subject demographics are 
shown in Table 6.1.
6.2.2.2.Imaging
T1-weighted volumetric MR brain scans were performed on a 1.5 Tesla Signa unit (General 
Electric, Milwaukee), using the standard protocol for all subjects except 11 AD and 11 
controls who were scanned using the MIRIAD protocol (see Appendix Three). All scans 
were transferred to a Sun workstation (Sun Microsystems Inc., Mountain View, CA) for 
analysis. The software package MIDAS (Freeborough et al., 1997) was used for all manual 
segmentation. Each hippocampus was carefully manually edited in both the coronal and 
sagittal planes to improve accuracy of delineation (see Appendix Four).
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Table 6.1 Subject demographics.
Controls AD
Number 50 32
M/F 26/24 13/19
Age (Years) 59.6(13.8) 59.0(11.3)
Mean (SD) baseline 
MMSE (Max=30) 29.4 (0.8) 19.4 (5.0)
Mean interval 
(Days)
418(172) 456 (311)
Sporadic / Familial NA 19/13
APOE status Not available 24 APOE (11-/-, 12 -/e4, 1 e4/ e4 , 
8 not available)
NA = not applicable
6.2.2.3.Cross-sectional and Longitudinal Measurements 
Prior to hippocampal measurement, the follow-up scans were accurately registered onto the 
baseline images, using a nine degrees of freedom (dof) registration algorithm (Freeborough 
et al., 1996b). The hippocampus was always measured on the right-hand side of the 
presented image using mirror-image volumetry (see page 101). The baseline and registered 
repeat scans were presented simultaneously in a random order. The first hippocampal 
region was pasted onto the second scan to ensure consistency of arbitrary boundaries
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between scans. This region was then manually edited where necessary. The investigator 
was blinded to the subject’s name, diagnosis, left-right orientation of the scan and whether 
measurements were being performed on the baseline or registered-repeat image.
6.2.2.4.Statistical Analysis 
Data were analysed using STATA version 8 (see Chapter 3, page 96). Geometric means of 
the right and left hippocampal volumes and their ratio were calculated according to disease 
status and visit. A student’s one-sample t test was used to investigate whether there was 
significant asymmetry in either the hippocampal volumes, or the atrophy rates in the two 
groups. Two sample t-tests (assuming unequal variances) were used to make comparisons 
between the disease and control groups. F tests were used to investigate the difference in 
standard deviation in ratios and raw hippocampal volumes between the two groups. 
Standard methods were used to calculate retrospective sample sizes that gave 90% 
statistical power to detect a significant difference in atrophy rates between the right and left 
hippocampal rates in AD at the 5% significance level. Similar methods were used to 
calculate the sample sizes required to detect a significant difference in atrophy rates 
between the APOE e4+ and APOE s4- carriers.
6.2.3. 6.2.3 Results
Table 6.2 shows geometric mean levels of right and left hippocampal volumes and their 
ratio in AD patients and controls at baseline and repeat visit. Comparison of the changes in 
this ratio over time provided evidence (p=0.02) of a difference between groups as shown in 
Figure 6.1. In controls the right hippocampal volumes were, on average, around 2% (mean 
of both visits 1.7% Cl -0.3 and 3.7%) greater than the left hippocampal volumes. This was 
not statistically significant (p=0.1). In AD cases, at baseline, right hippocampal volumes 
were also, on average, about 2% greater than left hippocampal volumes. However at the 
follow-up visit (on average 15 months later) right and left hippocampal volumes were 
similar. This reduction in the right to left ratio in cases was statistically significant 
(p=0.02). Additionally, the variability in the ratio of one volume to the other was 
substantially larger in the AD cases than in controls at baseline (p=0.02) but not at repeat 
(p=0.06). Figure 6.2 shows the hippocampal ratio of ratios (right/left hippocampus at 
baseline divided by the same measure at repeat imaging). This figure demonstrates the 
significant decrease in right/left asymmetry in AD subjects and the greater variability in this
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measure over time compared with the control group. There was no evidence of differences 
in hippocampal ratio by gender at baseline or repeat imaging (p> 0.1). There was no 
evidence of a significant association between hippocampal ratio at baseline and either 
MMSE (p = 0.84), or age (p = 0.32) in the AD group. There was no evidence of a 
significant association between age and hippocampal ratio at baseline imaging in controls 
(p= 0.52).
The reduction in the right to left ratio in AD patients was reflected in greater atrophy in the 
right than the left hippocampus although this just failed to reach statistical significance 
(p=0.05). In controls, atrophy rates were much lower than in AD patients (p<0.001, both 
for left and right) and similar in the two hippocampi (p=0.9). Retrospective power 
calculations showed that in order to detect a significant difference in atrophy rates between 
the right and left hippocampus in AD subjects, 115 subjects would be required.
The presence of an APOEe4 allele had no significant effect on left or right hippocampal 
size or their ratio at baseline and repeat in this study (p>0.4). Mean (95% Cl) right/left 
hippocampal ratios at baseline for the APOEs4- and APOEe4+ groups were 1.01 (0.92, 
1.10) and 1.03 (0.97, 1.09) respectively (p=0.76). At repeat the mean (95% Cl) ratios for 
the APOEs4- and APOEe4+ groups were 0.99 (0.92, 1.06) and 1.00 (0.94, 1.06) 
respectively (p=0.80). The presence of an APOEe4 allele had no significant effect on the 
atrophy rates of either the left or the right hippocampus in this study (both p>0.2). Mean 
(95% Cl) rates for the left and right hippocampus in the APOEe4- patients were 3.3 (1.1, 
5.4) and 5.3 (2.9, 7.8) respectively; in the APOEs4+ patients these were 4.9 (2.4 7.4) and 
6.9 (4.7 9.2) respectively. Retrospective power calculations revealed that in order to detect 
a difference in left hippocampal rates between APOE e4+ carriers and non-carriers, 105 
subjects would be required. Analogous statistics for the right hippocampus revealed that 
122 subjects would be required to show a difference.
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Table 6.2 Mean (95% Cl) hippocampal volumes at baseline and repeat imaging with corresponding atrophy rates in control and AD groups
RIGHT (mm3) LEFT (mm3) R/L Ratio ATROPHY (%/YR)
RIGHT LEFT
CONTROLS BASELINE
2715
(2631,2801)
2669 
(2586, 2754)
1.017 
(0.996, 1.039) 1.1 
(0.5, 1.8)
1.2 
(0.5, 1.8)
REPEAT
2683 
(2600, 2769)
2637
(2551,2727)
1.017 
(0.996, 1.039)
AD BASELINE
2262
(2110,2425)
2220 
(2075, 2375)
1.019 
(0.981, 1.058) 6.3 
(4.9, 7.8)
4.6 
(3.3, 6.0)
REPEAT
2095
(1941,2261)
2108 
(1970, 2256)
0.994 
(0.957, 1.032)
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Figure 6.1 Ratios of hippocampi (right /left) at baseline and repeat imaging in control and AD groups.
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6.2.4. Discussion
Normal Controls
In this study, a trend towards right-greater-than-left hippocampal volume asymmetry in 
healthy controls was demonstrated, which concurs with previous studies (Howard et al., 
1995; Jack et al., 1989). An average right>left asymmetry of approximately 2% in 
normal controls was reported, which is somewhat lower than previous studies (Geroldi 
et al., 2000; Soininen et al., 1994). One possible cause of this discrepancy might be the 
different segmentation methodologies employed by different research groups (Pruessner 
et al., 2000). In particular, there may be variations in the boundaries chosen for 
hippocampal delineation. In this study, to aid consistency of the arbitrary boundaries of 
the segmentation both baseline and repeat images were presented to the rater 
simultaneously. In addition, raters were blinded to chronological order and laterality of 
the scans and patient information to limit potential measurement bias. Another possible 
explanation for the difference between this and other studies may result from 
differences in the composition of groups selected for such studies. Of two studies 
assessing healthy elderly cohorts, one reported no significant hippocampal asymmetry 
(Kaye et al., 1997), whilst another found a minor left>right asymmetry (Ashtari et al., 
1999), raising the possibility that hippocampal asymmetry may be affected by age, or 
that asymmetry is an inconsistent finding across different subject groups.
Alzheimer’s Disease
The hippocampal volume reductions in individuals with AD were consistent with 
numerous previous publications (Convit et al., 1993; Du et al., 2004; Kohler et al., 
1998; Krasuski et al., 1998; Laakso et al., 1995; Mega et al., 2002).
Several cross-sectional studies have suggested that alterations in right-greater-than-left 
asymmetry in hippocampal volume may be associated with age-associated memory 
impairment (Soininen et al., 1994), the possession of the APOEs4 allele (Geroldi et al., 
2000; Soininen et al., 1995), or the process of AD (Geroldi et al., 2000), and that such 
changes reflect altering rates of left/right hippocampal atrophy as the disease progresses. 
However, other studies have suggested that AD may be associated with preferential 
involvement of the left hemisphere (Scahill et al., 2002; Thompson et al., 2001; 
Thompson et al., 1998). Metabolic deficits have also been shown to be more severe on 
the left than the right in individuals with increased genetic risk of developing AD (Small
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et al., 2000). Another study suggested there was no interaction between laterality of the 
hippocampus and AD -  control volume differences (Du et a l , 2004).
A non-significant right>left asymmetry of approximately 2% was found in the subjects 
with AD at baseline but no asymmetry at repeat. This was caused by a borderline- 
significant trend for higher atrophy rates in the right hippocampus. This resulted in a 
decline in the degree of asymmetry in the patient group over the period of assessment 
which was just statistically significant, however, as Figure 6.1 shows there is a wide 
range in the right/left ratios. Retrospective sample size calculations showed that a 
sample of 115 subjects would be required to detect a significant difference between left 
and right hippocampal rates in the AD group.
Hippocampal atrophy rates were greater in patients than controls, in keeping with 
previous longitudinal studies (Du et al., 2004; Jack et a l, 1998; Jack et a l, 2000; Jack 
et a l, 2004; Laakso et a l, 2000b) (see Table 1.3). The combined hippocampal atrophy 
rate of 5.5% per annum in patients with AD (including those with young onset FAD) is 
similar to other studies (3.5% (Jack et a l, 2000), 4.0% (Jack et a l, 1998), 3.0-3.6% 
(Jack et a l, 2004) 5.4% (Cardenas et a l, 2003), 5.9% (Du et a l, 2004), 7.2% (Laakso et 
a l, 2000b), 4-8% (Fox et a l, 1996b)). If hippocampal asymmetry changes over the 
course of AD, as suggested by Geroldi et a l, a significant right-greater-than-left atrophy 
rate should be detected by longitudinal studies. In previous longitudinal series (28 
subjects with AD), Jack et a l  concluded that annual rates of volume change for the left 
and right hippocampus did not differ (Jack et a l, 1998). Laakso et a l found significant 
loss of right hippocampus compared to controls, but non-significant loss of left 
hippocampus compared to controls (Laakso et a l, 2000b) suggesting the possibility of 
greater right hippocampal atrophy.
In this study, the fact that nearly half of the patients had familial rather than sporadic 
AD might have independently affected hippocampal atrophy rates. Increased variability 
within the AD atrophy rates compared with controls was also found which may be a 
reflection of a variety of disease severities or true heterogeneity. Greater variability in 
the AD group is supported by the finding of increased cortical variability (variability of 
deep sulci) in subjects with AD compared to controls (Thompson et a l, 1998). This 
increased variability may possibly explain the range of results in the literature and
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reduces the power of a relatively small study to comment on extremely subtle 
volumetric findings.
No significant association between the asymmetry at baseline or repeat visit and the 
presence of the APOEe4 allele was found. This is consistent with a number of studies 
(Jack, Jr. et al., 1998; Reiman et al., 1998). In addition, it was found that the APOEe4 
allele had no significant effect on the atrophy rates of either the left or right 
hippocampus. These findings are consistent with a number of reports (Bigler et al., 
2002; Jack et al., 1998) but contradict findings of another study which suggested a gene 
dose effect of APOEs4 causing increased reversal of asymmetry (Geroldi et al., 2000). 
This study, much like the results reported in this chapter, had relatively little power to 
detect subtle effects of numbers of patients 14 APOEe4 -/- 9 APOEs4 +/- and 5 
APOEc4 +/+. The study reported in this section of this chapter had relatively small 
numbers of patients with APOE confirmed status although one would expect if there 
were any effects of the magnitude found by Geroldi then a significant trend in either 
asymmetry or atrophy rates would have been found. However, it must be noted that the 
presence of at least one APOEe4 led to higher mean atrophy rates in both left and right 
hippocampi in the results reported in this chapter. It may be that owing to the high 
variability of, and small numbers in, the two groups, there was not enough power to 
detect a significant difference. Retrospective sample size calculations showed that a 
sample of 115 subjects would be required to detect a significant difference between left 
and right hippocampal rates in the AD group. In addition, as nearly half the AD group 
consisted of familial cases it is possible that any subtle effects caused by the e4 allele 
were masked. Further research is required to establish any interaction between the e4 
allele and other known genotypes in these familial cases.
Whilst these findings suggest a disease-related reduction in asymmetry caused by 
increased right hippocampal atrophy a greater variability in asymmetry and atrophy 
rates is also reported. For these reasons, it is suggested that alterations in the normal 
right-left asymmetry of the hippocampus are not necessarily a reliable indicator of 
disease progression in AD. Furthermore, caution is suggested in accepting the right 
hippocampus is a superior surrogate marker of AD compared to left hippocampus or 
that hippocampal measurement should necessarily be restricted to the right in studies. 
Instead, taking the average of left and right hippocampal measures may reduce the 
effect of measurement error without a loss of sensitivity to change.
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6.2.5. Conclusions
Using mirror-image volumetry it has been demonstrated that a non-significant right>left 
asymmetry in hippocampal volumes in healthy subjects. Right>left asymmetry was 
present in the AD at baseline but reduced at repeat (approximately 15 months later) and 
this measure was associated with greater variability compared to controls. Reduction in 
asymmetry was caused by a borderline significantly greater atrophy rate in the right 
hippocampus. In this group, neither volumes, asymmetry ratios nor rates were affected 
by the presence of an c4 allele.
6.3. Hippocampal volumes and atrophy rates in presymptomatic
FAD
6.3.1. Introduction
The hippocampus is one of the earliest sites of pathological alteration in AD (Braak et 
al., 1993). The pathology has been shown to be present in about 85% of subjects with 
MCI, a stage considered to be a transitional between normal ageing and AD (Morris et 
al., 2001). Quantification of AD pathological changes within the hippocampus have 
been shown to correlate with hippocampal volumetric measures using post-mortem MRI 
(Bobinski et al., 2000; Gosche et al., 2002). In addition, several in-vivo imaging studies 
have shown significant hippocampal volume reduction in patients with a clinical 
diagnosis of AD compared with controls (Jack, Jr. et al., 1992), even in the early mild 
stages of the disease (Jack et al., 1997) and in patients with MCI (Jack et al., 1999).
Although most AD cases are sporadic, rare familial forms of the disease exist with an 
autosomal dominant pattern of inheritance. As discussed in Chapter 1, page 20), 
mutations in three genes have been identified; APP, PS-1 and PS-2 (Hardy, 1997). 
FAD results in significantly younger ages of onset than SAD; however, patients develop 
a similar pattern of insidious onset and progressive decline affecting episodic memory 
followed by global cognitive dysfunction (Fox et al., 1998).
Serial imaging of mutation carriers from presymptomatic to affected provides an 
opportunity to track MRI changes that may precede clinical manifestations. Their 
relatively young age at disease onset minimises the confounding effect of age-related 
co-morbidity. In a previous longitudinal MRI study from this centre, Schott et al.
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estimated that atrophy of medial temporal lobe structures preceded the clinical onset of 
the disease by an average of 3.5 years (Schott et a l, 2003). This was, however, based 
on only 5 FAD subjects who had 15 scan points in total over 2-4 years of assessment.
This study expands on previous work by including further FAD subjects and scanning 
time-points. This permits the use of hierarchical modelling of how hippocampal and 
whole brain volumes change as the disease progresses from the pre-symptomatic stage 
through to AD diagnosis.
6.3.2. Methods 
6.3.2.1.Subjects
Nine carriers (four males) of autosomal dominant AD mutations (five with mutations in 
APP and four with mutations in PS-1) were recruited from the Cognitive Disorder’s 
Clinic at the National Hospital for Neurology and Neurosurgery. Twenty-five age- and 
gender-matched controls (2-3 controls per mutation carrier) were recruited from spouses 
(n=7), unaffected relatives including those with negative genetic test results (n=4), and 
healthy volunteers (n=14). All subjects gave informed written consent with assent of 
next-of-kin of all clinically-affected mutation carriers, as approved by the local ethics 
committee. Clinical assessments and scanning were preformed between the years 1991 
and 2005. All mutation carriers underwent comprehensive clinical and 
neuropsychological assessments including the MMSE (Folstein et al., 1975) (see 
Appendix Two), and volumetric MRI scans at each visit (41 visits: 3-8 per subject). 
Each control subject had two MRI scans (except two subjects who had four scans each) 
adding up to 54 scans in total. The clinical status of each mutation carrier was classified 
at each time-point as: 1) FAD affected, if the subject fulfilled National Institute of 
Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and 
Related Disorders (NINCDS-ADRDA) diagnostic criteria for probable AD (McKhann 
et a l, 1984) (see Appendix One) 2) MCI, if the subject fulfilled the MCI criteria 
(Petersen et al., 1999), and 3) presymptomatic, if subjects fell short of both NINCDS- 
ADRDA and MCI criteria. All mutation carriers eventually became affected and so 
have a known date of onset, except one who has remained presymptomatic. In this case, 
the age of onset was estimated from the mean age of onset from other affected members 
in the subject’s pedigree.
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6.3.2.2.MRI Acquisition 
In the period 1991-2000, imaging was performed on a 1.5T GE Signa scanner (General 
Electric Medical Systems, Waukesha, WI, USA) according to the standard protocol (see 
Appendix Three). In the period 2001-2005, volumetric coronal Ti-weighted MR 
imaging was performed on a different 1.5T GE Signa scanner running software version 
5.8 (General Electric Medical Systems, Waukesha, WI, USA) using the following 
protocol: a inversion recovery prepared fast spoiled gradient-echo technique (256x256 
matrix, FOV 24x18 cm, TR/TE/TI/NEX/FA = 14 ms/5.4 ms/650ms/l/15° yielding 124 
contiguous 1.5-mm-thick slices).
6.3.2.3.Image processing 
Volumetric image analysis was performed blind to subject details using the MIDAS 
software. Brain regions were extracted from surrounding tissue using a semi-automated 
technique and manually edited where necessary to obtain a whole brain volume (see 
Appendix Four). TIV was calculated in order to adjust for differences in head size 
between individuals as previously described (Whitwell et al., 2001) (see Appendix 
Four).
Change in whole brain volume was calculated using the BSI (Freeborough and Fox, 
1997). The BSI was performed first by registering each repeat scan to its baseline pair 
using an affine (12 dof) algorithm, and then calculating the volume change directly over 
the entire 3D brain-CSF interface. Annualised rates of whole-brain atrophy were 
calculated as a percentage of the baseline-adjusted brain volume for each scanning 
interval. Atrophy rates that span the change in MRI scanner were ignored, as the BSI 
may not be reliable, due to differences in image quality between scanners.
For hippocampal volume measurements, all scans were first registered to a standard 
brain template (MNI 305) (Mazziotta et al., 1995) using six dof algorithm to reduce any 
variability in landmarks used in delineating the hippocampus. Repeat scans were then 
registered to corresponding baseline scans using a nine dof algorithm. Each 
hippocampus was manually traced using multiple views to include the comu ammonis, 
gyrus dentatus and subiculum (see Appendix Four). Left, right and total (left+right) 
hippocampal volumes were calculated and adjusted for TIV as previously described. 
Changes in adjusted total hippocampal volumes were calculated by subtracting repeat 
from the baseline hippocampal volumes for each scan pair. Annualised rates of
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hippocampal atrophy were calculated as a percentage of the baseline hippocampal 
volume for each scan pair.
6.3.3. Statistical analysis 
Mean adjusted whole brain and total hippocampal volumes were calculated for each 
subject category (controls, presymptomatic, MCI and AD). The presymptomatic and 
AD stages were further subcategorised into earliest and latest stages, as most mutation 
carriers had more than one scan in each of these categories. Rates of atrophy across 
category transitions (last presymtomatic to MCI transition, MCI (or last 
presymptomatic, if no MCI stage identified) to earliest AD transition) and within 
categories (earliest presymptomatic to latest presymptomatic, earliest AD to latest AD) 
were also calculated. Imaging data of patients in each category were compared with 
controls using two-sample t-tests with allowance for unequal variances.
Separate hierarchical models were developed for adjusted whole brain and total 
hippocampal volumes using SAS Proc Mixed. The models related the repeated volume 
measures to time to clinical diagnosis of AD. Random intercepts and slope terms, where 
needed, were fitted to allow for the repeated within-subject measurements.
In order to compare volumes and atrophy rates between controls and mutation carriers, 
the date of a control’s last scan was assumed to correspond to date of clinical diagnosis 
in mutation carriers. A constant atrophy rate for controls was assumed.
Fixed quadratic terms in time were allowed to assess evidence of acceleration in atrophy 
in the mutation carrier group. Where there was evidence it was needed and estimation 
was possible, separate variance parameters for the control and AD groups were fitted. 
Log-transformation of volume measurements was performed to model percentage 
changes. Since some patients had scans on two different scanners, a fixed scanner 
effect covariate was added. To account for the small sample size, adjusted degrees of 
freedom were used for the confidence intervals of fixed effects (Kenward and Roger, 
1997).
A separate hierarchical model was fitted to the BSI-derived measures of brain volume 
changes between consecutive scans, allowing for the additional within-subject 
correlation structure of direct measures of change (Frost et a l, 2004). The outcome
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variable was the logarithm of the ratio of volume at the second scan to the volume at the 
first scan, with the volume at the second calculated using the volume at the first and the 
BSI change.
6.3.4. Results
Table 6.3 shows that adjusted total hippocampal volumes of mutation carriers were 
smaller than those of age- and gender-matched controls at each stage, but the 
differences were not statistically significant until the MCI stage. There were statistically 
significant differences in adjusted whole brain volumes only once mutation carriers 
fulfilled the clinical criteria for AD. However, there was statistically significant 
evidence that rates of hippocampal atrophy and whole brain atrophy were already higher 
in the presymptomatic and subsequent MCI and AD stages for mutation carriers 
compared with controls (Table 6.4). As mutation carriers moved through the clinical 
stages of AD, both total hippocampal and whole brain mean atrophy rates 
correspondingly increased.
In the control group, there was statistically significant hippocampal asymmetry with the 
right hippocampus (mean±SD) larger than the left (29811230 vs. 28151177, p<0.0001). 
Although the mean right hippocampal volume was consistently larger in value than the 
mean left hippocampal volume in mutation carriers at every clinical stage, the left/right 
differences were not statistically significant (paired t-tests, all p>0.05). There was no 
evidence that unaffected relatives differed from the other controls in either volume or 
atrophy rates, for either total hippocampus or whole brain (all p>0.2).
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Table 6.3 Cross-sectional analysis o f the data according to clinical status.
Controls,
n=25
Presymptomatic,
n=8
MCI,
n=6
AD,
n=7
Subcategory* Mean Earliest latest mean earliest latest
Age (years), mean (SD) 46.5 (10) 43.4 (7.1) 44.7 (6.5) 49.4 (6.6) 49.8 (7.6) 50.8 (7.9)
Males, n (%) 9(36) 3 (38) 3(38) 3(50) 3(43) 3(43)
Years from AD diagnosis, mean (SD) NA -4.6 (2.1) -3.3 (2.1) -1.8 (1.7) 0.5 (0.8) 1.5 (1.5)
MMSE, mean (SD) NA 28.9(1.1) 28.0(1.7) 27.0 (2.5) 23.9 (4.0) 18.9 (7.8)
Adjusted brain voIume(TR) (ml), 
mean (SD)
1212.6
(42.3)
1214.7
(49.6)
p=0.92
1205.4
(48.6)
p=0.71
1162.9
(71.6)
p=0.15
1129.5
(54.0)
p=0.005
1103.5
(74.0)
p=0.007
Adjusted total hippocampal volume 
(mm3), mean (SD)
5797.1
(378.7)
5502.9
(710.7)
p=0.29
5367.7
(748.8)
p=0.16
4989.5
(780.3)
p=0.05
4624.9
(741.9)
p=0.005
4366.0
(925.2)
p=0.006
P-values are for two-sample t-tests comparing patients in each category with controls.
* Earliest refers to the earliest scans/clinical assessment available in that stage; latest refers to the latest scans/clinical assessment available in that 
stage; mean refers to the mean values available from scans/clinical assessments available at that stage.
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Table 6.4 Longitudinal analysis o f the data according to transition stage.
Transition* Control-
control
N=25
presymptomatic-
presymptomatic
N=6
Presymptomatic-
MCI*
N=5
Presymptomatic
/MCI-AD*
N=6
AD-AD 
N=5
Age, (years), mean (SD) 46.5 (10.2) 42.9 (7.6) 49.0 (7.2) 48.0 (7.8) 52.1 (7.8)
Mean years from diagnosis 
of AD, mean (SD)
NA -3.9 (1.6) -2.6 (2.0) -0.2 (0.5) 1.43 (1.03)
Males, n (%) 9(36) 3(50) 2(40) 3(50) 2(40)
Mean MMSE, mean (SD) NA 28.3(1.3) 27.0(1.4) 26.0 (2.1) 19.5 (3.9)
Scan interval (years), mean 
(SD)
1.5 (0.8) 1.8 (0.9) 1.5 (0.6) 1.5 (1.0) 1.3 (0.7)
Rate of MMSE decline 
(points/year), mean (SD)
NA 0.7 (1.1) 0.7 (2.2) 0.8 (0.9) 4.1 (4.3)
Brain atrophy rate 
(%/year), mean (SD)
0.00 (0.57) 0.51 (0.32)
p=0.01
0.52 (0.51)
p=0.08
1.82 (0.87) 
p=0.003
1.79 (0.74) 
p=0.004
Total hippocampal atrophy 
rate (%/year), mean (SD)
0.31 (1.25) 1.74(1.12)
p=0.03
3.02(1.85)
p=0.03
3.44(1.25)
p=0.0007
6.52 (2.31) 
p=0.003
P-values are for two-sample t-tests comparing patients in each category with controls.
* Comparison was between the latest scan/clinical assessment available in earlier stage and the earliest scan/clinical assessment o f the later stage.
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Figure 6.3 shows the adjusted total hippocampal volume measurements for mutation 
carriers and controls. The hierarchical model showed strong evidence of hippocampal 
atrophy (p<0.0001) and acceleration (p<0.0013) in the mutation carrier group. The 
estimated mean difference in adjusted total hippocampal volume between mutation 
carriers and controls therefore increased with time, with the difference becoming 
statistically significant at the 5% significance level just over three years before fulfilling 
the clinical criteria for AD (Figure 6.4). By that time, the mean total adjusted 
hippocampal volume of mutation carriers was estimated to be 90.16% (95% Cl 81.72%, 
99.47%) that of controls.
The model estimated the annualised total hippocampal atrophy rate in controls to be 
0.23% (95% Cl -0.19%, 0.66%). The estimated difference in the mean hippocampal 
atrophy rate between mutation carriers and control groups became statistically 
significant (5% level) 5.5 years prior to the time of clinical conversion to AD, with a 
difference of 1.55% (95% Cl 0.04%, 3.04%) (see Figure 6.5). The mean hippocampal 
atrophy rate difference was estimated to increase by 0.40% (95% Cl 0.17%, 0.63%) per 
year.
Figure 6.6 shows the adjusted whole brain volumes for mutation carriers and controls. 
The model for adjusted whole brain volumes showed strong evidence of increasing 
atrophy in the mutation carrier group (p<0.0001). The estimated mean difference in the 
adjusted whole brain volume between mutation carriers and controls thus increased with 
time, with the difference becoming statistically significant one year before clinical 
diagnosis (see Figure 6.7), by which time, the mean whole brain volume of mutation 
carriers was estimated to be 96.36% (95% Cl 92.95%, 99.91%) that of controls. There 
was evidence (p<0.0001) of a scanner effect in this model with a mean difference of 
4.77% (95% Cl 3.21%, 6.35%) in brain volume measurement between the two scanners, 
with the former providing larger volumes.
From the hierarchical model for BSI-derived whole brain changes, the annualised rate 
of atrophy in controls was estimated to be 0.01% (95% Cl -0.14, 0.16%). There was 
strong evidence of whole brain atrophy in the mutation carriers (p<0.001), and also of 
acceleration in the whole brain atrophy rate (p<0.001). The estimated difference in 
mean whole brain atrophy rates between mutation carriers and controls became 
statistically significant around 3.5 years prior to AD diagnosis, with a mean difference
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(3.5 years prior to conversion) of 0.51% (95% Cl 0.12%, 0.89%) (see Figure 6.8). The 
mean difference increased by 0.26% (95% Cl 0.16%, 0.37%) per year.
There was no evidence that either total hippocampal or whole brain atrophy rates 
differed according to gender at each of the clinical stages within the mutation carrier 
group (unpaired t-tests; all p>0.05), or from the hierarchical models for total 
hippocampal volume and whole brain volume (both p>0.2). There was statistically 
significant evidence from the model for BSI-derived whole brain changes that the 
atrophy rate was greater male mutation carriers than in women (p=0.03), although with 
such small numbers this may well be due to confounding.
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Figure 6.3 Adjusted total hippocampal volume measurements o f mutation carriers 
(relative to time of clinical diagnosis o f AD) and controls (relative to the date o f their 
last scan).
The y-axis scale is logarithmic. AD= Alzheimer’s disease.
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Figure 6.4 Model estimated mean adjusted total hippocampal volume o f mutation 
carriers as a percentage o f mean adjusted total hippocampal volume o f controls. 
Short dashed lines indicate approximate 95% confidence interval limits for the mean 
difference. The y-axis scale is logarithmic. He = hippocampus.
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Figure 6.5 Model estimated mean difference in total hippocampal rate between 
mutation carriers and controls.
Short dashed lines indicate approximate 95% CIs for the mean difference.
He = hippocampus
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Figure 6.6 Adjusted whole-brain volume measurements o f mutation carriers (relative to 
time o f clinical diagnosis o f AD) and controls (relative to the date o f their last scan). 
The y-axis scale is logarithmic.
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Figure 6.7 Model estimated mean adjusted whole-brain volume o f mutation carriers as 
a percentage of mean adjusted whole-brain volume o f controls.
Short dashed lines indicated approximate 95% Cls for the mean difference. The y-axis 
scale is logarithmic.
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Figure 6.8 Model estimated mean difference in BSI-derived whole brain atrophy rates 
between mutation carriers and controls.
Short dashed lines indicate approximate 95% confidence interval limits for the mean 
difference.
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6.3.5. Discussion
This study demonstrates evidence of atrophy of whole brain and hippocampus as seen 
on serial MRI, which predates the clinical diagnosis of AD. The study has shown that 
by the time AD was diagnosed clinically, the estimated mean hippocampal volume in 
patients was 18.1% smaller than in controls and mean whole brain volumes were 5.4% 
smaller. Longitudinal measures of hippocampal and whole brain atrophy were more 
sensitive than cross-sectional volume measures at detecting group differences, with the 
former detecting change 2-3 years earlier than the latter. This is somewhat unsurprising 
since cross-sectional data are more susceptible to inter-subject variability than 
longitudinal measures. By using more mutation carriers and assessment/scanning data 
points than previously reported, this study was able to 1) demonstrate statistical 
evidence of acceleration in the atrophy rates of whole brain and hippocampus in the 
years preceding and following the diagnosis of AD, and 2) provide more precise 
estimates of volumes and rates of atrophy at different clinical stages of the disease than 
previously published (Schott et al., 2003).
In this study, there was no evidence of progressive atrophy in the control subjects, 
which probably reflects their young age (mean=46 years). Previous work has shown 
evidence of whole brain and hippocampal atrophy as a result of normal ageing with 
acceleration above the age of 70 years (Scahill et al., 2003).
Although the hippocampal region is not the only region of interest in the evolution of 
AD neuropathology, the hippocampus was chosen as an example of a region that has 
been shown to be affected early in the disease process, and it was monitored as to how it 
changed in relation to the clinical stage. Understanding the involvement of other brain 
regions remains an important issue to be addressed in future studies. This would require 
either manual segmentation of other brain regions (such as the entorhinal cortex) or 
evaluating the pattern of atrophy without prior assumptions of where the pathology 
starts (for example, using voxel based morphometry).
There are a few limitations to this study. Generalisation of our findings based on FAD 
cases to sporadic AD is limited by the potential biological differences in the two forms 
of the disease, with the former having definite genetic risk factors and significantly 
younger age at disease onset than the sporadic form. Nonetheless our findings accord
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with previous studies in sporadic AD and MCI which have shown atrophy of medial 
temporal lobe structures and whole brain prior to clinical diagnosis (Fox and Schott, 
2004; Jack et al., 2000; Jack et al., 2004; Kaye et al., 2005; Rusinek et al., 2003; Stoub 
et al., 2006). One advantage of the study of individuals at risk for FAD is that it is 
feasible to study asymptomatic subjects longitudinally for many years prior to clinical 
onset. Another strength of this cohort is that their young age means they have relatively 
little age-related co-morbidity such as vascular disease that may confound assessment of 
the earliest effects of AD pathology in older sporadic AD.
One potential source of bias in our study is the exclusion of five other scans among 
mutation carriers due to sub-optimal quality, which could have provided further data 
points. Another source is that control subject had less scans per subject than mutation 
carriers. As a result, a constant atrophy rate in controls had to be assumed and these 
results extrapolated under the assumption they are constant. Although having fewer 
scans results in less precise estimates, attempts were made to improve the estimates by 
including more controls in comparison to mutation carriers (25 vs. 9).
It is acknowledged that although this is the largest analysis of serial imaging in FAD 
reported (n=9 having a total of 41 scans/assessments), the sample size is still relatively 
small. In addition, although imaging resolution was consistent, scanning was done on 
two units with different sequence parameters. This is inevitable due to scanner and 
sequence upgrades over the 14 years of assessment. An attempt was made to control for 
this by avoiding BSI measurements across scanners and by including scanner-unit as a 
covariate in our statistical models. Finally, hierarchical models that allowed volumes to 
vary as a quadratic function of time were fitted, which is clearly a simplification of the 
truth. Estimates are conditional on this parameterisation, and therefore should be viewed 
with appropriate caution. However, this is more realistic than a model assuming 
constant rates of atrophy (Schott et al., 2003). With larger datasets it will be possible to 
fit more sophisticated patterns of atrophy.
In conclusion, this study provides evidence of acceleration of brain atrophy with 
disproportionate hippocampal involvement preceding the clinical diagnosis of AD in 
mutation carriers.
- 189-
6.4. Chapter conclusions
This chapter shows the use of combining cross-sectional and longitudinal data in 
investigating both subtle questions such as asymmetry and to establish when changes 
can be detected in hippocampal volumes prior to the development of symptoms.
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7. AUTOMATED SUBDIVISION OF MANUAL SEGMENTATIONS
7.1. Chapter introduction
Subdivision o f structures
As described earlier in Chapters 4 and 5 (pages 98 and 134), there is evidence to suggest 
that pathological processes such as AD affect the cingulate at an early stage of the 
disease. Moreover, evidence from a number of imaging modalities and pathological 
studies have suggested that some sections may be more affected than others; PET 
imaging has revealed hypometabolism principally in the posterior sections, and MRS 
has shown metabolite changes again in the posterior, and volumetric MR imaging has 
revealed differential patterns of volume of subsections along the length of the cingulate 
(Callen et al., 2001; Killiany et al., 2000) (see results presented in Chapter 4, page 108 
and Chapter 5 (page 148)). Measuring atrophy in sections of the cingulate may 
therefore be a more useful and sensitive marker of the disease, particularly in the early 
stages. In addition, understanding which section is affected may mean reduction in the 
amount of labour-intense delineation of regions in the future as one section may require 
segmentation.
Manual segmentation
It has been shown that subdivision of the cingulate region into smaller ROIs reveals 
patterns of atrophy which differ between patient groups (see Chapter 4 (page 109) and 
Chapter 5 (page 148)). However, this requires an initial segmentation of the cingulate 
gyrus which takes approximately fifty minutes followed by manual subdivision taking a 
further ten minutes. Manual subdivision requires application of subdivision protocols 
and much like any other protocol, the interpretation of this may introduce operator 
errors. Furthermore, the cingulate is a complex structure with convoluted folds, 
together with a large degree of inter-individual variation in gyral and sulcal patterns 
within and proximal to the gyrus. As described in detail in Chapter 4 (page 98), this 
makes consistent labelling and subdivision difficult as the manual subdivision is 
dependent on landmarks which are not proximal or intrinsic to the structure; the anterior 
and posterior commisures are located at some distance from the gyrus and as a result the 
application of protocols dependent on these structures could potentially introduce bias, 
and/or variability or inaccuracy in these results. Therefore subdivision of the cingulate 
according to approximate tissue types as described in Chapter 4 and Chapter 5 (see 
pages 106 and 141 respectively) may be unnecessarily effortful.
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As discussed in Chapter 4 and Chapter 5, subdivision of regions may be appropriate in 
many cases; however scale must be considered. The care taken per voxel when 
segmenting small structures as a proportion of the whole structure is much greater than 
the care taken with larger structures. Therefore, this form of subdivision may not be 
appropriate in all cases and instead, further manual demarcation protocols may be 
developed for the smaller structures of interest for example, the retrosplenial cortex.
Other methods used for subdivision
Other structures which may be considered to be similar to the cingulate in structure have 
been subdivided automatically. The corpus callosum is a white matter structure which 
runs along the inferior of cingulate gyrus which joins the two cerebral hemispheres. 
This structure has been studied in AD by segmenting it on the mid-sagittal slice and 
subdividing into a number of sections using a template mask see Figure 7.1 (Hampel et 
al., 1998). Problems with accuracy may arise when using this type of method as it is 
theoretically not robust to differences in the relative anatomy (see Figure 7.2) which are 
particularly extensive in the cingulate (Ono et al., 1990) (see Figure 7.3). Instead, for 
the cingulate, a method which models the curve of the structure and divides according 
to its relative length may be more appropriate and potentially less susceptible to the 
diameter of the structure affecting the borders of the subdivisions.
Bezier method application to cingulate gyrus
In this chapter a method of subdivision of the cingulate into distinct sections i.e., RAC, 
CAC and PC using a Bezier curve method of automated subdivision is described and 
assessed. This chapter aims to describe the application of this technique and the 
potential advantages in using this for structures such as the cingulate gyrus.
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Figure 7.1 Subdivision of the corpus callosum using Hampel’s box method.
Measurement of the corpus callosum subregions is performed in the midsagittal slice (cl: rostrum and genu; c2-c4: truncus; c5: isthmus 
and splenium).
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Figure 7.2 A demonstration of the problem of Hampel’s box method.
Structures ‘b-d’ are edited variations of structure V  which have been enlarged and extended inferiorly in regions marked by arrows. By 
changing the diameter of the structure at the inferior border (arrows), the template box rotates and the segmentation of all subdivisions is 
influenced.
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Figure 7.3 Segmentations of the cingulate gyrus.
This shows variety of different types of topology in the cingulate region in four different subjects (a-d).
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7.2. Methods
7.2.1. Subjects and Imagine
Nineteen AD and eleven control subjects with mean ages approximately 56 years were 
included in this study. For further details of these subject groups see Chapter 5 (see 
page 135 and Table 5.1). Each subject had two scans taken at over one year inter-scan 
interval.
7.2.2. Cinsulate segmentation
The manually-delineated cingulate ROIs which were used for subdivision were 
described in Chapter 5 (page 134).
7.2.3. Cinsulate subdivision
The Bezier method of subdivision by (Boyes et al., 2004) was used. Briefly, the 
cingulate is segmented on Tl-weighted volumetric MRI scans to define a binary mask 
that identifies the structure on the scan (see Figure 7.3). The method finds an 
approximation to the central axis of the cingulate by fitting a Bezier curve through the 
volume and then partitions the mask using a plane perpendicular to this axis. This 
method takes a cingulate ROI defined on a volumetric MR scan and fits (in a least 
squares sense) a cubic Bezier curve to this mask. This curve is used as a smooth 
approximation to the central axis of the cingulate, enabling the estimation of the length 
of the structure, and also the partitioning of the three dimensional mask into sections. 
The fitting process requires that start and end points of the curve are manually fixed. 
These were selected to be the lowest point of the posterior cingulate and in the middle 
of the anterior cingulate on the same sagittal slice (see Figure 7.4). The cingulate was 
then divided into thirds on the baseline and repeat ROIs. Rates of atrophy were 
calculated in the way described previously (see Chapter 5, page 141).
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Figure 7.4 Schematic diagram showing landmarks 1 and 2 are manually selected by the 
use for Bezier-based cingulate subdivision.
‘a ’shows the curve of the cingulate is modelled by a Bezier curve. The user selects 
which region of the ROI to subdivide. The subdivision is based on the relative length of 
the curve ‘b ' which is selected by the user. The result ‘c ’ is a 3D rendered example of a 
subdivided ROI.
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7.2.4. Testing for consistency
As a test for the consistency of the Bezier curve fitting method, the scans of the 11 
healthy subjects at two time points were used, assuming no disease-related change in 
the cingulate. The proportion of the PC volume to the whole cingulate volume was 
calculated for all subjects using both manual and automated methods. The proportion 
measure was tested for differences in variance between methods at both baseline and 
repeat imaging using Pitman’s test. The proportions were tested for a difference in 
means and variances between the two time points for both methods.
7.2.5. Rates o f atrophy in disease groups
The Bezier curve method was then applied to the AD subjects in addition to the healthy 
control subjects. Cingulate masks were cleaved into thirds using Bezier curves at both 
time points, approximating each as the RAC, CAC and PC. Mean (SD) volumes 
corrected for TIV, according to Equation 4.1, at baseline imaging were calculated. 
Paired t tests were performed on each subdivision according to method to establish 
whether each method was sampling approximately the same volume. Atrophy rates 
(mean % loss/year) of the whole cingulate and the three divided regions were calculated 
for all subjects. Student’s t tests allowing for unequal variances were used to test 
differences in AD vs. controls for each automated cingulate subdivision.
7.3. Results
7.3.1. Consistency
The initial test comparing the Bezier curve cleaving method with manual segmentation 
of the PC showed that the difference in the variance in PC as a proportion of cingulate 
in the control group was reduced using the automated method at both time points 
(baseline (p=0.009) and repeat imaging (p = 0.013)). There was no evidence that this 
proportion was less variable over time (p = 0.53) using the automated measurement.
7.3.2. AD and controls across the subdivisions
Volumes of the cingulate on baseline imaging according to manual and automated 
methods are presented in Table 7.1 with associated p values. Mean volumes were 
significantly different in each subdivision according to method except for the posterior 
cingulate in controls. At baseline, only the PC was significantly different in volume 
between the AD and control group (p=0.0051 for manual methods and p=0.00072 for 
automated methods). The rates of atrophy of the cingulate and its sub-regions were
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different in means between AD and control subjects (Table 7.2 and Figure 7.5). Within 
the AD group the PC had a higher rate of atrophy than the whole cingulate, although it 
was not significant (p = 0.078).
Table 7.1 Mean (SD) volumes o f the cingulate gyrus in AD and controls according to 
method at baseline imaging.
Controls AD
Manual Automated p value Manual Automated p value
RAC 7733 (1426) 4568 (825) <0.0001 7168(1400) 4543 (1080) <0.0001
CAC 3861 (1043) 5910(1298) 0.0006 3409 (635) 5135 (812) <0.0001
PC 5594(1166) 6560 (1297) 0.15 4324(1067) 5140(1044) <0.0001
Table 7.2 Mean and (SD) rates o f atrophy by partitioning cingulate automatically using 
Bezier curves. ___ _________________  ___
Cingulate RAC CAC PC
Controls -0.3 (1.2) 0.5 (6.5) -0.5 (3.0) -2.2 (3.8)
AD 5.9 (3.5) 4.2 (5.4) 5.5 (4.4) 8.1 (5.4)
p-values <0.0001 0.12 0.0001 < 0.0001
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Figure 7.5 Rates of atrophy in the whole cingulate and its three major subdivisions.
-200-
7.4. Discussion
This study has shown that subdivision of the cingulate can be automated and the Bezier 
method is provides more consistent proportions of the cingulate than manual 
subdivisions. However, as the mean volumes of each subregion differed according to 
method this may be the result of differing regions being sampled by each method. For 
example, the cleaved PC region was larger and therefore included areas which were 
generally less variable. Another explanation may be due to the fact that the method is 
fully automated and does not require any user intervention apart from the initial 
selection of start and end points and the selection of the fractional length. Altogether, 
the automated method is a consistent and reproducible way of measuring subsections of 
the cingulate gyrus.
Although it has been shown in Chapter 4 and Chapter 5 (see pages 106 and 141) that the 
cingulate gyrus can be manually subdivided into regions that are thought to approximate 
functionally and histologically distinct regions, these regions cannot actually be seen on 
MRI. In addition there is little evidence that AD pathology or its atrophic effects 
perfectly respect functional or histological boundaries. As a result, this sort of method 
may be less biased as it does not assume the location of borders of these histological or 
function regions.
Within the AD group the PC had a higher rate of atrophy than the other subdivisions. 
There is little published in the literature with respect to atrophy rates of the subdivisions 
of the cingulate gyrus. Chapter 5 (page 134) details a study on these patients which is 
the first to describe rates of atrophy in the cingulate however, cross-sectional volumetric 
studies have been performed and both show reduced volume of the cingulate in the 
posterior sections (Callen et al., 2001; Killiany et al., 2000). Studies involving other 
imaging modalities including PET and SPECT have shown the posterior cingulate to be 
affected in AD (Matsuda et a l, 2002; Minoshima et al., 1997; Valla et al., 2001).
Improvements to the method’s application could be made by performing the analyses on 
a more consistent scan interval and protocol, which may reduce the amount of variation 
in the measurements. Fitting Bezier curves to the cingulate provides an accurate 
approximation to its central axis as the structure is long, reasonably thin and has a 
definite start and end point. Irregularities such as concavities and/or convexities are
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smoothed out as the ratio of these to the overall length of the structure are relatively 
insignificant. Any large deformations in the structure would have an adverse affect on 
the final fit, however. This method may be unsuitable for other structures if the central 
axis is not as apparent as that of the cingulate. An ideal structure for subdivision using 
this method would be the corpus callosum as it has a well defined central axis, and is 
also smooth. Although it is assumed that this method of subdivision may be less biased 
to the anatomical differences in structure borders as Hampel’s method, this study did 
not assess this and as a result this remains purely a theoretical advantage.
7.5. Chapter conclusion
Automation may allow more precise subdivisions of structures to be made from larger 
ROIs with little extra manual intervention. These methods may reveal different patterns 
of atrophy across structures.
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8. SEMI-AUTOMATED METHODS OF MEASURING CHANGES IN THE 
HIPPOCAMPUS
8.1. Chapter Introduction
Background
The previous work (Chapters 5 and 6) describing segmentation of the hippocampus 
using the “gold standard” measure of atrophy requires the outlining of the ROI on each 
MRI “slice”. This technique is time-consuming, and errors in labelling the 
hippocampus may reduce the sensitivity of this method to detect group differences. In 
cross-sectional analysis, the interpretation of differences from controls (e.g. for 
diagnosis) is limited by the large degree of inter-individual variation in brain 
morphology (see Chapter 4, page 97). Examination of volumetric change over time 
within individuals using serial scanning reduces problems of inter-individual variability 
and may provide better group discrimination (Fox et al., 1996a) as well as providing a 
means to monitor disease progression. However, errors in manual delineation become 
very important when small differences are being measured; the hippocampus typically 
loses 3-6 % of its volume over a year in AD (Cardenas et al., 2003; Jack et a l, 1998) 
which is the same order of magnitude as delineation errors in hippocampal 
measurement.
As a result there has been interest in developing methods for automated segmentation of 
the hippocampus, for example (Andreasen et a l, 1996; Csemansky et a l, 1998; Gosche 
et a l, 2001) (see Table 2.1). Fully automated methods to delineate baseline and follow 
up scans using a template often rely on the identification of a number of landmarks, 
which may also be time-consuming and still subject to errors. An alternative approach 
is to use a manually segmented region on a baseline scan to derive subsequent ROIs, 
which can be used to calculate rates of atrophy.
Chapter objectives
Until the automated techniques as described in Table 2.1 become fully validated, semi­
automated approaches may be the most appropriate approach to measuring change in 
the hippocampus. This chapter investigates the use of linear registration of serial 
hippocampi followed by either application of the boundary shift integral (BSI), or a 
further non-linear registration step to calculate the deformation in hippocampal region, 
to measure change over the scanning interval.
-2 0 3 -
8.2. BSI-based methods of automating change
8.2.1. Introduction
One semi-automated approach to measuring change in the brain over time is application 
of the BSI (Fox and Freeborough, 1997) following linear registration to accurately align 
brain structures. This method was designed for the calculation of change in both whole 
brain (Freeborough and Fox, 1997) and has also been applied to ventricular regions 
(Ezekiel et al., 2004; Schott et al., 2005). Both regions involve boundaries which 
exclusively involve CSF and brain. This section describes the first study which applies 
the BSI to smaller grey matter structures which are both complex in shape (see 
Appendix Figure 3) and have borders of mixed tissue types: grey matter, white matter 
and CSF.
In this study this technique was applied to the hippocampus to investigate its utility in 
measuring change in this smaller structure where pathology is known to be 
concentrated, especially at the early stages of the disease. Where the BSI was 
measuring change was assessed, assuming this to be predominantly the grey matter -  
CSF border of the hippocampus. This was compared this semi-automated measure of 
hippocampal change with conventional manual outlining of the hippocampus on serial 
MRI. These measures were applied to subjects with AD and normal controls in order to 
assess their diagnostic utility.
8.2.2. Materials and Methods
8.2.2.1. Subjects
A group of 32 AD subjects and 47 controls who each had two volumetric MRI scans 
were selected, and were matched for age, sex and scan interval. All patients fulfilled 
NINCDS-ADRDA criteria for probable AD (see Appendix One). In addition, three 
subjects had histological confirmation of AD and 12 were from families with familial 
AD and had genetic confirmation. Table 8.1 shows the subject demographics.
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Table 8.1 Subject demographics.
Control AD
Number 47 32
M/F 25/22 14/18
Mean (SD) age in years 59.2(14.1) 59.5(11.3)
Mean (SD) MMSE 29(1) 19 (5)
Mean (SD) scan interval in days 423 (176) 397 (134)
8.2.2.2.Image Acquisition 
MR imaging was performed on a 1.5T GE Signa Unit (General Electric Medical 
Systems, Milwaukee, WI). Fifty-seven subjects (36 controls and 21 AD subjects) were 
scanned using the standard protocol, and 22 subjects (11 controls and 11 AD subjects) 
were scanned using the MIRIAD protocol (see Appendix 3).
8.2.2.3.Manual Hippocampal Segmentation
Scans were transferred to a Sun workstation (Sun Microsystems Inc., Mountain View, 
CA). The software package MIDAS was used for all manual segmentation 
(Freeborough et al., 1997). The hippocampus was segmented according to a previously 
validated protocol (see Appendix 4). No time limits were imposed, and the average 
segmentation time per hippocampus was 45 minutes.
8.2.2.4.Hippocampal BSI
Figure 8.1 and Figure 8.2 summarise the series of steps which demonstrate how the BSI 
measure was derived. Serial brain images were first registered (spatially matched using 
nine degrees of freedom (dof)) applying whole brain to whole brain matching, details of 
the registration technique have been described previously (Woods et al., 1998). The 
resulting rigidly registered-repeat scan B was then registered locally onto scan A using 
six dof, resulting in accurate spatial matching of the hippocampi. The region created by
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subtracting an eroded (by one voxel) intersection region from a dilated (by one voxel) 
union region of the resulting two brain regions (brain region A and locally registered 
brain region B) was generated and a dilated (by one voxel) baseline hippocampal region 
was used to mask this to allow calculation of the BSI in this region of interest area, E . 
This gives a boundary region containing the intensity shift of the hippocampal border.
The BSI was calculated by evaluating a sum over the group of voxels in the region E of 
the two scans (see Figure 8.1). It was calculated as a volume, Av, effectively the 3D 
integral of all the boundary shifts (see Figure 8.2 for a example of an idealised one 
dimensional boundary shift):
A V =  ^  - Y , { c l i P ( I base(X ^ y ^ ) J 1, I 2 ) - c l ip ( I re g ( X , y , Z ) , I l , I 2 ) )
M  2 Jt.y.zeE
Equation 8.1
Where
clip(a,Il, l 2) =
12 (a < 12) 
a(l2 < a < I x)
A (<*>/,)
Equation 8.2
and K is the voxel volume, I base, I reg are the normalised baseline and registered repeat 
intensities, I2, l x define the bounds of the clipping function. Using / 2 and Ix a window 
size ( / 2 - 7j), /„ , and window centre ( ( /2 + IX)I2), Ic, was calculated which are user
defined input parameters to the BSI calculation as detailed previously (Freeborough and 
Fox, 1997).
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Baseline Brain (A) Repeat Brain (B)
Step 1. 9 dof 
registration of whole 
repeat brain onto 
whole baseline brain
Step 2. 6 dof 
registration using 
manually outlined 
baseline hippocampal 
region as a mask. 
Typically, this is 
1500 -3500 mm3
Step 3. Region 
created over which 
the BSI is calculated. 
This whole brain 
region is masked by 
the hippocampus and 
the BSI is only 
calculated in this 
area, E
m i
2
V
Figure 8.1 Summary o f steps necessary to generate HBS1.
This demonstrates the registration steps leading to HBSI generation, involving two 
registration steps, first nine degrees of freedom (dof) to match whole brains and then six 
dof to match hippocampi. Following this, the region that contains the hippocampal 
boundary shift is generated and the HBSI is calculated in this region only.
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base
CSF Hippocampus / Brain
Displacement along line through hippocampal boundary
Figure 8.2. Example o f an idealised one dimensional boundary shift in the 
hippocampus.
Area A is divided by the span o f the intensity window 11 -12  to give the approximate 
distance over which the boundary has shifted, Ax, between hose and Ireg- This can be 
extended to three dimensions to approximate the volume loss, Av.
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8.2.2.5. Assessment and optimisation o f the BSI 
Optimisation of the BSI was performed on eight controls (average age 46 +/- 6 years) 
and eight genetically confirmed familial AD patients (average age 46 +/- 4 years) 
matched for age, sex and scan interval. These were a subset of the main group and their 
results are displayed separately in Figure 8.4, Figure 8.5 and Figure 8.6. The BSIs of 
this set of 32 hippocampi were calculated using ninety separate combinations of I w and
7r . Agreement for each combination was assessed between the BSI and the difference
between baseline and registered-repeat manual segmentations. A window width of 0.3 
and centre of 0.65 (0.5 -  0.8) were chosen based on these analyses and these parameters 
were applied to all subsequent hippocampal BSI (HBSI) calculations. This window is 
higher and narrower than that usually used for whole brain BSI measures (a width and 
centre of 0.5 and 0.5 (0.25 -  0.75) (Freeborough and Fox, 1997)).
8.2.2.6.Assessment o f location o f BSI change measurement
In order to assess where the BSI measured change in the hippocampus a subgroup of 
baseline hippocampi were edited according to the following rules (see Figure 8.3). At a 
grey matter / CSF matter border, a line of voxels was removed and the regions were 
saved (GM-CSF negative regions). Loading the original hippocampus again, at the grey 
matter / white matter border, a line of grey matter voxels was removed and the edited 
region saved (GM-WM negative regions). Again the original hippocampus was loaded 
and the region was edited such that a line of CSF voxels was added to the hippocampus 
(GM-CSF positive regions); in a similar way, at the grey matter / white matter border a 
line of white matter voxels was added (GM-WM positive regions), and the regions were 
saved. The hippocampal BSI was then performed on these regions.
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Figure 8.3 Edited hippocampal regions for experiment to assess location of border where BSI measures change in the hippocampus, 
a) is a standard hippocampus which is edited to generate: b) GM-CSF positive, where the hippocampal border was extended by one voxel 
at the grey matter- CSF border, c) GM-CSF negative, where a layer o f voxels one voxel thick were removed at the grey matter -  CSF 
border d) GM-WM negative, where the hippocampal border was extended by one voxel at the grey matter- white matter border, and e) 
GM-WM positive hippocampi, where a layer of voxels one voxel thick were removed at the grey matter -  white matter border.
8.2.2.7.Statistical Analysis 
Data were analysed using ST AT A version 8 (see Chapter 3, page 96). All hippocampal 
volumes were corrected for TIV, which was derived according to a previously described 
protocol (Whitwell et al., 2001). The logs of the mean baseline and registered-repeat 
hippocampal volumes of the control group (n=36) were regressed against the logs of the 
mean TIV measures to establish the slope of the relationship between TIV and 
hippocampal volume. The resulting coefficient (a) was used to correct the TIV volumes 
as described in Equation 4.1.
Annualised rates of atrophy were calculated on the log scale assuming a constant 
proportionate rate of hippocampal loss. The relationship between TIV and rates of 
atrophy was investigated using logistic regression and as no evidence of a relationship 
was found, TIV was not included as a covariate in atrophy rate calculation. All 
hippocampal atrophy rates (BSI and manual) were calculated as left plus right 
hippocampus. Pitman’s test was used to assess whether hippocampal BSI reduced the 
variation in hippocampal atrophy rates in AD and controls compared with the manual 
results. Specificities of the two techniques for a chosen sensitivity cut-off were 
calculated using a clinical diagnostic decision rule. Logistic regression was used to 
assess whether rates from hippocampal BSI were better than manually-derived rates in 
discriminating between the AD and control groups. Logistic regression was also used 
to assess whether atrophy rates derived from hippocampal BSI were in combination 
with the baseline volume better at discriminating between AD and controls compared to 
hippocampal BSI alone. Unpaired t tests (allowing for unequal variances in the two 
groups) were used to assess whether mean baseline hippocampal volume differed in AD 
and controls, both with and without TIV correction.
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8.2.3. Results
Figure 8.4 shows the sum of left and right hippocampal volume at baseline with TIV 
correction. The means (+/- SD) of the AD and control groups were significantly 
different (AD 4568 mm3 (+/- 727) and controls 5405 mm3 (+/- 515) (p< 0.001)). 
However, there was a large degree of overlap between the AD and control groups. The 
mean difference (+/- standard error) between cases and controls with TIV correction 
was 838 mm3 (+/-149) and without TIV correction was 841 mm3 (+/-171). For a 90% 
sensitivity the specificity of baseline adjusted hippocampal volumes was 43%. Figure 
8.5 shows the sum of left and right hippocampal volume at registered-repeat MRI 
(approximately 15 months later) with TIV correction. Again the means of the AD and 
control groups were significantly different (AD 4303 mm3 (+/-719) and controls 5350 
mm3 (+/- 534)), but there was still a large degree of overlap. The mean difference (+/- 
standard error) between cases and controls was 1047 mm3 (+/-149) with TIV correction 
and 1057mm3 (+/-168) without correction. For a 90% sensitivity the specificity of 
registered-repeat adjusted hippocampal volumes was 53%.
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Figure 8.4 Manual measures o f total (left plus right) hippocampal volume at baseline.
This figure shows the volumes o f the manually outlined hippocampi at baseline with TIV correction. The optimisation set in both controls and patients 
are presented to the left alongside those from the whole group.
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Figure 8.5 Manual measures o f total (left plus right) hippocampal volume at repeat imaging.
This figure shows the volumes of the manually outlined hippocampi at repeat scanning with TIV correction. The optimisation set in both controls and 
patients are presented alongside those from the whole group.
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Table 8.2 and Figure 8.6 show the rates of hippocampal atrophy in the total group of 
AD subjects compared with controls. In controls the variability in rates was 
significantly reduced using hippocampal BSI (p <0.001). The mean rate was also 
significantly reduced (p <0.01). In cases neither the mean rate, nor the variance differed 
significantly between the two methods of measurement.
Table 8.2 Mean (SD) rates o f hippocampal atrophy, % year 1 using both manual and
Mean Rate (Manual) Mean Rate (BSI)
Control 0.99(1.88) 0.20(1.06)
AD 5.77 (3.44) 5.86 (3.69)
This demonstrates rates of atrophy in both normal controls and AD subjects using both 
techniques. The optimisation set in both controls and patients are presented alongside 
those from the whole group.
Figure 8.7 shows the discriminatory ability of the two techniques. The sensitivity of the 
BSI-derived rates is greater than that of the manual rates at all specificity cut-offs 
largely because of the reduced HBSI rates in the control subjects. For a 90% sensitivity 
the BSI-derived rate had a specificity of 98% whereas the manually-derived rate had a 
specificity of 81%.
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Figure 8.6 Manually-derived and BSI-derived rates o f atrophy in control and AD subjects (% year 1). 
Optimisation group is shown to the left alongside each group and method.
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Figure 8.7 ROC graph o f manually- and BSI-derived hippocampal atrophy rates.
This figure shows the sensitivity and specificity o f both techniques in distinguishing between AD and control groups.
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Figure 8.8 Scatterplots showing the associations o f standard BSI measures against those from edited hippocampal regions.
GM-WM positive HBSI (standard hippocampal region with addition o f white matter voxels at white matter border). GM-CSF positive HBSI (standard 
hippocampal region with addition of CSF voxels at CSF border). GM-WM negative HBSI (standard hippocampal region with removal o f grey matter 
voxels at white matter border). GM-CSF negative HBSI (standard hippocampal region with removal o f grey matter voxels at CSF border).
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From logistic regression models a 1% increase in BSI-derived rates of atrophy was 
associated with an 11 fold (Cl 3, 36) increase in the odds of a diagnosis of AD. For 
manually-derived rates the equivalent odds ratio was 3 (Cl 2, 4). Multiple logistic 
regression models showed that BSI-derived rates were significantly better than 
manually-derived rates in discriminating between cases and controls and provided no 
strong evidence that adding manual rates of atrophy to BSI-derived rates increased 
discriminatory power, for manually-derived rates (p= 0.07) and for BSI-derived rates 
(p< 0.01) in the multiple regression model. Furthermore, there was no strong evidence 
that adding adjusted baseline hippocampal volumes to the BSI-derived atrophy rates 
increased discriminatory power (p= 0.09).
Figure 8.8 a-d show the associations of hippocampal BSI calculated from the standard 
delineated regions (x axes on a-d) and from those from the edited standard regions (y 
axes on a-d). The edited HBSIs increased with standard HBSIs in an approximately 
linear fashion in all cases except that of the HBSI calculated using the CSF negative 
region (see Figure 8.8). This reflects the inability of the HBSI to calculate change in 
this case. This lack of ability to detect change was due to the fact that the area over 
which this atrophy was calculated did not include the grey matter - CSF border, and that 
change detected by the HBSI is calculated in this region.
8.2.4. Discussion and Conclusion 
This study assessed the hippocampal BSI by comparison with the current “gold 
standard” of rates derived from manually outlined hippocampi on baseline and 
registered-repeat images. There was considerable overlap between control and AD 
groups in terms of hippocampal volumes (baseline and follow-up) even when these 
regions were corrected for differences in intra-cranial volumes. This concurs with 
previous studies that have shown considerable overlap between groups despite 
statistically significant group differences in hippocampal volumes (Convit et al., 1993; 
Krasuski et al., 1998; Mega et al., 2002). In this study, adjusted baseline hippocampal 
volumes in the AD group were on average 20% smaller than those in the control group, 
but the diagnostic sensitivity and specificity of this measure was limited. A year later 
the follow up MRI showed the progression in hippocampal atrophy in the AD subjects 
had increased the difference between the groups but there was still considerable overlap 
between the AD and controls.
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Rates of hippocampal atrophy had greater discriminatory power than either the baseline 
or follow-up hippocampal volumes. Mean rates of atrophy were six times higher in the 
AD group than in the control group (approximately 5-6% per year versus approximately 
1% per year). The hippocampal BSI measure reduced overlap between the groups 
relative to the manual measurements by reducing both mean rate and variability in the 
control group. The HBSI is likely to underreport change as it primarily measures 
changes along the brain / CSF border. In the hippocampus, not all borders are brain / 
CSF. Large mis-registration or non-linear changes may also be a potential source of 
underreporting since the shifts in the CSF/hippocampal boundaries may not be fully 
captured. In addition, there is likely to be a bias in underreporting change between the 
control and AD groups. Relative to the AD group, the control group may have a lower 
proportion of their hippocampal border as CSF as less atrophy would have occurred 
before the first scan. Because of this, less change may be calculated along the 
hippocampal border. The control group is also likely to have much less intrinsic 
variability in hippocampal atrophy rates between subjects. Reducing measurement error 
will therefore make more of a difference to the variance in rates of atrophy in the 
control group than in the AD group where there is considerable between subject 
variability in disease progression.
Rates of atrophy calculated by the BSI were 0.2% per year in the control group and 
5.9% per year in the AD group. This was higher than quoted in the group of AD 
patients quoted in Chapter 5 (3.4% per year) (see page 143). This maybe due to the fact 
that the groups of patients were different, in this study the AD group was clinically- 
defined whereas those in Chapter 5 were post-mortem confirmed cases. In the PM- 
confirmed subjects, more than half of them were familial AD, whereas only just over 
one third of the subjects included in this study were familial AD. The differences seen 
may also be chance since the variance in the rates of atrophy measurements is high. 
However, the results from this study are consistent with the range of previously 
published rates of atrophy; a small study (n=4) showed early symptomatic familial AD 
rates were 4-8% per annum (Fox et al., 1996b). Several studies by Jack and colleagues 
of older sporadic AD cases (mean ages 74-79 years in the different studies) have 
reported annualised rates of hippocampal atrophy of 3-4% with age-matched controls 
(mean ages 77-80 years) having rates of atrophy of 1.4-1.7% per year and similarly aged 
MCI subjects have intermediate rates at 1.8-3.7% per year (Jack et al., 1998; Jack et al., 
2000; Jack et a l, 2004). Other groups have reported rates of atrophy in controls to be
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0.8 % per year (mean ages 76 -77) and 5-6 % per year in AD subjects (mean ages 75- 
76) (Cardenas et a l, 2003; Du et al., 2004). These differences may be due to 
differences in subjects (e.g. age or disease severity), in addition some differences may 
be ascribed to variation in segmentation protocols and differences in image quality and 
acquisition (Pruessner et a l, 2000).
The BSI is semi-automated and because it calculates change directly from differences 
between the MR images it is not so susceptible to errors of manual outlining. The BSI 
in the hippocampus calculates rates of atrophy by measuring the shift in the grey matter 
-  CSF border and removal of hippocampal voxels at this border reduced the BSI 
measurement. Addition or subtraction of voxels along the grey matter -  white matter 
border or addition of voxels along the grey matter -  CSF border did not alter the 
calculation of the BSI greatly. The BSI has previously been shown to be a reliable and 
repeatable measure of whole brain atrophy in AD (Fox and Freeborough, 1997). The 
advantage of using the local hippocampal BSI is that it is possible to assess an area 
known to be susceptible to pathology at an early stage rather than the whole brain which 
includes large volumes that may not be affected by the disease at all or not until later in 
the course of the disease (Braak et a l, 1993; Braak and Braak, 1991; Scahill et a l, 
2002). The BSI (or a variant thereof) has been applied to the general medial temporal 
lobe area in a normal-ageing cohort and was able to predict accurately 89% of those 
who would soon go on to decline cognitively (Rusinek et a l, 2003).
This study also demonstrates the existence of heterogeneity in rates of hippocampal 
change within the control and AD groups. This heterogeneity can only be partly 
explained by manual errors, misdiagnoses, or scan artefact; a significant component of 
the heterogeneity is due to true differences in progression of disease or natural ageing. 
Even with careful outlining manual errors can occur in a number of areas of the 
segmentation. Some error is inevitable in a small structure that varies in morphology 
between subjects and has a number of arbitrary cut offs and subjective judgements in 
outlining. Figure 8.9 shows two corresponding hippocampal “slices” manually 
delineated on baseline and registered-repeat scans of a control that yielded average 
results in both the BSI measure and manual measures. There are small differences in 
the manual outlining of arbitrary boundaries of the two hippocampi. This demonstrates 
that even with reference to another segmentation and registered image, small errors in 
delineation can occur. Other ways exist that are able to reduce the variance caused by
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these errors in manual segmentation. These include repeating manual measures on the 
same images and calculating the average of the volumes for each hippocampus. 
Repeated measures should reduce errors however this can be very labour-intensive and 
in large studies or trials this may not be a practical solution.
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Figure 8.9 Manual segmentations of the hippocampus on baseline and registered-repeat 
scan.
These show two corresponding slices o f hippocampi of a control subject at baseline and 
repeat imaging delineated using manual segmentation which gave average results using 
both manually-derived and BSI-derived techniques. This figure shows how small 
differences in segmentation (especially in the medial areas) can lead to noise in the 
manual measurements.
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This study also established where the BSI was calculating change and confirmed that 
the BSI was measuring change at the CSF-GM border. This is somewhat unsurprising 
since it is known that the window width and centre (chosen by agreement with manual 
measures) were at levels which would predominantly measure this shift. It is this grey 
matter-CSF shift which is most obvious to the eye when flicking between baseline and 
repeat registered hippocampi. There is some evidence from other studies both 
volumetric (Csemansky et al., 2000) and pathological studies (Von Gunten et al., 2005), 
that it is the CA1 region (see Figure 8.10) which is most greatly affected by AD 
pathology. The CA1 region is a grey matter region located close to a CSF border in the 
lateral aspect of the hippocampus. As a result it may be the shift in this border that is 
predominantly measured by manual editing.
This study demonstrates how semi-automated measures of atrophy can potentially 
reduce within-subject manual errors, but Figure 8.6 shows that semi-automated 
techniques do not eradicate all errors in measurement. The negative values in Figure 3 
represent potentially erroneous “hippocampal growth”, and negative values were 
calculated using the HBSI measure. This may be due to errors in delineation, 
registration errors or quality differences between baseline and registered-repeat images. 
Figure 8.6 also demonstrates that semi-automated techniques do not totally remove 
overlap between the controls and AD. The remaining heterogeneity, present largely in 
the AD group, may be due to differing disease progression, differing involvement of the 
hippocampus, scan artefact, or between-subject delineation errors. In addition, only half 
of AD patients had the diagnosis of AD confirmed genetically or pathologically. In the 
other half of the AD group one cannot be sure that the underlying pathology is AD or 
purely AD (previous studies suggest diagnostic accuracy of around 90% (Galasko et al., 
1994)).
While the “gold standard” for measurement of atrophy of ROIs remains manual 
segmentation, various other methods have been proposed to assess atrophy rates either 
more easily and/or more precisely. Further research in these areas is needed. Non­
linear registration may be used to propagate a baseline hippocampal region onto 
subsequent scans (Crum et al., 2001). However, the clinical utility of this method, and 
susceptibility to scan artefact has not yet been assessed. Other techniques currently 
available require the manual selection of specific landmarks to guide non-linear 
registration of a template hippocampus onto the target hippocampus (Csemansky et al.,
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1998; Haller et al., 1996; Hsu et al., 2002). Automation of segmentation is the natural 
goal for assessment of ROIs, however the manual intervention necessary for available 
“automated” techniques suggests a semi-automated approach is a reasonable step 
towards this goal.
In conclusion, rates of atrophy derived from serial MRI (two scans about one year apart) 
are superior to single measures of hippocampal volume in distinguishing between AD 
and controls. The BSI-derived rates of atrophy proved to be similar to manually- 
derived atrophy rates in terms of group discrimination. With only the baseline scans 
requiring hippocampal segmentation, application of the BSI method reduced both 
operator time and error, which is of particular importance when the hippocampus is to 
be used as an outcome measure in therapeutic trials.
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Figure 8.10 Schematic diagram overlaid on MRI image describing the anatomy of the 
hippocampus.
i) coronal view and ii) sagittal view o f the hippocampus. Dashed line on ii) represents 
position ofi) in the sagittal view. Key: (1) temporal horn o f lateral ventricle;(2) internal 
digitations; (3) cornu ammonis( a CA1, b CA2, c CA3 and d CA4); (4) subiculum;(5) 
parahippocampal gyrus; (6) uncal sulcus; (7) subiculum in uncinate gyrus; (8) 
accessory basal nucleus o f amygdala; (9) cortical nucleus of amygdala.
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8.3. Automated measurement of hippocampal atrophy using fluid-
registered serial MRI in AD and controls
8.3.1. Introduction
Various attempts at automated hippocampal segmentation have been made (see Table 
2.1). Most require user intervention of some sort, and many of these techniques have 
not been tested in a clinical setting (Ashton et al., 1997; Csemansky et al., 1998; 
Csemansky et al., 2000; Ghanei et al., 1998; Gosche et al., 2001; Haller et al., 1996; 
Shen et al., 2002). These methods have been developed mostly for the segmentation of 
hippocampal volumes at one time-point for volumetric group analyses. Only a small 
number of papers has applied an automated technique, which requires definition of a 
number of landmarks, to describe longitudinal volumetric changes in the hippocampus 
(Cardenas et al., 2003; Du et al., 2004; Wang et al., 2003).
The term “fluid registration” (Christensen et al., 1996; Freeborough and Fox, 1998) 
describes non-linear warping techniques based on the physical model of a compressible 
viscous fluid. These techniques make it possible to define a region (such as the 
hippocampus) on a baseline scan, and for this region to be fluidly-propagated through to 
subsequent serial scans. This can produce results at the same resolution as manual 
volumetry (i.e. a voxel is either “in” or “out” of the region of interest (ROI)). In 
addition, a sub-voxel level measure of change can be calculated by integrating the 
resulting Jacobian field. Fluid propagation methodology has been applied to the 
hippocampus, and has been shown to provide a reproducible measure with self- 
consistency better than a human rater (Crum et al., 2001).
In this section fluid-based techniques are assessed, comparing atrophy rates at the sub­
voxel and voxel-level resolutions and compare these results with those calculated from 
standard manual segmentation.
8.3.2. Methods 
8.3.2.1.Subjects
Fifty-five controls and 32 AD subjects had two serial volumetric MRI assessments. The 
AD group comprised 14 FAD and 18 SAD cases; clinical details of these subjects are 
shown in Table 8.3. All subjects underwent clinical assessment including the MMSE 
(see Appendix Two) (Folstein et al., 1975), and all patients fulfilled standard
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NINCDS/ADRDA criteria (see Appendix One) (McKhann et al., 1984) for the 
diagnosis of probable AD.
8.3.2.2. MR Imaging
T1-weighted volumetric MR brain scans were performed on a 1.5 Tesla Signa unit 
(General Electric, Milwaukee). The majority of scans (21 AD, 44 controls) were 
imaged using the standard protocol (see Appendix 3). Later scans (11 AD, 11 controls) 
were taken using the MIRIAD protocol (see Appendix 3). All volumetric scans were 
acquired as 124 contiguous 1.5mm coronal slices, which were transferred to a Sun 
workstation (Sun Microsystems Inc., Mountain View, Calif., USA) for analysis.
8.3.2.3.Region Segmentation
Brain regions were segmented on scans using a semi-automated iterative procedure 
using the software package MIDAS (Freeborough et al., 1997). Prior to hippocampal 
segmentation, each scan pair (baseline and repeat) was co-registered with nine dof (rigid 
plus scaling) using the two segmented brain regions to accurately align the brains. 
Manual segmentation of the hippocampi was performed by two investigators according 
to previously described methodology (Scahill et al., 2003; Watson et al., 1992). 
Segmentations were performed using “mirror-image” volumetry (see page 101) such 
that all hippocampi were segmented on the right side of the image. The intra-rater 
reliability co-efficient (see Equation 2.3) for segmentation of the hippocampus was 
0.98. Raters were blind to all patient information in addition to structural laterality and 
imaging time-point.
-227 -
Table 8.3 Subject Demographics.
Controls AD
Number 55 32
M/F 27/28 13/19
Mean (SD) age in years 57.1 (15.5) 59.1 (11.4)
Mean (SD) baseline MMSE 29(1) 19(5)
Sporadic/F amilial NA 18/14
Mean (SD) scan interval in days 449 (275) 450 (305)
NA = Not applicable
8.3.2.4.Fluid registration 
Following the nine dof brain-brain registration an additional local rigid, six dof 
registration step was performed to optimise the match between the baseline- and repeat- 
scan hippocampi. This registration used the baseline hippocampus as a mask to limit 
the area over which the cost function was calculated.
The registered-repeat image was then fluidly registered to the baseline image. Details 
of the hippocampal fluid registration and propagation have been described previously 
(Crum et al., 2001). The fluid registration was performed over a sub-volume of the 
images: a cuboid enclosing the hippocampal region as defined manually on the baseline 
scan. The repeat sub-volume image was warped to the baseline sub-volume image. The 
fluid algorithm iteratively drove the deformation field to maximise the cost function, 
which was the cross-correlation, whilst enforcing the deformation field to satisfy the 
fluid model. This ensured that the deformation field was diffeomorphic (invertible, 
differentiable).
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The fluid equations were solved to give the velocity field, which was converted to 
displacement by multiplication with a suitable time-step. The time-step was set at each 
iteration to limit the maximum displacement within the hippocampal region. During the 
registration, trilinear interpolation was used. Once the exit criteria were met, 50 
additional iterations were performed using sine interpolation which provided further 
convergence to the optimal solution, but which was more computationally expensive 
than trilinear interpolation.
8.3.2.5.Choice o f exit criteria
Potential exit criteria were assessed by observing the behaviour of various outputs of the 
fluid at each iteration for 2000 iterations. The potential candidates were the body force 
(the derivative of the cost function), the similarity of the fluidly-registered image and 
the baseline image (calculated as cross-correlation) and the amount of Jacobian change. 
These three were calculated over the whole hippocampus which was masked using the 
baseline hippocampal region. Exit criteria were initially assessed in a small group (two 
AD and two control subjects).
8.3.2.6.Fluid Propagation
The deformation field obtained from the fluid registration was then inverted to give the 
equivalent deformation field needed to deform the baseline to the repeat scan. The 
baseline hippocampal region was transformed by subdividing voxels in the repeat 
region and calculating from the inverse deformation field where each sub-voxel centre 
had displaced from the baseline image. For each voxel, if more than half of the sub­
voxel centres had come from within the hippocampal region, it was included in the 
propagated region, otherwise it was excluded. Applying intensity thresholding to this 
binary propagated region ensured the hippocampus was labelled correctly on the repeat 
scan, and was consistent with the manual segmentation protocol. All fluid registrations 
and fluid-propagated regions were visually assessed.
8.3.2.7.Jacobian quantification
A field of Jacobian values was calculated from the deformation field obtained from the 
fluid registration. This gave the amount of contraction or expansion at each voxel. The 
amount of change within the hippocampal region was calculated at a sub-voxel level. 
This was achieved by integrating the Jacobian values within the baseline hippocampal 
mask.
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8.3.2.8.Statistical analysis 
Data were analysed using STATA version 8 and SAS (see Chapter 3, page 96). 
Atrophy rates were analysed for the total hippocampal region (left and right together) on 
a logarithmic scale [(log (follow-up volume/baseline volume))/interval] in order that 
doublings and halvings in volume be treated as effects of equal magnitude. Mean 
atrophy rates were calculated by back transformation with SDs calculated from variance 
transformation formulae. Comparisons between AD and control subjects were 
performed using t-tests allowing for unequal variances between the subject groups. 
Comparisons between methods for means and variances in the log atrophy rates were 
performed using paired t-tests and Pitman’s test respectively. Sample sizes for 
randomised controlled clinical trials required to achieve a particular statistical power to 
detect a particular proportional reduction in an outcome variable in AD subjects are 
proportional to the square of the coefficient of variation (CV) of the outcome variable in 
cases. The relative numbers of patients required for two different outcome variables is 
therefore given by the square of the ratio of the respective CVs. 95% bootstrap 
confidence intervals (bias corrected) for such relative sample sizes (using a logarithmic 
transform for reasons of symmetry on a relative scale) were calculated using 10000 
replicates.
Logistic regression was used to assess whether rates from any of the fluid measures 
were better than manually-derived rates in discriminating between the AD and control 
groups. ROC curves were generated to demonstrate graphically subject group 
separation according to technique. Sensitivities for 90% specificities cut-offs were 
calculated for each method. Linear regression was used to assess whether different 
scanning protocols influenced atrophy rates (adjusting for age) within each disease 
group and using each method.
8.3.3. Results
The results for running potential exit criteria are shown below in Figure 8.11-Figure 
8.13 None of the output variables were stable enough to model the behaviour and 
establish non-arbitrary exit criteria. As result the body force was chosen and arbitrary 
criteria were established. These were satisfied when the mean body force ratio within 
the hippocampal region fell below 5.5* 10'7. This was used for all resultant 
hippocampal pairs.
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Figure 8.11 Potential exit criterion: R2 o f the baseline and fluidly generated image within the hippocampal region.
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Figure 8.12 Potential exit criterion: Jacobian change between the baseline and repeat image within the hippocampal region.
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Figure 8.13 Potential exit criterion: Body force calculated within the hippocampal region.
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Total hippocampal atrophy rates derived from manual, fluid-propagated regions and 
Jacobians are shown in Table 8.4 and Figure 8.14. Atrophy rates were significantly 
higher in AD patients compared with controls for all techniques (all p<0.0001). There 
was no evidence that different scanning protocols influenced atrophy rates within 
subject group using any method (p>0.06 for all comparisons). In AD patients there was 
no evidence that atrophy rates differed between the fluid propagation and manual rates 
in either means (p=0.55) or variances (p=0.71). However, there was evidence that rates 
using the Jacobian method were smaller in mean (p=0.002) and variance (p=0.026) 
compared with the manual rates.
In AD patients, the relative sample size for the fluid propagation method compared with 
manual atrophy rates was 0.83 but was not statistically significant (95% Cl 0.48,1.42). 
The equivalent comparison of Jacobian rates with manual atrophy rates was also not 
statistically significant (relative sample size 1.14 (95% CIs 0.67,1.93)) reflecting the 
fact that both the mean and SDs were reduced using Jacobian rates.
In controls the mean atrophy rate from the fluid propagation was lower than that from 
the manual method but this difference was not statistically significant (p=0.12). There 
was strong evidence that control rates from the fluid propagation method were less 
variable (p<0.0001). As in AD patients, there was some evidence that Jacobian rates 
were smaller in mean (p=0.014) and less variable (p<0.0001) than the manual method.
Table 8.4 Mean atrophy rates (SDs) (%/year) for patients and controls derived from 
manual and fluid-based measures._________________________________________
Controls AD
Manual volumetry 1.31 (2.00) 5.09 (3.59)
Fluid-propagated (with 
intensity thresholding)
0.89 (0.75) 5.34 (3.43)
Jacobian 0.56(1.12) 3.55 (2.70)
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All methods calculating atrophy rates were significant predictors of disease (p<0.0001). 
Figure 8.15 shows ROC curves for the total hippocampal rates using the three different 
techniques. For 91% specificity (50/55), the sensitivity of the manually-derived atrophy 
rate was 56% (18/32), and for fluid-propagated-derived rates this was 84% (27/32) and 
the Jacobian rates this was 72% (23/32). Multiple logistic regression analyses revealed 
that the combination of fluid-propagated atrophy rates and manual rates were better than 
manual alone (p<0.001) but not fluid-propagated alone (p=0.679), suggesting that the 
fluidly-propagated rate was a better discriminator.
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Figure 8.14 Rates o f atrophy (left and right hippocampus, % per year) calculated from manual segmentations, andfluidly propagated regions with 
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Figure 8.15 ROC curve showing group discrimination using manual, fluidly propagated and Jacobian rates o f atrophy in the total (left plus right) 
hippocampus.
- 23 7-
8.3.4. Discussion
In this chapter the ability of two measures of change calculated from hippocampal fluid 
registration to reproduce results similar to the manual measures and to discriminate 
between AD and controls was assessed. It was demonstrated that hippocampal rates 
derived from fluid propagation agree well with those derived from manual 
segmentation. The mean atrophy rates using the fluid propagation were slightly higher 
than manual atrophy rates in the AD subjects. This may be due to the fact that the 
intensity thresholding may also remove voxels from other areas of the hippocampus due 
to image artefact, real atrophy (i.e. the hippocampal fissure or uncal sulcus as it 
enlarges), or real biological change causing changes in signal intensity from the tissue 
which may not be volume loss (see Figure 8.16). One issue with such thresholding is 
that it is directionally biased as it will always remove voxels from the repeat region 
without including ones that may have been excluded from the first owing to artefact or 
noise. As a result, the atrophy rates calculated using such re-thresholding may be slight 
over-estimates in both subject groups. This study also showed that rates derived from 
fluid propagation were superior at separating AD subjects from controls than manually- 
derived rates. There was also a suggestion that fewer people would be needed within a 
trial compared with manual segmentation although this was not statistically significant 
and CIs around the relative sample size were wide.
The Jacobian measure of change is not subject to the arbitrary constraints of the voxel 
level measures (either intensity or voxel level binary thresholding). In theory, the 
Jacobian results should give the most accurate representation of change according to the 
fluid registration. Rates were found to be higher in AD than controls which was 
consistent with the voxel-level atrophy rates. The Jacobian measures were still 
significant predictors of subject group with manual measures in the same statistical 
model suggesting they each measure something different with respect to hippocampal 
change. However, Jacobian measures gave poorer separation between AD and controls 
than the fluidly-propagated atrophy rates. This may be due to the fact that real loss 
shown as small holes opening or appearing in the hippocampus will be missed by the 
Jacobian values as such holes will appear to have deformed from within the baseline 
hippocampus (see Figure 8.16). The Jacobian integration therefore will include the 
expansion of the hole itself, which will cancel out the compression of the surrounding 
area to leave a net change of zero. Small errors in baseline hippocampal delineation (for 
example including partial volume voxels, particularly in the uncal sulcus) may also
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cause the loss calculated to be underestimated as these areas may expand between the 
baseline and repeat scans as the hippocampus decreases in size and this expansion may 
be included in the Jacobian value. Such delineation errors may lead to increases in the 
variance of Jacobian atrophy rates as well as the decrease of the means. The fluid- 
propagation circumvents this problem by including the intensity thresholding term.
This work builds upon a previous hippocampal fluid validation paper which described 
the technique for serial hippocampal region generation (Crum et a l, 2001). In that paper 
it was noted that where there was a great amount of change between scans of a pair, 
there was greatest mismatch between repeat manual and fluid-generated volumes. In 
this study the registration procedure was refined, including a further local rigid-body 
registration to optimise the matching of hippocampi prior to fluid registration and 
region propagation, which reduces the likelihood of mismatch influencing results. In 
addition exit criteria were applied to the fluid registration process so that each 
hippocampal pair finished when a similar level of matching had been achieved.
In this study, atrophy rates were significantly higher in patients with AD than controls, 
which was consistent with many previous studies (see Table 1.3). The atrophy rate 
calculated from Jacobian integration over the whole baseline hippocampal volume did 
have lower mean atrophy rates for both AD and control groups than is generally 
reported for manual studies for reasons described earlier (see Figure 8.16). The rates 
determined from the manual and fluidly-propagated methods were higher to those 
calculated in the post-mortem confirmed group described in Chapter 5 (see page 143), 
but Jacobian rates in this study were similar to the post-mortem rates. Discrepancies in 
mean rates calculated in different studies may be due to individual segmentation 
protocols employed by each research group, scan acquisitions, scan intervals or 
different ages and disease durations of cohorts being studied (Pruessner et a l, 2000).
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Figure 8.16 Schematic diagram demonstrating cause o f potential differences in 
Jacobian and fluidly propagated rates.
Diagram showing coronal baseline (A) and registered-repeat (B) image o f the right 
hippocampus o f an AD patient demonstrating an increase in size o f hippocampal fissure 
or uncal sulcus over the inter-scan interval (double arrow on figure A denotes fissure). 
Inter-scan interval is approximately one year. Figure A shows the manually-delineated 
baseline hippocampal ROI including some voxels which contain both hippocampal 
tissue and CSF (single line arrows); figure B shows the resulting fluidly-propagated 
region from the manually-delineated baseline. Figure C shows the region which may 
be labelled as repeat hippocampus according to the Jacobian method. Any partial 
volume uncal sulcus voxels included in the baseline segmentation (single line arrows on 
A) may be calculated as expansion by the Jacobian method of quantifying change and 
therefore these corresponding voxels on the registered repeat scan will be included
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within the repeat region (single line arrow on C). This expansion will negate the same 
amount o f contraction calculated within the hippocampus as the Jacobians are 
integrated over the baseline hippocampal region. The baseline and fluidly-propagated 
repeat hippocampal regions are shown on the actual registered MR images D and E 
respectively.
One study which utilised semi-automated non-linear registration measures to quantify 
change over time found loss in the hippocampus to be 2-2.5% in normal subjects (mean 
age 73 years) and 4-5% in mildly cognitively impaired / mild AD subjects (mean age 74 
years) (Wang et al., 2003). However, this technique differed from the fluid technique 
described in this study as it used a template hippocampus and non-linear registration to 
segment both the baseline and repeat hippocampi in all subjects and calculate the 
atrophy from the difference in volumes. Two other studies using a similar technique, 
both from the same research group, found similar results to Wang et al., in that those 
subjects with dementia (Cardenas et al., 2003) or AD (Du et al., 2004) had higher rates 
of atrophy (5-6% per year) than control subjects (1-2% per year).
The fluid-based methods reported as part of this study gave good subject group 
separation. Many methods applied to structural imaging have been assessed for their 
ability to separate AD from controls. Within structural imaging, cross-sectional, semi- 
quantitative measurement of hippocampal atrophy has been shown to discriminate AD 
from controls with similar levels of sensitivity (81%) but slightly lower specificity 
(67%) than this study (Scheltens et al., 1992). In addition, a combination of linear 
measures of the medial temporal lobe have also proved useful with a sensitivity of 85% 
for a specificity of 95% (Frisoni et al., 1996b). Cross-sectional quantitative 
measurement of specific areas of the brain have also shown reasonable levels of group 
discrimination especially in the hippocampus and entorhinal cortex (Juottonen et al., 
1999; Killiany et al., 2002; Pennanen et al., 2004).
One strength of this study is the fact that there were relatively large groups of AD and 
control patients. Confirmation of the diagnosis of AD was available in 12 of the AD 
patients (two post-mortem and ten with proven pathogenic FAD mutations). A result of 
including FAD patients is that the mean age of the AD group was lower than that may 
be found in normal clinical practice. As atrophy of the brain (including hippocampus) 
increases with age (Scahill et al., 2003), it is possible that the results reported may be
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influenced by the relatively young age of the subjects and therefore this may need to be 
taken into consideration when relating results to an older cohort of subjects.
Manual segmentation, although the standard volumetric technique in current practice, is 
not a perfect measure of hippocampal volume. Arbitrary decisions are required to 
determine the boundaries of the hippocampus, and these can become particularly 
difficult to match on serial scans. Manual outlining may be open to bias, although an 
attempt was made to minimize this by presenting the scans in a random order with raters 
blinded to all scan and patient information. The exit criteria were based on the fluid 
achieving an arbitrary target (a body force ratio below a certain level). This 
convergence level and the intensity thresholding chosen in this study may need 
alteration when applying this methodology to separate cohorts with different scan 
protocols and qualities.
It can be concluded that fluid propagation has the potential to track volume changes in 
serial scans and is a valuable means of quantifying serial change in the hippocampus; 
with only the baseline hippocampus requiring segmentation, application of this 
technique reduces operator time. There may be benefits in using fluid propagation over 
manual segmentation of the hippocampus both for the purposes of diagnosis and 
monitoring disease progression. However, more work is required to establish whether 
this is the case in larger groups of subjects with differing clinical diagnoses, and more 
work is required technically to understand why the fluid does not seem to converge.
8.4. Chapter conclusions
Semi-automated measures of hippocampal atrophy are diagnostically useful and halve 
the amount of manual work performed by operators. In addition to this there is 
evidence that they can reduce the amount of operator error. As a result these measures 
may be useful in clinical trials and large studies where a large number of serial 
hippocampi may require segmentation or analysis of change within the region.
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9. AUTOMATIC CALCULATION OF HIPPOCAMPAL ATROPHY RATES 
USING THE BOUNDARY SHIFT INTEGRAL
9.1. Chapter Introduction
Background
The development and validation of non- or minimally-invasive markers of disease is 
important in AD to aid diagnosis of the disease and to track disease progression. Early 
diagnosis is particularly important as it is those patients at the very earliest stages of the 
disease who may theoretically derive most benefit from disease-modifying therapies 
should they become available. For imaging markers to become useful diagnostically it 
is important that they become automated to reduce both the cost and labour. As 
described and discussed in Chapters 4 and 6 hippocampal volume has been shown with 
MRI to be reduced in AD subjects cross-sectionally although change in this volume 
obtained from serial scanning may have clinical advantages both for diagnosis and 
measurement of disease progression (see Chapters 5 and 8).
As described in Chapters 2,4,5, and 8, most volumetric studies of the hippocampus have 
used manual segmentation (Chan et al., 2001b; Fox et a l, 1996b; Jack, Jr. et a l, 1992; 
Killiany et a l, 2002; Laakso et a l, 1995): this is currently considered to be the “gold 
standard” for measurement but is both time consuming and requires trained operators. 
Each hippocampus at each time-point takes approximately 45 minutes to delineate. In 
addition, manual outlining has a variable degree of operator error. As a result, efforts 
have been made to decrease the amount of operator interaction required for 
hippocampal segmentation. A number of semi-automated techniques have been
developed (see Table 2.1). These may require manual outlining of the baseline 
hippocampus of a scan pair and measurement of shifts at the boundary of the 
hippocampus using the BSI (see Chapter 8, page 204) or fluid registration and 
integration of the voxel compression map to estimate atrophy in the hippocampal region 
(Crum et a l, 2001). Other methods require the definition of a number of landmarks on 
each scan to permit automated segmentation (Csemansky et a l, 2000; Duchesne et al, 
2002; Ghanei et a l, 1998; Gosche et a l, 2001; Haller et a l, 1997; Shen et a l, 2002; 
Wang et a l, 2003). One semi-automated technique has applied the BSI to measure 
longitudinal change in a region which approximates to the medial temporal lobe 
(Rusinek et a l, 2003). Further advances in automatically calculating hippocampal
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volume or rates of atrophy may be of benefit both for diagnostic and clinical trial 
purposes.
Chapter Objective
The objective of the study described in this chapter was to develop an automated 
method of calculating hippocampal atrophy using inter and intra-subject registration and 
to compare this with both semi-automated hippocampal BSI methods and manual 
measurements.
9.2. Methods
9.2.1. Subjects
This study included 55 subjects: 36 clinically diagnosed AD patients and 19 age- 
matched healthy controls (one control and two AD subjects subsequently underwent 
autopsy with confirmation of diagnosis in all cases). Subjects were from the MIRIAD 
cohort (see section 3.3, page 92). All subjects underwent clinical assessment including 
the MMSE (Folstein et al., 1975)(see Appendix Two), and all patients fulfilled standard 
NINCDS/ADRDA criteria (McKhann et al., 1984) (see Appendix One) for the 
diagnosis of probable AD. Exclusion criteria were change in diagnosis at subsequent 
follow-up, or post-mortem confirmation of a differing underlying pathology. Subject 
demographics can be seen in Table 9.1.
9.2.2. Scanning protocol
T1 -weighted volumetric MR brain scans were performed using the MIRIAD protocol 
(see Appendix Three).
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Table 9.1 Subject Demographics.
Controls AD
Number 19 36
M/F 9/10 14/22
Mean (SD) age in 
years
68.7 (7.0) 69.6 (7.3)
Mean (SD) MMSE at 
baseline imaging
29.5 (0.7) 19.4 (4.1)
Mean (SD) scan 
interval in days
365 (5) 365 (18)
9.2.3. Manual Segmentations 
All segmentations were performed using MIDAS software (Freeborough et al., 1997). 
Brain regions on the baseline and repeat images were segmented using a previously 
described method (Freeborough et al., 1997)(see Appendix Four), and all images were 
registered into MNI 305 atlas space (Mazziotta et al., 1995) using six degrees of 
freedom (dof) to ensure all images were in a similar orientation. Following this the 
repeat images (second time-point) were registered to the baseline images using nine dof 
registration, to align the brains within a scan pair accurately. Hippocampi were 
delineated for each subject on the baseline and nine dof brain-brain registered-repeat 
images. The regions were delineated using “mirror-image” volumetry (see page 101). 
The baseline and registered repeat images were loaded simultaneously with the scans in 
a random chronological order. The hippocampus was always measured on the right- 
hand side of the presented image with the investigator blinded to the subject’s name, 
diagnosis, chronological order, and left-right orientation of the scans. The protocol used 
is detailed in Appendix Four.
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9.2.4. Generation o f standard automated single person template 
hippocampal BSI measures 
The standard automated hippocampal mask was generated using the following 
registration and quantification methodology (see Figure 9.1):
A single-subject template was chosen from the group of hippocampi (AD and controls). 
This 76 year old male control subject (MMSE 30/30) had average hippocampal volumes 
(manually-delineated) compared with the whole group.
1. Template to subject: Brain-Brain
An affine (12 dof) brain-brain registration of the single-subject template onto the 
baseline subject scan was performed (Woods et al., 1998). The template hippocampal 
region was resliced using the obtained transformation parameters (all reslicing of 
regions of interest utilised trilinear interpolation with thresholding and interpolation of 
the images utilised Chirp Z (Rabiner et al., 1969)).
2. Template to subject: Hippocampus-Hippocampus
Following this, an affine (12 dof) hippocampus-hippocampus registration of template 
scan to baseline subject scan was performed to align the hippocampi more precisely. 
The template hippocampal region was again resliced using the obtained local 
transformation parameters. This transformed template hippocampus was copied to the 
baseline subject image.
3. Subject follow-up to subject baseline: Brain-Brain
The repeat subject image used was that of the registered brain-brain (nine dof) to the 
baseline subject image (also used for the manual delineation). The repeat brain region 
and image were resliced using the obtained transformation parameters.
4. Subject follow-up to subject baseline: Hippocampus-Hippocampus
The repeat subject image was registered hippocampus-hippocampus (six dof) to the 
baseline subject brain using the transformed template hippocampus as the mask for the 
registration. The transformation parameters for this registration were applied to both 
the subject repeat brain image and region.
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Figure 9.1 Registration methodology for generation of automated hippocampus masks.
A template was chosen from the group of hippocampi (AD and controls). This 
individual had average hippocampal volumes (manually delineated) compared with the 
whole group. H =  hippocampus, HM is the transformed template hippocampal mask.
The volume of hippocampal atrophy was then estimated by calculating the BSI 
(Freeborough and Fox, 1997) over volume E where:
E = HMn (d(bl u  n  ))
Equation 9.1
Where HM is transformed template hippocampal region, b\ is the baseline subject brain 
region, b2 is the transformed repeat subject brain region, d is a dilation by one voxel 
and e is the erosion by one voxel. E was dilated by two voxels to incorporate as many 
of the hippocampal boundaries as possible. This estimate is referred to as the 
“automated HBSI”. The semi-automated HBSI was also calculated as previously 
described to allow comparison of measures (see Chapter 8, page 204). A window centre 
of 0.55 and a window width of 0.2 was used for the BSI in both the automated and
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semi-automated measures (Freeborough and Fox, 1997). These procedures were 
completed for both left and right hippocampi. All intra-subject registrations were 
visually assessed to ensure mis-registration did not occur. This hippocampal BSI 
measure will be referred to as standard aHBSI from this point.
9.2.5. Influence o f simple morphological operators and 
incorporation o f inter-individual variability 
In addition to the main experiment described above, the influence of different 
parameters on the segmentation of the baseline hippocampus and subsequent calculation 
of the standard aHBSI, were tested. These included the manipulation of the baseline 
hippocampal region following the single-person template segmentation described 
above, and the incorporation of some inter-individual variability into the template 
hippocampal region by creating a multiple subject template and regions. Accuracy was 
tested by comparing the new template-based segmentations with manually-delineated 
regions. The automated HBSIs calculated subsequent to the production of new baseline 
segmentations were compared with manual measures, HBSI, and standard aHBSI.
9.2.5.1.Assessment o f different region manipulation schemes 
Manipulations of single-person baseline regions, generated from the regions produced 
by trilinear interpolation, were achieved to establish whether the baseline segmentation 
accuracy could be improved by simple means. Baseline hippocampal regions created 
by the standard aHBSI single-person template were manipulated in a number of ways 
(see Figure 9.2) initially in a subset of the total cohort (three AD patients and three 
controls). The most accurate of these manipulations calculated using a similarity index 
(see Equation 2.2) was then performed in all subjects. HBSI was then performed using 
these manipulated regions instead of the single-person segmented template regions and 
the resulting rates of atrophy were converted to a rate of change to compare with the 
existing measures. From this point this will be termed manipulated aHBSI. There was 
one deviation from the standard aHBSI method which was that the hippocampal mask 
over which HBSI was calculated was only dilated by one voxel.
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Single-person template 
segmentation of baseline
1
Threshold using 70% mean 
brain intensity
I
Region 1
Threshold using 110% mean 
brain intensity
Region 2
1
Dilate region by one voxel if 
thresholds are between 70 and 
110% mean brain intensity
Region 3
Dilate region by one voxel if 
thresholds are between 70 and 
110% mean brain intensity
Region 4
Figure 9.2 Manipulations o f single-person template based segmentations. 
Regions were saved at each stage o f this process allowing four new regions to be 
compared with the manually delineated baseline segmentations.
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9.2.5.2. Assessment o f average template hippocampal region 
To assess whether the region in the template could be improved by incorporating inter­
individual variability an average region was made. The average template region was 
produced by randomly assigning half of the AD and control subjects to a template 
generation group and half to a group on which the average template was to be assessed. 
This registration and template region production process can be seen in Figure 9.3. In 
brief, the scans from the template generation group were affine-registered brain to brain 
to the individual subject used as the single-person template previously (see page 246). 
The hippocampi were then rigidly-registered to this template and the binary regions 
were used to make a probability map where voxels had values between 0 and 1 (0 being 
no probability of containing hippocampus and 1 being all hippocampi occupy the 
voxel).
This map was then used to create regions (illustrated in Figure 9.3) according to this 
probability map: a region which encompassed all hippocampal regions (in other words, 
a region containing any hippocampal voxels in all scans) was generated and labelled 
“100% region”, similarly regions were also created which encompassed 80% and 60% 
of all hippocampal voxels in all scans were created and labelled “80%” and “60% 
regions”. These three new regions were used in generating new baseline hippocampal 
regions and subsequently the HBSI as described in Figure 9.1 in the remaining half of 
subjects. From this point this is named multi-subject aHBSI. Again, there was one 
deviation from the standard aHBSI method which was that the hippocampal mask over 
which HBSI was calculated was only dilated by one voxel.
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Figure 9.3 Schematic diagram showing production of multi-subject hippocampal 
template regions.
Half of the AD and control subjects (purple brains) were registered to the single-person 
template image used previously. This registration was performed A. brain to brain and 
B. hippocampus to hippocampus. Hippocampal regions were resliced at both stages 
and the transformed regions were summed producing a probability map which enabled 
the creation of probability-based regions (shown in the inset boxes). These are 
smoothed and rendered regions and percentages relate to the level at which voxels 
encompass the hippocampal regions in all subjects i.e. all hippocampi fall within the 
100% region. These created regions were used in the generation of multi-subject 
aHBSIs by feeding the regions into the automated HBSI algorithm shown in Figure 9.1. 
Key: H -  hippocampus, Sup. =  superior, Inf. =  inferior, Med. =  medial, Lat. =  lateral, 
Ant. =  anterior, Pos. =  posterior.
9.2.6. Statistical Analysis
9.2.6.1.Standard aHBSI single-person template analysis 
HBSI and aHBSI were applied to each image pair and the resulting quantification was 
expressed as an annualised volume loss of total (left plus right) hippocampus. 
Equivalent measures for manual atrophy rates were calculated in the same way. Means 
of atrophy rates between AD patients and controls for each method were compared 
using t tests allowing for unequal variances. The means calculated by the different 
methods were compared using paired t tests. Differences in variances between the
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methods were assessed using Pitman’s tests. Each method’s ability to separate AD 
subjects from controls was assessed using logistic regression. Power calculations were 
used to estimate how many subjects would be required using each method in a clinical 
trial to provide 90% power to detect a 20% reduction in atrophy rate at the 5% 
significance level. To assess the accuracy of the baseline segmentation using the 
template-based measures, the voxel similarity between manual and automated 
hippocampal regions was calculated described in Equation 2.2. This was assessed in the 
AD and control groups separately. To assess whether there was a difference in voxel 
similarity between AD and controls t tests were used allowing for unequal variances.
9.2.6.2. Analyzing influences o f region manipulation schemes 
incorporation o f multi-subject variability 
The accuracy of segmentations generated by manipulating aspects of the registration 
and template segmentation process was assessed by comparing voxel similarity with 
manual regions (see Equation 2.2). The resulting HBSIs were calculated as above 
(expressed as an annualised volume loss of total (left plus right) hippocampus). Where 
accuracy of baseline segmentations were reasonable (>0.6 voxel similarity), relative 
annualised hippocampal rates of atrophy were also calculated. Paired t tests were 
performed separately in AD and control groups to establish whether the altered 
automated baseline segmentations were significantly more accurate than the standard 
automated segmentation. Manipulated aHBSIs generated from these altered regions 
were compared with standard aHBSI and semi-automated HBSI as well as manually- 
derived rates to assess whether any improvement of accuracy of segmentation was 
reflected in an improvement in association with the more validated measures. Similar 
analyses were performed with the multi-subject aHBSI measures.
9.3. Results
9.3.1. Standard single person template-based HBSI 
Table 9.2 shows the mean (SD) annualised rates of total (left plus right) hippocampal 
atrophy for manual, HBSI and standard aHBSI, and the voxel similarity for the 
automated region. Rates were calculated on an absolute scale since the accuracy of the 
baseline regions generated from the template were relatively low. Figure 9.4 shows 
individual results using each method in control and AD groups. There was evidence of a 
difference in rates of atrophy between the AD and control groups (p < 0.001 for each 
method). There was no evidence of a difference in means between HBSI and manual
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methods (p = 0.33) or standard aHBSI and manual methods (p = 0.75). SDs were 
comparable using HBSI, standard aHBSI and manual measures. Differences did not 
reach significance for any comparison (p > 0.2).
There was generally good individual agreement between HBSI and standard aHBSI 
methods, with the SD of the difference between the methods being 36.61 mm3. Such 
agreement was not as good when comparing manual and HBSI, and manual and 
standard aHBSI with the SDs of the differences between methods being 82.77 and 91.28 
mm3 respectively.
Table 9.2 Annualised hippocampal atrophy rates (mm3 loss /year) (mean (SD)) using 
manual, HBSI, and standard aHBSI measures._______________________
Manual HBSI aHBSI
Voxel Similarity of 
aHBSI region to 
manual region
Level of manual 
outlining
Baseline and 
follow-up
Baseline only
Template
only
Controls 18.1 (53.5) 15.3 (50.2) 11.3 (50.4) 0.49 (0.05)
AD 174.6 (106.5) 159.4(101.2) 172.1 (123.1) 0.43 (0.07)
Manual (outlining o f both baseline and repeat scans, , HBSI (outlining just the baseline
scan), and standard aHBSI (fully automated template-based BSI) measures.
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Figure 9.4 Manual, semi-automated HBSI and fully-automated standard aHBSI measures in control and AD groups.
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All three methods of generating hippocampal atrophy significantly discriminated AD 
from controls (p <0.01) (see Figure 9.6). The combination of manual and HBSI was a 
significantly better discriminator than HBSI alone (p = 0.011) and manual alone (p = 
0.023), suggesting that the two methods together could improve discrimination. The 
combination of manual and standard aHBSI was significantly better than standard 
aHBSI alone (p = 0.0033) and significantly better than manual alone (p = 0.01), 
suggesting again that the two methods together could improve discrimination. For a 
90% specificity cut-off, sensitivities were 72% for manual, 78% for HBSI and 83% for 
standard aHBSI. For an 80% specificity cut-off, sensitivities were 81% for manual, 
86% for HBSI and 83% for standard aHBSI. Power calculations showed that in a trial 
with 90% power to detect a 20% reduction in atrophy rate of the AD group at the 5% 
level, 196 subjects per treatment arm would be required of manually-derived measures, 
compared with 212 for HBSI and 270 for standard aHBSI.
9.3.2. Influence o f differing parameters in the generation of the 
automated HBSI
9.3.2.1.Manipulated aHBSI 
Table 9.3 shows the initial voxel similarity results for the single-person template 
manipulations assessed in the subset of the cohort (three AD subjects and three normal 
controls).
Region 4 (corresponding to the 70% thresholding and two conditional dilations if voxels 
were between 70-110% mean brain intensity) was the most accurate over these six 
subjects so this was extended to all baseline segmentations.
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Table 9.3 Mean (SD) voxel similarity results for the manipulation o f standard single- 
person template segmentations.
Control AD Total
Single-person template 0.430 (0.077) 0.480 (0.066) 0.455 (0.072)
Region 1 0.524 (0.064) 0.491 (0.025) 0.507 (0.047)
Region 2 0.530 (0.055) 0.481 (0.032) 0.506 (0.048)
Region 3 0.609 (0.063) 0.573 (0.050) 0.591 (0.054)
Region 4 0.622 (0.055) 0.592 (0.065) 0.607 (0.056)
Mean (SD) voxel similarity for the whole group based on this type of manipulation was 
0.62 (0.07) for the control group and 0.61 (0.07) for the AD group. The resultant rates 
of atrophy based on these regions are shown below in Table 9.4 and Figure 9.5. All 
methods showed significant differences in rates of atrophy between control and AD 
groups (p<0.001) which is demonstrated in Figure 9.6.
There was evidence of a difference between the HBSI and manipulated aHBSI 
(p=0.034) with the SD of the difference from the HBSI being 36.85mm3. However, 
there was no difference between the manipulated aHBSI and the manual difference 
(p=0.997) with the SD of the difference being 87.73mm3.
-256 -
Table 9.4 Mean (SD) annualised absolute rates o f atrophy in controls and AD using 
manual, semi-automated HBSI, standard automated HBSI (aHBSI) and manipulated 
aHBSI (mHBSI).________________________________________________________
M anual HBSI aHBSI mHBSI
Controls 18.1 (53.5) 15.3 (50.2) 11.3 (50.4) 15.3 (56.5)
AD 174.6 (106.5) 159.4(101.2) 172.1 (123.1) 176.0(114.6)
Owing to the relative accuracy of segmentation (see Figure 9.7, Figure 9.8 and Figure 
9.9 for plots of association and Bland-Altman plots of manipulated region volumes 
against manual volumes in left, right and total hippocampus, and Figure 9.10 for group 
separation of manual and manipulated baseline volumes), relative rates of atrophy were 
also calculated using this technique using the manipulated baseline volumes (see Table 
9.5). There was no evidence of a difference in the rates of atrophy calculated between 
manual and manipulated aHBSI methods (p=0.71), with the SD of the difference being 
2.16%. The association of these two measures is shown in Figure 9.11.
Table 9.5 Mean annualised relative rates o f atrophy in controls and AD using the 
manual, standard HBSI, and aHBSI calculated from the manipulated baseline region 
(mHBSI).__________________________ ___________________ ________________
M anual HBSI mHBSI
Controls 0.28 (0.90) 0.32 (0.93) 0.28 (1.01)
AD 4.06 (2.61) 4.57 (2.98) 4.43 (3.06)
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Figure 9.5 Figure demonstrating difference in AD and control groups using manual measures, semi-automated HBSI, standard aHBSI and HBSI 
generated from manipulating the single-person template automated hippocampal region (manipulated aHBSI).
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Figure 9.7 A. Association o f automated manipulated and manual left hippocampal 
volumes in AD and control subjects (R2 for combined subject groups = 0.48). B. Bland- 
Altman plot o f automated manipulated and manual left hippocampal volumes in AD and 
control subjects.
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Figure 9.8 A. Association o f automated manipulated and manual right hippocampal 
volumes in AD and control subjects (R2 for combined subject groups = 0.58). B. Bland- 
Altman plot o f automated manipulated and manual right hippocampal volumes in AD 
and control subjects.
-2 61 -
E °  
E 00
M
3ex
i ,
i s
«  CO Q*
M
134-Jo
*S °  ° o » o
E *
J3
?
T3o
o Controls
AD
o o
o
o
o o
o
*  ?
o o o
o
•  •  •  
* • - * 8 *
• I
o
o o _ o 
3  CM 1
3 2000 4000 6000
Manual volume of total hippocampus (mm3)
8000
B
M
3ex
E o
3  O ) Uoex
a
•  mm
JS
n °■4-»o
<4- *
o
o>
E °O -22 o>
0> o
3 °c  00a>v- v
o Controls 
AD • *
•
♦••
•
♦ ... ♦ . •* t
*  *•; • ♦ o
• • • * o 
• •
O
• <^o o 
O 0   o---------
o
o
o
o
o
2000 3000 4000 5000 6000 7000
Average volume of total hippocampus (mm3)
8000
Figure 9.9 A. Association o f automated manipulated and manual total (left plus right) 
hippocampal volumes in AD and control subjects (R2 for combined subject groups = 
0.65). B. Bland-Altman plot o f automated manipulated and manual total (left plus right) 
hippocampal volumes in AD and control subjects.
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9.3.2.2.Multi-subject aHBSI.
The accuracies of segmentation of each probability-thresholded region (denoted by the 
percentage region used followed by aHBSI) are displayed in Table 9.6. Rates for each 
level of hippocampal probability (denoted by the percentage region used followed by 
automated HBSI) are shown in Figure 9.12 together with semi-automated HBSI and 
standard aHBSI and manual measures. Mean (SD) rates are shown below in Table 9.7). 
All methods showed significant differences in rates of atrophy between control and AD 
groups (p<0.001) which is demonstrated in Figure 9.13. Rates of atrophy differed 
between the semi-automated and group template region-based HBSI at every probability 
level (p<0.03). The probability region of 60% gave rates which were most similar to 
the semi-automated HBSI measures with the SD of the difference from the semi­
automated being 36.84mm3.
Table 9.6 Mean (SD) voxel similarity results for the average template region.
Control AD Total
Standard single-person template 0.50 (0.06) 0.44 (0.44) 0.46 (0.07)
100% aHBSI 0.43 (0.03) 0.29 (0.05) 0.35 (0.08)
80% aHBSI 0.55 (0.05) 0.42 (0.09) 0.47 (0.10)
60% aHBSI 0.50 (0.05) 0.40 (0.11) 0.44 (0.10)
Table 9.7 Mean (SD) absolute rates o f atrophy using the multiple-person template 
hippocampus probability thresholded at differing levels.
Manual HBSI aHBSI 100% aHBSI 80% aHBSI 60% aHBSI
Controls 20.4 (52.3) 10.3 (62.1) 2.6 (59.7) 14.7 (147.4) -3.7 (76.1) -4.4 (50.9)
AD
171.9
(105.2)
145.2
(106.9)
173.9
(111.9)
470.4
(291.9)
264.3
(181.4)
182.6
(116.6)
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9.4. Discussion
In this chapter a way of automating the calculation of hippocampal atrophy rates in AD 
and control subjects is described. The standard aHBSI method utilised a template 
hippocampal region and did not require manual segmentation of each subjects’ scans. 
The standard aHBSI method gave similar results to a semi-automated method of 
generating atrophy rates (HBSI), and to manual measures. There was no significant 
difference in discriminating the AD and control groups using any method, although it 
may be that a combination of one of the HBSI methods and manual measures may be 
superior in separating AD patients from controls compared with any one of the methods 
alone.
The results presented here for the standard aHBSI are on an absolute scale (mm3 loss 
per year). On a relative scale, the findings are in keeping with those in the literature with 
respect to rates of atrophy in elderly controls, and AD subjects. Mean atrophy rates were 
around 170mm3 per year in AD (which approximates to 4-5% per year) compared with 
less than 20mm3 per year (under 0.5% per year) in controls. This is within the range of 
previously published hippocampal rates of atrophy for AD patients of this age group 
(see Table 1.3).
Other techniques exist for automatically or semiautomatically segmenting the 
hippocampal region. These methods are summarised in Table 2.1. One of these studies 
has reported atrophy rates by applying their technique to serial imaging (Wang et al., 
2003). This technique also used a single-subject template hippocampus and applied 
non-linear registration methods to propagate this label onto baseline and repeat scans for 
18 subjects with mild dementia and 26 controls. This technique requires the application 
of a number of operator-placed landmarks for the technique to be successful with 
atrophy rates calculated to be approximately 5% (200mm3) per year in the mildly 
demented subjects and 2% (100mm3) per year in the normal controls. This rate is 
similar to that which was found in our AD subjects however the rates reported in 
controls were lower. This may be a reflection of the different methodologies employed 
by the two studies or differences in the composition of the control groups, for example, 
our control group was approximately 5 years younger than that reported by Wang et al. 
(Wang et al., 2003). Another study used similar techniques to (Wang et al., 2003) and
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gave relatively comparable mean atrophy rate results in both AD and control groups 
(Du et al., 2004).
The influences of a number of factors in the automatic segmentation of the baseline 
hippocampal regions were also assessed. Manipulating the automatic segmentation of 
the baseline region using conditional dilations and intensity-thresholding improved the 
accuracy of the baseline hippocampal regions. This technique also slightly improved 
the agreement of this HBSI measure with manual segmentations compared with a 
similar comparison of standard aHBSI and manual measures. The volumes of these 
manipulated automated regions were accurate enough to use to generate a relative rate 
of atrophy. Using this technique showed no differences between manual and the 
automated techniques.
Using an average region generated from half of the subjects did not greatly improve the 
accuracy of the generated region compared with the manual regions. As a result, this 
did not improve upon the generation of HBSI measure when comparing with the semi­
automated HBSI. In this case, only an average of the hippocampal ROIs were created, 
rather than the images. It may be that some form of combining variability of both 
images and regions, such as complex statistical models, may produce templates which 
can allow more accurate segmentation of the hippocampal region on other scans.
Other features of this template generation and transference of hippocampal labels may 
affect both the accuracy of segmentation and subsequent HBSI generation. These 
include the choice of template image, the type of registration method used and the 
interpolation scheme utilised in the registration process of these images and regions 
throughout the inter- and intra-subject registration stages. One obvious step to consider 
is to create a library of manually segmented hippocampi which may be used to segment 
new scans. By testing the correspondence of the hippocampal region with the library, 
the most accurate match can be chosen as the single-subject template.
Despite finding large and significant differences in AD subjects’ rates of atrophy from 
controls a large degree of overlap between subject groups was still observed. With 
respect to control subjects this may reflect true group heterogeneity, scan artefacts or 
measurement error. In the AD group this may also reflect different disease progression 
or stage of disease. In this study there was only confirmation of disease in two of the
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AD group and one of the controls, therefore there may be some uncertainty as to the 
pathological status of all of the subjects.
Most of the results presented here could not be shown accurately on a relative scale 
since the baseline segmentation of the hippocampus using linear inter-subject 
registration and region transformation did not give accurate volumes. This was 
demonstrated by the voxel similarity being relatively low for the standard automated 
region compared with the manual region. This is in keeping with other studies which 
suggest that affine hippocampal segmentation methods have a similarity measure of 
around 0.4 for cohort-based atlases (Carmichael et al., 2005; Crum et al., 2004b). The 
results achieved for the standard aHBSI methodology were marginally better than 0.4 
and this may be partly due to the extra hippocampus-hippocampus affine step in the 
inter-subject stage of the registration procedure. Techniques such as non-linear 
registration and region propagation may give improved segmentation accuracy of the 
baseline hippocampi enabling relative rates to be accurately calculated (Carmichael et 
a l, 2005; Crum et al., 2004b). It was found that by manipulating the region using a 
combination of intensity thresholding and conditional dilations that this segmentation 
accuracy improved. The level of accuracy achieved is similar to that shown my non­
linear registration techniques such as fluid-based registration (Carmichael et al., 2005; 
Crum et a l, 2004b).
One potential problem in the intra-subject stage of the methodology that may affect both 
HBSI and automated HBSI is the possible mis-registration of baseline and repeat 
hippocampi. Such potential misalignment of hippocampal borders may cause errors in 
calculating boundary shifts in such a small area of the brain. However, all intra-subject 
registrations were visually assessed and this did not appear to be an issue.
In one dataset, the HBSI has previously been shown to be at least as good as manual 
segmentation in differentiating AD from controls (see Chapter 8, page 204). In this 
study the automated HBSI and HBSI gave results that were similar to the manual 
measures. In addition, manual measures were generated by one operator giving this 
measure a degree of consistency that may not be possible in a multi-centre clinical trial 
where numerous operators are employed and different scanners will present scans with 
different intensities and contrasts. It may be that the automated method is most 
beneficial in a clinical trial situation. Furthermore, this automated hippocampal analysis
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in this small study took 20 minutes processor time per hippocampal pair to complete on 
a 3.4 GHz Intel Xeon server, whereas manual delineation of a hippocampal pair took 90 
minutes of trained operator time following a period of three months operator training.
9.5. Chapter Conclusion
In conclusion, hippocampal atrophy rates may be calculated using a combination of 
inter- and intra-subject registration and application of the hippocampal boundary shift 
integral. This may be of use both diagnostically, and in large studies where many serial 
scans require analysis.
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10. DETECTING THE LOCATION OF HIPPOCAMPAL LOSS IN AD
10.1. Introduction
As discussed in Chapters 1, 4 and 6 differences in volume of the hippocampus in AD 
compared with controls are frequently reported in the literature, with AD patients 
having lower hippocampal volumes compared with matched controls (see Table 1.1). 
Changes in these volumes over time, often reported as a rate of atrophy, are also widely 
reported, with AD patients having greater changes than controls (see Chapters 1, 5, and 
6 and specifically Table 1.3).
The “gold-standard” method of measuring hippocampal volume loss (as used to 
generate results in Chapters 4, 5 and 6) utilises separate manual measurements at each 
time-point with the generation of binary masks (where a voxel is either labelled “in” or 
“out”) which are used to calculate volumes. Rate of change in volume over time 
(atrophy rate) is usually calculated by taking the second volume from the first and 
normalising this difference to the inter-scan interval. However, summarising the data in 
this manner loses information about the spatial distribution of atrophy which may have 
occurred as a result of the disease or its progression, such as which parts of the 
hippocampus may be preferentially affected by the disease. This information may be 
useful for early diagnosis, differential diagnosis or to understand the natural history of 
the effects of the disease.
A number of methods have been utilised for whole-brain analysis to assess where 
differences in the amount of grey matter can be found when comparing a group of AD 
subject scans with a group of control scans. One such technique, VBM, has been shown 
to highlight hippocampal involvement in AD both cross-sectionally (Baron et al., 2001; 
Karas et al., 2003) and longitudinally (Scahill et al., 2002). Using another group-level 
method which statistically assesses grey matter volume following cortical pattern 
matching, it was also found that the temporal lobe including hippocampus was affected 
by AD (Ballmaier et al., 2004).
One potential problem with using group-level whole-brain techniques is that they 
require an alignment step which spatially matches the brain regions. As a result, there is 
evidence that small structures such as the hippocampus may not be accurately aligned 
(Mosconi et al., 2005). This impacts upon the ability of these whole-brain based
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analyses to give reliable results regarding 1) the involvement of the hippocampus in a 
specific group of scans compared with another or 2) which sections of the hippocampus 
may be affected. This problem with alignment combined with variability of 
hippocampal sizes and shapes seen in a disease population may explain how some 
studies have shown little hippocampal involvement in severe AD (Scahill et a l, 2002).
Some work has attempted to circumvent this by spatially matching hippocampi. 
Thompson’s group has published methods of spatially matching hippocampi using a 
process of whole-brain registration to a template (ICBM152), manual delineation of 
hippocampi, and surface-based registration of the smoothed regions (Thompson et al., 
2004a) (erratum in press). These methods have been shown to detect cross-sectional 
differences at baseline and repeat imaging in the hippocampi of both AD (n= 17) and 
control subjects (n=14, mean age approximately 70 years). These differences were 
located particularly in the left hippocampal head, however, surprisingly, rates of atrophy 
in the left hippocampus were similar in controls and AD subjects.
Methods have also been published methods for assessing spatial differences in 
hippocampi using surface deformations which can be applied both cross-sectionally 
(inter-subject) (Csemansky et al., 2000) and longitudinally (intra-subject and inter­
subject) (Wang et al., 2003). These methods involve using a labelled single-person 
cohort template to propagate hippocampal regions onto the remainder of the cohort 
whilst storing the deformations required to map the template hippocampus to the cohort. 
These stored deformations are then analysed using methods similar to principle 
component analysis which produces maps of average inward or outward deformation of 
the hippocampal surface. These methods have shown that the hippocampus is deformed 
in dementia of the Alzheimer type compared with controls and the authors claim that 
this inward deformation is mainly specific to the hippocampal head and the CA1 region 
of the hippocampus in AD subjects in their mid-seventies (Csemansky et al., 2000).
These methods of hippocampal matching may be preferable to matching whole-brains 
assuming the hippocampi are adequately aligned. However, there is still an assumption 
that remains with all these techniques that there is correspondence between specific 
parts of the structure in all hippocampi.
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The aim of this chapter is to investigate the distribution of atrophy within the 
hippocampus in AD subjects compared with controls both cross-sectionally and 
longitudinally.
10.2. Methods
10.2.1. Subjects
Subjects were used from the MIRIAD cohort comprising a group of 36 elderly sporadic 
AD subjects and 19 age-matched controls. This is the same group of subjects and scans 
as used in Chapter 9. For subject demographics see Table 9.1 and for further details see 
Chapter 9 (page 244).
10.2.2. Scan acquisition
T1-weighted volumetric MR brain scans were performed using the MIRIAD protocol 
(see Appendix Three).
10.2.3. Hippocampal segmentation
All segmentations were performed using MIDAS software. Brain regions on the 
baseline and repeat images were segmented using a previously described method 
(Freeborough et al., 1997)(see Appendix Four), and all images were registered into 
MNI 305 atlas space (Mazziotta et al., 1995) using six degrees of freedom (dof) to 
ensure all images were in a similar orientation. Following this the repeat images 
(second time-point) were registered to the baseline images using nine dof registration, to 
align the brains within a scan-pair accurately. Hippocampi were delineated for each 
subject on the baseline and nine dof brain-brain registered-repeat images. Mirror-image 
volumetry (see page 101) was used for the hippocampal segmentation process. The 
baseline and registered-repeat images were loaded simultaneously with the scans in a 
random chronological order. The hippocampus was always measured on the right-hand 
side of the presented image with the investigator blinded to the subject’s name, 
diagnosis, chronological order, and left-right orientation of the scans. The protocol used 
is detailed in Appendix Four.
10.2.4. Generation o f averas e AD and control maps
All hippocampi were affine registered (12 dof) brain to brain to the individual subject 
used as the single person template in Chapter 9 (see page 246, and Figure 10.1). The 
hippocampi were then rigidly registered (six dof) to this labelled template’s
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hippocampus and the resulting binary regions in template space were stored. The 
volume over which the cost function for this registration was calculated was the 
template hippocampal region dilated by two voxels. The cost function used for all 
registrations was the SD of baseline image / repeat image. One year interval 
hippocampi were also used transformed into this template space by applying the 
transformation parameters calculated from transforming the baseline hippocampi into 
the template space. These masks were again stored. Within each subject group average 
maps were created from these masks, for left and right hippocampi at baseline and 
repeat imaging, giving a total of eight hippocampal maps. These were used to overlay 
results from the voxel-wise significance tests. For purposes of presentation, difference 
images showing one map minus the other (AD -  controls) are also presented.
High a v . VOXEL VALUE Low
TEM PLATE SCAN 
AND AVERAGE 
MAPS OF THE 
HIPPOCAM PUS 
FO R  THE AD AND 
CONTROL 
SUBJECT CROUPS
TEM PLATE GENERATION 
BASELINE SUBJECT SCAN, 
BRAIN AND H REGION
TRANSFORM ED 
BASELINE SUBJECT 
SCAN, BRAIN 
REG IO N  AND 
TRANSFORM ED H 
REG IO N
TEM PLATE SCAN, 
BRAIN AND H 
REGIONS
C. Transformed H 
regions stored and 
used to make average 
maps
A Brain-Brain 12 dof
B H-H 6 dof
Figure 10.1 Schematic diagram showing creation of the average maps of the 
hippocampus in AD and control subjects.
H =  hippocampus, Sup. =  superior, Lat. =  lateral, Med. =  medial, Inf. -  inferior, Pos. =  
posterior, Ant =  anterior.
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10.2.5. Statistical analysis 
The hippocampal masks transformed into template space were tested both cross- 
sectionally between subject groups and longitudinally within subject group. Owing to 
the binary nature of the data, Fisher’s exact test was performed at each voxel to 
establish whether there were cross-sectional differences between subject groups. 
Results were reported for two-tailed tests as well as left and right tailed tests. This was 
performed in the left and right hippocampus separately, and at both baseline and repeat 
scanning time-point. To assess whether changes could be detected over time 
McNemar’s test was used in a similar way, testing voxel by voxel over the mask data 
sets with subject group over time. This test was performed in both left and right 
hippocampi. Results of these statistical tests are presented as colour overlays on the 
average control maps created above.
10.3. Results
10.3.1. Cross-sectional analysis 
Figure 10.2 and Figure 10.3 show the difference images between the AD and control 
average maps at baseline imaging. There are widespread differences between 
hippocampal regions in the two groups demonstrated by presence of white and black in 
the images. White represents areas present in controls which are not present in AD. 
Black represents areas present in AD subjects which are not present in controls. The 
white areas are located in the superior and lateral regions of the image, approximately 
corresponding to CA regions 1-4, gyrus dentatus and the uncinate gyrus. Images 
through the hippocampal head show that differences can also be seen in the uncal 
sulcus. Areas which appear dark are mainly located in the subiculum. Similar patterns 
are seen at repeat imaging (see Figure 10.4 and Figure 10.5).
Figure 10.6 and Figure 10.7 show results of the two-tailed Fishers exact test overlaid on 
the average control maps. These show two main areas where the AD and control masks 
differ (blue on overlay), in the superior region and a region in the inferior of the 
hippocampus. The regions which correspond to these differences are those highlighted 
from the difference images above, namely CA regions 1-4, gyrus dentatus and uncinate 
gyrus and subiculum. Areas in the uncal sulcus did not appear significantly different. 
This is possibly due to the variability seen in this region in AD.
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Figure 10.8 and Figure 10.9 show the overlay of the left-tailed Fisher’s exact test. 
These blue regions show where AD subjects have significantly fewer voxels labelled 
hippocampus (blue on overlay) overlaid on the average control maps. This shows that 
control hippocampi are larger than AD in the superior, medial and lateral regions 
corresponding to the CA 1-4 regions, the gyrus dentatus, and some areas of the uncinate 
gyrus.
Figure 10.10 and Figure 10.11 show the overlay of the right-tailed Fisher’s exact test. 
These blue regions show where AD subjects have significantly more voxels labelled 
hippocampus (blue on overlay) overlaid on the average control maps. This shows that 
AD hippocampi appear to be larger than controls in inferiorly.
Figure 10.12, Figure 10.13 and Figure 10.14 show two-tailed, left-tailed and right-tailed 
results respectively in the hippocampi at repeat imaging (blue on overlay) overlaid on 
the average control maps. Only sagittal images are shown as the areas of significance 
are very similar to those of the baseline imaging.
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Figure 10.2 Coronal difference images o f hippocampal maps of AD vs. controls at baseline imaging.
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in the right (a and c) and left (b and d) hippocampus. White shows
where AD < controls and black where AD > controls, grey shows no difference between the two.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG.
uncinate gyrus, US: uncal sulcus.
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Figure 10.3 Sagittal difference images of hippocampal maps of AD vs. controls at baseline imaging.
Images taken through the hippocampus in the right (e) and left (f) hippocampus. White shows where AD < controls and black where AD > controls, 
grey shows no difference between the two.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: 
uncinate gyrus, US: uncal sulcus.
These imply that in the sagittal view the hippocampus is atrophying along its length and being displaced postero-inferiorly, the overlays also suggest 
the opening of the uncal sulcus is a characteristic feature o f a characteristic feature o f the loss.
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Figure 10.4 Coronal difference images o f hippocampal maps o f AD vs. controls at repeat imaging.
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in the right (a and c) and left (b and d) hippocampus. White shows 
where AD < controls and black where AD > controls, grey shows no difference between the two.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: 
uncinate gyrus, US: uncal sulcus.
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Figure 10.5 Sagittal difference images o f hippocampal maps of AD vs. controls at repeat imaging.
Images taken through the hippocampus in the right (e) and left (f) hippocampus. White shows where AD < controls and black where AD > controls, 
grey shows no difference between the two.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: 
uncinate gyrus, US: uncal sulcus.
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Figure 10.6 Coronal images of control average maps overlaid with Fisher's exact test 
results showing where AD and controls are significantly different at baseline imaging. 
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in 
the right (a and c) and left (b and d) hippocampus. The overlay shows p<0.05 where 
blue and p>0.05 where red.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2- 
4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus.
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Figure 10.7 Sagittal images of control average maps overlaid with Fisher s exact test results showing where AD and controls are significantly 
different at baseline imaging.
Images taken of both the right (e) and left (f) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: 
uncinate gyrus, US: uncal sulcus.
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Figure 10.8 Coronal images of control average maps overlaid with Fisher's exact test 
results showing where AD significantly < controls at baseline imaging.
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in 
the right (a and c) and left (b and d) hippocampus. The overlay shows p<P.05 where 
blue and p>0.05 where red.
Anatomical labels: CA1: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2- 
4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus.
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Figure 10.9 Sagittal images of control average maps overlaid with Fisher's exact test results showing where AD significantly < controls at baseline 
imaging.
Images taken of both the right (e) and left (f) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT: hippocampal 
tail.
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Figure 10.10 Coronal images of control average maps overlaid with Fisher’s exact test 
results showing where AD significantly > controls are significantly different at 
baseline imaging.
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in 
the right (a and c) and left (b and d) hippocampus. The overlay shows p<0.O5 where 
blue and p>0.05 where red.
Anatomical labels: CAl: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2- 
4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus.
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Figure 10.11 Sagittal images of control average maps overlaid with Fisher’s exact test results showing where AD significantly > controls at baseline 
imaging.
Images taken of both the right (e) and left (f) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT: hippocampal 
tail.
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Figure 10.12 Sagittal images of control average maps overlaid with Fisher's exact test results showing where AD and controls are significantly 
different at repeat imaging.
Images taken of both the right (a) and left (b) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT: hippocampal 
tail.
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Figure 10.13 Sagittal images of control average maps overlaid with Fisher s exact test results showing where AD significantly < controls at repeat 
imaging.
Images taken of both the right (a) and left (b) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, FIT: hippocampal 
tail.
RIGHT LEFT
Figure 10.14 Sagittal images of control average maps overlaid with Fisher’s exact test results showing where AD significantly > controls at repeat 
imaging.
Images taken of both the right (a) and left (b) hippocampus. The overlay shows p<0.05 where blue and p>0.05 where red.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT: hippocampal
10.3.2. Longitudinal analysis 
Figure 10.15 and Figure 10.16 show the difference images between time-points of the 
control group in both left and right hippocampi. Figure 10.17 and Figure 10.18 show 
the difference images between time-points in the AD group in both left and right 
hippocampi.
When applying McNemar’s tests to these longitudinal data, no voxels were shown to be 
significantly different in terms of whether they were labelled as hippocampi on either 
the left or right and in either the AD or control groups. As a result no images of these 
statistical maps are presented.
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Figure 10.15 Coronal difference images of hippocampal maps o f controls at baseline vs. repeat imaging. . xm.it* c
Images taken through hippocampal body (a and b) and hippocampal head (c
where baseline < repeat and black where baseline > repeat, grey shows no difference between the two time-points.
Anatomical labels: CAl: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, . su icu um, 
uncinate gyrus.
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Figure 10.16 Sagittal difference images o f hippocampal maps of controls at baseline vs. repeat imaging.
Images taken through the right (e) and left (f) hippocampus. White shows where baseline < repeat and black where baseline > repeat, giey shows no 
difference between the two time-points.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT. hippocampal 
tail.
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Figure 10.17 Coronal difference images o f hippocampal maps o f AD subjects at baseline vs. repeat imaging.
Images taken through hippocampal body (a and b) and hippocampal head (c and d) in the right (a and c) and left (b and d) hippocampus. White shows 
where baseline < repeat and black where baseline > repeat, grey shows no difference between the two time-points.
Anatomical labels: CAl: cornu Ammonis section 1, CA2-4: cornu Ammonis sections 2-4, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: 
uncinate gyrus.
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Figure 10.18 Sagittal difference images o f hippocampal maps of AD subjects at baseline vs. repeat imaging.
Images taken through the right (e) and left (f) hippocampus. White shows where baseline < repeat and black where baseline > repeat, grey shows no 
difference between the two time-points.
Anatomical labels: CA: cornu Ammonis, GD: gyrus dentatus or dentate gyrus, S: subiculum, UG: uncinate gyrus, US: uncal sulcus, HT: hippocampal 
tail.
10.4. Discussion
Cross-sectional findings
The cross-sectional analyses in this study showed differences between AD and control 
hippocampi at both baseline and repeat time-points. The difference images of the 
average maps (Figure 10.2 - Figure 10.5) allowed an assessment of the localisation of 
these differences. Specific areas that were consistently implicated as showing AD < 
controls include CA1-4, the gyrus dentatus, the uncinate gyrus and the uncal sulcus. 
The dark areas in the inferior of the subiculum represent areas where controls < AD 
subjects, suggesting a downward displacement of the hippocampus in AD subjects 
which was not removed by linear transformations. When testing for significant 
differences between subject groups at baseline and repeat imaging, the areas which 
showed significant differences (AD < controls) approximated to CA1-4, gyrus dentatus, 
and the uncinate gyrus. The uncal sulcus did not show to be significantly different, 
perhaps owing to the variability in the position and labelling of this feature. As could 
be inferred from the difference images, the area where significant differences were seen 
(controls < AD) approximated to the subiculum.
These results are similar to those shown in previous studies (Csemansky et al., 2000; 
Csemansky et al., 2005; Thompson et al., 2004a). One study showed differences at 
both baseline and follow-up (1.5 years following baseline scanning) in the groups of 
AD and control patients (Thompson et al., 2004a). In this study the differences between 
AD and controls were principally located in the head of the hippocampus which 
includes the dentate gyms and subregions CA1-4. Csemansky’s group found that in 
their subjects (18 mild AD and 18 controls, mean ages 74 years) the location of the 
atrophy was in the head and lateral aspects of the hippocampus. In this study they 
differentiate between expansion and contraction of the fitted surfaces (similar to the left- 
and right-tailed tests reported in the results section of this chapter) (Csemansky et al., 
2000). However, the areas where the results presented as part of this chapter showed 
AD to be greater than controls (inferior regions) are not displayed as part of that paper. 
Csemansky’s study concludes that the CAl subfield is most affected by early AD. The 
methods employed by these studies differ from those reported in this chapter as they 
utilise surface-based registration techniques which generate correspondence between 
points of the mesh framework in all hippocampi in a group of subjects. At the stage of 
generation of surfaces, the binary masks created in the first instance were smoothed 
which allows the borders of hippocampi to go through voxels. As a result of this, these
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methods may be more sensitive to smaller deformations of the hippocampus than the 
technique reported in this study.
Pathology remains the gold-standard in determining which sub-regions of the 
hippocampus may be affected by a disease process. However, pathological load may 
not directly relate to volume loss which can be measured using MRI. A number of 
studies have been conducted assessing the pathological load and location in Alzheimer’s 
disease, in addition to neuronal counts. One study assessed cognitively normal people, 
determined at date of recruitment, over time until death. Some of these subjects over 
the period of clinical assessment became demented. Pathological examination of the 
brains revealed that those who were demented had higher amyloid lesion load and 
presence of NFTs in the neocortex, with NFT load associated with MMSE. Presence of 
NFTs and amyloid plaques in those who were not classified as demented had the 
predilection for limbic areas, suggesting that lesion load in areas such as the 
hippocampus may not be related to presence of dementia (Green et al., 2000). Other 
studies which have assessed sub-regions of the hippocampus have shown some varied 
results: amyloid in the subiculum being a predictor of the stage of dementia, but the 
amyloid being heterogeneous in both location and volume (Bussiere et al., 2002); NFT 
and neuron counts in the CAl subregion being associated with MMSE but amyloid not 
being a good predictor of MMSE (Giannakopoulos et a l , 2003); and that variability in 
CDR is best explained by NFT numbers in the CA2 region and dentate gyrus, not by 
neuronal loss in the CAl region (Von Gunten et al., 2005). Although these studies 
seem to reveal conflicting results between the association of pathology and stage of 
disease, one of the latter three studies found that volumes in the CAl and subiculum 
were reduced in AD (CDR > 0.5 -5) compared with controls (CDR 0 -  0.5) (Bussiere et 
a l , 2002), and another showed a reduction in neuron numbers in the CAl region in AD 
(CDR 0.5-2) compared with controls (CDR 0) (subiculum not measured in this study) 
(Von Gunten et a l , 2005). The results presented in this chapter agree with the measures 
reported in these papers in terms of areas affected apart from our findings in the 
subiculum as this structure may not have been optimally aligned. In addition, changes 
in the uncinate gyrus were found which were not analysed as part of the pathological 
studies mentioned above.
Some areas of the hippocampus were shown to be greater in AD than controls. These 
areas were located along the inferior part of the hippocampus in the subiculum. This
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result may reflect mal-alignment of the hippocampi or a shape change in the 
hippocampus of AD patients which allows the subiculum to become more curved. Mal­
alignment may be caused by other areas of the hippocampus having more of an impact 
on the registration, i.e. having a greater influence on the cost function, and as a result 
the inferior border of the subiculum may become poorly registered. A shape change in 
the inferior subiculum grey / white matter border may be due to the fact that as the 
hippocampus and its supporting structures in the medial temporal lobe become 
atrophied this causes a structural change such that the whole parahippocampal gyrus 
dips and curves more than in those subjects in which no atrophy has occurred.
Longitudinal findings
The longitudinal analysis showed no areas of loss were detected in particular regions of 
the hippocampus over time. One other study has found differences over time in a 
relatively large group of early AD patients (MMSE 25) and age matched controls 
(Wang et al., 2003). In that study paired Wilcoxon’s sign rank tests showed significant 
areas of inward deformation in the early AD cases and ascribed this to specific losses in 
the CA1 subfield of the hippocampus (see Figure 8.10 for labelling of hippocampal 
subfields). That study differed from the study reported here in terms of the methods 
employed to detect change. Much like Thompson’s group, surface-based registration 
and therefore correspondence and deformations were obtained. In addition to this the 
scanning interval was over two years (twice as long as the scanning interval used to 
generate longitudinal results in this chapter) making the changes in the hippocampus 
greater and potentially easier to detect. Using the techniques reported in the methods 
section of this chapter, the hippocampus would have to shrink by at least a voxel in 
places surrounding the hippocampus and these areas would have to be well aligned in 
order to generate significant longitudinal patterns of atrophy.
General discussion
Differences between the study presented in this chapter and those of others are not only 
methodological. Differences in the cohorts in terms of stage of disease or disease 
progression may account for varying results. Age might also contribute to the 
differences seen. Heterogeneity of the distribution of pathology caused by AD as 
demonstrated by pathological studies may also influence where differences in the 
hippocampus can be seen (Bussiere et al., 2002).
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This study is limited by a number of factors. First the interpolation scheme chosen to 
generate hippocampi from their original space to template space may not be optimal. 
Trilinear interpolation was used for this procedure but it may be that another method 
provides more accurate transformation of the hippocampal regions. The registration 
algorithm used to align the hippocampi into template space may also require 
investigation. Affine brain-brain registration was used to obtain an approximate spatial 
match followed by rigid-body hippocampus to hippocampus registration. It may be that 
non-linear registration with increased degrees of freedom would match the hippocampi 
more accurately; however such registration might also remove the differences between 
hippocampi the experiment is designed to detect. The technique of registering brain to 
brain in the first instance may not optimally correct for head-size. This may be 
important since some of the variance in the hippocampal regions, which will affect the p 
values obtained, may be accounted for in terms of head-size. Lastly, correction for 
multiple comparisons was not performed following generation of the statistical maps. 
Essentially, performing many statistical tests over the whole hippocampal region is 
likely to lead to detection of false-positive voxels and the results presented here did not 
correct for this potential source of error.
One potential problem that this type of research highlights is that such studies rely on 
inter-subject correspondence which is assumed rather than necessarily obtained. Such 
correspondence is hard to measure and assess and as a result it is difficult to establish 
that one area of the hippocampus is differentially affected by the disease. This may be 
the result of the registration procedure finding better alignment of one particular region 
rather than true correspondence. For example, it may be that the inferior boundary of 
the hippocampus in the head region gives the best cost function results following 
registration, leading to the differences being found at the superior border when this 
region is not necessarily the area from which the tissue has been lost. Surface-based 
techniques usually rely upon correspondence between parametric meshes created from 
the binary masks. This type of matching assumes that point A on one hippocampus 
relates to point A’ on another hippocampus, whereas it may be that point A relates to 
80% point A’, 10% point B’ and 10% point C’. Such assumptions may influence results 
found by these techniques.
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10.5. Chapter conclusion
In conclusion, differences between AD and controls in the location of regions labelled 
hippocampus by manual segmentation methods can be seen cross-sectionally. This 
study highlights areas which may be preferentially affected by AD which include the 
uncinate gyrus, CA regions 1-4 and the dentate gyrus. However, this study also 
highlights issues of aligning structures such as the hippocampus between subjects which 
can lead to assumptions as to which areas of the hippocampus may be preferentially 
affected by the disease.
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11. APPLICATIONS OF SEMI-AUTOMATED TECHNIQUES TO A CLINICAL 
TRIAL
11.1. Chapter introduction
Background
Previous chapters have demonstrated the utility of hippocampal rates of atrophy in 
diagnosis of disease (Chapters 5 and 6, pages 134 and 162), detection of early change 
(Chapter 6, page 174), and their potential in tracking the progression of disease (Chapter 
6, page 174 and Chapter 5, page 153). Chapters 8 and 9 demonstrated automation of 
these measures in a controlled situation where the acquisition and subjects were selected 
by the research group performing the atrophy measures. Two studies featured earlier 
have been based at one site only (see Chapter 5, page 153, and Chapter 9, page 243), the 
remainder of the studies utilised scans from a small number of sites (<4). This type of 
analysis is useful for establishing the concept of methods for determining the rates of 
atrophy, however there is a risk that the methods developed from such studies are not 
robust to problems associated with scanning at multiple sites.
Few clinical trials or large studies have been conducted reporting hippocampal rates of 
atrophy as an outcome measure. One reported on the results of a trial of a melameline 
(a muscarinic receptor agonist). This therapy was proposed to augment diminished 
cholinergic function which occurs in AD. The trial was suspended due to lack of 
efficacy but 100 of the treated and 92 of the placebo subjects completed the MR 
analysis part of the study. This study showed MR results to be reliable across sites with 
decline more consistently seen with MR rather than clinical measures (Jack et al., 
2003).
Another trial involved active immunisation of subjects against one possible pathological 
substrate of AD: aggregated A6 protein (see Chapter 1, page 20). This trial showed 
manually-derived hippocampal rates of atrophy to be greater in those treated compared 
with those in the placebo arm, and although this difference was not significant in the 
hippocampus, there were significant differences in both rates of ventricular expansion 
and brain shrinkage (higher in the treatment arm) (Fox et al., 2005). The trial was 
suspended due to adverse events in the treatment arm, with encephalitis being detected 
in a number of cases (Orgogozo et al., 2003).
-301 -
One other trial investigated the effect of an acetylcholinesterase inhibitor (donepezil) on 
MR-based markers in AD (Krishnan et al., 2003). This pilot study ran for 24 weeks and 
found that the treated patients had reduced loss of the hippocampus compared with the 
placebo arm. However, the results for this study were surprising in that the rate of 
change seen over the 24 weeks in the placebo arm would approximately equate to over a 
16% hippocampal loss per year. In addition, the results in the treatment arm were 
asymmetric; the left and right hippocampi had changes of equal magnitude, but in 
different directions (i.e. loss was seen in the left and gain on the right).
In order to establish whether the techniques for assessment of hippocampal atrophy 
rates described earlier have utility in clinical trials, it is important to test them in a 
multi-centre setting.
Chapter outline
This chapter aims to evaluate the variability of hippocampal rates of atrophy generated 
by a semi-automated measure (HBSI) in and the discrimination between the placebo and 
treatment groups in a clinical trial setting. The data used is from the AN1792 trial of 
AB immunisation (Fox et al., 2005) where manual measurements were already available 
as a comparison.
11.2. Methods
11.2.1. Patients
Patients and sites are described in detail elsewhere (Fox et al., 2005; Gilman et al., 
2005). Patients included in the trial were aged 50 to 85 years, met the criteria for a 
diagnosis of probable AD as defined by the NINCDS-ADRDA (see Appendix One) and 
had an MRI brain scan supporting the clinical diagnosis of AD. This study assessed the 
differences in those who were treated with the drug and responded to treatment (this 
was defined as those subjects who had an antibody response of a serum anti-AN1792 
IgG (total) titre of >1:2,200 at any time after injection 1 and included those subjects that 
developed encephalitis) and those subjects in the placebo group (see Table 11.1).
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Table 11.1 Subject demographics.
Placebo Responders
Number 57 45
M/F 23/34 24/21
Mean age (SD), in years 70.7 (8.2) 72.2 (7.1)
Mean (SD) MMSE 20.2 (3.5) 20.8 (3.5)
Mean duration of AD 
years (SD)
3.9 (1.8) 3.8 (2.1)
11.2.2. Trial details
The study was conducted at 28 centres in five countries between September 2001 and 
December 2002. Patients were randomly assigned in a double-blind manner to receive 
treatment with AN1792 225 fig (Elan Pharmaceuticals, South San Francisco, CA) and 
QS-21 50 ng (Antigenics, Framingham, MA) containing 0.4% polysorbate 80 or normal 
saline in a 4:1 ratio. The assignment code was held by an independent statistician. 
Patients received only one to three (day 0, months 1 and 3) of the planned six injections 
because of the premature discontinuation of the study because of the development of 
encephalitis in 6% of the treated patients. All patients who had been enrolled in the 
study could participate in the safety follow-up period, occurring for at least nine months 
after their last dose of study treatment.
11.2.3. Image acquisition
Images were collected at 17 scanning sites owing to pooling of the 28 clinical 
assessment centres. The study outcomes included measures derived from volumetric 
MRI brain scans performed at baseline and at month 12 or early termination. Patients 
were imaged on 1.5 T MR units using a standardised protocol; all efforts were made to 
ensure each follow-up scan was performed on the same scanner using the same imaging 
protocol as the baseline assessment.
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Volume measurements were derived from a Tl-weighted three-dimensional gradient 
echo sequence. Exact acquisition parameters varied depending on the scanner 
manufacturer (see supplementary information from (Fox et al., 2005)); all were coronal 
volumetric acquisitions lasting 7.5 minutes (to minimise movement artefact), with the 
slice (partition) thickness of 1.5 to 1.8 mm adjusted to cover the entire brain, a within- 
plane field of view of 25 x 25 cm, and an effective matrix size of 256 x 256 x 124. At 
the baseline visit, each site also performed standard imaging (including T2-weighted or 
fluid-attenuated inversion recovery sequences) to exclude non-AD pathology.
11.2.4. Image processing 
Prior to hippocampal segmentation, all scans had brain regions segmented and 
subsequently were rigidly registered to the MNI 305 brain template to ensure similar 
orientation of scans. Scan pairs were co-registered using nine degrees of freedom (dof). 
Hippocampal volumes were manually delineated from each individual’s scan pair. Left 
and right hippocampi were delineated as described in Appendix Four using “mirror- 
image” volumetry (see Chapter 4 page 101). One protocol deviation necessary for this 
trial was the application of 60% as the lower threshold rather than the usual 70% mean 
brain intensity. This was due to differences in scanning acquisition which meant the 
70% caused some hippocampal tissue to be excluded from the hippocampal region. 
Segmentations were performed by three operators. The operators were blind to all 
patient information and other measurements at the time of segmentations. Tracing of 
the hippocampal boundaries was performed with each scan of the registered pair viewed 
side by side to improve consistency. Each subject (baseline and repeat image, left and 
right hippocampus) was segmented by only one segmentor. All measurements were 
performed blinded to treatment group, time-point or subject details. The detailed results 
of the MRI measures are reported and discussed in (Fox et al., 2005). In summary, the 
subjects who developed a predetermined titre of antibodies (responders) had increased 
brain volume loss (3% vs. 2%) compared with the placebo group. Manual hippocampal 
volumetry showed a non-significant loss (3 (3)% vs. 4 (3) % loss in placebo and 
responder groups respectively).
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11.2.5. HBS1 calculation
Following completion of the trial, information regarding each subject’s scan dates, 
treatment group assignment and antibody titre were given to the Dementia Research 
Centre. HBSI was then calculated in a similar manner to that described in Chapter 8, 
page 205. In brief, the manually-drawn baseline hippocampi were used and the HBSI 
was calculated on DBC-corrected nine dof registered scan pairs. The window widths 
and window centres that were selected for this dataset were 0.2 and 0.55 respectively.
11.2.6. Statistical analysis
Mean rates of atrophy were calculated for total (left plus right) hippocampi. Atrophy 
rates were analysed on a logarithmic scale [(log (follow-up volume/baseline 
volume))/interval] in order that doublings and halvings in volume be treated as effects 
of equal magnitude. Follow-up volume with the HBSI technique was calculated as 
baseline volume -  HBSI measure. Mean atrophy rates were calculated by back 
transformation with SDs calculated from variance transformation formulae. Tests of 
means and variances were performed on a log scale. Paired t tests were used to assess 
whether the mean rates of atrophy differed according to method within each subject 
group. Pitman’s tests were used to assess whether variances differed between methods 
within each subject group. Student’s t tests (allowing for unequal variances) were used 
to assess whether mean rates of atrophy differed between each group according to 
method. Linear regression was used to assess the association between the two methods 
in each subject group.
11.3. Results
The mean (SD) rates of atrophy (% per year) for all responder and placebo subjects 
were 3.61 (3.25) for manual and 3.42 (3.60) for HBSI. Mean (SD) rates of atrophy by 
group are displayed in Table 11.2 and Figure 11.1. As shown in Table 11.2, there was 
evidence of a difference between responders and placebo using the HBSI which was not 
shown using manually-derived rates of atrophy. HBSI and manual measures were not 
significantly different in the placebo group in terms of means (p=0.185) or variances 
(p=0.163). There was some evidence that there was a difference between the methods 
in both means (HBSI > manual, p=0.022) and variances (HBSI > manual p=0.007) in 
the responder group. Removing encephalitis cases from the responder group, manual 
and HBSI generated rates of atrophy gave mean (SD) rates of atrophy of 3.94 (3.02) and 
4.73 (3.69) respectively, (p=0.077).
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Figure 11.2 shows the association of rates of atrophy according to each method within 
each subject group. Those responders who developed encephalitis are shown as 
triangles. There was some association between the two methods with R2 being 0.47 
(p<0.0001) in the responders and 0.25 (p=0.0001) in the placebo groups.
Table 11.2 Mean (SD) atrophy rates in placebo and responder groups (%/year).
Manual HBSI
Placebo 3.23 (3.54) 2.64 (3.02)
Responders 4.08 (2.82) 5.08 (3.82)
p value p= 0.177 p < 0.001
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Figure 11.1 Annualised rates o f atrophy o f the placebo and responder group using both manual and HBSI methods.
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11.4. Discussion
This study has shown that HBSI gives consistent results in a clinical trial situation (17 
sites). The fact that a significant difference could be detected between subject groups 
using HBSI but not manual measures is due to the mean rate being lower in the placebo 
group (although not significantly) and corresponding rate in the treatment group being 
significantly higher. A similar comparison of means between subject groups using 
manual measures did not reveal a significant difference. This may be due to a number 
of factors. First the HBSI was calculated using differentially bias-corrected images 
owing to the inconsistent bias field between baseline and repeat scans, whereas manual 
measures were performed on image pairs which were not corrected in this way. 
Measuring hippocampi on these images following DBC may have also revealed 
significantly different results between subject groups. Secondly, HBSI may reduce 
some of the variance caused by operator error as discussed in Chapter 8, page 219. 
Removal of the encephalitis cases reduced the difference between mean atrophy rates 
generated from HBSI and manual measures, inferring that the greater atrophy rates 
calculated in the encephalitis cases using HBSI may have contributed to the overall 
higher rate in the responder group.
Although the HBSI detected a significant difference between the two subject groups, 
there remained a great deal of overlap in the results of the two subject groups. This is 
perhaps unsurprising since rates of atrophy in AD subjects have been shown to be 
heterogeneous in studies described in this thesis (see Chapters 5,6,8,9, pages 143, 156, 
166, 174, 178, 212, 230, and 252). The rates of atrophy calculated as part of this study 
are similar to other studies described and Table 1.3, but in the placebo group, are 
slightly lower than other mean rates calculated in this thesis. The rates of atrophy in the 
placebo arm are also lower than the placebo arms of both of the other two multi-centre 
trials which have used hippocampal atrophy rates as an outcome measure. In the 
melameline trial, median rates of atrophy were approximately 5% (Jack et al., 2003). In 
the donepezil trial, the inter-scan interval was relatively short (24 weeks) and the change 
calculated over that period was 8.2% (Krishnan et al., 2003). However these changes 
roughly equate to more than a 16% annualised rate of hippocampal atrophy which 
would be higher than any other annualised rate reported (see Table 1.3).
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The lower rates of atrophy quoted in this trial may be due to the range of sites and 
scanners used in this trial. This may also be caused by the application of DBC during 
the brain-brain registration procedure. DBC has been shown to cause slight 
underestimation of the subsequent atrophy measure (BSI) since some of the atrophy is 
modelled as part of the differential bias. However, this underestimation may occur in 
all subjects irrespective of group, and the benefits of using such correction may 
outweigh the cost. As a result the relative difference between groups may be a more 
important assessment. Further work is required to assess the effect of DBC on the BSI 
of small regions such as the hippocampus.
Although significant differences between the two groups were shown using the HBSI it 
is important to note that change in the other regions (brain and ventricular BSI) also 
showed significant differences. HBSI does not reveal a group difference which has not 
been shown in these subject previously using different structures (Fox et al., 2005).
The treatment administered as part of this trial was intended to raise an immune 
response against one of the supposed pathological substrates of AD (A8 amyloid 
protein). The exact cause of the increased rates of atrophy seen in the responder group 
remains unexplained. One theory which may partly explain this increased rate of 
atrophy is that the protein is removed from the brain and as a result the brain decreases 
in size by that volume. Some supporting evidence for this theory is derived from 
reports of patients who were immunised and had subsequently died. Post-mortem of 
their brain material suggests widespread and sometimes patchy removal of the AB 
amyloid protein (Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2003). Post­
mortem measures of the volume of amyloid in the hippocampus have been calculated to 
be approximately 1% in AD cases (calculated from sampling of tissue in CA1-3 
subregions and the dentate gyrus in 90-100 year old subjects with a CDR of 1-2) (Von 
Gunten et al., 2005). A similar study in younger subjects which were more severely 
affected (CDR 2-5, average age 89 years) showed the amyloid load of the CA1-3, 
dentate gyrus and subiculum to be approximately 6-7% (Bussiere et al., 2002). 
Amyloid removal (Nicoll et al., 2003) may therefore partly account for the increased 
hippocampal loss in the responder group.
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11.5. Conclusion
HBSI appears to be a viable measure in a multi-site trial, providing comparable results 
to those generated by manual volumetry. One advantage of using this technique is that 
only half of the number of hippocampal segmentations may be required, potentially 
reducing operator error in addition to reducing the workload substantially.
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12. META-ANALYSIS
12.1. Chapter introduction
Background
A relatively large number of studies assessing longitudinal hippocampal change have 
been reported in the literature (see Table 1.3). Many different methods have been used 
to generate these rates of atrophy and different populations of patients have also been 
included in the different studies. To the best of my knowledge, no statistical review of 
the literature has been conducted to date. Such a review is required to assess 
heterogeneity of reported studies to allow understanding of the effects of age and 
disease severity on the calculated atrophy rates, and to pool the results from these 
studies to estimate the rate of atrophy of the hippocampus in AD and matched control 
groups. It may also be useful in identifying outlier results where the methodology 
employed may deserve critical review.
Chapter objective
This chapter focuses on the meta-analysis of hippocampal atrophy rates in patients with 
AD and matched controls from studies reported in the peer-reviewed literature.
12.2. Methods
The following protocol was produced for conducting the study.
12.2.1. Protocol 
General study inclusion criteria
All observational and randomised trials were included, regardless of quality of the 
study.
Studies in which patients were given symptomatic treatment were included. If the study 
was a randomised controlled trial (RCT) in which some patients underwent an 
intervention which was shown to alter the atrophy rate of the whole brain as part of the 
trial (for example interventions developed to remove the pathological substrate thought 
to cause the disease or those which may prevent cell death) this arm of the study was 
excluded, however the placebo arm was included.
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Studies in which MRI scans were used were included, but no restrictions were made as 
to the scanning protocol or strength of magnet used to image the patients or 
segmentation protocol used to determine the atrophy rate.
Studies reporting results from patients with AD of any age or gender were included. 
There were no restrictions on the method used to diagnose AD. Unpublished studies 
were not included and studies where the mean inter-scan interval was less than nine 
months were also excluded owing to the lack of precision in determining the mean 
atrophy rates (Schott et al., 2005). As MCI was not a subject group being formally 
assessed as part of this meta-analysis, cognitively impaired subject groups with an 
MMSE >26 were also excluded.
Outcome measure
Mean (arithmetic) atrophy rate specified as % loss of baseline volume per year.
Search methods for identification o f studies
Searches for relevant studies were performed using electronic and other sources.
1) Electronic sources
PubMed and Google Scholar were searched for studies from any period using the 
following keywords: hippocampus, AD, atrophy, Alzheimer’s, MRI, rates.
2) Other sources
Journals searched included: Neurology, Annals of Neurology, Archives of Neurology, 
Neurobiology of Aging, American Journal of Neuroradiology, Brain, Cerebral Cortex, 
Cortex, European Journal of Neurology, Hippocampus, Journal of Neurology, Journal 
of Neurology, Neurosurgery and Psychiatry, Lancet Neurology, Neurodegeneration, 
Neuroimage, Neuropathology, Neuroradiology, Practical Neurology, Dementia and 
Gereatric Cognitive Disorders, Journal of Alzheimer’s disease, American Journal of 
Alzheimer’s disease and other dementias, Alzheimer’s disease and associated disorders, 
Lancet, PNAS, Nature.
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3) Personal communications
The list of published studies generated were shown to another researcher in this field 
from a different research group (Laura van de Pol from VU, Amsterdam) who checked 
whether there were any studies that may have not been included. Once the potential list 
was finalised between the two research groups, all authors of the studies were contacted 
to ensure that correct information was being used and any information which was 
lacking (such as MMSEs, or mean rates of atrophy) was requested. As a result of this 
request, errors within one published paper were found and an erratum is now in 
submission (Thompson et al., 2004a). A personal communication with another author 
highlighted problems with methodology and subsequent results within another paper 
(Hampel et al., 2005). In addition, the total list was sent to each author to ensure there 
were no other studies which had been missed by the searches performed. Published 
studies resulting from searches which are not in English were to be included when 
possible through contact with authors where necessary.
Quality assessment
Once studies had been selected for the meta-analysis, each was assessed for quality by 
tabulating the following variables which may explain heterogeneity of the results 
published in the studies: cohort used (population, case/control, case series), AD 
diagnostic criteria and exclusion criteria, APOE genotyping, other medications, drop­
out rate if RCT, assessment of and exclusion criteria for controls, magnet strength, 
number of scanning sites, scan “slice” thickness, hippocampal measurement method, 
number of raters, registered images or TIV corrected, whole hippocampus measured, 
reliability of method, and blinding of raters to patient information and chronology of 
scan ordering.
12.3. Statistical analysis
From each study the mean atrophy rate and its standard deviation for the AD patients 
(and separately for controls where available) was obtained, together with means and 
standard deviations of the ages, MMSEs and inter-scan intervals in each subject group. 
Calculation of the standard error required for meta-analysis was made using the 
standard deviation and the number of patients for all studies.
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Data synthesis (meta-analysis)
A random effects meta-analysis was performed, consistent with the belief that each 
study is estimating a different mean atrophy rate. Restricted maximum likelihood was 
used to estimate the between-study variance. For studies which reported results 
separately for different subgroups of AD patients, the means and standard errors were 
combined to form an overall mean and standard error for the study. Each subgroup was 
weighted in proportion to the inverse of its mean’s standard error, as in a fixed effects 
meta-analysis. For studies which contained both a control and an AD group, the mean 
difference in atrophy rates between the two groups was calculated. These differences 
were then entered in a further random-effects meta-analysis in order to estimate the 
overall mean within-study difference in rates between AD and control groups.
Assessment of heterogeneity
The extent of heterogeneity between the studies was assessed through examination of 
the between study variance which was estimated in the random effects meta-analysis. 
The I2 statistic was calculated to estimate the proportion of heterogeneity which was not 
attributable to chance.
Assessment o f reporting bias
Due to the focus of this meta-analysis, it was assumed that studies would not be 
published on the basis of the estimated size of mean atrophy in AD patients. However, 
this was examined with funnel plots.
Subgroup analysis and investigation o f heterogeneity
Heterogeneity in atrophy rates between studies may be explained by the mean age or 
disease severity (MMSE score) of study participants, or inter-scan interval, through use 
of meta-regression. It was recognised that estimation of such effects may be limited if 
only a small number of studies are available.
The ability to estimate the effect of such an explanatory variable on heterogeneity relies 
on there being sufficient variability in the variable between studies. For the studies 
which reported results for separate subgroups of AD patients, these subgroups were 
entered in the meta-regression separately. However, since the groups originate from the 
same study, they will have many characteristics in common. This was accounted for 
through the sharing of the same study-specific random effect.
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12.4. Results
The resulting studies included in this meta-analysis are displayed in Table 12.1. The 
quality of these studies is reported in Table 12.2, and those studies which were excluded 
are detailed in Table 12.3.
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Table 12.1 Studies included in the meta analysis.
Study
Author, Year
Checked with 
author
Research
Group
Subject
groups
it
MMSE/30 
at baseline
Mean (SD)
Age, years at 
first MRI
Mean (SD)
Annualised loss 
of total (left plus 
right
hippocampi)
Mean %  year 
(SD)
Interval
(years unless 
specified) 
Mean (SD)
(Jack et a l,  2004)
Yes
Means and SDs 
provided by 
personal 
communication
Jack
C stab 40
29.0 (0.9) 
<34>
78.2(7.7) 1.4 (0.7) 4.3 (0.7)
AD slow 31
22.3 (4.4) 
<30>
73.9(6.9) 3.9 (2.6) 1.4 (0.4)
AD
fast
33
19.5 (4.0) 
<32>
77.8(8.4) 4.8 (3.2) 1.4 (0.4)
(Du et al., 2004) Yes Weiner
C 25 29.0(1.0) 76.8 (7.8) 0.8 (1.7) 2.0 (0.7)
AD 20 21.0 (7.2) 75.3 (7.2) 5.9 (2.4) 1.8 (0.7)
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Study
Author, Year
Checked with 
author
Research
Group
Subject
groups
n
MMSE/30 
at baseline
Mean (SD)
Age, years at 
first MRI
Mean (SD)
Annualised loss 
of total (left plus 
right
hippocampi)
Mean %  yearml 
(SD)
Interval
(years unless 
specified) 
Mean (SD)
(Hashimoto et al., 
2005)
Yes Hashimoto
AD no 
treat
93 21.6 (2.8) 70.5 (9.1) 5.04 (2.54) 392 (35) days
AD treat 54 21.8(3.9) 69.5 (9.5) 3.82 (2.84) 388 (29) days
(Barnes et al., 2005) Yes Fox
C 50 29.4 (0.8) 59.6(13.8) 1.15(1.86) 418(172)
AD 32 19.4 (5.0) 59.0(11.3) 5.49 (3.12) 456 (311)
(Thompson et al., 
2004a)
Erratum in 
press. Values 
here are correct.
Thompson
C 14 29.5 (0.9) 71.4 (3.2) 2.1 (2.8) 2.6 (1.0)
AD 17 16.8(6.6) 68.7(6.8) 6.8(10.2) 1.3 (0.9)
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Study
Author, Year
Checked with 
author
Research
Group
Subject
groups
n
MMSE/30 
at baseline
Mean (SD)
Age, years at 
first MRI
Mean (SD)
Annualised loss 
of total (left plus 
right
hippocampi)
Mean % yearml 
(SD)
Interval
(years unless 
specified) 
Mean (SD)
(Jack e t  a l ., 2003)
Means and SDs 
given by 
personal 
communication
Jack (trial) AD 192 2 0 . 8 ( 4 . 1 ) 7 2 . 8 ( 7 . 7 ) 5 . 5  ( 3 . 3 ) 1 . 0  ( 0 . 1 )
(Fox e t  a l ., 2005) Yes Fox (trial)
AD
placebo
57 20.2 (3.5) 70.7 (8.2) 3 . 1 6 ( 3 . 5 1 )
10.9(1.1)
months
(Wang e t  a l , 2003) Yes Csemansky
C 26
2 9 . 0  ( 1 . 3 )  
< 1 3 >
73 (7.0) 2 . 3  ( 1 . 9 ) 2.2 (0.53)
DAT 18
2 5 . 7  ( 3 . 9 )  
< 1 2 >
74 (4.4) 5 . 1  ( 2 . 8 ) 2.0 (0.37)
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Study
Author, Year
Checked with 
author
Research
Group
Subject
groups
n
MMSE /30 
at baseline
Mean (SD)
Age, years at 
first MRI
Mean (SD)
Annualised loss 
of total (left plus 
right
hippocampi)
Mean % year 
(SD)
Interval
(years unless 
specified) 
Mean (SD)
(Kaye et a l , 2005) Yes Kaye
C 88 28.3(1.5) 83.0 (7.0) 2.2 (6.0)
2.04(1.42)Mild 27 21.7 (4.5) 76.1 (7.1) 2.9 (7.8)
Moderate 17 16.8 (6.7) 75.1 (6.2) 3.2 (6.8)
Key
AD Alzheimer’s disease 
C control
DAT dementia of Alzheimer type 
! percentage decline over scanning interval rather than rate 
<> number of subjects on which information has been obtained 
italicised = information from personal communication
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Table 12.2 Quality assessment o f studies included in the meta-analysis.
(Jack et al.., 
2004)
(Du et a lt  
2004)
(Hashimoto et 
a lt  2005)
(Barnes et 
a lt  2005)
(Thompson et 
a lt  2004a)
(Jack e ta l,  
2003)
(Fox et a lt 
2005)
(Wang e ta lt  
2003)
(Kaye etal 
2005)
Cohort 
Population 
Case/control 
Case series
Case / control
Control / 
control
Case series Case / control Case / control Case series Case series Case / control Case / control
AD Diagnostic 
criteria
(imaging used in 
criteria)
NINCDS
ADRDA
General
committee
consensus
NINCDS
ADRDA
(Imaging used 
to exclude other 
neuropathol.)
NINCDS
ADRDA
MMSE >15
NINCDS
ADRDA
Imaging 
compatible 
with AD
NINCDS
ADRDA
Mild-moderate
AD
> 50 years old
NINCDS
ADRDA
Imaging 
supporting AD
DAT = CDR of 
0.5
NINCDS
ADRDA
Mixture of 
community and 
clinical cohorts
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(Jack et al., 
2004)
(Du et a l , 
2004)
(Hashimoto et 
a l,  2005)
(Barnes et 
a l,  2005)
(Thompson et 
a l,  2004a)
(Jack et a l,  
2003)
(Fox e ta l ,  
2005)
(Wang e ta l ,  
2003)
(Kaye e ta l , 
2005)
AD Exclusion 
criteria
Symptoms 
unrelated to AD
Other
neuropathol.
Other
neuropathol. / 
mental disorders 
/ congnitive- 
affecting 
treatments
N/R
White matter 
lesions > 3mm 
on T2 images
Substance abuse
Depression
Vascular
disease
Non-AD
disorders
Major and/or 
unstable 
conditions 
such as 
seizure, PD or 
tumour
Significant
other
neurological 
diseases. 
Medications 
which affect 
cognition.
Unstable 
regimen of 
drugs which 
may alter 
cognition
Other
confounding
neuropsychol.
N/R
APOE genotype
(% E4)
C=40
Slow=55
Fast=56
N/R
AD-C=65 
AD treated=54
AD=54 N/R N/R AD=55 N/R
C=22
Mild AD=59 
Moderate =71
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(Jack et a l,  
2004)
(Du et a l , 
2004)
(Hashimoto et 
a l , 2005)
(Barnes et 
a l,  2005)
(Thompson et 
a l , 2004a)
(Jack e ta l,  
2003)
(Fox eta/., 
2005)
(Wang et a l,  
2003)
(Kaye eta/., 
2005)
Gender (% male)
C=42
Slow=39
Fast=42
C=44
AD=40
AD-C=22
AD-T=24
C=52
AD=41
C=50
AD=50
AD-C=40
AD-T=41
AD=40
C=46
AD=61
C=48 
Mild=52 
Moderate=71
Treatments N/R N/R
Donepezil (AD- 
T). AD-C Vit E 
etc allowed
N/R N/R N/R
Donepezil 60%
Galantamine
5%
Rivistimine
21%
HRT 21%
VitE 32%
N/R N/R
Drop out if RCT N/A N/A N/A N/A N/A N/R
15 due to no
post-baseline
scan
N/A N/A
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(Jack et al., 
2004)
(Du et a l,  
2004)
(Hashimoto et 
al., 2005)
(Barnes et 
a l,  2005)
(Thompson et 
a l,  2004a)
(Jack e ta l,  
2003)
(Fox e ta l ,  
2005)
(Wang e ta l,  
2003)
(Kaye etal., 
2005)
Assessment of 
controls
Normal
neurological
exam
Community
dwelling
MRI excluding 
neuropathol.
N/A N/R N/R N/A N/A CDR 0.0
Yearly
assessment of 
neuropsychol., 
physical and 
medical exam
Exclusion criteria 
for controls
No active
neurological
disorder
Psychoactive
medication
Clinical history 
of alcoholism, 
psychiatric 
illness, epilepsy, 
hypertension, 
diabetes, major 
heart disease or 
head trauma 
(Du et al., 
2003).
N/A N/R Same as AD N/A N/A N/R N/R
Magnet strength 
(Tesla)
1.5 1.5 1.5 1.5 2 0.5-1.5 1.5 1.5 1.5
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(Jack et al 
2004)
(Du et aly 
2004)
(Hashimoto et 
a l y 2005)
(Barnes et 
aly  2005)
(Thompson et 
aly  2004a)
(Jacket a/., 
2003)
(Fox eta/., 
2005)
(Wang et aly 
2003)
(Kaye et al.y 
2005)
Sites N/R 1 1 N/R 1 38 17 1 1
Protocol 
(thickness (mm))
1.6
1.4 (from other 
publication)
1.5 1.5 N/R 1.6 1.5-1.8 1
4 (detailed in 
(Kaye et al., 
1997)
Measurement
method
Manual Semi-automated Manual Manual Manual Manual Manual Semi-automated Manual
Number of raters N/R 1 1 2 1 1 3
1 rater for 
template as in 
(Haller et a l , 
1997)
N/R for
landmark
placement
N/R
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(Jack et aly 
2004)
(Du et a l , 
2004)
(Hashimoto et 
a l ,  2005)
(Barnes et 
a l ,  2005)
(Thompson et 
a l y 2004a)
(Jack e ta l ,  
2003)
(Fox et aly 
2005)
(Wang e ta l ,  
2003)
(Kaye eta ly  
2005)
Registered scans 
or TIV corrected
Registered N/R N/R Registered Registered
Registered as 
referenced in 
(Jack et al., 
1998)
Registered N/R N/R
Whole He 
measured
No (small part 
of tail excluded)
No (small part 
of tail excluded) 
as in (Hsu et al. 
2002)
No (white matter 
excluded)
No (small part 
of tail 
excluded)
No (small part 
of tail excluded)
No (small part 
of tail 
excluded)
No (small part 
of tail 
excluded)
No (exclusion of 
white matter of 
alveus and 
fimbria some of 
tail excluded)
No. Body of 
hippocampus 
only as in (Kaye 
etal. 1997)
Reliability
On volume unless 
specified
ICC 0.91
On rate not 
volume
ICC 0.94
ICC 0.98 
CV 2.7%
Mean absolute 
difference as a 
percentage 3%
ICC 0.99 CV=0.28 N/R
ICC 0.93
On volumes 
derived from 
scans 1 month 
apart.
ICC 0.90
Blinding of raters 
to diagnosis
Yes
Visually 
checked blinded 
to diagnosis
Yes Yes Yes Yes Yes N/R N/R
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(Jack et al.y 
2004)
(Du et aly 
2004)
(Hashimoto et 
al.y 2005)
(Barnes et 
aly  2005)
(Thompson et 
aly  2004a)
(Jack et al., 
2003)
(Fox et al.y 
2005)
(Wang eta ly  
2003)
(Kaye eta ly  
2005)
Blinding of raters 
to order of scans
Yes N/R Yes Yes Yes Yes Yes N/R N/R
Key
AD Alzheimer’s disease 
C control
DAT Dementia of Alzheimer Type
ICC Intraclass Correlation Coefficient
CV coefficient of variation
AD-C control group of AD patients
AD-T treated AD patients
N/A not applicable
N/R not reported
CDR Clinical dementia rating
MMSE mini mental state examination
neuropathol. neuropathologies
neuropsychol. neuropsychologies
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Table 12.3 Studies excluded from the meta-analysis.
Study
Reason for 
exclusion
Group Subject groups N
Mean (SD) 
MMSE
Mean (SD) age in 
years
Rate of atrophy
Mean (SD) scanning 
interval in years unless 
specified
(Mungas et al> 
2005)
VaD included
Weiner
DeCarli
C (CDR 0.0) 58 29.0(1.4) 74.1 (6.7) 1.1 (1.4) 4.0(1.1-6.9)
Dementia: AD 
and VaD (CDR > 
1.0)
11 23.6 (3.4) 76.5 (9.7) 2.9 (2.0) 2.9(1.1-5.1)
(Cardenas e ta l , 
2003)
VaD included Weiner
C 16 29.1 (1.0) 76 (5) 1.8 (0.8) 2.6(1)
Dementia
7 (5  AD)
2 (AD + 
VaD)
24.6 (2.6) 76(8) 5.4 (2.8) 2.6(1)
(Moffat et al.y 
2000)
Controls only Resnick
C e4 + 13 27.9 (2.5) 68.5 (5.9) 2.86 X 2.7 (0.6)
C e 4 - 13 29.1 (1.1) 69.7 (6.8) 0.85 X 2.6 (0.8)
(Jack etal., 1998)
Overlap with Jack 
et al. 2000 paper
Jack
C 24 28.79(1.28) 81.04 (3.78) 1.55 (1.38) 1.96 (0.75)
AD 24 20.74 (4.60) 80.42 (4.02) 3.98(1.92) 1.89 (0.68)
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Study
Reason for 
exclusion
Group Subject groups N
Mean (SD) 
MMSE
Mean (SD) age in 
years
Rate of atrophy
Mean (SD) scanning 
interval in years unless 
specified
(Mori eta ly  2002)
Overlap with 
Hashimoto et a l  
2005
Hashimoto
AD e4 + 38 19.2 (5.1) 72.4 (5.5) 9.76 (4.27) 378 (18) days
AD e4 - 17 19.1 (6.3) 71.1 (6.4) 6.99 (4.24) 372 (20) days
(Silbert et al.y 
2003)
Overlap with Kaye 
et a l  2005
Kaye
e f t 8 28.4(1.4) 86.6 (8.5) 2.6 (3.2)
4.1 (2.2)
Dementedft 20 22.8 (7.4) 81.4 (8.5) 3.1 (5.7)
(Krishnan et al.y 
2003)
Short interval Rogers
Placebo AD 334 19.0 (4.6) 4 72.4(10.1)4 8.2 (9.9)! 24 wks
Treated AD 344 19.5 (4.8) 4 74.4 (7.0) 4 -0.4 (2.9)! 24 wks or endpoint
(Jack etal., 2000) Overlap of subjects 
with Jack et a l  
2004
Jack
C total
Stab
conv
58 = 48 
+ 10
28(1.6)
28(1.7)
80.4 (6.4) 
82.3 (5.8)
1.9
(1.1)
total
1.7 (0.9)
2.8 (1.7)
3.0 (0.5) 
3.3 (0.4)
AD 28 22 (4.3) 73.8(11.3) 3.5 (1.8) 2.9 (0.5)
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Study
Reason for 
exclusion
Group Subject groups N
Mean (SD) 
MMSE
Mean (SD) age in 
years
Rate of atrophy
Mean (SD) scanning 
interval in years unless 
specified
(Kaye et al., 2005)
Subgroup excluded 
(MMSE > 26) Kaye v.mild 23 26.2 (2.0) 83.0 (7.8) 4.3 (7.4) 2.04(1.42)
(Hampel et al., 
2005)
Mean rates not 
published. 
Methodological 
problems and 
errors in paper.
Hampel AD 22 23.1 (4.0) 67.8 (7.9) 15.6(10.5) 18.4 (9.4) months
(Jack etal., 2004) Subgroup excluded 
(MMSE > 26)
Jack C conv 15 28.4 (1.4) <12> 80.2 (4.6) 3.1 (1.6) 3.6 (0.9)
(Laakso et al., 
2000b)
Cannot provide 
original data 
annualised
Soininen
C 8 28.4(1.6) 69 (8) 1.2 (5.0)t
36 (8.9) months
AD 27 22.0 (3.6) 70 (5) 2.4 (6.7)t
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Key
X No SD given on the % loss. Mean (SD) rate initially quoted as 71.2 (19.8) s4+ and 20.1 (16.5) e4- mm3 loss per year. 
ftOnly 28 subjects had more than one scan and therefore summary statistics are slightly incorrect.
A median and min-max
* Standard error rather than standard deviation
£ No SD given on the % loss. Percentage loss expressed over the two year interval as (controls: left 4.0, right 5.5, DAT: left 8.3, 10.2 % loss) 
t  summary statistics given for a wider group than on which hippocampal changes were calculated.
t  calculated rates of atrophy (loss quoted in publication over 3 year period actual rates over 3 years 3.6 (15.1) for controls and 7.2 (20.1) % of 
hippocampus.)
VaD = vascular dementia
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Data synthesis and heterogeneity
Figure 12.1 is a Forest plot demonstrating the results of the AD subjects from the 
individual studies included in the meta-analysis (n=591). The estimate of the overall 
mean atrophy rate in these groups from a random-effects meta-analysis was 4.71% per 
year (95% Cl 3.90, 5.52). The I2 squared statistic from this analysis was 78.5%, 
suggesting that most of the variability observed between the studies is true 
heterogeneity as opposed to sampling variability. Figure 12.2 is a Forest plot of the 
matched control groups (n=243). The estimated overall mean atrophy rate in these 
groups from a random-effects meta-analysis was 1.52% per year (95% Cl 0.89, 2.15). 
The I2 squared statistic was 59%, suggesting just over half of the observed variability 
was due to genuine heterogeneity, as opposed to sampling variability. Figure 12.3 
shows the differences between the control and AD groups in those studies where both 
groups were studied (six studies in total). Using data from these studies, and combining 
AD subgroups within studies, using a random effects meta-analysis the estimate of the 
mean difference in atrophy rates between controls and AD subjects was 3.35% per year 
(95% Cl 1.71 to 4.99). The I2 estimate for this AD-control difference was 74.8%, again 
suggesting that most of the observed variability in differences is due to true 
heterogeneity.
Publication bias
Figure 12.4 and Figure 12.5 show funnel plots of AD and AD-control differences 
respectively against the standard error of the estimate. Although few conclusions can be 
drawn given the small number of studies, there was no suggestion of publication bias.
Subgroup analysis and meta-regression
Plots of the study/subgroup mean atrophy rates against age, MMSE and inter-scan 
interval are shown in Figure 12.6, to Figure 12.8 respectively. There were no apparent 
relationships between these variables and mean atrophy rate. The corresponding meta­
regression models showed that there was no evidence that these variables were 
associated with mean rates of atrophy in the AD groups (p>0.05).
- 33 2-
Study
Random effects analysis of AD groups
Jack 2004 (AD slow)
(AD fast)
Du 2004
Hashimoto 2005 (AD no treat) 
(AD treat)
Barnes 2005
Thompson 2004
Jack 2003
Fox 2005
Wang 2003
Kaye 2005 (Mild)
(Moderate)
Overall
i
0
¥
~r
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T
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T
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Mean atrophy rate (%/year)
10 11 12
Figure 12.1 Forest p lo t o f rates o f atrophy in the hippocampus in AD subjects allowing fo r  sub-groups o f the same study to be entered separately.
The size o f the squares are proportional to l/(variance(study i) + between-study variance). The solid lines represent 95% CIs.
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Random effects meta-analysis of controls
Study 
Jack 2003
Du 2004
Barnes 2005
Thompson 2004
Wang 2003
Kaye 2005
Overall
0
n i r
1 2 3
Mean atrophy rate (%/year)
Figure 12.2 Forest plot o f rates o f atrophy in the hippocampus in matched control subjects.
The size o f the squares are proportional to l/(variance(study i) + between-study variance). The solid lines represent 95% CIs.
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Study 
Jack 2004
Du 2004
Barnes 2005
Thompson 2004
W ang 2003
Kaye 2005
Overall
Random effects analysis of AD/control differences
0
~r
1 2 3 4 5 6 7 8 9  
AD/control atrophy rate difference (%/year)
T~
7
T
8 10 11
Figure 12.3 Forest plot showing the difference between AD and control subjects in studies where both were reported.
The size o f the squares are proportional to l/(variance(study i) + between-study variance). The solid lines represent 95% CIs.
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Funnel plot with pseudo 95% confidence limits
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Figure 12.4 Funnel plot o f AD rates o f atrophy with pseudo 95% confidence limits.
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Funnel plot with pseudo 95% confidence limits
o  -
0
0 LO 
*
0oc<D 1_ 
0
TD
O iou
o  T_k_i_
0
"Dv_
0
"O CMc0
CO
in
cvi
/
/
/ •
/
/
/
/  •
/
/
/
/
/
/
/
/
/
\
\
\
\
\
\
\
\
\
\
\
0 2 4 6
AD/control atrophy rate difference (%/year)
8
Figure 12.5 Funnel plot o f AD-control differences with pseudo-95% confidence limits.
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12.5. Discussion
This study aimed to estimate the mean rates of hippocampal atrophy across a number of 
published studies. In addition, this study aimed to formally assess some aspects of the 
heterogeneity in these studies. Meta-analysis plays an important role in summarising 
results from studies owing to between-study heterogeneity. It may be that the effects of 
confounders such as disease severity or age are lessened when the results from all 
studies are pooled, making the results more applicable to the wider population.
It was found that hippocampal rates of atrophy were consistently greater in AD subjects 
than controls in all studies included in this meta-analysis. Synthesised mean rates of 
atrophy were 1.5% in the control subjects and 4.7% in AD subjects. This is consistent 
with the mean difference between AD and control groups being 3.4% for the subset of 
studies where both controls and AD subjects had been assessed and reported. Most of 
the heterogeneity in these studies was due to true heterogeneity rather than sampling 
error.
Some aspects of the heterogeneity of studies are difficult to formally assess due to the 
lack of reporting of certain variables (see Table 12.2). These variables include patient- 
related information such as other administered medications and APOE genetic status. 
Treatments may be particularly difficult for case-control or population-based studies to 
report accurately, since many of these studies will be conducted at a tertiary referral 
centre whereas it may be the general physician at the primary level who is responsible 
for both prescribing and monitoring the administration of medication.
Other scan and hippocampal delineation methods may also have an effect on the 
atrophy rates being determined such as scan “slice” thickness or segmentation protocol. 
It may be that differences in anatomical structures included in the delineation of 
hippocampi do not have substantial effects on the atrophy rate determined if the same 
protocol is used for both baseline and follow-up scans. This implies that rates of 
atrophy are not different in separate anatomical locations within the hippocampus (for 
example, rate of atrophy of the hippocampal tail is similar to the hippocampal head). 
Meta-analysis on the AD-control differences should be robust to these potential 
confounders since the hippocampal rates determined in both subject groups should have 
been determined in the same way.
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Formal meta-regression analyses showed no significant associations between mean 
atrophy rates quoted in the studies included in the meta-analysis and age, MMSE and 
interval. However, it may be that these relationships do exist; the ability of meta­
regression to detect such associations depends upon there being sufficient variability in 
the explanatory variable between studies. There was little variability in mean age 
between studies relative to within studies, perhaps explaining the lack of association. A 
number of studies (not included here) have examined rates of hippocampal atrophy in 
normal ageing and have shown that age does influence hippocampal atrophy rates in 
“healthy controls”. There was some variability in mean MMSE score between studies. 
The included studies contained a wide range of mean interval between scans, and thus 
the data suggest no association between mean interval and mean atrophy rate.
This study has a number of limitations. Although this meta-analysis attempted to be as 
inclusive of as many studies as possible and there was no evidence of publication bias, 
there were only nine studies that were analysed owing to a number of reasons (see Table 
12.3). Larger numbers of studies would allow a more precise estimate of the mean rates 
to be calculated and for associated meta-regression analyses to be more robust. 
Collating the individual patient data from these studies would enable much more precise 
estimation of relationships between factors such as age and disease severity with 
hippocampal atrophy rates. Associations using individual patient data within studies 
would not be confounded by study-level factors, such as scan acquisition protocols and 
methods to determine hippocampal atrophy rate. Also, variability both within and 
between studies could be used to increase the precision of estimation of these 
associations.
12.6. Chapter Conclusions
The hippocampal atrophy rate is on average 1.5% in normal controls with the range of 
the quoted mean age ages being 59-83 years. In AD subjects this rate is on average 
4.7%. Age, disease severity (determined by the MMSE) and scanning interval did not 
appear to be associated with these mean rates within the AD groups.
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13. THESIS CONCLUSIONS
13.1. Clinical findings
The main focus of this thesis was to assess rates of atrophy in AD and try and improve 
upon the operator-intensive nature of measures of atrophy of small areas of the brain 
(particularly the hippocampus) currently used for diagnosis and assessment of 
progression in AD. In order to assess new techniques, the “gold standard” manual- 
outlining method of atrophy required analysis. In order to understand the potential 
benefits and limitations of analysis of small regions in clinical practice, the ways in 
which these regions are affected by disease needed to be appreciated.
A protocol for delineation of the cingulate gyrus, an area of the brain highlighted in 
many studies as a region specifically affected by AD, was developed. The cingulate 
gyrus was shown to be smaller in AD compared with controls, particularly posteriorly. 
Applying this technique to longitudinal images in groups of pathologically confirmed 
AD, FTLD and age-matched controls, the cingulate was shown to atrophy at a greater 
rate in disease groups than controls, with FTLD overall showing a greater atrophy rate 
than AD. In both groups the atrophy rate of the cingulate exceeded that of the 
hippocampus, allowing the conclusion to be drawn that the cingulate is at least as 
affected in AD and FTLD as the hippocampus. Differences were also seen in the 
pattern of atrophy along the length of the hippocampus between the AD and FTLD 
group with relatively more posterior compared with anterior atrophy in AD and the 
reverse in FTLD. Rates of cingulate atrophy have not previously been reported in these 
groups. This study shows the use of regional analysis in the differential diagnosis of 
dementia.
Measures of hippocampus and amygdala volume were calculated in a relatively large 
group of pathologically confirmed AD and FTLD. The results from this analysis 
showed that both the amygdala and hippocampus were significantly affected in AD and 
FTLD. Further analysis showed that the hippocampal to amygdala ratio was similar in 
AD to controls but that the volumes of both structures were reduced. This ratio was 
altered in FTLD with the amygdala being disproportionately smaller in FTLD. This is 
consistent with the anterior/posterior gradient of atrophy described in the cingulate in 
FTLD. Overall, FTLD subjects had lower volumes than AD subjects although there 
was difficulty assessing and comparing the severity of these two diseases. Dividing the
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FTLD group into its subtypes, this study showed that the differential pattern of atrophy 
between the hippocampus and amygdala on the left and right sides differed according to 
clinical rather than pathological subtype. Semantic dementia patients showed greater 
asymmetry whilst fvFTD subjects showed greater amygdala involvement. Again, this 
type of analysis has implications for the differential diagnosis of dementia.
Many studies, including those described as part of this thesis, have evaluated rates of 
atrophy of the hippocampus with inter-scan intervals at one year or greater. Chapter 5 
showed that hippocampal change could be used to separate AD subjects from controls at 
intervals of less than one year, specifically six months. Rates of atrophy of the 
hippocampus were greater in AD subjects than controls and were comparable at a group 
level (although less precise) than the corresponding rates calculated using a 12 month 
interval. This is an interesting finding since longitudinal measures of atrophy of areas 
such the hippocampus may be useful in clinical trials, where the cost of the trial may be 
substantially reduced by shorter follow-up intervals. This gain is offset by the greater 
sample size (albeit non-significantly greater as reported in Chapter 5) needed as a result 
of the higher variance in measured rates of atrophy.
In one further study the asymmetry of the hippocampus was evaluated as there was 
some evidence from the literature that a change in the normal right > left asymmetry 
could be a potential maker of AD. Although it was found that there was some evidence 
of a reduction in this normal asymmetry resulting from greater right than left rates of 
atrophy in AD, this was by no means a consistent finding, and it was therefore 
concluded that this was not a useful marker of AD. As part of this same study, the 
effect of APOE status (s4 positive carriers vs. e4 negative carriers) on both hippocampal 
volume and rate of atrophy was assessed. Only a subgroup of the AD subjects had this 
information available and it was not possible to show that APOE s4 status had a 
significant effect on volume or rate of atrophy of the hippocampus. However, this 
subgroup was small and a larger average atrophy rate was seen in the e4 positive 
carriers. Were this analysis performed in a larger group or using a method which 
reduced manual errors such a study may detect this to be a significant effect.
A study of the hippocampal region in familial AD subjects revealed that longitudinal 
changes in this structure could be measured approximately five and a half years prior to 
clinical diagnosis of AD, whereas whole brain change could be detected approximately
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three and a half years before diagnosis. This finding highlights the importance of the 
development and improvement of measures of such change in order that early disease 
may be detected and “disease modifying” medication administered as early as possible 
should it become available.
Finally, a meta-analysis of hippocampal atrophy rates was performed to synthesise a 
rate of atrophy from those rates already published. This rate was calculated as 4.7% per 
year in AD subjects, with age, severity of disease (measured using MMSE) and 
scanning interval having no significant effect on the rates of atrophy in the AD subjects.
1 3 . 2 .  I m a g e  a n a l y s i s  d e v e l o p m e n t s
Segmentation methodology for the cingulate gyrus was developed and evaluated as part 
of this thesis. This work showed that areas different in morphology to those often 
segmented in AD (hippocampus, amygdala and entorhinal cortex) could be delineated 
reliably. Moreover, these regions could be subdivided reproducibly. Chapter 7 in this 
thesis showed that subdivision could also be automated by the application of Bezier 
curves, a technique widely used in computer graphics. Development of such measures 
provides useful information with little operator intervention and may help to reveal 
differential patterns of atrophy between subject groups. In addition, this type of 
subdivision may be applicable to other structures in the brain.
The majority of the technical work within this thesis focused on the hippocampus, 
specifically on building upon current techniques and methodology to enable automatic 
serial analysis of the structure to aid diagnosis and disease tracking in AD. In all 
studies, comparisons of new techniques or developments were made with manual 
measures.
First application of the BSI to the hippocampus was described. This was found to be 
effective at reducing the manual error associated with serial hippocampal segmentation 
and as a result to have diagnostic utility. The HBSI was also applied to a large trial 
dataset (17 sites internationally) and was shown to give results which were similar to 
manual measures in the placebo arm and revealed a significant difference between that 
arm of the trial and the treatment arm.
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Secondly, another technique, fluid-propagation of hippocampi and Jacobian calculation, 
first described in a separate study, was applied to a larger group of subjects. Advances 
to the procedure were made including an extra local rigid alignment of hippocampi prior 
to fluid-registration and development of exit criteria allowing all hippocampal pairs to 
attain the same level of matching. These fluid-based techniques also showed a 
reduction in the human error associated with longitudinal hippocampal demarcation. 
Both HBSI and fluid-techniques may be particularly useful as they reduce operator time 
by eliminating the need for hippocampal segmentation of one of the pair of scans.
Thirdly, the hippocampal BSI technique was completely automated by the application 
of an affine alignment of template hippocampus to the baseline of every image pair. 
Evaluations were made to establish whether improvements could be made to this initial 
step. Simple operations of region intensity thresholding and conditional dilations 
improved the accuracy of this initial segmentation. However, the BSI measure was 
robust enough that this did not make substantial improvements to the measure of change 
as assessed by similarity to the standard HBSI measure (calculated using the manually 
segmented baseline region). Averaging a number of regions from half of the cohort to 
create a population-based template also slightly improved the baseline template-based 
segmentation at some probability thresholds, but did not improve the similarity of the 
automated HBSI measure to the standard HBSI measure.
Finally, the location of differences in the hippocampus was assessed using a voxel by 
voxel test of hippocampal masks, affine-registered whole brain -  whole brain followed 
by rigid-registered hippocampus -  hippocampus to a single-person cohort template 
image. These assessments showed that regions such as the superior of the hippocampus 
were greatly reduced in AD compared with controls at both baseline and repeat 
imaging. However, this study also revealed the AD subjects had more voxels labelled 
as hippocampus in the inferior of the region, potentially caused by differential 
registration errors in AD and control groups, or differential shape changes of the 
hippocampus which were not accommodated by the final rigid registration step. This 
study highlights the problems associated with making judgments of location-specific 
atrophy caused by a disease using inter-subject registration with voxel by voxel 
significance tests. Further work is needed to ascertain whether non-linear registration 
can improve the hippocampal match without removing the location-specific atrophy 
which the experiment is designed to detect.
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13.3. Conclusions
This thesis shows that measures of small regions of the brain can be made reliably and 
can reveal distinctive patterns which may aid the diagnosis and tracking of Alzheimer’s 
disease and other dementias. Such measures can be made with less operator 
involvement with application of registration-based methodologies, reducing both time 
and associated human errors.
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PUBLICATIONS
This section documents published book chapters and peer-review papers based on the 
results in this thesis. I would like to thank everyone who was involved in generating 
and analysing these results and their contributions are stated below.
Chapter 1
Barnes J, Archer H and Fox NC 
Imaging in Alzheimer’s Disease
Book chapter for: Research Progress in Alzheimer's Disease and Dementia (In press) 
Clinical contributions to this were made by Hilary Archer and this was drafted by Nick 
Fox, Hilary Archer and me.
Chapter 4
Jones BF, Barnes J, Uylings HB, Fox NC, Frost C, Witter MP, Scheltens P.
Differential Regional Atrophy of the Cingulate Gyrus in Alzheimer Disease: A 
Volumetric MRI Study.
Cereb. Cortex. 2006; 16 (12): 1701-1708
Measurements o f the cingulate and its subdivisions were made by Bethany Jones and 
myself Bethany performed measurements o f the RS alone. Analysis was performed by 
Chris Frost. Drafting o f the publication was performed by Bethany Jones and me. 
Supervision and guidance was given by Philip Scheltens and Nick Fox. Harry Uylings 
and M Witter provided supportive anatomical information.
and
Barnes J, Whitwell JL, Frost C, Josephs KA, Rossor MN, Fox NC 
Measurements of the amygdala and hippocampus in pathologically confirmed 
Alzheimer’s disease and frontotemporal lobar degeneration.
Archives of Neurology. 2006; 63 (10): 1434-1439
Post-mortem reports were examined by Keith Josephs. Measurements were performed 
by Jenny Whitwell (amygdala) and me (hippocampus). Chris Frost and I  performed the 
analysis. The manuscript was drafted by Jenny Whitwell and me. Supervision was 
given by Martin Rossor and Nick Fox.
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Chapter 5
Barnes J, Godbolt AK, Frost C, Boyes RG, Jones BF, Scahill RI, Rossor MN, Fox NC. 
Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD.
Neurobiol Aging 2007; 28 (1): 20-28.
Alison Godbolt assessed patient information and I performed all the measurements. 
Chris Frost and I performed the analysis. Richard Boyes helped with some technical 
details. I drafted the manuscript. Rachael Scahill, Martin Rossor and Nick Fox 
supervised the study.
and
Barnes J, Scahill RI, Frost C, Schott JM, Rossor MN, Fox NC.
Increased hippocampal atrophy rates in AD over six months using serial MR imaging 
Neurobiology of Aging. 2007 (In Press)
I performed all the measurements and the analysis under the supervision o f Chris Frost. 
I drafted the manuscript under the supervision o f Nick Fox, Martin Rossor and Rachael 
Scahill. Jon Schott collected all the scans.
Chapter 6
Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC.
Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross- 
sectional and longitudinal volumetric MRI study.
Dement Geriatr Cogn Disord. 2005;19(5-6):338-44.
Rachael Scahill and I performed all the measurements. Chris Frost and I  performed the 
analysis. Jonathan Schott helped with drafting the manuscript. Martin Rossor and 
Nick Fox supervised the project.
and
Ridha BH, Barnes J, Bartlett JW, Godbolt AG, Pepple T, Rossor MN, Fox NC. 
Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study.
Lancet Neurology 2006; 5 (10): 828-834.
Basil Ridha and I evaluated the scans that were used and performed all the 
hippocampal measurements. Tracey Pepple calculated BSI measures. Jonathan Bartlett 
and Basil Ridha performed the analyses. Alison Godbolt evaluated patients and 
assessed their clinical severities by date. Basil Ridha, Jonathan Bartlett and I drafted 
the manuscript under the supervision o f Nick Fox and Martin Rossor.
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Chapter 7
Boyes RG, Barnes J and Fox NC
MIUA conference proceedings 2004
Partitioning the Cingulate Gyrus using Bezier curves
Richard Boyes wrote the code for subdividing the cingulate using Bezier curves. I made 
all the measurements and performed the analysis. Richard and I drafted the short 
conference paper. Nick Fox supervised the project.
Chapter 8
Barnes J, Scahill RI, Boyes RG, Frost C, Lewis EB, Rossor CL, Rossor MN, Fox NC. 
Differentiating AD from aging using semiautomated measurement of hippocampal 
atrophy rates.
Neuroimage. 2004 Oct;23(2):574-81.
Rachael Scahill and I performed all the manual measurements. Richard Boyes and 
Emma Lewis helped with technical aspects with application o f the BSI to the 
hippocampus. Charlotte Rossor provided some extra measurements to aid our 
understanding o f the application o f the BSI to the hippocampus. I performed the 
analysis under the supervision o f Chris Frost. I drafted the manuscript. Martin Rossor
I
and Nick Fox provided supervision for the project, 
and
Barnes J, Lewis EB, Scahill RI, Bartlett JW, Frost C, Schott JM, Rossor MN, Fox NC. 
Automated measurement of hippocampal atrophy using fluid-registered serial MRI in 
AD and controls.
JCAT: 2006 (In Press)
Rachael Scahill and I performed all the manual measurements. Emma Lewis and I 
analysed output from the fluid code. Jonathan Bartlett and I performed the statistical 
analysis. I drafted the manuscript with input from Emma Lewis, Nick Fox and Jonathan 
Bartlett. Martin Rossor, Nick Fox and Rachael Scahill provided supervision for the 
project.
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Chapter 9
Barnes J, Boyes RG, Lewis EB, Schott JM, Frost C, Scahill RI, Fox NC
Automatic calculation of hippocampal atrophy rates using a hippocampal template and
the boundary shift integral
Neurobiology of Aging 2006 (In press but available online)
/  performed all segmentations o f the hippocampi and developed the registration 
algorithm described in the publication. Richard Boyes and Emma Lewis provided 
technical support. Jonathan Schott recruited and assessed all the subjects in the 
MIRIAD study. Chris Frost provided statistical analysis advice and Chris and I 
performed the analyses. Rachael Scahill and Nick Fox provided supervision and gave 
advice regarding both the methods and the drafting. The majority o f the drafting was 
done by myself but all authors had input into this.
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Appendix One: DIAGNOSTIC CRITERIA
Diagnosis was made on the basis of the criteria detailed below. Assessments were 
performed by clinicians involved in the Specialist Cognitive Disorders Clinic.
DEMENTIA
Criteria given by the Diagnostic and Statistical Manual of Mental Disorders (4th 
Edition) (DSM-IV) (American Psychiatric Association, 1994):
I. The development of multiple cognitive deficits manifested by both:
a) Memory impairment (impaired ability to learn new information or to recall 
previously learned information)
b) One (or more) of the following cognitive disturbances are required for diagnosis:
(i) Aphasia (language disturbance)
(ii) Apraxia (impaired ability to carry out motor activities despite intact 
motor function)
(iii) Agnosia (failure to recognize or identify objects despite intact sensory 
function)
(iv) Disturbance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting)
II. The cognitive deficits in Criteria la and lb each cause significant impairment in 
social or occupational functioning and represent a significant decline from a previous 
level of functioning
III. The deficits do not occur exclusively during the course of a delirium 
Dementia if:
All criteria (I, II and III) are answered with “yes”
(Note that only one of the features listed under lb has to be present)
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ALZHEIMER’S DISEASE
Criteria given by the National Institute of Neurological and Communicative Disorders 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
(McKhann et al., 1984):
PROBABLE ALZHEIMER’S DISEASE
I. The diagnosis of PROBABLE Alzheimer’s disease is supported by:
a) Dementia established by clinical examination and documented by the Mini-Mental 
Test; Blessed Dementia Scale, or some similar examination, and confirmed by 
neuropsychological tests
b) Deficits in two or more areas of cognition
c) Progressive worsening of memory and other cognitive functions
d) No disturbance of consciousness
e) Onset between ages 40 and 90, most often after age 65
f) Absence of systemic disorders or other brain diseases that in and of themselves could 
account for the progressive deficits in memory and cognition
II. The diagnosis of PROBABLE Alzheimer‘s disease is supported by:
a) Progressive deterioration of specific cognitive functions such as language (aphasia), 
motor skills (apraxia), and perceptions (agnosia)
b) Impaired activities of daily living and altered patterns of behaviour
c) Family history of similar disorders, particularly if confirmed neuropathologically
d) Normal lumbar puncture as evaluated by standard techniques
e) Normal pattern or non-specific changes in EEG, such as increased slow-wave activity
f) Evidence of cerebral atrophy on CT with progression documented by serial 
observation
III. Other clinical features consistent with the diagnosis of PROBABLE Alzheimer‘s 
disease:
a) Plateaus in the course of progression of the illness
b) Associated symptoms of depression, insomnia, incontinence, delusions, illusions, 
hallucinations, catastrophic verbal, emotional, or physical outbursts, sexual disorders, 
and weight loss
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c) Other neurologic abnormalities in some patients, especially with more advanced 
disease and including motor signs such as increased muscle tone, myoclonus, or gait 
disorder
d) Seizures in advanced disease
e) CT normal for age
IV. Features that make the diagnosis of PROBABLE Alzheimer‘s disease uncertain or 
unlikely:
a) Sudden, apoplectic onset
b) Focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, and 
incoordination early in the course of the illness
c) Seizures or gait disturbances at the onset or very early in the course of the illness
Probable Alzheimer's disease if:
- all criteria I are answered with “yes”
POSSIBLE ALZHEIMER'S DISEASE
- may be made on the basis of the dementia syndrome, in the absence of other 
neurologic, psychiatric, or systemic disorders sufficient to cause dementia, in the 
presence of variations in the onset, in the presentation, or in the clinical course
- may be made in the presence of a second systemic or brain disorder sufficient to 
produce dementia, which is not considered to be the cause of the dementia
- should be used in research studies when a single, gradually progressive severe 
cognitive deficit is identified in the absence of other identifiable cause
Possible Alzheimer's disease if:
- criteria above are appropriate
DEFINITE ALZHEIMER’S DISEASE
Definite AD refers to histopathologically confirmed disease. The methods by which 
pathologists should make this diagnosis are described in Mirra et al. (Mirra et al., 1991; 
Mirra et al., 1993). Histopathological methods (and AD criteria) are imperfect and 
continue to be refined but in essence depend on demonstrating sufficient age-related 
densities of neurofibrillary tangles and amyloid plaques (Newell et al., 1999).
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FRONTOTEMPORAL LOBAR DEGENERATION
Criteria given by Neary et al. (Neary et al., 1998)
I. Core diagnostic features
a) Insidious onset and gradual progression
b) Early decline in social interpersonal conduct
c) Early impairment in regulation of personal conduct
d) Early emotional blunting
e) Early loss of insight
II. Supportive diagnostic features
a) Behavioural disorder
(i) Decline in personal hygiene and grooming
(ii) Mental rigidity and inflexibility
(iii) Distractibility and impersistence
(iv) Hyperorality and dietary changes
(v) Perseverative and stereotyped behaviour
(vi) Utilization behaviour
b) Speech and Language
(i) Altered speech output
Aspontaneity and economy of speech 
Press of speech
(ii) Stereotypy of speech
(iii) Echolalia
(iv) Perseveration
(v) Mutism
c) Physical signs
(i) Early primitive reflexes
(ii) Early incontinence
(iii) Akinesia, rigidity, and tremor
(iv) Low and labile blood pressure
d) Investigations
(i) Neuropsychology: significant impairment on frontal lobe tests in the absence 
of severe amnesia, aphasia, or perceptuospatial disorder
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(ii) Electroencephalography: normal on conventional EEG despite clinically 
evident dementia
(iii) Brain imaging (structural and/or functional): predominant frontal and/or 
anterior temporal abnormality
Extension list for Frontotemporal Dementia, Progressive Nonfluent Aphasia, and 
Semantic Dementia
III. Supportive Features
a) Onset before 65: positive family history of similar disorder in first-degree relative
b) Bulbar palsy, muscular weakness and wasting, fasciculations (associated motor 
neuron disease present in a minority of patients)
IV. Diagnostic exclusion features
a) Historical and clinical
(i) Aprupt onset with ictal events
(ii) Head trauma related to onset
(iii) Early, severe amnesia
(iv) Spatial disorientation
(v) Festinant speech with loss of train of thought
(vi) Myoclonus
(vii) Corticospinal weakness
(viii) Cerebellar ataxia
(ix) Choreoathetosis
b) Investigation
(i) Brain imaging: predominant postcentral structural or functional 
deficit, multifocal lesions on CT or MRI
(ii) Laboratory tests indicating brain involvement or inflammatory 
disorder such as MS, syphilis, AIDS and herpes simplex encephalitis.
V. Relative diagnostic exclusion features
a) Typical history of chronic alcoholism
b) Sustained hypertension
c) History of vascular disease (such as angina, claudication).
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FTLD if:
- all core diagnostic features for FTLD (I a-e) are answered with “yes”
AND
none of the exclusion criteria under IV is answered with “yes”
DEMENTIA WITH LEWY BODIES
Criteria given by McKeith et a l (McKeith et al., 1996)
1. Central feature required for a diagnosis of DLB
a) Progressive cognitive decline
b) Cognitive decline interferes with normal social or occupational function.
2. Core features
a) Fluctuating cognition with pronounced variations in attention and alertness
b) Recurrent visual hallucinations that are typically well formed and detailed
c) Spontaneous motor features of parkinsonism
3. A diagnosis of DLB is less likely in the presence of
a) Stroke disease, evident as focal neurologic signs or on brain imaging
b) Evidence on physical examination and investigation of any physical illness or other 
brain disorder sufficient to account for the clinical picture.
Possible Lewy Body Dementia if:
- both criteria 1 are answered with “yes”
AND
- none of criteria 3 are answered with “yes”
AND
- at least one of the core features 2 are answered with “yes”
Probable Lewy Body Dementia if:
- both criteria 1 are answered with “yes”
AND
- none of criteria 3 are answered with “yes”
AND
- two of the core features 2 are answered with “yes”
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VASCULAR DEMENTIA
Criteria given by the National Institute of Neurological Disorders and Stroke - 
Association Internationale pour la Recherche et L’Enseignement en Neurosciences 
(NINDS-AIREN) (Roman et a l , 1993)
I. Criteria for the clinical diagnosis of PROBABLE vascular dementia include all of the 
following:
a) Dementia defined by cognitive decline from a previously higher level of functioning 
and manifested by impairment of memory and of two or more cognitive domains 
(orientation, attention, language, visuospatial functions, executive functions, motor 
control, and praxis), preferably established by clinical examination and documented by 
neuropsychological testing; deficits should be severe enough to interfere with activities 
of daily living not due to physical effects of stroke alone.
Exclusion criteria: cases with disturbance of consciousness, delirium, psychosis, 
severe aphasia, or major sensorimotor impairment precluding neuropsychological 
testing. Also excluded are systemic disorders or other brain diseases (such as AD) that 
in and of themselves could account for deficits in memory and cognition.
b) Cerebrovascular disease (CVD), defined by the presence of focal signs on neurologic 
examination, such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, 
hemianopia, and dysarthria consistent with stroke (with or without history of stroke), 
and evidence of relevant CVD by brain imaging (CT or MRI) including multiple large- 
vessel infarcts or a single strategically placed infarct (angular gyrus, thalamus, basal 
forebrain, or PCA or ACA territories), as well as multiple basal ganglia and white 
matter lacunes or extensive periventricular white matter lesions, or combinations 
thereof.
c) A relationship between the above two disorders, manifested or inferred by the 
presence of one or more of the following:
(i) onset of dementia within three 3 months following a recognised stroke
(ii) abrupt deterioration in cognitive functions; or fluctuating, stepwise 
progression of cognitive deficits.
II. Clinical features consistent with the diagnosis of PROBABLE vascular dementia 
include the following:
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a) Early presence of a gait disturbance (small-step gait or marche a petits pas, or 
magnetic, apraxic-ataxic or parkinsonian gait)
b) History of unsteadiness and frequent, unprovoked falls
c) Early urinary frequency, urgency, and other urinary symptoms not explained by 
urologic disease
d) Pseudobulbar palsy
e) Personality and mood changes, abulia, depression, emotional incontinence, or other 
subcortical deficits including psychomotor retardation and abnormal executive function.
III. Features that make the diagnosis of vascular dementia uncertain or unlikely include
a) Early onset of memory deficit and progressive worsening of memory and other 
cognitive functions such as language (transcortical sensory aphasia), motor skills 
(apraxia), and perception (agnosia), in the absence of corresponding focal lesions on 
brain imaging;
b) Absence of focal neurologic signs, other than cognitive disturbance; and
c) Absence of cerebrovascular lesions on brain CT or MRI.
MCI
Criteria given by Petersen et al. (Petersen et al., 1999)
a) Memory complaint
b) Normal activities of daily living
c) Normal general cognitive function
d) Abnormal memory for age, and
e) Not demented
f) Absence of psychiatric symptoms
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Appendix Two: MINI MENTAL STATE EXAMINATION
Mini Mental State Examination (MMSE) described by Folstein et al. (Folstein et a l, 
1975)
-361 -
Appendix Three: IMAGE ACQUISITION PROTOCOLS
All volumetric scans were acquired on a 1.5 Tesla Signa unit (General Electric, 
Waukesha, WI, USA) as 124 contiguous 1.5mm coronal slices using one of the two 
following acquisitions:
Standard imaging protocol
Scans were performed by the staff at St Mary’s Hospital, Paddington and the Queen 
Square Imaging Centre. These were taken using a 256x128 image matrix with the field 
of view being 24cm (acquisition parameters: repetition time=35ms; echo time=5ms; flip 
angle=35°).
M1RIAD protocol
Scans were acquired by Dave MacManus of the NMR group, Queen Square. This 
protocol was an inversion recovery prepared fast SPGR sequence with a 256x256 image 
matrix and the field of view being 24cm (acquisition parameters: repetition time=15ms; 
echo time=5.4ms; flip angle=15°; inversion time=650ms).
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Appendix Four: VOLUMETRIC ANALYSIS
Volumetric analysis was performed using the MIDAS software, following the protocols 
detailed below. All segmentations were performed on T1-weighted images. 
Reproducibility error was estimated as the mean absolute percentage difference between 
repeat segmentations on the same scan and/or an ICC calculated from the same 
measurements.
Whole brain
Whole brain segmentation was performed using a protocol described in detail by 
Freeborough et a l (Freeborough et a l, 1997). This is a semi-automated algorithm 
which identifies voxels within the brain using interactive thresholding. Brain tissue was 
then isolated from the surrounding tissue such as scalp and dura using a series of 
erosions and dilations (see Appendix Figure 1). All segmentations were performed by 
Rachael Scahill, Rhian Jenkins, Jennifer Whitwell, Shona Price, Valerie Anderson and 
myself. Inter-rater reproducibility was 0.42% and intra-rater reproducibility was 0.36%.
Total Intracranial Volume
Total Intracranial Volume (TIV) was delineated using a protocol described by Whitwell 
et a l (Whitwell et a l, 2001). A lower threshold of 30% of the mean intracranial signal 
intensity was set to outline the outer border of dura, with manual editing where 
necessary. The inferior boundary was set as the lowest slice in which cerebellar tissue 
was present. An area measurement was performed on every tenth axial slice, and a 
volume estimate was obtained using linear interpolation. This is illustrated in Appendix 
Figure 2. All volumetric measurements were performed by Jennifer Whitwell, and intra­
rater reproducibility was 0.23%.
Hippocampus
See Appendix Figure 3. The hippocampus was delineated by reference to the 
neuroanatomical atlas by Duvemoy (Duvemoy, 1998). The caudal most measurement of 
the hippocampus was taken at the level of the crus of the fornix. The rostral boundary of 
the hippocampus was at its junction with the amygdala. Superiorly, medially and 
laterally the hippocampus was bounded by the ambient cistern and temporal horn of the 
lateral ventricle, and inferiorly by the subjacent white matter of the subiculum. This 
measure included the dentate gyrus, the hippocampus proper and the alveus. The
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hippocampal tail was excluded in order to achieve satisfactory reproducibility of 
segmentation, as recommended by Watson et al. (Watson et a l, 1992). A relative-to- 
brain threshold of 70% was used to aid delineation of grey matter from CSF. All 
segmentations were performed by Rachael Scahill, Basil Ridha, Valerie Anderson and 
myself. Inter-rater reproducibility error was 5% and intra-rater reproducibility error was 
3% (an ICC of 0.98).
Cingulate gyrus
See Appendix Figure 4. Cingulate segmentation was performed using the protocol 
(Jones et al, 2006). The posterior limit of the cingulate gyrus was taken as the splenial 
sulcus, the superior and anterior limit as the bottom of the cingulate sulcus and the 
inferior limit as the corpus collosum. The cingulate was outlined in the sagittal view 
(a), from medial to lateral parts using strict relative-to-brain thresholds of 70% and 
110% to aid delineation of grey matter from CSF and white matter respectively. The 
cingulate region was then edited coronally (b) and (c), with (b) showing the coronal 
slice at the posterior dashed line in (a), and (c) showing the more anterior coronal slice 
shown by the anterior dashed line in (a). Subdivisions were manually determined using 
the anterior and posterior comissures as cut-offs (arrows on (d) showing mid-sagittal 
“slice”). Cingulate gyrus anterior to the anterior commissure was considered to be 
rostral anterior cingulate (RAC), cingulate posterior to the posterior commissure is 
posterior cingulate (PC) and cingulate between these regions was caudal anterior 
cingulate (CAC). Segmentations were performed by Bethany Jones and myself, and the 
intra-rater reproducibility error of whole cingulate was 4% (a reliability coefficient of 
0.98), and the inter-rater reproducibility error of whole cingulate was 5% (an ICC of
0.98).
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Amygdala
See Appendix Figure 5. Amygdala segmentation was performed using a modification of 
a previously published protocol (Sheline et al., 1998). The rostral limit corresponds to 
the rostral extreme of the temporal stem. Caudally the amygdala was defined using the 
border with the lateral ventricle and the alveus, ending when the alveus disappears. 
Superiorly the boundary was set anteriorly by a line connecting the inferior point of the 
lateral fissure to the lateral most point of the paramedian cistemae, and posteriorly by 
the superior and lateral borders of the optic tract. Infero-laterally the amygdala was 
bounded by white matter and medially by the ambient cistem. All amygdala 
segmentations were performed by Jenny Whitwell, and the intra-rater reproducibility 
error was 4% (an ICC of 0.98).
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Appendix Figure 1: Whole brain segmentation in coronal view.
a) shows intensity thresholding and b) brain delineation following erosions and dilations
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Appendix Figure 2: TIV segmentation in sagittal view.
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Appendix Figure 3: Hippocampal segmentation.
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Appendix Figure 5: Segmentation of the amygdala.
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GLOSSARY
AC: Anterior cingulate
AD: Alzheimer’s disease
APOE: Apolipoprotein gene
APP: Amyloid precursor protein
BBSI: Brain boundary shift integral
BSI: Boundary shift integral
CAC: Caudal anterior cingulate
CSF: Cerebrospinal fluid
CT: Computed tomography
DLB: Dementia with Lewy bodies
dof: degrees of freedom
EEG: Electroencephalogram
FAD: Familial Alzheimer’s disease
fMRI: Functional Magnetic Resonance Imaging
FTLD: Fronto-temporal lobar degeneration, referring to the spectrum of diseases 
including fronto-temporal dementia, semantic dementia and primary progressive 
aphasia. The terminology covering these conditions is not always clear, and some 
authors use the term FTD to refer to the whole group, and others only to the frontal 
variant of this disorder.
fvFTD: Fronto-temporal dementia. This refers to the frontal variant of FTLD. 
MCI: Mild cognitive impairment
MIDAS: Medical Information Display and Analysis System
MIRIAD: Minimal Interval Resonance Imaging in AD
MMSE: Mini Mental State Examination
MRI: Magnetic Resonance Imaging
MRS: Magnetic Resonance Spectroscopy
MTL: Medial temporal lobe
NFT: Neurofibrillary tangle
PC: Posterior cingulate
PET: Positron Emission Tomography
PNFA: Progressive non-fluent aphasia, a clinical sub-type of FTLD 
RAC: Rostral anterior cingulate
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ROI: Region of interest
RTLA: Right temporal lobe atrophy, a sub-type of FTLD 
SAD: Sporadic Alzheimer’s disease
SD: Semantic dementia, a clinical sub-type of FTLD, and standard deviations in a 
statistical context.
SPECT: Single photon emission computed tomography
SPM: Statistical parametric mapping, the software package used for statistical analysis 
of structural and functional images
TE: Time to echo i.e. time between transmission of RF pulse and collection of signal 
TIV: Total intracranial volume -  a measure of total capacity within the skull, used as a 
maximum estimate of pre-morbid brain volume 
TR: Time to repeat i.e. time between RF pulses
VBM: Voxel-based morphometry, the application of SPM to highlight grey matter 
differences between groups, based on structural MRIs.
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